3-((Hetero-)Aryl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives

Abstract
The invention relates to 3-((hetero-)aryl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives, their preparation and their use in medicine, particularly in the treatment of pain.
Description

The invention relates to 3-((hetero-)aryl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives, their preparation and use in medicine, particularly in various neurological disorders, including but not limited to pain, neurodegenerative disorders, neuroinflammatory disorders, neuropsychiatric disorders, substance abuse/dependence.


Opioid receptors are a group of Gi/o protein-coupled receptors which are widely distributed in the human body. The opioid receptors are currently subdivided into four major classes, i.e. the three classical opioid receptors mu-opioid (MOP) receptor, kappa-opioid (KOP) receptor, and delta-opioid (DOP) receptor as well as the opioid receptor-like (ORL-1) receptor, which was more recently discovered based on its high homology with said classical opioid receptors. After identification of the endogenous ligand of the ORL-1 receptor, known as nociceptin/orphanin FQ, a highly basic 17 amino acid peptide isolated from tissue extracts in 1995, the ORL-1 receptor was renamed “nociceptin opioid peptide receptor” and abbreviated as “NOP-receptor”.


The classical opioid receptors (MOP, KOP and DOP) as well as the NOP receptor are widely distributed/expressed in the human body, including in the brain, the spinal cord, on peripheral sensory neurons and the intestinal tract, wherein the distribution pattern differs between the different receptor classes.


Nociceptin acts at the molecular and cellular level in very much the same way as opioids. However, its pharmacological effects sometimes differ from, and even oppose those of opioids. NOP-receptor activation translates into a complex pharmacology of pain modulation, which, depending on route of administration, pain model and species involved, leads to either pronociceptive or antinociceptive activity. Furthermore, the NOP receptor system is upregulated under conditions of chronic pain. Systemic administration of selective NOP receptor agonists was found to exert a potent and efficacious analgesia in non-human primate models of acute and inflammatory pain in the absence of side effects. The activation of NOP receptors has been demonstrated to be devoid of reinforcing effects but to inhibit opioid-mediated reward in rodents and non-human primates (Review: Schroeder et al, Br J Pharmacol 2014; 171 (16): 3777-3800, and references therein).


Besides the involvement of the NOP receptor in nociception, results from preclinical experiments suggest that NOP receptor agonists might be useful inter alia in the treatment of neuropsychiatric disorders (Witkin et al, Pharmacology & Therapeutics, 141 (2014) 283-299; Jenck et al., Proc. Natl. Acad. Sci. USA 94, 1997, 14854-14858). Remarkably, the DOP receptor is also implicated to modulate not only pain but also neuropsychiatric disorders (Mabrouk et al, 2014; Pradhan et al., 2011).


Strong opioids acting at the MOP receptor site are widely used to treat moderate to severe acute and chronic pain. However, the therapeutic window of strong opioids is limited by severe side effects such as nausea and vomiting, constipation, dizziness, somnolence, respiratory depression, physical dependence and abuse. Furthermore, it is known that MOP receptor agonists show only reduced effectiveness under conditions of chronic and neuropathic pain.


It is known that some of the above mentioned side-effects of strong opioids are mediated by activation of classic opioid-receptors within the central nervous system. Furthermore, peripheral opioid receptors, when activated, can inhibit transmission of nociceptive signals shown in both, clinical and animal studies (Gupta et al., 2001; Kalso et al., 2002; Stein et al., 2003; Zollner et al., 2008).


Thus, to avoid CNS-mediated adverse effects after systemic administration, one approach has been to provide peripherally restricted opioid receptor ligands that do not easily cross the blood-brain barrier and therefore distribute poorly to the central nervous system (see for instance WO 2015/192039). Such peripherally acting compounds might combine effective analgesia with limited side-effects.


Another approach has been to provide compounds which interact with both the NOP receptor and the MOP receptor. Such compounds have for instance been described in WO 2004/043967, WO 2012/013343 and WO 2009/118168.


A further approach has been to provide multi-opioid receptor analgesics that modulate more than one of the opioid receptor subtypes to provide additive or synergistic analgesia and/or reduced side effects like abuse liability or tolerance.


On the one hand, it would be desirable to provide analgesics that selectively act on the NOP receptor system but less pronounced on the classic opioid receptor system, especially MOP receptor system, whereas it would be desirable to distinguish between central nervous activity and peripheral nervous activity. On the other hand, it would be desirable to provide analgesics that act on the NOP receptor system and also to a balanced degree on the MOP receptor system, whereas it would be desirable to distinguish between central nervous activity and peripheral nervous activity.


There is a need for medicaments which are effective in the treatment of pain and which have advantages compared to the compounds of the prior art. Where possible, such medicaments should contain such a small dose of active ingredient that satisfactory pain therapy can be ensured without the occurrence of intolerable treatment-emergent adverse events.


It is an object of the invention to provide pharmacologically active compounds, preferably analgesics that have advantages compared to the prior art.


This object has been achieved by the subject-matter of the patent claims.


A first aspect of the invention relates to 3-((hetero-)aryl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives according to general formula (I)




embedded image


wherein


R1 and R2 independently of one another mean


—H;

—C1-C6-alkyl, linear or branched, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br, —I, —OH, —OCH3, —CN and —CO2CH3;


a 3-12-membered cycloalkyl moiety, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br, —I, —OH, —OCH3, —CN and —CO2CH3; wherein said 3-12-membered cycloalkyl moiety is optionally connected through —C1-C6-alkylene-, linear or branched, saturated or unsaturated, unsubstituted; or


a 3-12-membered heterocycloalkyl moiety, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br, —I, —OH, —OCH3, —CN and —CO2CH3; wherein said 3-12-membered heterocycloalkyl moiety is optionally connected through —C1-C6-alkylene-, linear or branched, saturated or unsaturated, unsubstituted;


or


R1 and R2 together with the nitrogen atom to which they are attached form a ring and mean —(CH2)3-6—; —(CH2)2—O—(CH2)2—; or —(CH2)2—NRA—(CH2)2—, wherein RA means —H or —C1-C6-alkyl, linear or branched, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br and —I;


preferably with the proviso that R1 and R2 do not simultaneously mean —H;


R3 means


—C1-C6-alkyl, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted;


a 3-12-membered cycloalkyl moiety, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said 3-12-membered cycloalkyl moiety is optionally connected through —C1-C6-alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted;


a 3-12-membered heterocycloalkyl moiety, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said 3-12-membered heterocycloalkyl moiety is optionally connected through —C1-C6-alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted;


a 6-14-membered aryl moiety, unsubstituted, mono- or polysubstituted; wherein said 6-14-membered aryl moiety is optionally connected through —C1-C6-alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted; or


a 5-14-membered heteroaryl moiety, unsubstituted, mono- or polysubstituted; wherein said 5-14-membered heteroaryl moiety is optionally connected through —C1-C6-alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted;


R4 means


—H;

—C1-C6-alkyl, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said —C1-C6-alkyl is optionally connected through —C(═O)—, —C(═O)O—, or —S(═O)2—;


a 3-12-membered cycloalkyl moiety, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said 3-12-membered cycloalkyl moiety is optionally connected through —C1-C6-alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted; or wherein said 3-12-membered cycloalkyl moiety is optionally connected through —C(═O)—, —C(═O)O—, —C(═O)O—CH2—, or —S(═O)2—;


a 3-12-membered heterocycloalkyl moiety, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said 3-12-membered heterocycloalkyl moiety is optionally connected through —C1-C6-alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted; or wherein said 3-12-membered heterocycloalkyl moiety is optionally connected through —C(═O)—, —C(═O)O—, —C(═O)O—CH2—, or —S(═O)2—;


a 6-14-membered aryl moiety, unsubstituted, mono- or polysubstituted; wherein said 6-14-membered aryl moiety is optionally connected through —C1-C6-alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted; or wherein said 6-14-membered aryl moiety is optionally connected through —C(═O)—, —C(═O)O—, —C(═O)O—CH2—, or —S(═O)2—; or


a 5-14-membered heteroaryl moiety, unsubstituted, mono- or polysubstituted; wherein said 5-14-membered heteroaryl moiety is optionally connected through —C1-C6-alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted; or wherein said 5-14-membered heteroaryl moiety is optionally connected through —C(═O)—, —C(═O)O—, —C(═O)O—CH2—, or —S(═O)2—;


R5 means


a 6-14-membered aryl moiety, unsubstituted, mono- or polysubstituted; or


a 5-14-membered heteroaryl moiety, unsubstituted, mono- or polysubstituted;


R11, R12, R13, R14, R15, R16, R17, R18, R19, and R20 independently of one another mean —H, —F, —Cl, —Br, —I, —OH, or —C1-C6-alkyl, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted;


wherein “mono- or polysubstituted” means that one or more hydrogen atoms are replaced by a substituent independently of one another selected from the group consisting of —F, —Cl, —Br, —I, —CN, —R21, —C(═O)R21, —C(═O)OR21, —C(═O)NR21R22, —C(═O)NH—(CH2CH2—O)1-30—CH3, —O—(CH2CH2—O)1-30—H, —O—(CH2CH2—O)1-30—CH3, ═O, —OR21, —OC(═O)R21, —OC(═O)OR21, —OC(═O)NR21R22, —NO2, —NR21R22, —NR21—(CH2)1-6—C(═O)R22, —NR21—(CH2)1-6—C(═O)OR22, —NR23—(CH2)1-6—C(═O)NR21R22, —NR21C(═O)R22, —NR21C(═O)—OR22, —NR23C(═O)NR21R22, —NR21S(═O)2R22, —SR21, —S(═O)R21, —S(═O)2R21, —S(═O)2OR21, and —S(═O)2NR21R22;


wherein


R21, R22 and R23 independently of one another mean


—H;

—C1-C6-alkyl, linear or branched, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br, —I, —CN, —OH, —NH2, —CO2H, —C(═O)O—C1-C6-alkyl, —C(═O)NH2, —C(═O)NHC1-C6-alkyl, —C(═O)N(C1-C6-alkyl)2, —O—C1-C6-alkyl and —S(═O)2—C1-C6-alkyl;


a 3-12-membered cycloalkyl moiety, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said 3-12-membered cycloalkyl moiety is optionally connected through —C1-C6-alkylene-, linear or branched, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br, —I, —CN, —OH, —NH2, —C1-C6-alkyl and —O—C1-C6-alkyl;


a 3-12-membered heterocycloalkyl moiety, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said 3-12-membered heterocycloalkyl moiety is optionally connected through —C1-C6-alkylene-, linear or branched, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br, —I, —CN, —OH, —NH2, —C1-C6-alkyl and —O—C1-C6-alkyl;


a 6-14-membered aryl moiety, unsubstituted, mono- or polysubstituted; wherein said 6-14-membered aryl moiety is optionally connected through —C1-C6-alkylene-, linear or branched, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br, —I, —CN, —OH, —NH2, —C1-C6-alkyl and —O—C1-C6-alkyl;


a 5-14-membered heteroaryl moiety, unsubstituted, mono- or polysubstituted; wherein said 5-14-membered heteroaryl moiety is optionally connected through —C1-C6-alkylene-, linear or branched, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br, —I, —CN, —OH, —NH2, —C1-C6-alkyl and —O—C1-C6-alkyl;


or R21 and R22 within —C(═O)NR21R22, —OC(═O)NR21R22, —NR21R22, —NR23—(CH2)1-6—C(═O)NR21R22, —NR23C(═O)NR21R22, or —S(═O)2NR21R22 together with the nitrogen atom to which they are attached form a ring and mean —(CH2)3-6—; —(CH2)2—O—(CH2)2—; —(CH2)2—S(═O)2—(CH2)2— or —(CH2)2—NRB—(CH2)2—, wherein RB means —H, —C1-C6-alkyl, —C(═O)—C1-C6-alkyl, or —S(═O)2—C1-C6-alkyl, wherein said —C1-C6-alkyl is linear or branched, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br —I, —OH, —CO2H, —C(═O)O—C1-C6-alkyl and —C(═O)NH2; and wherein said ring is unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br, —I, —CN, —OH, —NH2, —C1-C6-alkyl and —O—C1-C6-alkyl;


or a physiologically acceptable salt thereof.


“(Hetero-)aryl” means “heteroaryl or aryl”. Preferably, aryl includes but is not limited to phenyl and naphthyl. Preferably, heteroaryl includes but is not limited to -1,2-benzodioxole, -pyrazinyl, -pyridazinyl, -pyridinyl, -pyrimidinyl, -thienyl, -imidazolyl, -benzimidazolyl, -thiazolyl, -1,3,4-thiadiazolyl, -benzothiazolyl, -oxazolyl, -benzoxazolyl, -pyrazolyl, -quinolinyl, -isoquinolinyl, -quinazolinyl, -indolyl, -indolinyl, -benzo[c][1,2,5]oxadiazolyl, -imidazo[1,2-a]pyrazinyl, or -1H-pyrrolo[2,3-b]pyridinyl. Preferably, cycloalkyl includes but is not limited to -cyclopropyl, -cyclobutyl, -cyclopentyl and -cyclohexyl. Preferably, heterocycloalkyl includes but is not limited to -aziridinyl, -azetidinyl, -pyrrolidinyl, -piperidinyl, -piperazinyl, -morpholinyl, -sulfamorpholinyl, -oxiridinyl, -oxetanyl, -tetrahydropyranyl, and -pyranyl.


When a moiety is connected through an asymmetric group such as —C(═O)O— or —C(═O)O—CH2—, said asymmetric group may be arranged in either direction. For example, when R4 is connected to the core structure through —C(═O)O—, the arrangement may be either R4—C(═O)O-core or core-C(═O)O—R4.


In preferred embodiments of the compound according to the invention, R11, R12, R13, R14, R15, R16, R17, R18, R19, and R20 independently of one another mean —H, —F, —OH, or —C1-C6-alkyl; preferably —H.


In a preferred embodiment of the compound according to the invention, R1 means —H; and R2 means —C1-C6-alkyl, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted. Preferably, R1 means —H and R2 means —CH3.


In another preferred embodiment of the compound according to the invention, R1 means —CH3; and R2 means —C1-C6-alkyl, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted. Preferably, R1 means —CH3 and R2 means —CH3.


In still another preferred embodiment of the compound according to the invention, R1 and R2 together with the nitrogen atom to which they are attached form a ring and mean —(CH2)3-6—. Preferably, R1 and R2 together with the nitrogen atom to which they are attached form a ring and mean —(CH2)3—.


In yet another preferred embodiment,

    • R1 means —H or —CH3; and
    • R2 means a 3-12-membered cycloalkyl moiety, saturated or unsaturated, unsubstituted; wherein said 3-12-membered cycloalkyl moiety is connected through —CH2—, unsubstituted; preferably —CH2-cycloalkyl, —CH2-cyclobutyl or —CH2-cyclopentyl; or R2 means a 3-12-membered heterocycloalkyl moiety, saturated or unsaturated, unsubstituted; wherein said 3-12-membered heterocycloalkyl moiety is connected through —CH2—, unsubstituted; preferably —CH2-oxetanyl or —CH2-tetrahydrofuranyl.


In a preferred embodiment of the compound according to the invention, R3 means —C1-C6-alkyl, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted. Preferably, R3 means —C1-C6-alkyl, linear or branched, saturated or unsaturated, unsubstituted or monosubstituted with —OCH3.


In another preferred embodiment of the compound according to the invention, R3 means a 6-14-membered aryl moiety, unsubstituted, mono- or polysubstituted, optionally connected through —C1-C6-alkylene-, linear or branched, saturated or unsaturated, unsubstituted. In a preferred embodiment, R3 means -phenyl unsubstituted, mono- or polysubstituted. More preferably, R3 means -phenyl unsubstituted, mono- or disubstituted with —F, —Cl, —CH3, —CF3, —OH, —OCH3, —OCF3 or —OCH2OCH3, preferably —F. In another preferred embodiment, R3 means -benzyl unsubstituted, mono- or polysubstituted. More preferably, R3 means -benzyl unsubstituted, mono- or disubstituted with —F, —Cl, —CH3, —CF3, —OH, —OCH3, —OCF3 or —OCH2OCH3, preferably —F.


In still another preferred embodiment of the compound according to the invention, R3 means a 5-14-membered heteroaryl moiety, unsubstituted, mono- or polysubstituted. Preferably, R3 means -thienyl or -pyridinyl, in each case unsubstituted, mono- or polysubstituted. More preferably, R3 means -thienyl, -pyridinyl, -imidazolyl or benzimidazolyl, in each case unsubstituted or monosubstituted with —F, —Cl or —CH3.


In a preferred embodiment of the compound according to the invention, R4 means —H.


In another preferred embodiment of the compound according to the invention, R4 means —C1-C6-alkyl, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted. Preferably, R4 means —C1-C6-alkyl, linear or branched, saturated or unsaturated, unsubstituted or monosubstituted with a substituent selected from the group consisting of —F, —Cl, —Br, —I, —CN, —CF3, —OH, —O—C1-C4-alkyl, —OCF3, —O—(CH2CH2—O)1-30—H, —O—(CH2CH2—O)1-30—CH3, —OC(═O)C1-C4-alkyl, —C(═O)C1-C4-alkyl, —C(═O)OH, —C(═O)OC1-C4-alkyl, —C(═O)NH2, —C(═O)NHC1-C4-alkyl, —C(═O)NHC1-C4-alkylene-CN, —C(═O)NHC1-C4-alkylene-O—C1-C4-alkyl, —C(═O)N(C1-C4-alkyl)2; —S(═O)C1-C4-alkyl, and —S(═O)2C1-C4-alkyl; or with —C(═O)NR21R22 wherein R21 and R22 together with the nitrogen atom to which they are attached form a ring and mean —(CH2)3-6—, —(CH2)2—O—(CH2)2—, or —(CH2)2—NRB—(CH2)2—, wherein RB means —H or —C1-C6-alkyl; or with —C(═O)NH-3-12-membered cycloalkyl, saturated or unsaturated, unsubstituted or monosubstituted with —F, —Cl, —Br, —I, —CN, or —OH; or with —C(═O)NH-3-12-membered heterocycloalkyl, saturated or unsaturated, unsubstituted or monosubstituted with —F, —Cl, —Br, —I, —CN, or —OH. More preferably, R4 means —C1-C6-alkyl, linear or branched, saturated or unsaturated, unsubstituted or monosubstituted with —O—C1-C4-alkyl or —C(═O)N(C1-C4-alkyl)2.


In still another preferred embodiment of the compound according to the invention, R4 means a 3-12-membered cycloalkyl moiety, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein the 3-12-membered cycloalkyl moiety is connected through —C1-C6-alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted. Preferably, R4 means a 3-12-membered cycloalkyl moiety, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said 3-12-membered cycloalkyl moiety is connected through —CH2— or —CH2CH2—. More preferably, R4 means a 3-12-membered cycloalkyl moiety, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br, —I, —CN, —OH, —C1-C4-alkyl, —O—C1-C4-alkyl, —C(═O)OH, —C(═O)OC1-C4-alkyl, —C(═O)NH2, —C(═O)NHC1-C4-alkyl, —C(═O)N(C1-C4-alkyl)2, —S(═O)C1-C4-alkyl and —S(═O)2C1-C4-alkyl; wherein said 3-12-membered cycloalkyl moiety is connected through —CH2— or —CH2CH2—.


In a preferred embodiment of the compound according to the invention, R4 means a 3-12-membered heterocycloalkyl moiety, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said 3-12-membered heterocycloalkyl moiety is connected through —C1-C6-alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted. Preferably, R4 means a 3-12-membered heterocycloalkyl moiety, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said 3-12-membered heterocycloalkyl moiety is connected through —CH2— or —CH2CH2—. More preferably, R4 means -oxetanyl, -tetrahydrofuranyl or -tetrahydropyranyl, in each case unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br, —I, —CN, —OH, —C1-C4-alkyl, —O—C1-C4-alkyl, —C(═O)OH, —C(═O)OC1-C4-alkyl, —C(═O)NH2, —C(═O)NHC1-C4-alkyl, —C(═O)N(C1-C4-alkyl)2, —S(═O)C1-C4-alkyl and —S(═O)2C1-C4-alkyl; wherein said -oxetanyl, -tetrahydrofuranyl or -tetrahydropyranyl is connected through —CH2— or —CH2CH2—.


In yet another preferred embodiment of the compound according to the invention, R4 means a 6-14-membered aryl moiety, unsubstituted, mono- or polysubstituted; wherein said 6-14-membered aryl moiety is connected through —C1-C6-alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted. Preferably, R4 means -phenyl, unsubstituted, mono- or polysubstituted; wherein said -phenyl is connected through —CH2— or —CH2CH2—. More preferably, R4 means -phenyl, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br, —I, —CN, —OH, —C1-C4-alkyl, —O—C1-C4-alkyl, —C(═O)OH, —C(═O)OC1-C4-alkyl, —C(═O)NH2, —C(═O)NHC1-C4-alkyl, —C(═O)N(C1-C4-alkyl)2, —S(═O)C1-C4-alkyl and —S(═O)2C1-C4-alkyl; wherein said -phenyl is connected through —CH2— or —CH2CH2—.


In a further preferred embodiment of the compound according to the invention, R4 means a 5-14-membered heteroaryl moiety, unsubstituted, mono- or polysubstituted; wherein said 5-14-membered heteroaryl moiety is connected through —C1-C6-alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted. Preferably, R4 means a 5-14-membered heteroaryl moiety, unsubstituted, mono- or polysubstituted; wherein said -phenyl is connected through —CH2— or —CH2CH2—. More preferably, R4 means -pyridinyl, -pyrimidinyl, -pyrazinyl, or -pyrazolinyl, in each case unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br, —I, —CN, —OH, —C1-C4-alkyl, —O—C1-C4-alkyl, —C(═O)OH, —C(═O)OC1-C4-alkyl, —C(═O)NH2, —C(═O)NHC1-C4-alkyl, —C(═O)N(C1-C4-alkyl)2, —S(═O)C1-C4-alkyl and —S(═O)2C1-C4-alkyl; wherein said -pyridinyl, -pyrimidinyl, -pyrazinyl, or -pyrazolinyl is connected through —CH2— or —CH2CH2—.


In a preferred embodiment of the compound according to the invention, R5 means -phenyl, unsubstituted, mono- or polysubstituted. Preferably, R5 means -phenyl unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F; —Cl; —Br; —I; —CN; —OH; —C1-C4-alkyl; —CF3; -3-12-membered cycloalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted; preferably -cyclopropyl, saturated, unsubstituted; -3-12-membered heterocycloalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted; preferably -pyrrolidinyl, -piperidinyl, -morpholinyl, -piperazinyl, -thiomorpholinyl, or -thiomorpholinyl dioxide, in each case saturated, unsubstituted or monosubstituted with —C1-C4-alkyl; -6-14-membered aryl, unsubstituted, mono- or polysubstituted; preferably -phenyl, unsubstituted; —O—C1-C4-alkyl; —S—C1-C4-alkyl; —C(═O)OH; —C(═O)O—C1-C4-alkyl; —C(═O)NH2; —C(═O)NHC1-C4-alkyl; —C(═O)N(C1-C4-alkyl)2; —C(═O)N(C1-C4-alkyl)(C1-C4-alkyl-OH); —C(═O)NH—(CH2)1-3-3-12-membered cycloalkyl, saturated or unsaturated, unsubstituted or monosubstituted with —OH; preferably —C(═O)NH—(CH2)1-3-cyclobutyl, saturated or unsaturated, unsubstituted or monosubstituted with —OH; —C(═O)-3-12-membered heterocycloalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted; preferably —C(═O)-morpholinyl, saturated, unsubstituted; —S(═O)C1-C4-alkyl; —S(═O)2C1-C4-alkyl; and —S(═O)2N(C1-C4-alkyl)2.


In another preferred embodiment of the compound according to the invention, R5 means -1,2-benzodioxole, -pyrazinyl, -pyridazinyl, -pyridinyl, -pyrimidinyl, -thienyl, -imidazolyl, -benzimidazolyl, -thiazolyl, -1,3,4-thiadiazolyl, -benzothiazolyl, -oxazolyl, -benzoxazolyl, -pyrazolyl, -quinolinyl, -isoquinolinyl, -quinazolinyl, -indolyl, -indolinyl, benzo[c][1,2,5]oxadiazolyl, -imidazo[1,2-a]pyrazinyl, or -1H-pyrrolo[2,3-b]pyridinyl, in each case unsubstituted, mono- or polysubstituted; preferably -pyrazinyl, -pyridazinyl, -pyridinyl, -pyrimidinyl, or -thienyl, in each case unsubstituted, mono- or polysubstituted. Preferably, R5 means -pyrazinyl, -pyridazinyl, -pyridinyl, -pyrimidinyl, or -thienyl, in each case unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F; —Cl; —Br; —I; —CN; —OH; —C1-C4-alkyl; —CF3; -3-12-membered cycloalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted; preferably -cyclopropyl, saturated, unsubstituted; -3-12-membered heterocycloalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted; preferably -pyrrolidinyl, -piperidinyl, -morpholinyl, -piperazinyl, -thiomorpholinyl, or -thiomorpholinyl dioxide, in each case saturated, unsubstituted or monosubstituted with —C1-C4-alkyl; -6-14-membered aryl, unsubstituted, mono- or polysubstituted; preferably -phenyl, unsubstituted; —O—C1-C4-alkyl; —S—C1-C4-alkyl; —C(═O)OH; —C(═O)O—C1-C4-alkyl; —C(═O)NH2; —C(═O)NHC1-C4-alkyl; —C(═O)N(C1-C4-alkyl)2; —C(═O)N(C1-C4-alkyl)(C1-C4-alkyl-OH); —C(═O)NH—(CH2)1-3-3-12-membered cycloalkyl, saturated or unsaturated, unsubstituted or monosubstituted with —OH; preferably —C(═O)NH—(CH2)1-3-cyclobutyl, saturated or unsaturated, unsubstituted or monosubstituted with —OH; —C(═O)-3-12-membered heterocycloalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted; preferably —C(═O)-morpholinyl, saturated, unsubstituted; —S(═O)C1-C4-alkyl; —S(═O)2C1-C4-alkyl; and —S(═O)2N(C1-C4-alkyl)2.


In still another preferred embodiment of the compound according to the invention, R5 means a bicyclic 9-10-membered heteroaryl moiety, unsubstituted, mono- or polysubstituted. Preferably, R5 means imidazo[1,2-a]pyrazine, unsubstituted or monosubstituted with —C1-C4-alkyl.


Preferably, R5 means -phenyl, -1,2-benzodioxole, -pyrazinyl, -pyridazinyl, -pyridinyl, -pyrimidinyl, -thienyl, -imidazolyl, -benzimidazolyl, -thiazolyl, -1,3,4-thiadiazolyl, -benzothiazolyl, -oxazolyl, -benzoxazolyl, -pyrazolyl, -quinolinyl, -isoquinolinyl, -quinazolinyl, -indolyl, -indolinyl, -benzo[c][1,2,5]oxadiazolyl, -imidazo[1,2-a]pyrazinyl, or -1H-pyrrolo[2,3-b]pyridinyl, in each case unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of


—F; —Cl; —Br; —I;

—CN; —C1-C4-alkyl; —CF3; —C1-C4-alkyl-C(═O)NH2; —C1-C4-alkyl-S(═O)2—C1-C4-alkyl;


—C(═O)—C1-C4-alkyl; —C(═O)OH; —C(═O)O—C1-C4-alkyl; —C(═O)NH2; —C(═O)NHC1-C4-alkyl; —C(═O)N(C1-C4-alkyl)2; —C(═O)NH(C1-C4-alkyl-OH); —C(═O)N(C1-C4-alkyl)(C1-C4-alkyl-OH); —C(═O)NH—(CH2CH2O)1-30—CH3;


—NH2; —NHC1-C4-alkyl; —N(C1-C4-alkyl)2; —NHC1-C4-alkyl-OH; —NCH3C1-C4-alkyl-OH; —NH—C1-C4-alkyl-C(═O)NH2; —NCH3—C1-C4-alkyl-C(═O)NH2; —NHC(═O)—C1-C4-alkyl; —NCH3C(═O)—C1-C4-alkyl;


—OH; —O—C1-C4-alkyl; —OCF3; —O—C1-C4-alkyl-CO2H; —O—C1-C4-alkyl-C(═O)O—C1-C4-alkyl; —O—C1-C4-alkyl-CONH2;


—S—C1-C4-alkyl; —S(═O)C1-C4-alkyl; —S(═O)2C1-C4-alkyl; and —S(═O)2N(C1-C4-alkyl)2;


-3-12-membered cycloalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted;


wherein said 3-12-membered cycloalkyl is optionally connected through —CH2—, —NH—, —NCH3—, —NH—(CH2)1-3—, —NCH3(CH2)1-3—, —(C═O)—, —NHC(═O)—, —NCH3C(═O)—, —C(═O)NH—(CH2)1-3—, —C(═O)NCH3—(CH2)1-3—;


-3-12-membered heterocycloalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said 3-12-membered heterocycloalkyl is optionally connected through —CH2—, —NH—, —NCH3—, —NH—(CH2)1-3—, —NCH3(CH2)1-3—, —(C═O)—, —NHC(═O)—, —NCH3C(═O)—, —C(═O)NH—(CH2)1-3—, —C(═O)NCH3—(CH2)1-3—;


-6-14-membered aryl, unsubstituted, mono- or polysubstituted; wherein said 6-14-membered aryl is optionally connected through —CH2—, —NH—, —NCH3—, —NH—(CH2)1-3—, —NCH3(CH2)1-3—, —(C═O)—, —NHC(═O)—, —NCH3C(═O)—, —C(═O)NH—(CH2)1-3—, —C(═O)NCH3—(CH2)1-3—; or


-5-14-membered heteroaryl, unsubstituted, mono- or polysubstituted; wherein said 5-14-membered heteroaryl is optionally connected through —CH2—, —NH—, —NCH3—, —NH—(CH2)1-3—, —NCH3(CH2)1-3—, —(C═O)—, —NHC(═O)—, —NCH3C(═O)—, —C(═O)NH—(CH2)1-3—, —C(═O)NCH3—(CH2)1-3—.


In preferred embodiments, the compound according to the invention has a structure according to any of general formulas (II-A) to (VIII-C):




embedded image


embedded image


embedded image


embedded image


wherein in each case


R1, R2, R3, R4, and R5 are defined as above,


RC means —H, —OH, —F, —CN or —C1-C4-alkyl; preferably —H or —OH;


RD means —H or —F;


or a physiologically acceptable salt thereof.


Preferably, in the compounds according to general formula (I) or any of the compounds according to general formulas (II-A) to (VIII-C), R5 is selected from the group consisting of:




embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


In a particularly preferred embodiment of the compound according to the invention


R1 means —H or —CH3;


R2 means —C1-C6-alkyl, linear or branched, saturated, unsubstituted; cyclopropyl connected through —CH2—; or tetrahydropyranyl connected through —CH2—;


R3 means -phenyl, benzyl, -thienyl or -pyridinyl, in each case unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —CN, —CH3, —CH2CH3, —CH2F, —CHF2, —CF3, —OCF3, —OH, —OCH3, —C(═O)NH2, C(═O)NHCH3, —C(═O)N(CH3)2, —NH2, —NHCH3, —N(CH3)2, —NHC(═O)CH3, —CH2OH, SOCH3 and SO2CH3; or


R4 means


—H;

—C1-C6-alkyl, linear or branched, saturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br, —I, —CN, —OH, —O—C1-C4-alkyl, —C(═O)NH—C1-C6-alkyl, —C(═O)N(C1-C6-alkyl)2 or —C(═O)NRR′ wherein R and R′ together with the nitrogen atom to which they are attached form a ring and mean —(CH2)3-5—;


3-6-membered cycloalkyl, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br, —I, —CN, —OH, and —O—C1-C4-alkyl, wherein said 3-6-membered cycloalkyl is connected through —C1-C6-alkylene;


3-6-membered heterocycloalkyl, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br, —I, —CN, —OH, and —O—C1-C4-alkyl, wherein said 3-6-membered heterocycloalkyl is connected through —C1-C6-alkylene;


-phenyl, unsubstituted or monosubstituted with —OCH3; wherein said -phenyl isconnected through —C1-C6-alkylene-; or


-pyridyl, unsubstituted, mono- or polysubstituted; wherein said -pyridyl is connected through —C1-C6-alkylene-;


R5 means


-phenyl, -1,2-benzodioxole, -pyrazinyl, -pyridazinyl, -pyridinyl, -pyrimidinyl, -thienyl, -imidazolyl, -benzimidazolyl, -thiazolyl, -1,3,4-thiadiazolyl, -benzothiazolyl, -oxazolyl, -benzoxazolyl, -pyrazolyl, -quinolinyl, -isoquinolinyl, -quinazolinyl, -indolyl, -indolinyl, -benzo[c][1,2,5]oxadiazolyl, -imidazo[1,2-a]pyrazinyl, or -1H-pyrrolo[2,3-b]pyridinyl, in each case unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of

    • —F; —Cl; —Br; —I;
    • —CN; —C1-C4-alkyl; —C1-C4-alkyl-OH; —CF3; —C1-C4-alkyl-CF3; —C1-C4-alkyl-C(═O)NH2; —C1-C4-alkyl-C(═O)NHC1-C6-alkyl; —C1-C4-alkyl-C(═O)N(C1-C6-alkyl)2; —C1-C4-alkyl-S(═O)2—C1-C4-alkyl;
    • —C(═O)—C1-C4-alkyl; —C(═O)OH; —C(═O)O—C1-C4-alkyl; —C(═O)NH2; —C(═O)NHC1-C4-alkyl; —C(═O)N(C1-C4-alkyl)2; —C(═O)NH(C1-C4-alkyl-OH); —C(═O)N(C1-C4-alkyl)(C1-C4-alkyl-OH);
    • —C(═O)NH—(CH2CH2O)1-30—CH3;
    • —NH2; —NHC1-C4-alkyl; —N(C1-C4-alkyl)2; —NHC1-C4-alkyl-OH; —NCH3C1-C4-alkyl-OH; —NH—C1-C4-alkyl-C(═O)NH2; —NCH3—C1-C4-alkyl-C(═O)NH2; —NHC(═O)—C1-C4-alkyl; —NCH3C(═O)—C1-C4-alkyl;
    • —OH; —O—C1-C4-alkyl; —OCF3; —O—C1-C4-alkyl-CO2H; —O—C1-C4-alkyl-C(═O)O—C1-C4-alkyl; —O—C1-C4-alkyl-CONH2;
    • —S—C1-C4-alkyl; —S(═O)C1-C4-alkyl; —S(═O)2C1-C4-alkyl; and —S(═O)2N(C1-C4-alkyl)2;
    • -3-12-membered cycloalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said 3-12-membered cycloalkyl is optionally connected through —CH2—, —O—, —NH—, —NCH3—, —NH—(CH2)1-3—, —NCH3(CH2)1-3—, —(C═O)—, —NHC(═O)—, —NCH3C(═O)—, —C(═O)NH—(CH2)1-3—, —C(═O)NCH3—(CH2)1-3—;
    • -3-12-membered heterocycloalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said 3-12-membered heterocycloalkyl is optionally connected through —CH2—, —O—, —NH—, —NCH3—, —NH—(CH2)1-3—, —NCH3(CH2)1-3—, —(C═O)—, —NHC(═O)—, —NCH3C(═O)—, —C(═O)NH—(CH2)1-3—, —C(═O)NCH3—(CH2)1-3—;
    • -6-14-membered aryl, unsubstituted, mono- or polysubstituted; wherein said 6-14-membered aryl is optionally connected through —CH2—, —O—, —NH—, —NCH3—, —NH—(CH2)1-3—, —NCH3(CH2)1-3—, —(C═O)—, —NHC(═O)—, —NCH3C(═O)—, —C(═O)NH—(CH2)1-3—, —C(═O)NCH3—(CH2)1-3—; or
    • -5-14-membered heteroaryl, unsubstituted, mono- or polysubstituted; wherein said 5-14-membered heteroaryl is optionally connected through —CH2—, —O—, —NH—, —NCH3—, —NH—(CH2)1-3—, —NCH3(CH2)1-3—, —(C═O)—, —NHC(═O)—, —NCH3C(═O)—, —C(═O)NH—(CH2)1-3—, —C(═O)NCH3—(CH2)1-3—; and


      R11, R12, R13, R14, R15, R16, R17, R18, R19, and R20 mean —H.


In a particularly preferred embodiment of the compound according to the invention


R1 means —H or —CH3; and/or


R2 means —C1-C6-alkyl, linear or branched, saturated, unsubstituted; preferably, R2 means —CH3 or —CH2CH3; more preferably, R1 and R2 both mean —CH3; and/or


R3 means -phenyl, -thienyl or -pyridinyl, in each case unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —C1, —CN, —CH3, —CH2CH3, —CH2F, —CHF2, —CF3, —OCF3, —OH, —OCH3, —C(═O)NH2, C(═O)NHCH3, —C(═O)N(CH3)2, —NH2, —NHCH3, —N(CH3)2, —NHC(═O)CH3, —CH2OH, SOCH3 and SO2CH3;


preferably, R3 means -phenyl, -thienyl or -pyridinyl, in each case unsubstituted or substituted with —F; more preferably, R3 means phenyl, unsubstituted; and/or


R4 means


—H;

—C1-C6-alkyl, linear or branched, saturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br, —I, —CN, —OH, and —O—C1-C4-alkyl; or


3-6-membered cycloalkyl, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br, —I, —CN, —OH, and —O—C1-C4-alkyl, wherein said 3-6-membered cycloalkyl is connected through —C1-C6-alkylene;


preferably, R4 means 3-6-membered cycloalkyl, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br, —I, —CN, —OH, and —O—C1-C4-alkyl, wherein said 3-6-membered cycloalkyl is connected through —CH2— or —CH2CH2—; more preferably, R4 means -cyclobutyl, unsubstituted or monosubstituted with —OH, wherein said -cyclobutyl is connected through —CH2—; and/or


R5 means -phenyl, -pyrazinyl, -pyridazinyl, -pyridinyl, -pyrimidinyl, -thienyl, or imidazo[1,2-a]pyrazine, in each case unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F; —Cl; —Br; —I; —CN; —OH; —C1-C4-alkyl; —CF3; -3-12-membered cycloalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted; preferably cyclopropyl, saturated, unsubstituted; -3-12-membered heterocycloalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted; preferably -pyrrolidinyl, -morpholinyl, -piperazinyl, -thiomorpholinyl, or -thiomorpholinyl dioxide, in each case saturated, unsubstituted or monosubstituted with —C1-C4-alkyl; -6-14-membered aryl, unsubstituted, mono- or polysubstituted; preferably -phenyl, unsubstituted; —O—C1-C4-alkyl; —S—C1-C4-alkyl; —C(═O)OH; —C(═O)O—C1-C4-alkyl; —C(═O)NH2; —C(═O)NHC1-C4-alkyl; —C(═O)N(C1-C4-alkyl)2; —C(═O)N(C1-C4-alkyl)(C1-C4-alkyl-OH); —C(═O)NH—(CH2)1-3-3-12-membered cycloalkyl, saturated or unsaturated, unsubstituted or monosubstituted with —OH; preferably —C(═O)NH—(CH2)1-3-cyclobutyl, saturated or unsaturated, unsubstituted or monosubstituted with —OH; —C(═O)-3-12-membered heterocycloalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted; preferably —C(═O)-morpholinyl, saturated, unsubstituted; —S(═O)C1-C4-alkyl; —S(═O)2C1-C4-alkyl; and —S(═O)2N(C1-C4-alkyl)2; and/or


R11, R12, R13, R14, R15, R16, R17, R18, R19, and R20 mean —H.


Preferably, the compound according to the invention is selected from the group consisting of















SC_3001
cis-5-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-



diazaspiro[4.5]decan-3-yl]-pyrimidine-2-carbonitrile


SC_3002
cis-5-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-



diazaspiro[4.5]decan-3-yl]-pyrazine-2-carbonitrile


SC_3003
cis-5-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-



diazaspiro[4.5]decan-3-yl]-4-methoxy-pyrimidine-2-carbonitrile


SC_3004
cis-5-[8-Dimethylamino-1-(2-methoxy-ethyl)-2-oxo-8-phenyl-1,3-



diazaspiro[4.5]decan-3-yl]-pyrimidine-2-carbonitrile


SC_3005
cis-5-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-



diazaspiro[4.5]decan-3-yl]-pyrimidine-2-carboxylic acid amide


SC_3006
cis-5-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-



diazaspiro[4.5]decan-3-yl]-2-methylsulfonyl-pyrimidine-4-carbonitrile


SC_3007
cis-5-[1-(2-Methoxy-ethyl)-8-methylamino-2-oxo-8-phenyl-1,3-



diazaspiro[4.5]decan-3-yl]-pyrimidine-2-carbonitrile


SC_3008
cis-2-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-



diazaspiro[4.5]decan-3-yl]-5-methylsulfonyl-benzonitrile


SC_3009
cis-2-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-



diazaspiro[4.5]decan-3-yl]-benzamide


SC_3010
cis-3-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-



diazaspiro[4.5]decan-3-yl]-benzamide


SC_3011
cis-5-[8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-2-oxo-8-phenyl-1,3-



diazaspiro[4.5]decan-3-yl]-pyrimidine-2-carboxylic acid amide


SC_3012
cis-5-[1-(Cyclobutyl-methyl)-8-methylamino-2-oxo-8-phenyl-1,3-



diazaspiro[4.5]decan-3-yl]-4-methoxy-pyrimidine-2-carbonitrile


SC_3013
cis-5-[8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-2-oxo-8-phenyl-1,3-



diazaspiro[4.5]decan-3-yl]-pyrimidine-2-carbonitrile


SC_3014
cis-2-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-



diazaspiro[4.5]decan-3-yl]-pyrimidine-5-carbonitrile


SC_3015
cis-5-[8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-3-(2-methoxy-pyrimidin-



5-yl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one


SC_3016
cis-2-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-



diazaspiro[4.5]decan-3-yl]-pyrimidine-5-carboxylic acid amide


SC_3017
cis-4-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-



diazaspiro[4.5]decan-3-yl]-N-methyl-benzamide


SC_3018
cis-5-(8-Dimethylamino-2-oxo-8-phenyl-1-propyl-1,3-diazaspiro[4.5]decan-3-yl)-



pyrimidine-2-carbonitrile


SC_3019
cis-5-[8-Dimethylamino-1-(3-methoxy-propyl)-2-oxo-8-phenyl-1,3-



diazaspiro[4.5]decan-3-yl]-pyrimidine-2-carbonitrile


SC_3020
cis-5-[1-(Cyclopropyl-methyl)-8-dimethylamino-2-oxo-8-pheny1-1,3-



diazaspiro[4.5]decan-3-yl]-pyrimidine-2-carbonitrile


SC_3021
cis-4-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-



diazaspiro[4.5]decan-3-yl]-benzamide


SC_3022
cis-1-(Cyclobutyl-methyl)-8-dimethylamino-8-phenyl-3-[2-(trifluoromethyl)-



pyrimidin-5-yl]-1,3-diazaspiro[4.51decan-2-one


SC_3023
cis-8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-3-(2-hydroxy-pyrimidin-



5-yl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one


SC_3024
cis-5-[8-Dimethylamino-1-(2-methyl-propy1)-2-oxo-8-phenyl-1,3-



diazaspiro[4.5]decan-3-yl]-pyrimidine-2-carbonitrile


SC_3025
cis-5-[8-Dimethylamino-1-(2-hydroxy-ethyl)-2-oxo-8-phenyl-1,3-



diazaspiro[4.5]decan-3-yl]-pyrimidine-2-carbonitrile


SC_3026
cis-5-[1-(Cyclobutyl-methyl)-8-methylamino-2-oxo-8-phenyl-1,3-



diazaspiro[4.5]decan-3-yl]-4-methyl-pyridine-2-carbonitrile


SC_3027
cis-1-(Cyclobutyl-methyl)-3-(5-methoxy-pyrazin-2-yl)-8-methylamino-8-phenyl-



1,3-diazaspiro[4.5]decan-2-one


SC_3028
cis-4-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-



diazaspiro[4.5]decan-3-yl]-N,N-dimethyl-benzamide


SC_3029
cis-4-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-



diazaspiro[4.5]decan-3-yl]-N-ethyl-N-(2-hydroxy-ethyl)-benzamide


SC_3030
cis-2-[1-(Cyclobutyl-methyl)-8-methylamino-2-oxo-8-phenyl-1,3-



diazaspiro[4.5]decan-3-yl]-5-methylsulfonyl-benzonitrile


SC_3031
cis-1-(Cyclobutyl-methyl)-8-methylamino-3-[2-methylsulfony1-4-



(trifluoromethyl)-phenyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one


SC_3032
cis-4-[1-(Cyclobutyl-methyl)-8-methylamino-2-oxo-8-phenyl-1,3-



diazaspiro[4.5]decan-3-yl]-N,N-dimethyl-3-(trifluoromethyl)-benzenesulfonic



acid amide


SC_3033
cis-4-[1-(Cyclobutyl-methyl)-8-(ethyl-methyl-amino)-2-oxo-8-phenyl-1,3-



diazaspiro[4.5]decan-3-yl]-benzonitrile


SC_3034
cis-1-(Cyclobutyl-methyl)-8-(ethyl-methyl-amino)-8-phenyl-3-[2-



(trifluoromethyl)-pyrimidin-5-yl]-1,3-diazaspiro[4.5]decan-2-one


SC_3035
cis-5-[1-(Cyclobutyl-methyl)-8-(ethyl-methyl-amino)-2-oxo-8-phenyl-1,3-



diazaspiro[4.5]decan-3-yl]-pyrimidine-2-carbonitrile


SC_3036
cis-5-[8-Dimethylamino-1-](1-methyl-cyclobutyl)-methyl]-2-oxo-8-phenyl-1,3-



diazaspiro[4.5]decan-3-yl]-pyrimidine-2-carbonitrile


SC_3037
cis-2-[3-(2-Cyano-pyrimidin-5-yl)-8-dimethylamino-2-oxo-8-phenyl-1,3-



diazaspiro[4.5]decan-1-yl]-N,N-dimethyl-acetamide


SC_3038
cis-1-(Cyclobutyl-methyl)-8-methylamino-8-phenyl-3-[2-(trifluoromethyl)-



pyrimidin-5-yl]-1,3-diazaspiro[4.5]decan-2-one


SC_3039
cis-5-[8-Dimethy1amino-8-(3-fluorophenyl)-1-(4-methoxy-butyl)-2-oxo-1,3-



diazaspiro[4.5]decan-3-yl]-pyrimidine-2-carbonitrile


SC_3040
cis-5-[8-Dimethylamino-1-(3-methoxy-propyl)-2-oxo-8-phenyl-1,3-



diazaspiro[4.5]decan-3-yl]-4-methoxy-pyrimidine-2-carbonitrile


SC_3041
cis-5-[1-[(1-Cyano-cyclobutyl)-methyl]-8-dimethylamino-2-oxo-8-phenyl-1,3-



diazaspiro[4.5]decan-3-yl]-pyrimidine-2-carbonitrile


SC_3042
cis-N-(Cyclobutyl-methyl)-5-[1-(cyclobutyl-methyl)-8-dimethylamino-8-(3-



fluorophenyl)-2-oxo-1,3-diazaspiro[4.5]decan-3-yl]-pyrimidine-2-carboxylic acid



amide


SC_3043
cis-5-[1-(3-Methoxy-propyl)-8-methylamino-2-oxo-8-phenyl-1,3-



diazaspiro[4.5]decan-3-yl]-pyrimidine-2-carbonitrile


SC_3044
cis-5-[8-Dimethylamino-8-(3-fluorophenyl)-1-methyl-2-oxo-1,3-



diazaspiro[4.5]decan-3-yl]-pyrimidine-2-carbonitrile


SC_3045
cis-4-Methoxy-5-[1-(3-methoxy-propyl)-8-methylamino-2-oxo-8-phenyl-1,3-



diazaspiro[4.5]decan-3-yl]-pyrimidine-2-carbonitrile


SC_3046
cis-4-[8-Dimethylamino-1-(2-methoxy-ethyl)-2-oxo-8-phenyl-1,3-



diazaspiro[4.5]decan-3-yl]-pyrimidine-2-carbonitrile


SC_3047
cis-5-[8-Dimethylamino-1-(2-methoxy-ethyl)-2-oxo-8-phenyl-1,3-



diazaspiro[4.5]decan-3-yl]-4-methoxy-pyrimidine-2-carbonitrile


SC_3048
cis-4-[1-(Cyclobuty1-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-



diazaspiro[4.5]decan-3-yl]-pyrimidine-2-carbonitrile


SC_3049
cis-1-(Cyclobutyl-methyl)-8-dimethylamino-3-(6-methylsulfanyl-pyrimidin-4-yl)-



8-phenyl-1,3-diazaspiro[4.5]decan-2-one


SC_3050
cis-2-[3-(2-Cyano-pyrimidin-4-yl)-8-dimethylamino-2-oxo-8-phenyl-1,3-



diazaspiro[4.5]decan-1-yl]-N,N-dimethyl-acetamide


SC_3051
cis-6-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-



diazaspiro[4.5]decan-3-yl]-pyrimidine-4-carbonitrile


SC_3052
cis-2-(8-Dimethylamino-2-oxo-3,8-diphenyl-1,3-diazaspiro[4.5]decan-1-yl)-N,N-



dimethyl-acetamide


SC_3053
cis-1-(Cyclobutyl-methyl)-8-dimethylamino-3,8-diphenyl-1,3-



diazaspiro[4.5]decan-2-one


SC_3054
cis-2-[8-Dimethylamino-1-(2-methoxy-ethyl)-2-oxo-8-phenyl-1,3-



diazaspiro[4.5]decan-3-yl]-pyrimidine-5-carbonitrile


SC_3055
cis-8-Dimethylamino-1-(2-methoxy-ethyl)-3,8-diphenyl-1,3-diazaspiro[4.5]decan-



2-one


SC_3056
cis-5-[8-Dimethylamino-1-(2-methoxy-ethyl)-2-oxo-8-phenyl-1,3-



diazaspiro[4.5]decan-3-yl]-4-methyl-pyridine-2-carbonitrile


SC_3057
cis-N,N-Dimethyl-2-(8-methylamino-2-oxo-3,8-diphenyl-1,3-diazaspiro[4.5]decan-



1-yl)-acetamide


SC_3058
cis-5-[1-[(1-Cyano-cyclobutyl)-methyl]-8-methylamino-2-oxo-8-phenyl-1,3-



diazaspiro[4.5]decan-3-yl]-pyrimidine-2-carbonitrile


SC_3059
cis-5-[1-[(1-Cyano-cyclobutyl)-methyl]-8-(ethyl-methyl-amino)-2-oxo-8-phenyl-



1,3-diazaspiro[4.5]decan-3-yl]-pyrimidine-2-carbonitrile


SC_3060
cis-4-[8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-2-oxo-8-phenyl-1,3-



diazaspiro[4.5]decan-3-yl]-benzonitrile


SC_3061
cis-3-[8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-2-oxo-8-phenyl-1,3-



diazaspiro[4.5]decan-3-yl]-benzonitrile


SC_3063
cis-5-[1-[(1-Cyano-cyclobutyl)-methyl]-8-dimethylamino-2-oxo-8-phenyl-1,3-



diazaspiro[4.5]decan-3-yl]-pyridine-2-carbonitrile


SC_3064
cis-2-[3-(2-Cyano-pyrimidin-5-yl)-8-dimethylamino-2-oxo-8-phenyl-1,3-



diazaspiro[4.5]decan-1-yl]-N-propyl-acetamide


SC_3065
cis-5-[1-(Cyclobutyl-methyl)-8-(ethyl-methyl-amino)-2-oxo-8-phenyl-1,3-



diazaspiro[4.5]decan-3-yl]-4-methoxy-pyrimidine-2-carbonitrile


SC_3066
cis-4-[1-(Cyclobutyl-methyl)-8-methylamino-2-oxo-8-phenyl-1,3-



diazaspiro[4.5]decan-3-yl]-3-methoxy-benzonitrile


SC_3067
cis-5-[8-Dimethylamino-1-(3-methoxy-propyl)-2-oxo-8-phenyl-1,3-



diazaspiro[4.5]decan-3-yl]-6-methoxy-pyridine-2-carbonitrile


SC_3068
cis-4-[8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-2-oxo-8-phenyl-1,3-



diazaspiro[4.5]decan-3-yl]-benzamide


SC_3069
cis-5-[8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-2-oxo-8-phenyl-1,3-



diazaspiro[4.5]decan-3-yl]-pyridine-2-carbonitrile


SC_3070
cis-5-[8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-2-oxo-8-phenyl-1,3-



diazaspiro[4.5]decan-3-yl]-N-[(1-hydroxy-cyclobutyl)-methyl]-pyridine-2-



carboxylic acid amide


SC_3071
cis-2-[8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-2-oxo-8-phenyl-1,3-



diazaspiro[4.5]decan-3-yl]-benzonitrile


SC_3072
cis-3-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-



diazaspiro[4.5]decan-3-yl]-benzonitrile


SC_3073
cis-1-(Cyclobutyl-methyl)-8-dimethylamino-8-phenyl-3-[2-(trifluoromethyl)-



pyrimidin-5-yl]-1,3-diazaspiro[4.5]decan-2-one


SC_3074
cis-5-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-



diazaspiro[4.5]decan-3-yl]-4-methyl-pyridine-2-carboxylic acid methyl ester


SC_3075
cis-1-(Cyclobutyl-methyl)-8-dimethylamino-3-(5-methoxy-pyrazin-2-yl)-8-phenyl-



1,3-diazaspiro[4.5]decan-2-one


SC_3076
cis-1-(Cyclobutyl-methyl)-8-dimethylamino-3-(2-methoxy-pyrimidin-5-yl)-8-



phenyl-1,3-diazaspiro[4.5]decan-2-one


SC_3077
cis-4-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-



diazaspiro[4.5]decan-3-yl]-benzonitrile


SC_3078
cis-5-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-



diazaspiro[4.5]decan-3-yl]-4-methyl-pyridine-2-carbonitrile


SC_3079
cis-1-(Cyclobutyl-methyl)-8-dimethylamino-3-(5-fluoro-pyrimidin-2-yl)-8-phenyl-



1,3-diazaspiro[4.5]decan-2-one


SC_3080
cis-4-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-



diazaspiro[4.5]decan-3-yl]-3-methoxy-benzonitrile


SC_3081
cis-4-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-



diazaspiro[4.5]decan-3-yl]-benzoic acid methyl ester


SC_3082
cis-1-(Cyclobutyl-methyl)-8-dimethylamino-8-phenyl-3-(2-pyrrolidin-1-yl-



pyrimidin-4-yl)-1,3-diazaspiro[4.5]decan-2-one


SC_3083
cis-1-(Cyclobutyl-methyl)-8-dimethylamino-8-phenyl-3-(5-pyridin-2-yl-thiophen-



2-yl)-1,3-diazaspiro[4.5]decan-2-one


SC_3084
cis-1-(Cyclobutyl-methyl)-8-dimethylamino-3-[2-methylsulfonyl-4-



(trifluoromethyl)-phenyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one


SC_3085
cis-1-(Cyclobutyl-methyl)-8-dimethylamino-8-phenyl-3-[6-(trifluoromethyl)-



pyridin-3-yl]-1,3-diazaspiro[4.5]decan-2-one


SC_3086
cis-1-(Cyclobutyl-methyl)-3-(2,4-dimethoxy-phenyl)-8-dimethylamino-8-phenyl-



1,3-diazaspiro[4.5]decan-2-one


SC_3087
cis-2-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-



diazaspiro[4.5]decan-3-yl]-4-methylsulfonyl-benzonitrile


SC_3088
cis-5-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-



diazaspiro[4.5]decan-3-yl]-2-fluoro-benzonitrile


SC_3089
cis-4-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-



diazaspiro[4.5]decan-3-yl]-N,N-dimethyl-3-(trifluoromethyl)-benzenesulfonic acid



amide


SC_3090
cis-2-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-



diazaspiro[4.5]decan-3-yl]-benzonitrile


SC_3091
cis-1-(Cyclobutyl-methyl)-8-dimethylamino-3-(2-methyl-imidazo[1,2-alpyrazin-6-



yl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one


SC_3092
cis-1-(Cyclobutyl-methyl)-8-dimethylamino-3-(4-methylsulfonyl-phenyl)-8-



phenyl-1,3-diazaspiro[4.5]decan-2-one


SC_3093
cis-2-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-



diazaspiro[4.5]decan-3-yl]-5-methoxy-benzonitrile


SC_3094
cis-1-(Cyclobutyl-methyl)-8-dimethylamino-3,8-diphenyl-1,3-



diazaspiro[4.5]decan-2-one


SC_3096
cis-1-(Cyclobutyl-methyl)-8-dimethylamino-8-pheny1-3-pyrazin-2-yl-1,3-



diazaspiro[4.5]decan-2-one


SC_3097
cis-8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-3-(2-morpholin-4-yl-



pyrimidin-5-yl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one


SC_3098
cis-8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-3-[2-(4-methyl-piperazin-



1-yl)-pyrimidin-5-yl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one


SC_3099
cis-1-[(1-Hydroxy-cyclobutyl)-methyl]-8-methylamino-3-(2-morpholin-4-yl-



pyrimidin-5-yl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one


SC_3100
cis-8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-8-phenyl-3-(2-piperazin-



1-yl-pyrimidin-5-yl)-1,3-diazaspiro[4.5]decan-2-one hydrochloride


SC_3101
cis-1-[(1-Hydroxy-cyclobutyl1)-methyl]-8-methylamino-3-[2-(4-methyl-piperazin-



1-yl)-pyrimidin-5-yl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one


SC_3102
cis-1-[(1-Hydroxy-cyclobutyl)-methyl]-8-methylamino-8-phenyl-3-(2-piperazin-1-



yl-pyrimidin-5-yl)-1,3-diazaspiro[4.5]decan-2-one dihydrochloride


SC_3103
cis-1-(Cyclobutyl-methyl)-8-dimethylamino-3-[4-methyl-6-(trifluoromethyl)-



pyridin-3-yl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one


SC_3104
cis-1-(Cyclobutyl-methyl)-8-methylamino-3-[4-methyl-6-(trifluoromethyl)-pyridin-



3-yl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one


SC_3105
cis-1-(Cyclopropyl-methyl)-8-dimethylamino-3-(4-methylsulfonyl-phenyl)-8-



phenyl-1,3-diazaspiro[4.5]decan-2-one


SC_3106
cis-1-(Cyclopropyl-methyl)-8-methylamino-3-(4-methylsulfonyl-phenyl)-8-phenyl-



1,3-diazaspiro[4.5]decan-2-one


SC_3107
cis-1-(Cyclopropyl-methyl)-8-dimethylamino-3-(2-fluoro-4-methylsulfonyl-



phenyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one


SC_3108
cis-2-[8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-2-oxo-8-phenyl-1,3-



diazaspiro[4.5]decan-3-yl]-benzamide; formic acid


SC_3109
cis-2-[8-Dimethylamino-1-[2-(1-methoxy-cyclobutyl)-ethyl]-2-oxo-8-phenyl-1,3-



diazaspiro[4.5]decan-3-yl]-benzamide


SC_3110
cis-8-Dimethylamino-1-[2-(1-methoxy-cyclobutyl)-ethyl]-3-(2-methyl-pyrimidin-



5-yl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one


SC_3111
cis-5-[1-[(1-Hydroxy-cyclobutyl)-methyl]-8-methylamino-2-oxo-8-pheny1-1,3-



diazaspiro[4.5]decan-3-yl]-pyrimidine-2-carbonitrile


SC_3112
cis-2-[1-[(1-Hydroxy-cyclobutyl)-methyl]-8-methylamino-2-oxo-8-pheny1-1,3-



diazaspiro[4.5]decan-3-yl]-benzonitrile


SC_3113
cis-4-[1-[(1-Hydroxy-cyclobutyl)-methyl]-8-methylamino-2-oxo-8-pheny1-1,3-



diazaspiro[4.5]decan-3-yl]-3-methoxy-benzonitrile


SC_3114
cis-4-[8-Ethy1amino-1-[(1-hydroxy-cyclobutyl)-methyl]-2-oxo-8-phenyl-1,3-



diazaspiro[4.5]decan-3-yl]-3-methoxy-benzonitrile


SC_3115
cis-2-[8-Ethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-2-oxo-8-phenyl-1,3-



diazaspiro[4.5]decan-3-yl]-benzonitrile


SC_3116
cis-5-[1-[(1-Hydroxy-cyclobutyl)-methyl]-8-methylamino-2-oxo-8-pheny1-1,3-



diazaspiro[4.5]decan-3-yl]-4-methoxy-pyrimidine-2-carbonitrile


SC_3117
cis-2-[8-Dimethylamino-1-(oxetan-3-yl-methyl)-2-oxo-8-phenyl-1,3-



diazaspiro[4.5]decan-3-yl]-benzamide


SC_3118
cis-4-Methoxy-5-(8-methylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-



pyrimidine-2-carbonitrile


SC_3119
cis-2-(8-Methylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-benzamide


SC_3120
cis-8-Dimethylamino-3-[2-(3-oxo-piperazin-1-yl)-pyrimidin-5-yl]-8-phenyl-1,3-



diazaspiro[4.5]decan-2-one


SC_3121
cis-3-(2-Cyclopropyl-pyrimidin-5-yl)-8-dimethylamino-8-pheny1-1,3-



diazaspiro[4.5]decan-2-one


SC_3122
cis-8-Dimethylamino-3-[4-methyl-6-(trifluoromethyl)-pyridin-3-yl]-8-phenyl-1,3-



diazaspiro[4.5]decan-2-one


SC_3123
cis-8-Dimethylamino-3-(2-methylsulfonyl-phenyl)-8-phenyl-1,3-



diazaspiro[4.5]decan-2-one


SC_3124
cis-8-Dimethylamino-8-phenyl-3-(2-piperazin-1-yl-pyrimidin-5-yl)-1,3-



diazaspiro[4.5]decan-2-one


SC_3125
trans-2-(8-Ethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-benzamide


SC_3126
cis--2-(8-Ethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-benzamide


SC_3127
cis-2-(8-Ethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-benzamide


SC_3128
cis-2-(8-Ethylamino-2-oxo-8-pheny1-1,3-diazaspiro[4.5]decan-3-yl)-benzamide


SC_3129
cis-3-[5-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-



pyrimidin-2-yl]-benzonitrile


SC_3130
cis-8-Dimethylamino-3-[2-(4-methylsulfonyl-piperazin-1-yl)-pyrimidin-5-yl]-8-



phenyl-1,3-diazaspiro[4.5]decan-2-one


SC_3131
cis-3-[5-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-



pyrimidin-2-yl]-benzamide


SC_3132
cis-8-[(Cyclopropyl-methyl)-methy1-amino]-8-phenyl-3-[2-(trifluoromethyl)-



pyrimidin-5-yl]-1,3-diazaspiro[4.5]decan-2-one


SC_3133
cis-8-Dimethylamino-3-[2-(4-methyl-piperazine-1-carbonyl)-pyrimidin-5-yl]-8-



phenyl-1,3-diazaspiro[4.5]decan-2-one


SC_3134
trans-4-(8-Ethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-3-methoxy-



benzonitrile


SC_3135
cis-4-(8-Ethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-3-methoxy-



benzonitrile


SC_3136
cis-3-[2-(4-Acetyl-piperazin-l-yl)-pyrimidin-5-yl]-8-dimethylamino-8-phenyl-1,3-



diazaspiro[4.5]decan-2-one


SC_3137
cis-8-Dimethylamino-8-phenyl-3-(2-pyridin-4-yl-pyrimidin-5-yl)-1,3-



diazaspiro[4.5]decan-2-one


SC_3138
cis-8-Dimethylamino-8-phenyl-3-(2-pyridin-3-yl-pyrimidin-5-yl)-1,3-



diazaspiro[4.5]decan-2-one


SC_3139
cis-5-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-N-(2-



hydroxy-ethyl)-pyrimidine-2-carboxylic acid amide


SC_3140
cis-5-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)



pyrimidine-2-carboxylic acid amide


SC_3141
cis-8-Dimethylamino-3-[2-morpholin-4-yl-4-(trifluoromethyl)-pyrimidin-5-yl]-8-



phenyl-1,3-diazaspiro[4.5]decan-2-one


SC_3142
cis-4-[5-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-



pyrimidin-2-yl]-benzonitrile


SC_3143
cis-5-(8-Ethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-4-methoxy-



pyrimidine-2-carbonitrile


SC_3144
trans-5-(8-Ethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-4-methoxy-



pyrimidine-2-carbonitrile


SC_3145
cis-8-Dimethylamino-3-[2-(morpholine-4-carbonyl)-pyrimidin-5-yl]-8-phenyl-1,3-



diazaspiro[4.5]decan-2-one


SC_3146
cis-2-[4-[5-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-



pyrimidin-2-yl]-piperazin-1-yl]-acetic acid methyl ester


SC_3147
cis-8-Dimethylamino-3-[2-(methylsulfonyl-methyl)-phenyl]-8-phenyl-1,3-



diazaspiro[4.5]decan-2-one


SC_3148
cis-8-Dimethylamino-3-(4-methyl-2-morpholin-4-yl-pyrimidin-5-yl)-8-phenyl-1,3-



diazaspiro[4.5]decan-2-one


SC_3149
cis-8-Dimethylamino-3-[2-(1,1-dioxo-[1,4]thiazinan-4-yl)-pyrimidin-5-yl]-8-



phenyl-1,3-diazaspiro[4.5]decan-2-one


SC_3150
cis-8-Dimethylamino-3-(4-fluoro-pyridin-3-yl)-8-phenyl-1,3-diazaspiro[4.5]decan-



2-one


SC_3151
cis-5-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-N-(2-



hydroxy-ethyl)-N-methyl-pyrimidine-2-carboxylic acid amide


SC_3152
cis-5-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-2-



morpholin-4-yl-isonicotinonitrile


SC_3153
cis-4-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-benzamide


SC_3154
cis-8-Dimethylamino-3-(2-fluoro-4-methylsulfonyl-phenyl)-8-phenyl-1,3-



diazaspiro[4.5]decan-2-one


SC_3155
cis-4-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-3-fluoro-



benzonitrile


SC_3156
cis-4-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-3,5-



difluoro-benzonitrile


SC_3157
cis-8-Dimethylamino-3-(2-methoxy-pyrimidin-5-yl)-8-phenyl-1,3-



diazaspiro[4.5]decan-2-one


SC_3158
cis-3-[2-(Benzylamino)-pyrimidin-5-yl]-8-dimethylamino-8-phenyl-1,3-



diazaspiro[4.5]decan-2-one


SC_3159
cis-8-Dimethylamino-3-[2-(4-fluorophenyl)-pyrimidin-5-yl]-8-phenyl-1,3-



diazaspiro[4.5]decan-2-one


SC_3160
trans-8-Benzyl-8-dimethylamino-3-(2-morpholin-4-yl-pyrimidin-5-yl)-1,3-



diazaspiro[4.5]decan-2-one


SC_3161
cis-8-Benzyl-8-dimethylamino-3-(2-morpholin-4-yl-pyrimidin-5-yl)-1,3-



diazaspiro[4.5]decan-2-one


SC_3162
cis-8-Dimethylamino-8-phenyl-3-(2-pyridin-2-yl-pyrimidin-5-yl)-1,3-



diazaspiro[4.5]decan-2-one


SC_3163
cis-4-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-3,5-



difluoro-benzamide


SC_3164
cis-4-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-3-fluoro-



benzamide


SC_3165
cis-8-Benzyl-8-dimethylamino-3-[2-(trifluoromethyl)-pyrimidin-5-yl]-1,3-



diazaspiro[4.5]decan-2-one


SC_3166
trans-8-Benzyl-8-dimethylamino-3-[2-(trifluoromethyl)-pyrimidin-5-yl]-1,3-



diazaspiro[4.5]decan-2-one


SC_3167
cis-8-Dimethylamino-8-thiophen-2-yl-3-[2-(trifluoromethyl)-pyrimidin-5-yl]-1,3-



diazaspiro[4.5]decan-2-one


SC_3168
trans-8-Dimethylamino-8-thiophen-2-yl-3-[2-(trifluoromethyl)-pyrimidin-5-yl]-



1,3-diazaspiro[4.5]decan-2-one


SC_3169
cis-2-[2-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)



phenoxy]-acetic acid


SC_3170
cis-8-Dimethylamino-8-phenyl-3-(2-piperidin-1-yl-pyrimidin-5-yl)-1,3-



diazaspiro[4.5]decan-2-one


SC_3171
cis-8-Dimethylamino-8-phenyl-3-(2-pyrrolidin-1-yl-pyrimidin-5-yl)-1,3-



diazaspiro[4.5]decan-2-one


SC_3172
cis-8-Dimethylamino-8-phenyl-3-(2-pyrimidin-5-yl-pyrimidin-5-yl)-1,3-



diazaspiro[4.5]decan-2-one


SC_3173
cis-8-Dimethylamino-8-phenyl-3-[2-(piperazine-1-carbonyl)-pyrimidin-5-yl]-1,3-



diazaspiro[4.5]decan-2-one


SC_3174
trans-8-Benzyl-8-dimethylamino-3-[4-methyl-6-(trifluoromethyl)-pyridin-3-yl]-



1,3-diazaspiro[4.5]decan-2-one


SC_3175
cis-5-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-2-



morpholin-4-yl-pyridine-4-carboxylic acid amide


SC_3176
cis-8-Dimethylamino-3-[2-(3,5-dimethyl-isoxazol-4-yl)-pyrimidin-5-yl]-8-phenyl-



1,3-diazaspiro[4.5]decan-2-one


SC_3177
cis-3-[2-(Benzothiazol-6-yl)-pyrimidin-5-yl]-8-dimethylamino-8-phenyl-1,3-



diazaspiro[4.5]decan-2-one


SC_3178
cis-8-Dimethylamino-3-[2-fluoro-4-(trifluoromethyl)-phenyl]-8-phenyl-1,3-



diazaspiro[4.5]decan-2-one


SC_3179
cis-8-Dimethylamino-3-(6-morpholin-4-yl-pyridin-3-yl)-8-phenyl-1,3-



diazaspiro[4.5]decan-2-one


SC_3180
cis-8-Dimethylamino-8-phenyl-3-(2-phenyl-thiazol-4-yl)-1,3-diazaspiro[4.5[decan-



2-one


SC_3181
cis-8-Dimethylamino-8-phenyl-3-[2-(tetrahydro-pyran-4-ylamino)-pyrimidin-5-yl]-



1,3-diazaspiro[4.5]decan-2-one


SC_3182
cis-8-Dimethylamino-3-[2-(4-hydroxy-piperidin-1-yl)-pyrimidin-5-yl]-8-phenyl-



1,3-diazaspiro[4.5]decan-2-one


SC_3183
cis-8-Dimethylamino-8-phenyl-3-(4-phenyl-thiazol-2-yl)-1,3-diazaspiro[4.5]decan-



2-one


SC_3184
cis-8-Dimethylamino-8-phenyl-3-[2-(1H-pyrrolo[2,3-b]pyridin-1-yl)-pyrimidin-5-



yl]-1,3-diazaspiro[4.5]decan-2-one


SC_3185
cis-8-Dimethylamino-8-phenyl-3-[2-(3,4,5-trifluoro-phenyl)-pyrimidin-5-yl]-1,3-



diazaspiro[4.5]decan-2-one


SC_3186
cis-8-Dimethylamino-3-o-tolyl-8-phenyl-1,3-diazaspiro[4.5]decan-2-one


SC_3187
cis-8-Dimethylamino-3-m-tolyl-8-phenyl-1,3-diazaspiro[4.5]decan-2-one


SC_3188
cis-8-Dimethylamino-8-phenyl-3-p-tolyl-1,3-diazaspiro[4.5]decan-2-one


SC_3189
cis-8-Dimethylamino-8-phenyl-3-[4-(trifluoromethyl)-phenyl]-1,3-



diazaspiro[4.5]decan-2-one


SC_3190
cis-8-Dimethylamino-8-phenyl-3-[3-(trifluoromethyloxy)-phenyl]-1,3-



diazaspiro[4.5]decan-2-one


SC_3191
cis-8-Dimethylamino-8-phenyl-3-[4-(trifluoromethyloxy)-phenyl]-1,3-



diazaspiro[4.5]decan-2-one


SC_3192
cis-2-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-benzoic



acid methyl ester


SC_3193
cis-3-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-benzoic



acid methyl ester


SC_3194
cis-4-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-benzoic



acid methyl ester


SC_3195
cis-3-(1,3-Benzodioxol-5-yl)-8-dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-



2-one


SC_3196
cis-8-Dimethylamino-8-phenyl-3-quinolin-5-yl-1,3-diazaspiro[4.5]decan-2-one


SC_3197
cis-3-(2,3-Dihydro-1H-indol-6-yl)-8-dimethylamino-8-phenyl-1,3-



diazaspiro[4.5]decan-2-one


SC_3198
cis-5-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-4-methyl-



pyridine-2-carboxylic acid methyl ester


SC_3199
cis-8-Dimethylamino-3-(6-methoxy-4-methyl-pyridin-3-yl)-8-phenyl-1,3-



diazaspiro[4.5]decan-2-one


SC_3200
cis-8-Dimethylamino-3-[2-methyl-5-(trifluoromethyl)-2H-pyrazol-3-yl]-8-phenyl-



1,3-diazaspiro[4.5]decan-2-one


SC_3201
cis-8-Dimethylamino-3-(3-methoxy-pyridin-2-yl)-8-phenyl-1,3-



diazaspiro[4.5]decan-2-one


SC_3202
cis-8-Dimethylamino-8-phenyl-3-[5-(trifluoromethyl)-pyridin-2-yl]-1,3-



diazaspiro[4.5]decan-2-one


SC_3203
cis-5-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-



nicotinonitrile


SC_3204
cis-8-Dimethylamino-3-(3-methyl-pyridin-2-yl)-8-phenyl-1,3-



diazaspiro[4.5]decan-2-one


SC_3205
cis-8-Dimethylamino-3-(6-methoxy-pyridin-3-yl)-8-phenyl-1,3-



diazaspiro[4.5]decan-2-one


SC_3206
cis-8-Dimethylamino-8-phenyl-3-[3-(trifluoromethyl)phenyl]-1,3-



diazaspiro[4.5]decan-2-one


SC_3207
cis-3-(1,3-Benzodioxol-4-yl)-8-dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-



2-one


SC_3208
cis-8-Dimethylamino-3-[2-(2-oxo-1,3-dihydro-indol-4-yl)-pyrimidin-5-yl]-8-



phenyl-1,3-diazaspiro[4.5]decan-2-one


SC_3209
cis-8-Dimethylamino-3-[2-(3,5-dimethyl-1H-pyrazol-1-yl)-pyrimidin-5-yl]-8-



phenyl-1,3-diazaspiro[4.5]decan-2-one


SC_3210
cis-8-Dimethylamino-3-[2-(3-hydroxy-piperidin-1-yl)-pyrimidin-5-yl]-8-phenyl-



1,3-diazaspiro[4.5]decan-2-one


SC_3211
cis-8-Dimethylamino-3-[2-(3-hydroxy-piperidin-1-yl)-pyrimidin-5-yl]-8-phenyl-



1,3-diazaspiro[4.5]decan-2-one


SC_3212
cis-8-Dimethylamino-3-[2-[4-(2-hydroxy-ethyl)-piperazin-1-yl]-pyrimidin-5-yl]-8-



phenyl-1,3-diazaspiro[4.5]decan-2-one


SC_3213
cis-2-[4-[5-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-



pyrimidin-2-yl]-piperazin-1-yl]-acetic acid


SC_3214
cis-8-Dimethylamino-3-[2-(1-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl)-pyrimidin-5-



yl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one


SC_3215
cis-8-Benzyl-8-dimethylamino-3-[4-methyl-6-(trifluoromethyl)-pyridin-3-yl]-1,3-



diazaspiro[4.5]decan-2-one


SC_3216
trans-8-Dimethylamino-3-[4-methyl-6-(trifluoromethyl)-pyridin-3-yl]-8-thiophen-



2-yl-1,3-diazaspiro[4.5]decan-2-one


SC_3217
cis-8-Dimethylamino-3-[4-methyl-6-(trifluoromethyl)-pyridin-3-yl]-8-thiophen-2-



y1-1,3-diazaspiro[4.5]decan-2-one


SC_3218
cis-8-Dimethylamino-3-[2-(1,1-dioxo-[1,4]thiazinan-4-yl)-4-(trifluoromethyl)-



pyrimidin-5-yl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one


SC_3219
cis-8-Dimethylamino-8-(1-methyl-1H-benzoimidazol-2-yl)-3-[2-(trifluoromethyl)-



pyrimidin-5-yl]-1,3-diazaspiro[4.5]decan-2-one


SC_3220
cis-8-Dimethylamino-8-(1-methyl-1H-benzoimidazol-2-yl)-3-[4-methyl-6-



(trifluoromethyl)-pyridin-3-yl]-1,3-diazaspiro[4.5]decan-2-one


SC_3221
cis-8-Dimethylamino-3-[2-(2-hydroxy-ethylamino)-pyrimidin-5-yl]-8-phenyl-1,3-



diazaspiro[4.5]decan-2-one


SC_3222
cis-3-[2-(Benzyl-methyl-amino)-pyrimidin-5-yl]-8-dimethylamino-8-phenyl-1,3-



diazaspiro[4.5]decan-2-one


SC_3223
cis-5-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-N-[2-[2-



[2-(2-methoxy-ethoxy)-ethoxy]-ethoxy]-ethyl]-pyrimidine-2-carboxylic acid amide


SC_3224
cis-8-Dimethylamino-3-[2-(1H-indazol-1-yl)-pyrimidin-5-yl]-8-phenyl-1,3



diazaspiro[4.5]decan-2-one


SC_3225
cis-8-Dimethylamino-3-[2-[(2-hydroxy-ethyl)-methyl-amino]-pyrimidin-5-yl]-8-



phenyl-1,3-diazaspiro[4.5]decan-2-one


SC_3226
cis-3-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-benzamide


SC_3227
cis-8-Dimethylamino-3-[3-fluoro-5-(trifluoromethyl)-pyridin-2-yl]-8-phenyl-1,3-



diazaspiro[4.5]decan-2-one


SC_3228
cis-8-Dimethylamino-3-(5-methyl-pyrazin-2-yl)-8-phenyl-1,3-



diazaspiro[4.5]decan-2-one


SC_3229
cis-8-Dimethylamino-3-(5-fluoro-pyrimidin-4-yl)-8-phenyl-1,3-



diazaspiro[4.5]decan-2-one


SC_3230
cis-8-Dimethylamino-3-(5-fluoro-pyrimidin-2-yl)-8-pheny1-1,3-



diazaspiro[4.5]decan-2-one


SC_3231
cis-8-Dimethylamino-8-phenyl-3-pyrazin-2-yl-1,3-diazaspiro[4.5]decan-2-one


SC_3232
cis-3-([2,1,3]Benzoxadiazol-5-yl)-8-dimethylamino-8-phenyl-1,3-



diazaspiro[4.5]decan-2-one


SC_3233
cis-2-[2-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-



phenoxy]-acetamide


SC_3234
cis-8-Dimethylamino-8-phenyl-3-(5-pyridin-4-yl-thiophen-2-yl)-1,3-



diazaspiro[4.5]decan-2-one


SC_3235
cis-2-[2-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-



phenoxy]-acetic acid methyl ester


SC_3236
cis-8-Dimethylamino-3-(2-morpholin-4-yl-pyrimidin-4-yl)-8-phenyl-1,3-



diazaspiro[4.5]decan-2-one


SC_3237
cis-3-[2-(3,4-Difluoro-phenyl)-pyrimidin-5-yl]-8-dimethylamino-8-phenyl-1,3-



diazaspiro[4.5]decan-2-one


SC_3238
cis-2-[5-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-



pyrimidin-2-yl]-benzonitrile


SC_3239
cis-3-(2-Amino-pyrimidin-5-yl)-8-dimethylamino-8-phenyl-1,3-



diazaspiro[4.5]decan-2-one


SC_3240
cis-N-[5-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-



pyrimidin-2-yl]-cyclopropanecarboxylic acid amide


SC_3241
cis-2-[4-[5-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-



pyrimidin-2-yl]-piperazin-1-yl]-acetamide


SC_3242
cis-8-Dimethylamino-8-phenyl-3-(6-piperazin-1-yl-pyridin-3-yl)-1,3-



diazaspiro[4.5]decan-2-one


SC_3243
cis-8-Dimethylamino-3-[6-(4-methyl-piperazin-1-yl)-pyridin-3-yl]-8-phenyl-1,3-



diazaspiro[4.5]decan-2-one


SC_3244
cis-8-Dimethylamino-3-[2-(1,1-dioxo-[1,4]thiazinan-4-yl)-4-methyl-pyrimidin-5-



yl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one


SC_3245
cis-8-Dimethylamino-8-phenyl-3-[2-(trifluoromethyl)-pyrimidin-5-yl]-1,3-



diazaspiro[4.5]decan-2-one


SC_3246
cis-2-[8-Dimethylamino-1-(3-methoxy-propyl)-2-oxo-8-phenyl-1,3-



diazaspiro[4.5]decan-3-yl]-pyrimidine-5-carbonitrile


SC_3247
cis-8-Dimethylamino-3-[2-(4-methyl-piperazin-1-yl)-pyrimidin-5-yl]-8-phenyl-1,3-



diazaspiro[4.5]decan-2-one


SC_3248
cis-8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-8-phenyl-3-[2-



(trifluoromethyl)-pyrimidin-5-yl]-1,3-diazaspiro[4.5]decan-2-one


SC_3249
cis-2-[1-(3-Methoxy-propyl)-8-methylamino-2-oxo-8-phenyl-1,3-



diazaspiro[4.5]decan-3-yl]-pyrimidine-5-carbonitrile


SC_3250
cis-8-Dimethylamino-8-phenyl-3-[6-(trifluoromethyl)-pyridin-3-yl]-1,3-



diazaspiro[4.5]decan-2-one


SC_3251
cis-5-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-pyridine-



2-carbonitrile


SC_3252
cis-8-Dimethylamino-3-(2-morpholin-4-yl-pyrimidin-5-yl)-8-phenyl-1,3-



diazaspiro[4.5]decan-2-one


SC_3253
cis-8-Dimethylamino-3-(2-methyl-pyrimidin-5-yl)-8-phenyl-1,3-



diazaspiro[4.5]decan-2-one


SC_3254
cis-8-Dimethylamino-1-[(2-methoxyphenyl)-methyl]-3-(2-methyl-pyrimidin-5-yl)-



8-phenyl-1,3-diazaspiro[4.5]decan-2-one


SC_3255
cis-1-[(1-Hydroxy-cyclobutyl)-methyl]-8-methylamino-8-phenyl-3-[2-



(trifluoromethyl)-pyrimidin-5-yl]-1,3-diazaspiro[4.5]decan-2-one


SC_3256
cis-8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-3-(2-methyl-pyrimidin-5-



yl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one


SC_3257
cis-1-[(1-Hydroxy-cyclobutyl)-methyl]-8-methylamino-8-phenyl-3-pyrimidin-5-yl



1,3-diazaspiro[4.5]decan-2-one


SC_3258
cis-5-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-4-methyl-



pyridine-2-carbonitrile


SC_3259
cis-8-Dimethylamino-3-(2-methyl-pyrimidin-5-yl)-8-phenyl-1-(pyridin-2-yl-



methyl)-1,3-diazaspiro[4.5]decan-2-one


SC_3260
cis-8-Dimethylamino-8-phenyl-3-pyrimidin-5-yl-1,3-diazaspiro[4.5]decan-2-



one


SC_3261
cis-8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-8-phenyl-3-pyrimidin-5-



yl-1,3-diazaspiro[4.5]decan-2-one


SC_3262
cis-8-Amino-1-[(1-hydroxy-cyclobutyl)-methyl]-8-phenyl-3-[2-(trifluoromethyl)-



pyrimidin-5-yl]-1,3-diazaspiro[4.5]decan-2-one


SC_3263
cis-8-Dimethylamino-3-(3-fluorophenyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one


SC_3264
cis-8-Dimethylamino-3-(3-methylsulfonyl-phenyl)-8-phenyl-1,3-



diazaspiro[4.5]decan-2-one


SC_3265
cis-8-Dimethylamino-3-(4-methylsulfonyl-phenyl)-8-phenyl-1,3-



diazaspiro[4.5]decan-2-one


SC_3266
cis-8-Dimethylamino-8-phenyl-3-pyridazin-3-yl-1,3-diazaspiro[4.5]decan-2-one


SC_3267
cis-3-Methoxy-4-(8-methylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-



benzonitrile


SC_3268
cis-8-Dimethylamino-3-(2-fluorophenyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one


SC_3269
cis-8-Dimethylamino-8-phenyl-3-(2-phenyl-pyrimidin-5-yl)-1,3-



diazaspiro[4.5]decan-2-one


SC_3270
cis-8-Methylamino-1-(oxetan-3-yl-methyl)-8-phenyl-3-[2-(trifluoromethyl)-



pyrimidin-5-yl]-1,3-diazaspiro[4.5]decan-2-one


SC_3271
cis-1-(Cyclopropyl-methyl)-8-methylamino-8-phenyl-3-[2-(trifluoromethyl)-



pyrimidin-5-yl]-1,3-diazaspiro[4.5]decan-2-one


SC_3272
cis-4-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-



benzonitrile


SC_3273
cis-8-Dimethylamino-3-(4-fluorophenyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one


SC_3274
cis-2-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-



benzonitrile


SC_3275
cis-8-Ethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-8-phenyl-3-[2-



(trifluoromethyl)-pyrimidin-5-yl]-1,3-diazaspiro[4.5]decan-2-one


SC_3276
cis-1-[(1-Hydroxy-cyclobutyl)-methyl]-8-methylamino-3-(2-methyl-pyrimidin-5-



yl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one


SC_3277
cis-8-Dimethylamino-3-[2-(morpholin-4-yl-methyl)-pyrimidin-5-yl]-8-phenyl-1,3-



diazaspiro[4.5]decan-2-one


SC_3278
cis-8-Dimethylamino-3-[2-(methyl-tetrahydro-pyran-4-yl-amino)-pyrimidin-5-yl]-



8-phenyl-1,3-diazaspiro[4.5]decan-2-one


SC_3279
cis-5-[8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-2-oxo-8-phenyl-1,3-



diazaspiro[4.5]decan-3-yl]-N-[2-[2-[2-(2-methoxy-ethoxy)-ethoxyl-ethoxy]-ethyl]-



pyrimidine-2-carboxylic acid amide


SC_3280
cis-1-(Cyclopropyl-methyl)-3-(2-fluoro-4-methylsulfonyl-phenyl)-8-methylamino-



8-phenyl-1,3-diazaspiro[4.5]decan-2-one


SC_3281
cis-2-[[5-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-



pyrimidin-2-yl]-methyl-aminol-acetamide


SC_3282
cis-2-[[5-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-



pyrimidin-2-yl]amino]-acetamide


SC_3283
cis-1-(Cyclopropyl-methyl)-8-methylamino-3-[4-methyl-6-(trifluoromethyl)-



pyridin-3-yl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one


SC_3284
cis-1-(Cyclopropyl-methyl)-8-dimethylamino-3-[4-methyl-6-(trifluoromethyl)-



pyridin-3-yl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one


SC_3285
cis-N-[5-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-



pyrimidin-2-yl]-thiophene-2-carboxylic acid amide


SC_3286
cis-N-[5-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-



pyrimidin-2-yl]-benzamide


SC_3287
cis-8-Dimethylamino-8-phenyl-3-(5-phenyl-thiophen-2-yl)-1,3-



diazaspiro[4.5]decan-2-one


SC_3288
cis-1-(Cyclopropyl-methyl)-8-methylamino-3-[2-(methylsulfonyl-methyl)-



phenyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one


SC_3289
cis-1-(Cyclopropyl-methyl)-8-dimethylamino-3-[2-(methylsulfonyl-methyl)-phenyl]-



8-phenyl-1,3-diazaspiro[4.5]decan-2-one


SC_3290
cis-8-Dimethylamino-8-(3-fluorophenyl)-3-[2-(methylsulfonyl-methyl)-phenyl]-



1,3-diazaspiro[4.5]decan-2-one


SC_3291
cis-8-Dimethylamino-8-(4-fluorophenyl)-3-[2-(methylsulfonyl-methyl)-phenyl]-



1,3-diazaspiro[4.5]decan-2-one


SC_3292
cis-8-[Methyl-(tetrahydro-furan-3-yl-methyl)-amino]-8-phenyl-3-[2-



(trifluoromethyl)-pyrimidin-5-yl]-1,3-diazaspiro[4.5]decan-2-one (enantiomer 1)


SC_3293
cis-8-[Methyl-(tetrahydro-furan-3-yl-methyl)-amino]-8-phenyl-3-[2-



(trifluoromethyl)-pyrimidin-5-yl]-1,3-diazaspiro[4.5]decan-2-one (enantiomer 2)


SC_3294
cis-8-Dimethylamino-8-(3-fluorophenyl)-3-(4-methyl-2-morpholin-4-yl-pyrimidin-



5-yl)-1,3-diazaspiro[4.5]decan-2-one


SC_3295
cis-3-[6-(4-Acetyl-piperazin-1-yl)-4-methyl-pyridin-3-yl]-8-dimethylamino-8-



phenyl-1,3-diazaspiro[4.5]decan-2-one


SC_3296
cis-3-[2-(4-Acetyl-piperazin-1-yl)-4-methyl-pyrimidin-5-yl]-8-dimethylamino-8-



phenyl-1,3-diazaspiro[4.5]decan-2-one


SC_3297
cis-8-Dimethylamino-3-(4-methyl-6-pyridin-4-yl-pyridin-3-yl)-8-phenyl-1,3-



diazaspiro[4.5]decan-2-one


SC_3298
cis-3-[2-(4-Acetyl-piperazin-1-yl)-4-(trifluoromethyl)-pyrimidin-5-yl]-8-



dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one


SC_3299
cis-8-Dimethylamino-3-[2-(3-oxo-piperazin-1-yl)-4-(trifluoromethyl)-pyrimidin-5-



yl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one


SC_3300
cis-8-Dimethylamino-3-isoquinolin-4-yl-8-phenyl-1,3-diazaspiro[4.5]decan-2-one


SC_3301
cis-8-Dimethylamino-3-isoquinolin-5-yl-8-phenyl-1,3-diazaspiro[4.5]decan-2-one


SC_3302
cis-8-Dimethylamino-8-phenyl-3-(1H-pyrrolo[2,3-b]pyridin-4-yl)-1,3-



diazaspiro[4.5]decan-2-one


SC_3303
cis-8-Dimethylamino-8-phenyl-3-(2-pyridin-4-yl-thiazol-4-yl)-1,3-



diazaspiro[4.5]decan-2-one


SC_3304
cis-8-[Methyl-(tetrahydro-furan-3-yl-methyl)-amino]-3-(2-morpholin-4-yl-



pyrimidin-5-yl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (enantiomer 1)


SC_3305
cis-8-[Methyl-(tetrahydro-furan-3-yl-methyl)-amino]-3-(2-morpholin-4-yl-



pyrimidin-5-yl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (enantiomer 2)


SC_3306
cis-3-[2-(Azetidin-1-yl)-pyrimidin-5-yl]-8-dimethylamino-8-phenyl-1,3-



diazaspiro[4.5]decan-2-one


SC_3307
cis-3-[2-(3,3-Difluoro-azetidin-1-yl)-pyrimidin-5-yl]-8-dimethylamino-8-phenyl-



1,3-diazaspiro[4.5]decan-2-one


SC_3308
cis-8-Dimethylamino-3-[6-morpholin-4-yl-5-(trifluoromethyl)-pyridin-3-yl]-8-



phenyl-1,3-diazaspiro[4.5]decan-2-one


SC_3309
cis-8-Methylamino-3-[6-morpholin-4-yl-5-(trifluoromethyl)-pyridin-3-yl]-8-



phenyl-1,3-diazaspiro[4.5]decan-2-one


SC_3310
cis-8-Dimethylamino-8-phenyl-3-[5-(trifluoromethyloxy)-pyridin-2-yl]-1,3-



diazaspiro[4.5]decan-2-one


SC_3311
cis-8-Dimethylamino-3-(5-methylsulfonyl-pyridin-2-yl)-8-phenyl-1,3-



diazaspiro[4.5]decan-2-one


SC_3312
cis-6-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-



nicotinonitrile


SC_3313
cis-3-[2-(4-Cyclopropyl-1H-[1,2,3]triazol-1-yl)-pyrimidin-5-yl]-8-dimethylamino-



8-phenyl-1,3-diazaspiro[4.5]decan-2-one


SC_3314
cis-8-Dimethylamino-3-[4-methyl-2-(3-oxo-piperazin-1-yl)-pyrimidin-5-yl]-8-



phenyl-1,3-diazaspiro[4.5]decan-2-one


SC_3315
cis-5-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-pyridine-



2-carboxylic acid amide


SC_3316
cis-3-[4-(Azetidin-1-yl)-2-methyl-pyrimidin-5-yl]-8-dimethylamino-8-phenyl-1,3-



diazaspiro[4.5]decan-2-one


SC_3317
cis-2-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-benzamide


SC_3318
cis-8-Dimethylamino-3-[2-(methylsulfonyl-methyl)-phenyl]-8-thiophen-2-yl-1,3-



diazaspiro[4.5]decan-2-one


SC_3319
cis-8-Dimethylamino-8-(3-fluorophenyl)-3-[2-methyl-5-(trifluoromethyl)-2H-



pyrazol-3-yl]-1,3-diazaspiro[4.5]decan-2-one


SC_3320
cis-8-Dimethylamino-3-(4-methyl-2-morpholin-4-yl-pyrimidin-5-yl)-8-thiophen-2-



yl-1,3-diazaspiro[4.5]decan-2-one


SC_3321
cis-8-Dimethylamino-3-(6-methylsulfonyl-pyridin-3-yl)-8-phenyl-1,3-



diazaspiro[4.5]decan-2-one


SC_3322
cis-8-Dimethylamino-8-phenyl-3-(1H-pyrrolo[2,3-b]pyridin-5-yl)-1,3-



diazaspiro[4.5]decan-2-one


SC_3323
cis-N-[5-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-



pyrimidin-2-yl]-acetamide


SC_3324
cis-3-[2-(4-Methyl-piperazin-1-yl)-pyrimidin-5-yl]-8-[methyl-(tetrahydro-furan-3-



yl-methyl)-amino]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (enantiomer 1)


SC_3325
cis-3-[2-(4-Methyl-piperazin-1-yl)-pyrimidin-5-yl]-8-[methyl-(tetrahydro-furan-3-



yl-methyl)-amino]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (enantiomer 2)


SC_3326
cis-8-Dimethylamino-3-(4,6-dimethyl-2-morpholin-4-yl-pyrimidin-5-yl)-8-phenyl-



1,3-diazaspiro[4.5]decan-2-one


SC_3327
cis-8-Dimethylamino-3-(2-morpholin-4-yl-pyrimidin-5-yl)-8-thiophen-2-yl-1,3-



diazaspiro[4.5]decan-2-one


SC_3328
cis-6-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-pyridine-



3-carboxylic acid amide


SC_3329
cis-8-Dimethylamino-3-[2-methyl-5-(trifluoromethyl)-2H-pyrazol-3-yl]-8-



thiophen-2-yl-1,3-diazaspiro[4.5]decan-2-one


SC_3330
cis-8-Dimethylamino-3-[2-[(2-hydroxy-ethyl)-methyl-amino]-pyrimidin-5-yl]-8-



thiophen-2-yl-1,3-diazaspiro[4.5]decan-2-one


SC_3331
cis-8-Dimethylamino-3-[2-(2-oxo-1,3-dihydro-indol-4-yl)-pyrimidin-5-yl]-8-



thiophen-2-yl-1,3-diazaspiro[4.5]decan-2-one


SC_3332
cis-8-Dimethylamino-3-[4-methyl-6-(3-oxo-piperazin-1-yl)-pyridin-3-yl]-8-phenyl-



1,3-diazaspiro[4.5]decan-2-one


SC_3333
cis-8-Dimethylamino-3-(4-methyl-6-pyridin-2-yl-pyridin-3-yl)-8-phenyl-1,3-



diazaspiro[4.5]decan-2-one


SC_3334
cis-8-Dimethylamino-3-(4-methylsulfonyl-pyridin-3-yl)-8-phenyl-1,3-



diazaspiro[4.5]decan-2-one


SC_3335
cis-3-(Benzothiazol-7-yl)-8-dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-



one


SC_3336
cis-8-Dimethylamino-8-(4-fluorophenyl)-3-(4-methyl-2-morpholin-4-yl-pyrimidin-



5-yl)-1,3-diazaspiro[4.5]decan-2-one


SC_3337
cis-2-[8-Dimethylamino-3-[4-methyl-6-(trifluoromethyl)-pyridin-3-yl]-2-oxo-8-



phenyl-1,3-diazaspiro[4.5]decan-1-yl]-N,N-dimethyl-acetamide


SC_3338
cis-8-Dimethylamino-3-[2-(2-methyl-1-oxo-2,3-dihydro-isoindol-4-yl)-pyrimidin-



5-yl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one


SC_3339
cis-2-[[5-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-2-



methyl-pyrimidin-4-yl]amino]-acetamide


SC_3340
cis-2-[3-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-pyridin-



4-yl]-acetamide


SC_3341
cis-8-Dimethylamino-3-[4-(methylsulfonyl-methyl)-pyridin-3-yl]-8-phenyl-1,3-



diazaspiro[4.5]decan-2-one


SC_3342
cis-8-Dimethylamino-3-[6-(4-methyl-3-oxo-piperazin-1-yl)-pyridin-3-yl]-8-phenyl-



1,3-diazaspiro[4.5]decan-2-one


SC_3343
cis-8-Dimethylamino-3-(2,4-dimethyl-pyrimidin-5-yl)-8-phenyl-1,3-



diazaspiro[4.5]decan-2-one


SC_3344
cis-8-Dimethylamino-3-[2-(1-oxo-2,3-dihydro-isoindol-4-yl)-pyrimidin-5-yl]-8-



phenyl-1,3-diazaspiro[4.5]decan-2-one; 2,2,2-trifluoro-acetic acid


SC_3345
cis-8-Dimethylamino-3-[6-[(2-hydroxy-ethyl)-methyl-amino]-5-(trifluoromethyl)-



pyridin-3-yl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one


SC_3346
cis-8-Dimethylamino-8-phenyl-3-[2-[4-(trifluoromethyl)-1H-[1,2,3]triazol-1-yl]-



pyrimidin-5-yl]-1,3-diazaspiro[4.5]decan-2-one


SC_3347
cis-8-Dimethylamino-3-[2-(4-isopropyl-1H-[1,2,3]triazol-1-yl)-pyrimidin-5-yl]-8-



phenyl-1,3-diazaspiro[4.5]decan-2-one


SC_3348
cis-8-Dimethylamino-3-[6-(1,1-dioxo-[1,4]thiazinan-4-yl)-pyridin-3-yl]-8-phenyl-



1,3-diazaspiro[4.5]decan-2-one


SC_3349
cis-5-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-2-



morpholin-4-yl-nicotinonitrile


SC_3350
cis-8-Dimethylamino-3-(1-methylsulfonyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-8-



phenyl-1,3-diazaspiro[4.5]decan-2-one


SC_3351
cis-8-Dimethylamino-3-(1H-indol-4-yl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one


SC_3352
cis-8-Dimethylamino-3-(2-hydroxy-benzooxazol-7-yl)-8-phenyl-1,3



diazaspiro[4.5]decan-2-one


SC_3353
cis-8-Dimethylamino-3-[2-fluoro-4-(trifluoromethyloxy)-phenyl]-8-phenyl-1,3-



diazaspiro[4.5]decan-2-one


SC_3354
cis-4-[5-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-



pyrimidin-2-yl]-benzamide; 2,2,2-trifluoro-acetic acid


SC_3355
cis-8-Dimethylamino-3-(1-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl)-8-phenyl-1,3-



diazaspiro[4.5]decan-2-one


SC_3356
cis-3-(1-Acetyl-1H-indol-4-yl)-8-dimethylamino-8-phenyl-1,3-



diazaspiro[4.5]decan-2-one


SC_3357
cis-8-Dimethylamino-3-(1H-indol-3-yl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one


SC_3358
cis-6-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-5-methyl



nicotinonitrile


SC_3359
cis-6-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-5-fluoro



nicotinonitrile


SC_3360
cis-8-Dimethylamino-3-[4-methyl-6-(trifluoromethyl)-pyridin-3-yl]-1-(2-oxo-2-



pyrrolidin-1-yl-ethyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one


SC_3361
cis-6-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-5-methyl



pyridine-3-carboxylic acid amide


SC_3362
cis-6-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-5-fluoro-



pyridine-3-carboxylic acid amide


SC_3363
cis-8-Dimethylamino-3-[4-methyl-6-(trifluoromethyl)-pyridin-3-yl]-8-m-tolyl-1,3-



diazaspiro[4.5]decan-2-one


SC_3364
cis-3-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-



isonicotinonitrile


SC_3365
cis-8-Dimethylamino-3-[3-fluoro-5-(2-oxo-1,3-dihydro-indol-4-yl)-pyridin-2-yl]-8-



phenyl-1,3-diazaspiro[4.5]decan-2-one


SC_3366
cis-8-Dimethylamino-3-[4-methyl-6-(trifluoromethyl)-pyridin-3-yl]-8-[3 -



(trifluoromethyloxy)-phenyl]-1,3-diazaspiro[4.5]decan-2-one


SC_3367
cis-8-Dimethylamino-3-[4-methyl-6-(trifluoromethyl)-pyridin-3-yl]-8-[3-



(trifluoromethyl)phenyl]-1,3-diazaspiro[4.5]decan-2-one


SC_3368
cis-8-Dimethylamino-8-(3-methoxyphenyl)-3-[4-methyl-6-(trifluoromethyl)-



pyridin-3-yl]-1,3-diazaspiro[4.5]decan-2-one


SC_3369
cis-8-(5-Chloro-thiophen-2-yl)-8-dimethylamino-3-[4-methyl-6-(trifluoromethyl)-



pyridin-3-yl]-1,3-diazaspiro[4.5]decan-2-one


SC_3370
cis-8-Dimethylamino-8-(3-fluorophenyl)-3-[4-methyl-6-(trifluoromethyl)-pyridin-



3-yl]-1,3-diazaspiro[4.5]decan-2-one


SC_3371
cis-8-Dimethylamino-3-(2-methylamino-pyrimidin-5-yl)-8-phenyl-1,3-



diazaspiro[4.5]decan-2-one


SC_3372
cis-8-(5-Chloro-thiophen-2-yl)-8-dimethylamino-3-(4-methyl-2-morpholin-4-yl-



pyrimidin-5-yl)-1,3-diazaspiro[4.5]decan-2-one


SC_3373
cis-N-[5-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-



pyrimidin-2-yl]-N-methyl-cyclopropanecarboxylic acid amide


SC_3374
cis-N-[5-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-



pyrimidin-2-yl]-N,2,5-trimethyl-2H-pyrazole-3-carboxylic acid amide


SC_3375
cis-3-[4,6-Bis(trifluoromethyl)-pyridin-3-yl]-8-dimethylamino-8-phenyl-1,3-



diazaspiro[4.5]decan-2-one


SC_3376
cis-8-Dimethylamino-3-[2-[(2-hydroxy-ethyl)-methyl-amino]-quinazolin-6-yl]-8-



phenyl-1,3-diazaspiro[4.5]decan-2-one


SC_3377
cis-8-Dimethylamino-3-(2-morpholin-4-yl-quinazolin-6-yl)-8-phenyl-1,3-



diazaspiro[4.5]decan-2-one


SC_3378
cis-8-[Methyl-(oxetan-3-yl-methyl)-amino]-8-phenyl-3-[2-(trifluoromethyl)-



pyrimidin-5-yl]-1,3-diazaspiro[4.5]decan-2-one


SC_3379
cis-3-(1-Acetyl-1H-indol-3-yl)-8-dimethylamino-8-phenyl-1,3-



diazaspiro[4.5]decan-2-one


SC_3380
cis-8-Dimethylamino-8-phenyl-3-quinazolin-6-yl-1,3-diazaspiro[4.5]decan-2-one


SC_3381
cis-5-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-2-(2-oxo-



1,3-dihydro-indol-4-yl)-isonicotinonitrile


SC_3382
cis-N-[5-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-



pyrimidin-2-yl]-N-methyl-tetrahydro-pyran-4-carboxylic acid amide


SC_3383
cis-N-[5-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-



pyrimidin-2-yl]-N,2,2-trimethyl-propionamide


SC_3384
cis-8-Dimethylamino-3-[2-(1-methyl-2-oxo-1,3-dihydro-indol-4-yl)-pyrimidin-5-



yl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one


SC_3385
cis-8-Dimethylamino-3-(2-morpholin-4-yl-1H-benzoimidazol-5-yl)-8-phenyl-1,3-



diazaspiro[4.5]decan-2-one


SC_3386
cis-8-Dimethylamino-8-(3-fluoro-5-methyl-phenyl)-3-[4-methyl-6-



(trifluoromethyl)-pyridin-3-yl]-1,3-diazaspiro[4.5]decan-2-one


SC_3387
cis-8-Dimethylamino-3-[6-(2-oxo-1,3-dihydro-indol-4-yl)-pyridin-3-yl]-8-phenyl-



1,3-diazaspiro[4.5]decan-2-one


SC_3388
cis-8-Dimethylamino-8-(3-hydroxyphenyl)-3-[4-methyl-6-(trifluoromethyl)-



pyridin-3-yl]-1,3-diazaspiro[4.5]decan-2-one


SC_3389
cis-3-[6-(Azetidin-1-yl)-5-(trifluoromethyl)-pyridin-3-yl]-8-dimethylamino-8-



phenyl-1,3-diazaspiro[4.5]decan-2-one


SC_3390
cis-3-[1-(Cyclopropyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-



diazaspiro[4.5]decan-3-yl]-isonicotinonitrile


SC_3391
cis-3-[3,5-Bis(trifluoromethyl)-pyridin-2-yl]-8-dimethylamino-8-phenyl-1,3-



diazaspiro[4.5]decan-2-one


SC_3392
cis-8-Dimethylamino-3-(5-fluoro-6-morpholin-4-yl-pyridin-3-yl)-8-phenyl-1,3-



diazaspiro[4.5]decan-2-one


SC_3393
cis-8-(3-Chlorophenyl)-8-dimethylamino-3-[4-methyl-6-(trifluoromethyl)-pyridin-



3-yl]-1,3-diazaspiro[4.5]decan-2-one


SC_3394
cis-8-Dimethylamino-3-[5-(2-oxo-1,3-dihydro-indol-4-yl)-pyridin-2-yl]-8-phenyl-



1,3-diazaspiro[4.5]decan-2-one


SC_3395
cis-8-Dimethylamino-8-phenyl-3-[5-(trifluoromethyl)-[1,3,4]thiadiazol-2-yl]-1,3-



diazaspiro[4.5]decan-2-one


SC_3396
cis-8-Dimethylamino-3-(2-oxo-1,3-dihydro-indol-4-yl)-8-phenyl-1,3-



diazaspiro[4.5]decan-2-one


SC_3397
cis-8-Dimethylamino-3-[2-[(2-hydroxy-ethyl)-methyl-amino]-1H-benzoimidazol-



5-yl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one


SC_3398
cis-8-Dimethylamino-3-(5-methyl-6-morpholin-4-yl-pyridin-3-yl)-8-phenyl-1,3-



diazaspiro[4.5]decan-2-one


SC_3399
cis-1-(Cyclopropyl-methyl)-8-dimethylamino-8-(3-fluorophenyl)-3-(5-



methylsulfonyl-pyridin-2-yl)-1,3-diazaspiro[4.5]decan-2-one


SC_3400
cis-1-(Cyclopropyl-methyl)-8-(3-fluorophenyl)-8-methylamino-3-(5-



methylsulfonyl-pyridin-2-yl)-1,3-diazaspiro[4.5]decan-2-one


SC_3401
cis-1-(Cyclobutyl-methyl)-8-(3-fluorophenyl)-8-methylamino-3-[2-



(trifluoromethyl)-pyrimidin-5-yl]-1,3-diazaspiro[4.5]decan-2-one


SC_3402
cis-1-(Cyclopropyl-methyl)-8-dimethylamino-8-(3-fluorophenyl)-3-[2-



(trifluoromethyl)-pyrimidin-5-yl]-1,3-diazaspiro[4.5]decan-2-one


SC_3403
cis-1-(Cyclopropyl-methyl)-8-(3-fluorophenyl)-8-methylamino-3-[2-



(trifluoromethyl)-pyrimidin-5-yl]-1,3-diazaspiro[4.5]decan-2-one


SC_3404
cis-8-Dimethylamino-8-(3-fluorophenyl)-3-[2-(trifluoromethyl)-pyrimidin-5-yl]-



1,3-diazaspiro[4.5]decan-2-one


SC_3405
cis-1-(Cyclopropyl-methyl)-8-dimethylamino-8-(3-fluorophenyl)-3-[2-methyl-5-



(trifluoromethyl)-2H-pyrazol-3-yl]-1,3-diazaspiro[4.5]decan-2-one


SC_3406
cis-1-(Cyclopropyl-methyl)-8-(3-fluorophenyl)-8-methylamino-3-[2-methyl-5-



(trifluoromethyl)-2H-pyrazol-3-yl]1-1,3-diazaspiro[4.5]decan-2-one


SC_3407
cis-8-Methylamino-3-(4-methyl-2-morpholin-4-yl-pyrimidin-5-yl)-8-phenyl-1,3-



diazaspiro[4.5]decan-2-one


SC_3408
cis-3-[5-(Azetidin-1-yl)-3-methyl-pyridin-2-yl]-8-dimethylamino-8-(3-



fluorophenyl)-1,3-diazaspiro[4.5]decan-2-one


SC_3409
cis-8-Dimethylamino-8-(3-fluorophenyl)-3-(5-methylsulfonyl-pyridin-2-yl)-1,3-



diazaspiro[4.5]decan-2-one


SC_3410
cis-3-(6-(azetidin-1-yl)-4-fluoropyridin-3-yl)-8-(dimethylamino)-8-phenyl-1,3-



diazaspiro[4.5]decan-2-one


SC_3411
cis-3-(6-(azetidin-1-yl)pyridin-3-yl)-8-(dimethylamino)-8-(3-fluorophenyl)-1,3-



diazaspiro[4.5]decan-2-one


SC_3412
cis-3-(1-(cyclopropanecarbonyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl)-8-



(dimethylamino)-8-(3-fluorophenyl)-1,3-diazaspiro[4.5]decan-2-one


SC_3413
cis-8-(dimethylamino)-8-(3-fluorophenyl)-3-(1-(2-hydroxyethyl)-3-



(trifluoromethyl)-1H-pyrazol-5-yl)-1,3-diazaspiro[4.5]decan-2-one


SC_3414
cis-3-(1-(cyclopropylmethyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl)-8-



(dimethylamino)-8-(3-fluorophenyl)-1,3-diazaspiro[4.5]decan-2-one


SC_3415
cis-8-(dimethylamino)-8-(3-fluorophenyl)-3-(1-(methylsulfonyl)-3-



(trifluoromethyl)-1H-pyrazol-5-yl)-1,3-diazaspiro[4.5]decan-2-one


SC_3416
cis-1-(cyclopropylmethyl)-8-(dimethylamino)-8-(3-fluorophenyl)-3-(1-



(methylsulfonyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl)-1,3-diazaspiro[4.5]decan-



2-one


SC_3417
cis-2-(5-(8-(dimethylamino)-8-(3-fluorophenyl)-2-oxo-1,3-diazaspiro[4.5]decan-



3-yl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)-N,N-dimethylacetamide


SC_3418
cis-2-(5-(1-(cyclopropylmethyl)-8-(dimethylamino)-8-(3-fluorophenyl)-2-oxo-1,3-



diazaspiro[4.5]decan-3-yl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)-N,N-



dimethylacetamide


SC_3419
cis-8-(dimethylamino)-3-(1-methyl1-1H-pyrrolo[2,3-b]pyridin-5-yl)-8-phenyl-1,3-



diazaspiro[4.5]decan-2-one


SC_3420
cis-8-(dimethylamino)-3-(3-fluoro-1H-pyrrolo[2,3-b]pyridin-5-yl)-8-phenyl-1,3-



diazaspiro[4.5]decan-2-one


SC_3421
cis-8-(dimethylamino)-8-phenyl-3-(1H-pyrrolo[2,3-c]pyridin-4-yl)-1,3-



diazaspiro[4.5]decan-2-one


SC_3422
cis-8-(dimethylamino)-8-phenyl-3-(2-(pyridazin-4-yl)pyrimidin-5-yl)-1,3-



diazaspiro[4.5]decan-2-one


SC_3423
cis-8-(dimethylamino)-3-(2-(2-oxo-1,2-dihydropyridin-4-yl)pyrimidin-5-yl)-8-



phenyl-1,3-diazaspiro[4.5]decan-2-one


SC_3424
cis-8-(dimethylamino)-8-(3-fluorophenyl)-3-(1-methyl-3-(thiophen-2-yl)-1H-



pyrazol-5-yl)-1,3-diazaspiro[4.5]decan-2-one


SC_3425
cis-8-(dimethylamino)-8-(3-fluorophenyl)-3-(1-methyl-3-morpholino-1H-pyrazol-



5-yl)-1,3-diazaspiro[4.5]decan-2-one


SC_3426
cis-8-(dimethylamino)-8-phenyl-1-(2,2,2-trifluoroethyl)-3-(2-



(trifluoromethyl)pyrimidin-5-yl)-1,3-diazaspiro[4.5]decan-2-one


SC_3427
cis-8-(dimethylamino)-8-phenyl-3-(2-(trifluoromethyl)pyrimidin-5-yl)-1-(3,3,3-



trifluoropropyl)-1,3-diazaspiro[4.5]decan-2-one


SC_3428
cis-3-(4-methyl-6-(trifluoromethyl)pyridin-3-yl)-8-(methylamino)-8-phenyl-1,3-



diazaspiro[4.5]decan-2-one


SC_3429
cis-3-(1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl)-8-(methylamino)-8-phenyl-



1,3-diazaspiro[4.5]decan-2-one


SC_3430
cis-8-(dimethylamino)-8-(3-fluorophenyl)-3-(4-(methylsulfonyl)pyridin-3-yl)-1,3-



diazaspiro[4.5]decan-2-one


SC_3431
cis-8-(dimethylamino)-3-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-5-yl)-8-(3 -



fluorophenyl)-1,3-diazaspiro[4.5]decan-2-one


SC_3432
cis-3-(1-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-5-yl)-8-(dimethylamino)-8-(3-



fluorophenyl)-1,3-diazaspiro[4.5]decan-2-one


SC_3433
cis-8-(dimethylamino)-8-(3-fluorophenyl)-3-(1-(oxetan-3-ylmethyl)-3-



(trifluoromethyl)-1H-pyrazol-5-yl)-1,3-diazaspiro[4.5]decan-2-one


SC_3434
cis-8-(dimethylamino)-8-(3-fluorophenyl)-3-(1-(2-(methylsulfonyl)ethyl)-3-



(trifluoromethyl)-1H-pyrazol-5-yl)-1,3-diazaspiro[4.5]decan-2-one


SC_3435
cis-8-(dimethylamino)-8-(3-fluorophenyl)-3-(4-methyl-2-(methylamino)pyrimidin-



5-yl)-1,3-diazaspiro[4.5]decan-2-one


SC_3436
cis-3-(2-cyclopropoxy-4-methylpyrimidin-5-yl)-8-(dimethylamino)-8-(3-



fluorophenyl)-1,3-diazaspiro[4.5]decan-2-one


SC_3437
cis-N-(5-(8-(dimethylamino)-8-(3-fluorophenyl)-2-oxo-1,3-diazaspiro[4.5]decan-3-



yl)-4-methylpyrimidin-2-yl)-N-methylcyclopropanecarboxamide


SC_3438
cis-N-(5-(8-(dimethylamino)-8-(3-fluorophenyl)-2-oxo-1,3-diazaspiro[4.5]decan-3-



yl)-4-methylpyrimidin-2-yl)-N-methylpivalamide


SC_3439
cis-3-(4-(azetidin-1-yl)-2-(trifluoromethyl)pyrimidin-5-yl)-8-(dimethylamino)-8-



(3-fluorophenyl)-1,3-diazaspiro[4.5]decan-2-one


SC_3440
cis-8-(dimethylamino)-8-(3-fluorophenyl)-3-(4-(oxetan-3-ylmethoxy)-2-



(trifluoromethyl)pyrimidin-5-yl)-1,3-diazaspiro[4.5]decan-2-one


SC_3441
cis-3-(2-cyclopropyl-4-(2,2,2-trifluoroethoxy)pyrimidin-5-yl)-8-(dimethylamino)-



8-(3-fluorophenyl)-1,3-diazaspiro[4.5]decan-2-one


SC_3442
cis-3-(2-cyclopropyl-4-((2-hydroxyethyl)(methyl)amino)pyrimidin-5-yl)-8-



(dimethylamino)-8-(3-fluorophenyl)-1,3-diazaspiro[4.5]decan-2-one










and the physiologically acceptable salts thereof.


According to the invention, unless expressly stated otherwise, “—C1-C4-alkyl”, “—C1-C6-alkyl” and any other alkyl residues can be linear or branched, saturated or unsaturated. Linear saturated alkyl includes methyl, ethyl, n-propyl, n-butyl, n-pentyl and n-hexyl. Examples of branched saturated alkyl include but are not limited to iso-propyl, sec-butyl, and tert-butyl. Examples of linear unsaturated alkyl include but are not limited to vinyl, propenyl, allyl, and propargyl.


According to the invention, unless expressly stated otherwise, “—C1-C4-alkyl”, “—C1-C6-alkyl” and any other alkyl residues can be unsubstituted, mono- or polysubstituted. Examples of substituted alkyl include but are not limited to —CH2CH2OH, —CH2CH2OCH3, —CH2CH2CH2OCH3, —CH2CH2S(═O)2CH3, —CH2C(═O)NH2, —C(CH3)2C(═O)NH2, —CH2C(CH3)2C(═O)NH2, and —CH2CH2C(═O)N(CH3)2.


According to the invention, unless expressly stated otherwise, “—C1-C6-alkylene-”, “—C1-C4-alkylene” and any other alkylene residue can be unsubstituted, mono- or polysubstituted. Examples of saturated alkylene include but are not limited to —CH2—, —CH(CH3)—, —C(CH3)2—, —CH2CH2—, —CH(CH3)CH2—, —CH2CH(CH3)—, —CH(CH3)—CH(CH3)—, —C(CH3)2CH2—, —CH2C(CH3)2—, —CH(CH3)C(CH3)2—, —C(CH3)2CH(CH3)—, C(CH3)2C(CH3)2—, —CH2CH2CH2—, and —C(CH3)2CH2CH2—. Examples of unsaturated alkylene include but are not limited to —CH═CH—, —C≡C—, —C(CH3)═CH—, —CH═C(CH3)—, —C(CH3)═C(CH3)—, —CH2CH═CH—, —CH═CHCH2—, —CH═CH—CH═CH—, and —CH═CH—C≡C—.


According to the invention, unless expressly stated otherwise, “—C1-C6-alkylene-”, “—C1-C4-alkylene” and any other alkylene residue can be unsubstituted, mono- or polysubstituted. Examples of substituted —C1-C6-alkylene- include but are not limited to —CHF—, —CF2—, —CHOH— and —C(═O)—.


According to the invention, moieties may be connected through —C1-C6-alkylene-, i.e. the moieties may not be directly bound to the core structure of compound according to general formula (I), but may be connected to the core structure of compound according to general formula (I) or its periphery through a —C1-C6-alkylene- linker.


According to the invention, “3-12-membered cycloalkyl moiety” means a non-aromatic, monocyclic, bicyclic or tricyclic moiety comprising 3 to 12 ring carbon atoms but no heteroatoms in the ring. Examples of preferred saturated 3-12-membered cycloalkyl moieties according to the invention include but are not limited to cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, cyclooctane, hydrindane, and decaline. Examples of preferred unsaturated 3-12-membered cycloalkyl moiety moieties according to the invention include but are not limited to cyclopropene, cyclobutene, cyclopentene, cyclopentadiene, cyclohexene, 1,3-cyclohexadiene, and 1,4-cyclohexadiene. The 3-12-membered cycloalkyl moiety, which is bonded to the compound according to the invention, in its periphery may optionally be condensed with a 3-12-membered heterocycloalkyl moiety, saturated or unsaturated, unsubstituted, mono- or polysubstituted; and/or with a 6-14-membered aryl moiety, unsubstituted, mono- or polysubstituted; and/or with a 5-14-membered heteroaryl moiety, unsubstituted, mono- or polysubstituted. Under these circumstances, the ring atoms of the condensed moieties are not included in the 3 to 12 ring atoms of the 3-12-membered cycloalkyl moiety. Examples of 3-12-membered cycloalkyl moieties condensed with 3-12-membered heterocycloalkyl moieties include but are not limited to octahydro-1H-indol, decahydroquinoline, decahydroisoquinoline, octahydro-2H-benzo[b][1,4]oxazin, and decahydro-quinoxalin, which in each case are connected through the 3-12-membered cycloalkyl moiety. Examples of 3-12-membered cycloalkyl moieties condensed with 6-14-membered aryl moieties include but are not limited to 2,3-dihydro-1H-indene and tetraline, which in each case are connected through the 3-12-membered cycloalkyl moiety. Examples of 3-12-membered cycloalkyl moieties condensed with 5-14-membered heteroaryl moieties include but are not limited to 5,6,7,8-tetrahydroquinoline and 5,6,7,8-tetrahydroquinazoline, which in each case are connected through the 3-12-membered cycloalkyl moiety.


According to the invention, the 3-12-membered cycloalkyl moiety may optionally be connected through —C1-C6-alkylene-, i.e. the 3-12-membered cycloalkyl moiety may not be directly bound to the compound according to general formula (I) but may be connected thereto through a —C1-C6-alkylene- linker. Examples include but are not limited to —CH2-cyclopropyl, —CH2-cyclobutyl, —CH2-cyclopentyl, —CH2-cyclohexyl, —CH2CH2-cyclopropyl, —CH2CH2-cyclobutyl, —CH2CH2-cyclopentyl, and —CH2CH2-cyclohexyl.


According to the invention, unless expressly stated otherwise, the 3-12-membered cycloalkyl moiety can be unsubstituted, mono- or polysubstituted. Examples of substituted 3-12-membered cycloalkyl moieties include but are not limited to —CH2—1-hydroxy-cyclobutyl.


According to the invention, “3-12-membered heterocycloalkyl moiety” means a non-aromatic, monocyclic, bicyclic or tricyclic moiety comprising 3 to 12 ring atoms, wherein each cycle comprises independently of one another 1, 2, 3, 4 or more heteroatoms independently of one another selected from the group consisting of nitrogen, oxygen and sulfur, whereas sulfur may be oxidized (S(═O) or (S(═O)2), whereas the remaining ring atoms are carbon atoms, and whereas bicyclic or tricyclic systems may share common heteroatom(s). Examples of preferred saturated 3-12-membered heterocycloalkyl moieties according to the invention include but are not limited to aziridin, azetidine, pyrrolidine, imidazolidine, pyrazolidine, piperidine, piperazine, triazolidine, tetrazolidine, oxiran, oxetane, tetrahydrofurane, tetrahydropyrane, thiirane, thietane, tetra-hydrothiophene, diazepane, oxazolidine, isoxazolidine, thiazolidine, isothiazolidine, thiadiazoli-dine, morpholine, thiomorpholine. Examples of preferred unsaturated 3-12-membered heterocycloalkyl moiety moieties according to the invention include but are not limited to oxazoline, pyrazoline, imidazoline, isoxazoline, thiazoline, isothiazoline, and dihydropyran. The 3-12-membered heterocycloalkyl moiety, which is bonded to the compound according to the invention, in its periphery may optionally be condensed with a 3-12-membered cycloalkyl moiety, saturated or unsaturated, unsubstituted, mono- or polysubstituted; and/or with a 6-14-membered aryl moiety, unsubstituted, mono- or polysubstituted; and/or with a 5-14-membered heteroaryl moiety, unsubstituted, mono- or polysubstituted. Under these circumstances, the ring atoms of the condensed moieties are not included in the 3 to 12 ring atoms of the 3-12-membered heterocycloalkyl moieties. Examples of 3-12-membered heterocycloalkyl moieties condensed with 3-12-membered cycloalkyl moieties include but are not limited to octahydro-1H-indol, decahydroquinoline, decahydroisoquinoline, octahydro-2H-benzo[b][1,4]oxazin, and decahydro-quinoxalin, which in each case are connected through the 3-12-membered heterocycloalkyl moiety. An examples of a 3-12-membered heterocycloalkyl moiety condensed with a 6-14-membered aryl moiety includes but is not limited to 1,2,3,4-tetrahydroquinoline, which is connected through the 3-12-membered heterocycloalkyl moiety. An example of a 3-12-membered heterocycloalkyl moiety condensed with a 5-14-membered heteroaryl moieties includes but is not limited to 5,6,7,8-tetrahydro-[1,2,4]triazolo[1,5-a]pyrazine, which is connected through the 3-12-membered heterocycloalkyl moiety.


According to the invention, the 3-12-membered heterocycloalkyl moiety may optionally be connected through —C1-C6-alkylene-, i.e. the 3-12-membered heterocycloalkyl moiety may not be directly bound to the compound according to general formula (I) but may be connected thereto through a —C1-C6-alkylene- linker. Said linker may be connected to a carbon ring atom or to a hetero ring atom of the 3-12-membered heterocycloalkyl moiety. Examples include but are not limited to —CH2-oxetane, —CH2-pyrrolidine, —CH2-piperidine, —CH2-morpholine, —CH2CH2-oxetane, —CH2CH2-pyrrolidine, —CH2CH2-piperidine, and —CH2CH2-morpholine.


According to the invention, unless expressly stated otherwise, the 3-12-membered heterocycloalkyl moiety can be unsubstituted, mono- or polysubstituted. Examples of substituted 3-12-membered heterocycloalkyl moieties include but are not limited to 2-carboxamido-N-pyrrolidinyl-, 3,4-dihydroxy-N-pyrrolidinyl, 3-hydroxy-N-pyrimidinyl, 3,4-dihydroxy-N-pyrimidinyl, 3-oxo-N-piperazinyl, -tetrahydro-2H-thiopyranyl dioxide and thiomorpholinyl dioxide.


According to the invention, “6-14-membered aryl moiety” means an aromatic, monocyclic, bicyclic or tricyclic moiety comprising 6 to 14 ring carbon atoms but no heteroatoms in the ring. Examples of preferred 6-14-membered aryl moieties according to the invention include but are not limited to benzene, naphthalene, anthracen, and phenanthren. The 6-14-membered aryl moiety, which is bonded to the compound according to the invention, in its periphery may optionally be condensed with a 3-12-membered cycloalkyl moiety, saturated or unsaturated, unsubstituted, mono- or polysubstituted; and/or with a 3-12-membered heterocycloalkyl moiety, saturated or unsaturated, unsubstituted, mono- or polysubstituted; and/or with a 5-14-membered heteroaryl moiety, unsubstituted, mono- or polysubstituted. Under these circumstances, the ring atoms of the condensed moieties are not included in the 6 to 14 ring carbon atoms of the 6-14-membered heterocycloalkyl moieties. Examples of 6-14-membered aryl moieties condensed with 3-12-membered cycloalkyl moieties include but are not limited to 2,3-dihydro-1H-indene and tetraline, which in each case are connected through the 6-14-membered aryl moiety. An example of a 6-14-membered aryl moiety condensed with a 3-12-membered heterocycloalkyl moiety includes but is not limited to 1,2,3,4-tetrahydroquinoline, which is connected through the 6-14-membered aryl moiety. Examples of 6-14-membered aryl moieties condensed with 5-14-membered heteroaryl moieties include but are not limited to quinoline, isoquinoline, phenazine and phenoxacine, which in each case are connected through the 6-14-membered aryl moiety.


According to the invention, the 6-14-membered aryl moiety may optionally be connected through —C1-C6-alkylene-, i.e. the 6-14-membered aryl moiety may not be directly bound to the compound according to general formula (I) but may be connected thereto through a —C1-C6-alkylene- linker. Said linker may be connected to a carbon ring atom or to a hetero ring atom of the 6-14-membered aryl moiety. Examples include but are not limited to —CH2—C6H5, —CH2CH2—C6H5 and —CH═CH—C6H5.


According to the invention, unless expressly stated otherwise, the 6-14-membered aryl moiety can be unsubstituted, mono- or polysubstituted. Examples of substituted 6-14-membered aryl moieties include but are not limited to 2-fluorophenyl, 3-fluorophenyl, 2-methoxyphenyl and 3-methoxyphenyl.


According to the invention, “5-14-membered heteroaryl moiety” means an aromatic, monocyclic, bicyclic or tricyclic moiety comprising 6 to 14 ring atoms, wherein each cycle comprises independently of one another 1, 2, 3, 4 or more heteroatoms independently of one another selected from the group consisting of nitrogen, oxygen and sulfur, whereas the remaining ring atoms are carbon atoms, and whereas bicyclic or tricyclic systems may share common heteroatom(s). Examples of preferred 5-14-membered heteroaryl moieties according to the invention include but are not limited to pyrrole, pyrazole, imidazole, triazole, tetrazole, furane, thiophene, oxazole, isoxazole, thiazole, isothiazole, pyridine, pyridazine, pyrimidine, pyrazine, indolicine, 9H-chinolicine, 1,8-naphthyridine, purine, imidazo[1,2-a]pyrazine, and pteridine. The 5-14-membered heteroaryl moiety, which is bonded to the compound according to the invention, in its periphery may optionally be condensed with a 3-12-membered cycloalkyl moiety, saturated or unsaturated, unsubstituted, mono- or polysubstituted; and/or with a 3-12-membered heterocycloalkyl moiety, saturated or unsaturated, unsubstituted, mono- or polysubstituted; and/or with a 6-14-membered aryl moiety, unsubstituted, mono- or polysubstituted. Under these circumstances, the ring atoms of the condensed moieties are not included in the 6 to 14 ring carbon atoms of the 6-14-membered heterocycloalkyl moieties. Examples of 5-14-membered heteroaryl moieties condensed with 3-12-membered cycloalkyl moieties include but are not limited to 5,6,7,8-tetrahydroquinoline and 5,6,7,8-tetrahydroquinazoline, which in each case are connected through the 5-14-membered heteroaryl moiety. An examples of a 5-14-membered heteroaryl moiety condensed with a 3-12-membered heterocycloalkyl moiety includes but is not limited to 5,6,7,8-tetrahydro-[1,2,4]triazolo[1,5-a]pyrazine, which is connected through the 5-14-membered heteroaryl moiety. Examples of 5-14-membered heteroaryl moieties condensed with 6-14-membered aryl moieties include but are not limited to quinoline, isoquinoline, phenazine and phenoxacine, which in each case are connected through the 5-14-membered heteroaryl moiety.


According to the invention, the 5-14-membered heteroaryl moiety may optionally be connected through —C1-C6-alkylene-, i.e. the 5-14-membered heteroaryl moiety may not be directly bound to the compound according to general formula (I) but may be connected thereto through a —C1-C6-alkylene- linker. Said linker may be connected to a carbon ring atom or to a hetero ring atom of the 5-14-membered heteroaryl moiety. Examples include but are not limited to —CH2-oxazole, —CH2-isoxazole, —CH2-imidazole, —CH2-pyridine, —CH2-pyrimidine, —CH2-pyridazine, —CH2CH2-oxazole, —CH2CH2-isoxazole, —CH2CH2-imidazole, —CH2CH2-pyridine, —CH2CH2-pyrimidine, and —CH2CH2-pyridazine.


According to the invention, unless expressly stated otherwise, the 5-14-membered heteroaryl moiety can be unsubstituted, mono- or polysubstituted. Examples of 5-14-membered heteroaryl moieties include but are not limited to 2-methoxy-4-pyridinyl, 2-methoxy-5-pyridinyl, 3-methoxy-4-pyridinyl, 3-methoxy-6-pyridinyl, 4-methoxy-2-pyridinyl, 2-methylsulfonyl-5-pyridinyl, 3-methylsulfonyl-6-pyridinyl, 3-methoxy-6-pyridazinyl, 2-nitrilo-5-pyrimidinyl, 4-hydroxy-2-pyrimidinyl, 4-methoxy-pyrimidinyl, and 2-methoxy-6-pyrazinyl.


Preferably, the compound according to the invention has a structure according to general formula (I′)




embedded image


wherein R1 to R5, R11 to R20 are defined as above, or a physiologically acceptable salt thereof.


In one preferred embodiment, the excess of the cis-isomer so designated is at least 50% de, more preferably at least 75% de, yet more preferably at least 90% de, most preferably at least 95% de and in particular at least 99% de.


In a preferred embodiment, the compound according to the invention has a structure according to general formula (IX) or (X)




embedded image


wherein


R2 means —H or —CH3;


R3 means -phenyl or -3-fluorophenyl;


RC means —H or —OH;


RE means —H, —CH3, —F, —CF3, -cyclopropyl, -aziridinyl, —OH; —O—C1-C4-alkyl; —OCF3; —O—C1-C4-alkyl-CO2H; —O—C1-C4-alkyl-C(═O)O—C1-C4-alkyl; or —O—C1-C4-alkyl-CONH2;


RF means


—CF3, -cyclopropyl, —S(═O)2CH3,


—NH2; —NHC1-C4-alkyl; —N(C1-C4-alkyl)2; —NHC1-C4-alkyl-OH; —NCH3C1-C4-alkyl-OH; —NH—C1-C4-alkyl-C(═O)NH2; —NCH3—C1-C4-alkyl-C(═O)NH2; —NHC(═O)—C1-C4-alkyl; —NCH3C(═O)—C1-C4-alkyl;


-6-14-membered aryl, unsubstituted, mono- or polysubstituted; or


-5-14-membered heteroaryl, unsubstituted, mono- or polysubstituted;


U means ═CH— or ═N—; and


V means ═CH— or ═N—;


or a physiologically acceptable salt thereof


In a preferred embodiment, the compound according to the invention has a structure according to general formula (XI)




embedded image


wherein


R2 means —H or —CH3;


R3 means -phenyl or -3-fluorophenyl;


RH means


—CN; —C1-C4-alkyl; —CF3; —C1-C4-alkyl-C(═O)NH2; —C1-C4-alkyl-S(═O)2—C1-C4-alkyl; —C(═O)—C1-C4-alkyl; —C(═O)OH; —C(═O)O—C1-C4-alkyl; —C(═O)NH2; —C(═O)NHC1-C4-alkyl; —C(═O)N(C1-C4-alkyl)2; —C(═O)NH(C1-C4-alkyl-OH); —C(═O)N(C1-C4-alkyl)(C1-C4-alkyl-OH); —C(═O)NH—(CH2CH2O)1-30—CH3;


-3-12-membered cycloalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said 3-12-membered cycloalkyl is optionally connected through —CH2—, —NH—, —NCH3—, —NH—(CH2)1-3—, —NCH3(CH2)1-3—, —(C═O)—, —NHC(═O)—, —NCH3C(═O)—, —C(═O)NH—(CH2)1-3—, —C(═O)NCH3—(CH2)1-3—; or


-3-12-membered heterocycloalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted; 6-14-membered aryl, unsubstituted, mono- or polysubstituted; wherein said 3-12-membered heterocycloalkyl is optionally connected through —CH2—, —NH—, —NCH3—, —NH—(CH2)1-3—, —NCH3(CH2)1-3—, —(C═O)—, —NHC(═O)—, —NCH3C(═O)—, —C(═O)NH—(CH2)1-3—, —C(═O)NCH3—(CH2)1-3—;


RG means


—CF3, —S(═O)2CH3;


—NH2; —NHC1-C4-alkyl; —N(C1-C4-alkyl)2; —NHC1-C4-alkyl-OH; —NCH3C1-C4-alkyl-OH; —NH—C1-C4-alkyl-C(═O)NH2; —NCH3—C1-C4-alkyl-C(═O)NH2; —NHC(═O)—C1-C4-alkyl; —NCH3C(═O)—C1-C4-alkyl;


-3-12-membered cycloalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said 3-12-membered cycloalkyl is optionally connected through —CH2—, —NH—, —NCH3—, —NH—(CH2)1-3—, —NCH3(CH2)1-3—, —(C═O)—, —NHC(═O)—, —NCH3C(═O)—, —C(═O)NH—(CH2)1-3—, —C(═O)NCH3—(CH2)1-3—; or


-3-12-membered heterocycloalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted; 6-14-membered aryl, unsubstituted, mono- or polysubstituted; wherein said 3-12-membered heterocycloalkyl is optionally connected through —CH2—, —NH—, —NCH3—, —NH—(CH2)1-3—, —NCH3(CH2)1-3—, —(C═O)—, —NHC(═O)—, —NCH3C(═O)—, —C(═O)NH—(CH2)1-3—, —C(═O)NCH3—(CH2)1-3—,


or a physiologically acceptable salt thereof.


In a preferred embodiment, the compounds according to the invention are in the form of the free bases.


In another preferred embodiment, the compounds according to the invention are in the form of the physiologically acceptable salts.


For the purposes of the description, a “salt” is to be understood as being any form of the compound in which it assumes an ionic form or is charged and is coupled with a counter-ion (a cation or anion) or is in solution. The term is also to be understood as meaning complexes of the compound with other molecules and ions, in particular complexes which are associated via ionic interactions. Preferred salts are physiologically acceptable, in particular physiologically acceptable salts with anions or acids or also a salt formed with a physiologically acceptable acid.


Physiologically acceptable salts with anions or acids are salts of the particular compound in question with inorganic or organic acids which are physiologically acceptable, in particular when used in humans and/or mammals. Examples of physiologically acceptable salts of particular acids include but are not limited to salts of hydrochloric acid, sulfuric acid, and acetic acid.


The invention also includes isotopic isomers of a compound according to the invention, wherein at least one atom of the compound is replaced by an isotope of the respective atom which is different from the naturally predominantly occurring isotope, as well as any mixtures of isotopic isomers of such a compound. Preferred isotopes are 2H (deuterium), 3H (tritium), 13C and 14C.


Certain compounds according to the invention are useful for modulating a pharmacodynamic response from one or more opioid receptors (mu, delta, kappa, NOP/ORL-1) either centrally or peripherally, or both. The pharmacodynamic response may be attributed to the compound either stimulating (agonizing) or inhibiting (antagonizing) the one or more receptors. Certain compounds according to the invention may antagonize one opioid receptor, while also agonizing one or more other receptors. Compounds according to the invention having agonist activity may be either full agonists or partial agonists.


As used herein, compounds that bind to receptors and mimic the regulatory effects of endogenous ligands are defined as “agonists”. Compounds that bind to a receptor but produce no regulatory effect, but rather block the binding of ligands to the receptor, are defined as “antagonists”.


In certain embodiments, the compounds according to the invention are agonists at the mu opioid (MOP) and/or kappa opioid (KOP) and/or delta opioid (DOP) and/or nociceptin opioid (NOP/ORL-1) receptors.


The compounds according to the invention potently bind to the MOP and/or KOP and/or DOP and/or NOP receptors.


The compounds according to the invention can be modulators at the MOP and/or KOP and/or DOP and/or NOP receptors, and therefore the compounds according to the invention can be used/administered to treat, ameliorate, or prevent pain.


In some embodiments, the compounds according to the invention are agonists of one or more opioid receptors. In some embodiments, the compounds according to the invention are agonists of the MOP and/or KOP and/or DOP and/or NOP receptors.


In some embodiments, the compounds according to the invention are antagonists of one or more opioid receptors. In some embodiments, the compounds according to the invention are antagonists of the MOP and/or KOP and/or DOP and/or NOP receptors.


In some embodiments, the compounds according to the invention have both, (i) agonist activity at the NOP receptor; and (ii) agonist activity at one or more of the MOP, KOP, and DOP receptors.


In some embodiments, the compounds according to the invention have both, (i) agonist activity at the NOP receptor; and (ii) antagonist activity at one or more of the MOP, KOP, and DOP receptors.


In some embodiments, the compounds according to the invention have both, (i) antagonist activity at the NOP receptor; and (ii) agonist activity at one or more of the MOP, KOP, and DOP receptors.


In some embodiments, the compounds according to the invention have both, (i) antagonist activity at the NOP receptor; and (ii) antagonist activity at one or more of the MOP, KOP, and DOP receptors.


In some embodiments, preferably with respect to receptors of the peripheral nervous system, the compounds according to the invention have selective agonist activity at the NOP receptor. In some embodiments, preferably with respect to receptors of the peripheral nervous system, the compounds according to the invention

    • have agonist activity at the NOP receptor, but no significant activity at the MOP receptor;
    • have agonist activity at the NOP receptor, but no significant activity at the KOP receptor;
    • have agonist activity at the NOP receptor, but no significant activity at the DOP receptor;
    • have agonist activity at the NOP receptor, but no significant activity at the MOP receptor as well as no significant activity at the KOP receptor;
    • have agonist activity at the NOP receptor, but no significant activity at the MOP receptor as well as no significant activity at the DOP receptor; or
    • have agonist activity at the NOP receptor, but no significant activity at the MOP receptor as well as no significant activity at the KOP receptor as well as no significant activity at the DOP receptor.


In some embodiments, preferably with respect to receptors of the peripheral nervous system, the compounds according to the invention have balanced agonist activity at the NOP receptor as well as at the MOP receptor. In some embodiments, preferably with respect to receptors of the peripheral nervous system, the compounds according to the invention

    • have agonist activity at the NOP receptor as well as agonist activity at the MOP receptor;
    • have agonist activity at the NOP receptor as well as agonist activity at the MOP receptor as well as agonist activity at the KOP receptor;
    • have agonist activity at the NOP receptor as well as agonist activity at the MOP receptor as well as agonist activity at the DOP receptor;
    • can be regarded as opioid pan agonists, i.e. have agonist activity at the NOP receptor as well as agonist activity at the MOP receptor as well as agonist activity at the KOP receptor as well as agonist activity at the DOP receptor;
    • have agonist activity at the NOP receptor as well as agonist activity at the MOP receptor, but no significant activity at the KOP receptor;
    • have agonist activity at the NOP receptor as well as agonist activity at the MOP receptor, but no significant activity at the DOP receptor; or
    • have agonist activity at the NOP receptor as well as agonist activity at the MOP receptor, but no significant activity at the KOP receptor as well as no significant activity at the DOP receptor.


In some embodiments, preferably with respect to receptors of the peripheral nervous system, the compounds according to the invention have balanced agonist activity at the NOP receptor as well as at the KOP receptor. In some embodiments, preferably with respect to receptors of the peripheral nervous system, the compounds according to the invention

    • have agonist activity at the NOP receptor as well as agonist activity at the KOP receptor;
    • have agonist activity at the NOP receptor as well as agonist activity at the KOP receptor as well as agonist activity at the MOP receptor;
    • have agonist activity at the NOP receptor as well as agonist activity at the KOP receptor as well as agonist activity at the DOP receptor;
    • have agonist activity at the NOP receptor as well as agonist activity at the KOP receptor, but no significant activity at the MOP receptor;
    • have agonist activity at the NOP receptor as well as agonist activity at the KOP receptor, but no significant activity at the DOP receptor; or
    • have agonist activity at the NOP receptor as well as agonist activity at the KOP receptor, but no significant activity at the MOP receptor as well as no significant activity at the DOP receptor.


In some embodiments, preferably with respect to receptors of the peripheral nervous system, the compounds according to the invention have balanced agonist activity at the NOP receptor as well as at the DOP receptor. In some embodiments, preferably with respect to receptors of the peripheral nervous system, the compounds according to the invention

    • have agonist activity at the NOP receptor as well as agonist activity at the DOP receptor;
    • have agonist activity at the NOP receptor as well as agonist activity at the DOP receptor, but no significant activity at the MOP receptor;
    • have agonist activity at the NOP receptor as well as agonist activity at the DOP receptor, but no significant activity at the KOP receptor; or
    • have agonist activity at the NOP receptor as well as agonist activity at the DOP receptor, but no significant activity at the MOP receptor as well as no significant activity at the KOP receptor.


In some embodiments, preferably with respect to receptors of the peripheral nervous system, the compounds according to the invention have selective agonist activity at the KOP receptor. In some embodiments, preferably with respect to receptors of the peripheral nervous system, the compounds according to the invention

    • have agonist activity at the KOP receptor, but no significant activity at the MOP receptor;
    • have agonist activity at the KOP receptor, but no significant activity at the NOP receptor;
    • have agonist activity at the KOP receptor, but no significant activity at the DOP receptor;
    • have agonist activity at the KOP receptor, but no significant activity at the MOP receptor as well as no significant activity at the NOP receptor;
    • have agonist activity at the KOP receptor, but no significant activity at the MOP receptor as well as no significant activity at the DOP receptor; or
    • have agonist activity at the KOP receptor, but no significant activity at the MOP receptor as well as no significant activity at the NOP receptor as well as no significant activity at the DOP receptor.


In some embodiments, preferably with respect to receptors of the peripheral nervous system, the compounds according to the invention have agonist activity at the MOP receptor, agonist activity at the KOP receptor, and antagonist activity at the DOP receptor. In some embodiments, preferably with respect to receptors of the peripheral nervous system, the compounds according to the invention

    • have agonist activity at the MOP receptor as well as agonist activity at the KOP receptor as well as antagonist activity at the DOP receptor;
    • have agonist activity at the MOP receptor as well as agonist activity at the KOP receptor as well as antagonist activity at the DOP receptor as well as agonist activity at the NOP receptor;
    • have agonist activity at the MOP receptor as well as agonist activity at the KOP receptor as well as antagonist activity at the DOP receptor as well as antagonist activity at the NOP receptor; or
    • have agonist activity at the MOP receptor as well as agonist activity at the KOP receptor as well as antagonist activity at the DOP receptor, no significant activity at the NOP receptor.


In some embodiments, preferably with respect to receptors of the central nervous system, the compounds according to the invention have selective agonist activity at the NOP receptor. In some embodiments, preferably with respect to receptors of the central nervous system, the compounds according to the invention

    • have agonist activity at the NOP receptor, but no significant activity at the MOP receptor;
    • have agonist activity at the NOP receptor, but no significant activity at the KOP receptor;
    • have agonist activity at the NOP receptor, but no significant activity at the DOP receptor;
    • have agonist activity at the NOP receptor, but no significant activity at the MOP receptor as well as no significant activity at the KOP receptor;
    • have agonist activity at the NOP receptor, but no significant activity at the MOP receptor as well as no significant activity at the DOP receptor; or
    • have agonist activity at the NOP receptor, but no significant activity at the MOP receptor as well as no significant activity at the KOP receptor as well as no significant activity at the DOP receptor.


In some embodiments, preferably with respect to receptors of the central nervous system, the compounds according to the invention have selective antagonist activity at the NOP receptor. In some embodiments, preferably with respect to receptors of the central nervous system, the compounds according to the invention

    • have antagonist activity at the NOP receptor, but no significant activity at the MOP receptor;
    • have antagonist activity at the NOP receptor, but no significant activity at the KOP receptor;
    • have antagonist activity at the NOP receptor, but no significant activity at the DOP receptor;
    • have antagonist activity at the NOP receptor, but no significant activity at the MOP receptor as well as no significant activity at the KOP receptor;
    • have antagonist activity at the NOP receptor, but no significant activity at the MOP receptor as well as no significant activity at the DOP receptor; or
    • have antagonist activity at the NOP receptor, but no significant activity at the MOP receptor as well as no significant activity at the KOP receptor as well as no significant activity at the DOP receptor.


In some embodiments, preferably with respect to receptors of the central nervous system, the compounds according to the invention have antagonist activity at the NOP receptor as well as agonist activity at the DOP receptor. In some embodiments, preferably with respect to receptors of the central nervous system, the compounds according to the invention

    • have antagonist activity at the NOP receptor as well as agonist activity at the DOP receptor;
    • have antagonist activity at the NOP receptor as well as agonist activity at the DOP receptor, but no significant activity at the MOP receptor;
    • have antagonist activity at the NOP receptor as well as agonist activity at the DOP receptor, but no significant activity at the KOP receptor; or
    • have antagonist activity at the NOP receptor as well as agonist activity at the DOP receptor, but no significant activity at the MOP receptor as well as no significant activity at the KOP receptor.


For the purpose of the specification, “no significant activity” means that the activity (agonist/antagonist) of the given compound at this receptor is lower by a factor of 1000 or more compared to its activity (agonist/antagonist) at one or more of the other opioid receptors.


A further aspect of the invention relates to the compounds according to the invention as medicaments.


A further aspect of the invention relates to the compounds according to the invention for use in the treatment of pain. A further aspect of the invention relates to a method of treating pain comprising the administration of a pain alleviating amount of a compound according to the invention to a subject in need thereof, preferably to a human. The pain is preferably acute or chronic. The pain is preferably nociceptive or neuropathic.


A further aspect of the invention relates to the compounds according to the invention for use in the treatment of neurodegenerative disorders, neuroinflammatory disorders, neuropsychiatric disorders, and substance abuse/dependence. A further aspect of the invention relates to a method of treating any one of the aforementioned disorders, diseases or conditions comprising the administration of a therapeutically effective amount of a compound according to the invention to a subject in need thereof, preferably to a human.


Another aspect of the invention relates to a pharmaceutical composition which contains a physiologically acceptable carrier and at least one compound according to the invention.


Preferably, the composition according to the invention is solid, liquid or pasty; and/or contains the compound according to the invention in an amount of from 0.001 to 99 wt. %, preferably from 1.0 to 70 wt. %, based on the total weight of the composition.


The pharmaceutical composition according to the invention can optionally contain suitable additives and/or auxiliary substances and/or optionally further active ingredients.


Examples of suitable physiologically acceptable carriers, additives and/or auxiliary substances are fillers, solvents, diluents, colorings and/or binders. These substances are known to the person skilled in the art (see H. P. Fiedler, Lexikon der Hilfsstoffe fur Pharmazie, Kosmetik and angrenzende Gebiete, Editio Cantor Aulendoff).


The pharmaceutical composition according to the invention contains the compound according to the invention in an amount of preferably from 0.001 to 99 wt. %, more preferably from 0.1 to 90 wt. %, yet more preferably from 0.5 to 80 wt. %, most preferably from 1.0 to 70 wt. % and in particular from 2.5 to 60 wt. %, based on the total weight of the pharmaceutical composition.


The pharmaceutical composition according to the invention is preferably for systemic, topical or local administration, preferably for oral administration.


Another aspect of the invention relates to a pharmaceutical dosage form which contains the pharmaceutical composition according to the invention.


In one preferred embodiment, the pharmaceutical dosage form according to the invention is produced for administration twice daily, for administration once daily or for administration less frequently than once daily. Administration is preferably systemic, in particular oral.


The pharmaceutical dosage form according to the invention can be administered, for example, as a liquid dosage form in the form of injection solutions, drops or juices, or as a semi-solid dosage form in the form of granules, tablets, pellets, patches, capsules, plasters/spray-on plasters or aerosols. The choice of auxiliary substances etc. and the amounts thereof to be used depend on whether the form of administration is to be administered orally, perorally, parenterally, intravenously, intraperitoneally, intradermally, intramuscularly, intranasally, buccally, rectally or locally, for example to the skin, the mucosa or into the eyes.


Pharmaceutical dosage forms in the form of tablets, dragees, capsules, granules, drops, juices and syrups are suitable for oral administration, and solutions, suspensions, readily reconstitutable dry preparations and also sprays are suitable for parenteral, topical and inhalatory administration. Compounds according to the invention in a depot, in dissolved form or in a plaster, optionally with the addition of agents promoting penetration through the skin, are suitable percutaneous administration preparations.


The amount of the compounds according to the invention to be administered to the patient varies in dependence on the weight of the patient, on the type of administration, on the indication and on the severity of the disease. Usually, from 0.00005 mg/kg to 50 mg/kg, preferably from 0.001 mg/kg to 10 mg/kg, of at least one compound according to the invention is administered.


Another aspect of the invention relates to a process for the preparation of the compounds according to the invention. Suitable processes for the synthesis of the compounds according to the invention are known in principle to the person skilled in the art.


Preferred synthesis routes are described below:


The compounds according to the invention can be obtained via different synthesis routes. Depending on the synthesis route, different intermediates are prepared and subsequently further reacted.


In a preferred embodiment, the synthesis of the compounds according to the invention proceeds via a synthesis route which comprises the preparation of an intermediate according to general formula (IIIa):




embedded image


wherein R1, R2 and R3 are defined as above.


In another preferred embodiment, the synthesis of the compounds according to the invention proceeds via a synthesis route which comprises the preparation of an intermediate according to general formula (IIIb):




embedded image


wherein R1, R2 and R3 are defined as above and PG is a protecting group.


Preferably the protecting group is -p-methoxybenzyl. Therefore, in another preferred embodiment, the synthesis of the compounds according to the invention proceeds via a synthesis route which comprises the preparation of an intermediate according to general formula (IIIc):




embedded image


wherein R1, R2 and R3 are defined as above.


As already indicated, in general formula (IIIc), the -p-methoxybenzyl moiety represents a protecting group which can be cleaved in the course of the synthesis route.


In yet another preferred embodiment, the synthesis of the compounds according to the invention proceeds via a synthesis route which comprises the preparation of

    • an intermediate according to general formula (IIIa) and according to general formula (IIIb); or
    • an intermediate according to general formula (IIIa) and according to general formula (IIIc); or
    • an intermediate according to general formula (IIIb) and according to general formula (IIIc); or
    • an intermediate according to general formula (IIIa), according to general formula (IIIb) and according to general formula (IIIc).


The following examples further illustrate the invention but are not to be construed as limiting its scope.







EXAMPLES

“RT” means room temperature (23±7° C.), “M” are indications of concentration in mol/1, “aq.” means aqueous, “sat.” means saturated, “sol.” means solution, “conc.” means concentrated.


FURTHER ABBREVIATIONS

brine saturated aqueous sodium chloride solution


CC column chromatography


cHex cyclohexane


dba dibenzylideneacetone


DCM dichloromethane


DIPEA N,N-diisopropylethylamine
DMF N,N-dimethylformamide

Et ethyl


ether diethyl ether


EE ethyl acetate


EtOAc ethyl acetate


EtOH ethanol


h hour(s)


H2O water


HATU O-(7-aza-benzotriazol-1-yl)-N,N,N′,N′-tetramethyluroniumhexafluorophosphate


LDA lithium diisoproylamide


Me methyl


m/z mass-to-charge ratio


MeOH methanol


MeCN acetonitrile


min minutes


MS mass spectrometry


NBS N-bromosuccinimide
NIS N-iodosuccinimide

NEt3 triethylamine


PE petroleum ether (60-80° C.)


RM reaction mixture


RT room temperature


TFA trifluoroacetic acid


T3P 2,4,6-tripropyl-1,3,5,2,4,6-trioxatriphosphorinane-2,4,6-trioxide


tBME tert-butyl methyl ether


THF tetrahydrofurane


v/v volume to volume


w/w weight to weight


Xantphos 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene


The yields of the compounds prepared were not optimised. All temperatures are uncorrected.


All starting materials, which are not explicitly described, were either commercially available (the details of suppliers such as for example Acros, Aldrich, Bachem, Butt park, Enamine, Fluka, Lancaster, Maybridge, Merck, Sigma, TCI, Oakwood, etc. can be found in the Symyx® Available Chemicals Database of MDL, San Ramon, US or the SciFinder® Database of the ACS, Washington D.C., US, respectively, for example) or the synthesis thereof has already been described precisely in the specialist literature (experimental guidelines can be found in the Reaxys® Database of Elsevier, Amsterdam, NL or the SciFinder® Database of the ACS, Washington D.C., US, respectively, for example) or can be prepared using the conventional methods known to the person skilled in the art.


The mixing ratios of solvents or eluents for chromatography are specified in v/v.


All the intermediate products and exemplary compounds were analytically characterised by mass spectrometry (MS, m/z for [M+H]+). In addition 1H-NMR and 13C spectroscopy was carried out for all the exemplary compounds and selected intermediate products.


Remark Regarding Stereochemistry


CIS refers to the relative configuration of compounds described herein, in which both nitrogen atoms are drawn on the same face of the cyclohexane ring as described in the following exemplary structure. Two depictions are possible:




embedded image


TRANS refers to compounds, in which both nitrogen atoms are on opposite faces of the cyclohexane ring as described in the following exemplary structure. Two depictions are possible:




embedded image


Synthesis of Intermediates
Synthesis of INT-600: 5-(cis-8-(Dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)pyrimidine-2-carbonitrile



embedded image


Cs2CO3 (1.1 g, 3.66 mmol) was added to the solution of CIS-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-976) (0.5 g, 1.83 mmol), Xanthphos (0.158 g, 0.274 mmol), Pd2(dba)3 (0.083 g, 0.091 mmol) and 5-bromopyrimidine-2-carbonitrile (0.52 g, 2.74 mmol) in 1,4-dioxane (20 mL) under argon atmosphere. The reaction mixture was stirred for 16 h at 90° C., then cooled to RT and concentrated under reduced pressure. The residue was suspended in EtOAc (20 mL) and filtered through a plug of celite. The filtrate was concentrated under reduced pressure and the resulting residue was purified by flash chromatography on silica gel to afford 5-(cis-8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)pyrimidine-2-carbonitrile (INT-600) (0.4 g) as a white solid.


Synthesis of INT-799: CIS-8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one



embedded image


Step 1: CIS-1-((1-(benzyloxy)cyclobutyl)methyl)-3-(3,4-dimethoxybenzyl)-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one

NaOH (1.42 g, 35.5 mmol) was added to a solution of CIS-3-(3,4-dimethoxybenzyl)-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-794) (3 g, 7.09 mmol) in DMSO (90 mL) under argon atmosphere and the reaction mixture was stirred at 80° C. for 30 min. ((1-(Bromomethyl)cyclobutoxy)methyl)benzene (5.4 g, 21.3 mmol) was added and stirring was continued for 2 days at 80° C. The reaction completion was monitored by TLC. The reaction mixture was diluted with water (500 mL) and extracted with diethyl ether (4×300 mL). The combined organic extracts were dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by column chromatography (230-400 mesh silica gel; 65-70% EtOAc in petroleum ether as eluent) to afford 2.5 g (59%) of CIS-1-((1-(benzyloxy)cyclobutyl)methyl)-3-(3,4-dimethoxybenzyl)-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (TLC system: 10% MeOH in DCM; Rf: 0.8).


Step 2: CIS-8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one

TFA (12 mL) was added to CIS-1-((1-(benzyloxy)cyclobutyl)methyl)-3-(3,4-dimethoxybenzyl)-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (2.5 g, 4.18 mmol) at 0° C. and the resulting mixture was stirred at 70° C. for 6 h. The reaction completion was monitored by LCMS. The reaction mixture was concentrated under reduced pressure. To the residue sat. aq. NaHCO3 was added (until pH 10) and the organic product was extracted with DCM (3×150 mL). The combined organic extracts were dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by column chromatography (230-400 mesh silica gel; 5% MeOH in DCM as eluent) to afford 500 mg (33%) of CIS-8-dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-799) (TLC system: 10% MeOH in DCM; Rf: 0.5). [M+H]+ 358.2


Synthesis of INT-951: CIS-1-[(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl)-methyl]-cyclobutane-1-carbonitrile



embedded image


Step 1: 1-((CIS-8-(dimethylamino)-3-(4-methoxybenzyl)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl)methyl)cyclobutanecarbonitrile

NaH (50% in mineral oil) (2.44 g, 50.89 mmol) was added to a solution of CIS-8-dimethylamino-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1,3-diazaspiro [4.5]decan-2-one (INT-975) (5 g, 12.72 mmol) in DMF (100 mL) at 0° C. portionwise over 10 min. 1-(Bromomethyl)cyclobutanecarbonitrile (4.4 g, 25.44 mmol) was added dropwise over 10 minutes at 0° C. The reaction mixture was allowed to stir at RT for 3 h, then quenched with water and the organic product was extracted with ethyl acetate (3×200 mL). The combined organic extracts were dried over anhydrous Na2SO4 and concentrated under reduced pressure to afford 5 g (crude) of 1-((CIS-8-(dimethylamino)-3-(4-methoxybenzyl)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl)methyl)cyclobutane-carbonitrile as gummy brown liquid. The material was used for the next step without further purification.


Step 2: 1-((CIS-8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl)methyl) cyclobutanecarboxamide

TFA (100 mL) was added to 1-((CIS-8-(dimethylamino)-3-(4-methoxybenzyl)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl)methyl)cyclobutanecarbonitrile (5 g, 10.28 mmol) at 0° C. and the reaction mixture at mixture was stirred at RT for 2 days. The reaction mixture was concentrated in vacuo. To the residue sat. aq. NaHCO3 was added (until pH 10) and the organic product was extracted with dichloromethane (3×150 mL). The combined organic extracts were dried over anhydrous Na2SO4 and concentrated under reduced pressure to afford 3.5 g (crude) of 1-((CIS-8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl)methyl) cyclobutanecarboxamide. The material was used for the next step without further purification.


Step 3: 1-((cis-8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl)methyl)cyclobutane carbonitrile

Thionyl chloride (35 mL) was added to 1-((cis-8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl)methyl)cyclobutanecarboxamide (3.5 g, 9.11 mmol) at RT and the resulting mixture was stirred at reflux for 2 h. The reaction mixture was concentrated in vacuo. To the residue sat. aq. NaHCO3 was added (until pH 10) and the organic product was extracted with dichloromethane (3×150 mL). The combined organic layer was dried over anhydrous Na2SO4 and concentrated in vacuo. The residue was purified by column chromatography to afford 1.3 g (34% after three steps) of CIS-1-[(8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl)-methyl]-cyclobutane-1-carbonitrile (INT-951). [M+H]+ 367.2.


Synthesis of INT-952: CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-8-phenyl-3-[(4-methoxyphenyl)-methyl]-1,3-diazaspiro[4.5]decan-2-one



embedded image


To a solution of CIS-8-dimethylamino-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1,3-diazaspiro [4.5]decan-2-one (INT-975) (10 g, 25 mmol) in THF (500 mL) was added KOtBu (7.1 g, 63 mmol) at 50° C. The reaction mixture was heated up to reflux, cyclobutylmethylbromide (11.3 g, 76 mmol) was added in one portion, and stirring was continued at reflux for 12 h. KOtBu (7.1 g) and cyclobutylmethylbromide (11.3 g) were added again. The reaction mixture was allowed to stir another 2 h at reflux, then cooled to RT, diluted with water (150 mL) and the layers partitioned. The aqueous layer was extracted with EtOAc (3×300 mL). The combined organic layers were dried over Na2SO4 and then concentrated in vacuo. The residue was filtered through a plug of silica gel using a DCM/MeOH (19/1 v/v) mixture. The filtrate was concentrated in vacuo and the resulting solid was recrystallized from hot ethanol to yield 7.8 g of CIS-1-(cyclobutyl-methyl)-8-dimethylamino-8-phenyl-3-[(4-methoxyphenyl)-methyl]-1,3-diazaspiro[4.5]decan-2-one (INT-952). [M+H]+ 461.3.


Synthesis of INT-953: CIS-1-(Cyclobutyl-methyl)-8-(methyl-(2-methyl-propyl)-amino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one



embedded image


Step 1: 1-Cyclobutylmethyl-3-(4-methoxy-benzyl)-9,12-dioxa-1,3-diazadispiro[4.2.4.2]tetradecan-2-one

To a stirred solution of 3-(4-methoxy-benzyl)-9,12-dioxa-1,3-diazadispiro[4.2.4.2]tetradecan-2-one (4 g, 12.04 mmol) in anhydrous DMF (60 ml) was added NaH (1.38 g, 60% dispersion in oil, 36.14 mmol) at RT. The reaction mixture was stirred for 10 min, bromomethylcyclobutane (3 ml, 26.5 mmol) was added dropwise and stirring was continued for 50 h. TLC analysis showed complete consumption of the starting material. The reaction mixture was quenched with sat. aq. NH4Cl (50 ml) and extracted with EtOAc (3×200 ml). The combined organic phase was dried over Na2SO4 and concentrated under reduced pressure. The resulting residue was purified column chromatography (neutral aluminum oxide, EtOAc—petroleum ether (2:8)) to give 1-cyclobutylmethyl-3-(4-methoxy-benzyl)-9,12-dioxa-1,3-diazadispiro[4.2.4.2]tetradecan-2-one (2.4 g, 50%, white solid). TLC system:EtOAc—pet ether (6:4); Rf=0.48.


Step 2: 1-Cyclobutylmethyl-3-(4-methoxy-benzyl)-1,3-diaza-spiro[4.5]decane-2,8-dione

To a stirred solution of 1-cyclobutylmethyl-3-(4-methoxy-benzyl)-9,12-dioxa-1,3-diazadispiro[4.2.4.2]tetradecan-2-one (1 g, 2.5 mmol) in MeOH (7 ml) was added 10% aq. HCl (8 ml) at 0° C. The reaction mixture was warmed up to RT and stirred for 16 h. TLC analysis showed complete consumption of the starting material. The reaction mixture was quenched with sat. aq. NaHCO3 (30 ml) and extracted with EtOAc (3×50 ml). The combined organic phase was dried over Na2SO4 and concentrated under reduced pressure. The resulting residue was purified by column chromatography (silica gel, 230-400 mesh, EtOAc—pet ether (1:3)→(3:7)) to give 1-cyclobutylmethyl-3-(4-methoxy-benzyl)-1,3-diaza-spiro[4.5]decane-2,8-dione (650 mg, 73%, colorless viscous oil). TLC system:EtOAc—pet ether (6:4); R=0.40.


Step 3: 1-(cyclobutylmethyl)-8-(isobutyl(methyl)amino)-3-(4-methoxybenzyl)-2-oxo-1,3-diazaspiro[4.5]decane-8-carbonitrile

To a stirred solution of N-isobutyl-N-methylamine (1.34 ml, 11.23 mmol) and MeOH/H2O (8 ml, 1:1, v/v) was added 4N aq. HCl (1.5 ml) and the reaction mixture was stirred for 10 min at 0° C. (ice bath). A solution of 1-cyclobutylmethyl-3-(4-methoxy-benzyl)-1,3-diaza-spiro[4.5]decane-2,8-dione (1 g, 2.80 mmol) in MeOH (7 ml) and KCN (548 mg, 8.42 mmol) were added and the reaction mixture was stirred at 45° C. for 20 h. TLC analysis showed complete consumption of the starting material. The reaction mixture was diluted with water (30 ml), extracted with EtOAc (3×30 ml), the combined organic phase was dried over Na2SO4 and concentrated under reduced pressure to give 1-(cyclobutylmethyl)-8-(isobutyl(methyl)amino)-3-(4-methoxybenzyl)-2-oxo-1,3-diazaspiro[4.5]decane-8-carbonitrile (1.3 g, viscous yellow oil). TLC system:EtOAc—pet ether (1:1); Rf=0.45. The product was used for the next step without additional purification.


Step 4: CIS-1-(cyclobutylmethyl)-8-(isobutyl(methyl)amino)-3-(4-methoxybenzyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one

A round bottom flask containing 1-(cyclobutylmethyl)-8-(isobutyl(methyl)amino)-3-(4-methoxybenzyl)-2-oxo-1,3-diazaspiro[4.5]decane-8-carbonitrile (1.3 g, 2.81 mmol) was cooled in an ice bath (˜0° C.) and a solution of phenylmagnesium bromide (26 ml, ˜2M in THF) was added slowly at 0° C.-5° C. The ice bath was removed and the reaction mixture was stirred for 30 min, then diluted with sat. aq. NH4Cl (25 ml) and extracted with EtOAc (4×30 ml). The combined organic phase was dried over Na2SO4 and concentrated under reduced pressure to give pale yellow viscous oil. This residue was purified by column chromatography (silica gel, 230-400 mesh, eluent: EtOAc—pet ether (15:85)→(2:4)) to give CIS-1-(cyclobutylmethyl)-8-(isobutyl(methyl)amino)-3-(4-methoxybenzyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (135 mg, 10%, white solid). TLC system:EtOAc—pet ether (1:1); Rf=0.6


Step 5: CIS-1-(Cyclobutyl-methyl)-8-(methyl-(2-methyl-propyl)-amino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one

A round bottom flask containing CIS-1-(cyclobutylmethyl)-8-(isobutyl(methyl)amino)-3-(4-methoxybenzyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (130 mg, 0.25 mmol) was cooled in an ice bath and a mixture of TFA/CH2Cl2 (2.6 ml, 1:1, v/v) was added slowly at 0° C.-5° C. The reaction mixture was warmed to RT and stirred for 20 h, then quenched with methanolic NH3 (10 ml, ˜10% in MeOH) and concentrated under reduced pressure to give pale yellow viscous oil. This residue was purified twice by column chromatography (silica gel, 230-400 mesh, eluent: MeOH—CHCl3 (1:99)→(2:98)) to give CIS-1-(cyclobutyl-methyl)-8-(methyl-(2-methyl-propyl)-amino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-953) (65 mg, 66%, white solid). TLC system:MeOH—CHCl3 (5:95); Rf=0.25; [M+H]+ 384.3


Synthesis of INT-958: 4-Oxo-1-pyridin-2-yl-cyclohexane-1-carbonitrile



embedded image


Step 1: Ethyl 5-cyano-2-oxo-5-(pyridin-2-yl)cyclohexanecarboxylate

KOtBu (57.0 g, 508.4 mmol) was added to the solution of 2-(pyridin-2-yl)acetonitrile (50.0 g, 423.7 mmol) and ethyl acrylate (89.0 g, 889.8 mmol) in THF (500 mL) at 0° C. and stirred for 16 h at RT. The reaction mixture was quenched with sat. aq. NH4Cl and extracted with EtOAc (2×500 mL). The combined organic layer was washed with brine, dried over Na2SO4 and concentrated under reduced pressure to afford 68.0 g (60%; crude) of ethyl 5-cyano-2-oxo-5-(pyridin-2-yl)cyclohexanecarboxylate as a brown liquid (TLC system: 50% ethyl acetate in petroleum ether; Rf: 0.65).


Step 2: 4-Oxo-1-pyridin-2-yl-cyclohexane-1-carbonitrile

A solution of ethyl 5-cyano-2-oxo-5-(pyridin-2-yl)cyclohexanecarboxylate (68.0 g, 250.0 mmol) was added to a mixture of conc. aq. HCl and glacial acetic acid (170 mL/510 mL) at 0° C. The reaction mixture was heated to 100° C. for 16 h. All volatiles were evaporated under reduced pressure. The residue was diluted with sat. aq. NaHCO3 and extracted with ethyl acetate (3×300 mL). The combined organic layer was washed with brine, dried over Na2SO4 and concentrated under reduced pressure to afford 44.0 g (88%) of 4-oxo-1-pyridin-2-yl-cyclohexane-1-carbonitrile INT-958 as a brown solid (TLC system: 50% ethyl acetate in pet ether; Rf: 0.45). [M+H]+ 201.1


Synthesis of INT-961: 4-Dimethylamino-4-pyridin-2-yl-cyclohexan-1-one



embedded image


Step 1: 8-(pyridin-2-yl)-1,4-dioxaspiro[4.5]decane-8-carbonitrile

A solution of 4-oxo-1-pyridin-2-yl-cyclohexane-1-carbonitrile (INT-958) (44.0 g, 220.0 mmol), ethylene glycol (27.0 g, 440.0 mmol) and PTSA (4.2 g, 22.0 mmol) in toluene (450 mL) was heated to 120° C. for 16 h using Dean Stark apparatus. All volatiles were evaporated under reduced pressure. The residue was diluted with sat. aq. NaHCO3 and extracted with ethyl acetate (3×300 mL). The combined organic layer was washed with brine, dried over Na2SO4 and concentrated under reduced pressure to afford 45.0 g (85%) of 8-(pyridin-2-yl)-1,4-dioxaspiro[4.5]decane-8-carbonitrile as a light brown solid (TLC system: 50% ethyl acetate in petroleum ether; Rf: 0.55).


Step 2: 8-(pyridin-2-yl)-1,4-dioxaspiro[4.5]decane-8-carboxamide

Potassium carbonate (50.0 g, 368.84 mmol) and 30% aq. H2O2 (210.0 mL, 1844.2 mmol) were added to the solution of 8-(pyridin-2-yl)-1,4-dioxaspiro[4.5]decane-8-carbonitrile (45.0 g, 184.42 mmol) in DMSO (450 mL) at 0° C. and the resulting mixture was stirred at RT for 14 h. The reaction mixture was diluted with water (1.5 L) and stirred for 1 h. The precipitated solid was separated by filtration, washed with water, petroleum ether and dried under reduced pressure to get 32.0 g (66%) of 8-(pyridin-2-yl)-1,4-dioxaspiro[4.5]decane-8-carboxamide as a white solid. (TLC system: 10% MeOH in DCM Rf: 0.35).


Step 3: methyl 8-(pyridin-2-yl)-1,4-dioxaspiro[4.5]decan-8-ylcarbamate

A mixture of 8-(pyridin-2-yl)-1,4-dioxaspiro[4.5]decane-8-carboxamide (25.0 g, 95.41 mmol), sodium hypochlorite (5 wt % aq. solution, 700 mL, 477.09 mmol) and KF—Al2O3 (125.0 g) in methanol (500 mL) was heated to 80° C. for 16 h. The reaction mixture was filtered through celite and the solid residue was washed with methanol. The combined filtrate was concentrated under reduced pressure. The residue was diluted with water and extracted with ethyl acetate (3×500 mL). The combined organic layer was washed with brine, dried over Na2SO4 and concentrated under reduced pressure to afford 18.0 g (66%) of methyl 8-(pyridin-2-yl)-1,4-dioxaspiro[4.5]decan-8-ylcarbamate as a light brown solid. (TLC system: 5% MeOH in DCM Rf: 0.52.)


Step 4: 8-(pyridin-2-yl)-1,4-dioxaspiro[4.5]decan-8-amine

A suspension of methyl 8-(pyridin-2-yl)-1,4-dioxaspiro[4.5]decan-8-ylcarbamate (18.0 g, 61.64 mmol) in 10 wt % aq. NaOH (200 mL) was heated to 100° C. for 24 h. The reaction mixture was filtered through celite pad, the solid residue was washed with water and the combined filtrate was extracted with EtOAc (4×200 mL). The combined organic layer washed with brine, dried over Na2SO4 and concentrated under reduced pressure to afford 12.5 g (88%) of 8-(pyridin-2-yl)-1,4-dioxaspiro[4.5]decan-8-amine as a light brown semi-solid. (TLC system: 5% MeOH in DCM Rf: 0.22.).


Step 5: 4-Dimethylamino-4-pyridin-2-yl-cyclohexan-1-one

Sodium cyanoborohydride (13.7 g, 0.213 mol) was added portionwise to a solution of 8-(pyridin-2-yl)-1,4-dioxaspiro[4.5]decan-8-amine (12.5 g, 53.418 mmol) and 35 wt % aq. formaldehyde (45 mL, 0.534 mol) in acetonitrile (130 mL) at 0° C. The reaction mixture was warmed up to room temperature and stirred for 16 h. The reaction mixture was quenched with sat. aq. NH4Cl and concentrated under reduced pressure. The residue was dissolved in water and extracted with EtOAc (3×200 mL). The combined organic layer was washed with brine, dried over Na2SO4 and concentrated under reduced pressure to afford 10.5 g (72%) of 4-dimethylamino-4-pyridin-2-yl-cyclohexan-1-one (INT-961) as a light brown solid. (TLC system: 5% MeOH in DCM Rf: 0.32.). [M+H]+ 219.1


Synthesis of INT-965: 4-Dimethylamino-4-phenyl-cyclohexan-1-one



embedded image


Step 1: 8-(Dimethylamino)-1,4-dioxaspiro 4.5]decane-8-carbonitrile

Dimethylamine hydrochloride (52 g, 0.645 mol) was added to the solution of 1,4-dioxaspiro-[4.5]-decan-8-one (35 g, 0.224 mmol) in MeOH (35 mL) at RT under argon atmosphere. The solution was stirred for 10 min and 40 wt % aq. dimethylamine (280 mL, 2.5 mol) and KCN (32 g, 0.492 mol) were sequentially added. The reaction mixture was stirred for 48 h at RT, then diluted with water (100 mL) and extracted with EtOAc (2×200 mL). The combined organic layer was dried over anhydrous Na2SO4 and concentrated under reduced pressure to afford 44 g of 8-(dimethylamino)-1,4-dioxaspiro-[4.5]-decane-8-carbonitrile (93%) as a white solid.


Step 2: N,N-dimethyl-8-phenyl-1,4-dioxaspiro [4.5]decan-8-amine

8-(Dimethylamino)-1,4-dioxaspiro[4.5]decane-8-carbonitrile (35 g, 0.167 mol) in THF (350 mL) was added to the solution of 3M phenylmagnesium bromide in diethyl ether (556 mL, 1.67 mol) dropwise at −10° C. under argon atmosphere. The reaction mixture was stirred for 4 h at −10° C. to 0° C. and then at RT for 18 h. The reaction completion was monitored by TLC. The reaction mixture was cooled to 0° C., diluted with sat. aq. NH4Cl (1 L) and extracted with EtOAc (2×600 mL). The combined organic layer was dried over anhydrous Na2SO4 and concentrated under reduced pressure to afford 60 g of, N N-dimethyl-8-phenyl-1, 4-dioxaspiro-[4.5]-decan-8-amine as a liquid.


Step 3: 4-(dimethylamino)-4-phenylcyclohexanone

A solution of N,N-dimethyl-8-phenyl-1,4-dioxaspiro[4.5]decan-8-amine (32 g, 0.123 mol) in 6N aq. HCl (320 mL) was stirred at 0° C. for 2 h and then at RT for 18 h. The reaction completion was monitored by TLC. The reaction mixture was extracted with DCM (2×150 mL). The aqueous layer was basified to pH 10 with solid NaOH and extracted with ethyl acetate (2×200 mL). The combined organic layer was dried over anhydrous Na2SO4 and concentrated under reduced pressure. The solid residue was washed with hexane and dried in vacuo to afford 7 g of 4-dimethylamino-4-phenyl-cyclohexan-1-one (INT-965) (25% over 2 steps) as a brown solid. [M+H]+ 218.1


Synthesis of INT-966: 3-[(4-Methoxyphenyl)-methyl]-1,3-diazaspiro[4.5]decane-2,8-dione



embedded image


Step 1: 9,12-Dioxa-2,4-diazadispiro[4.2.4{circumflex over ( )}{8}.2{circumflex over ( )}{5}]tetradecane-1,3-dione

KCN (93.8 g, 1441.6 mmol) and (NH4)2CO3 (271.8 g, 1729.9 mmol) were added to the solution of 1,4-dioxaspiro[4.5]decan-8-one (150 g, 961 mmol) in MeOH:H2O (1:1 v/v) (1.92 L) at RT under argon atmosphere. The reaction mixture was stirred at 60° C. for 16 h. The reaction completion was monitored by TLC. The reaction mixture was cooled to 0° C., the precipitated solid was filtered off and dried in vacuo to afford 120 g (55%) of 9,12-dioxa-2,4-diazadispiro[4.2.4{circumflex over ( )}{8}.2{circumflex over ( )}{(5}]tetradecane-1,3-dione. The filtrate was extracted with DCM (2×1.5 L). The combined organic layer was dried over anhydrous Na2SO4 and concentrated under reduced pressure to afford additional 30 g (14%) of 9,12-dioxa-2,4-diazadispiro[4.2.4{circumflex over ( )}{8}.2{circumflex over ( )}{5}]tetradecane-1,3-dione (TLC system: 10% Methanol in DCM; Rf: 0.4).


Step 2: 2-[(4-Methoxyphenyl)-methyl]-9,12-dioxa-2,4-diazadispiro[4.2.4{circumflex over ( )}{8}.2{circumflex over ( )}{5}]tetradecane-1,3-dione

Cs2CO3 (258.7 g, 796.1 mmol) was added to the solution of 73a (150 g, 663.4 mmol) in MeCN (1.5 L) under argon atmosphere and the reaction mixture was stirred for 30 min. A solution of p-methoxybenzyl bromide (96 mL, 663.4 mmol) was added. The reaction mixture was stirred at RT for 48 h. The reaction completion was monitored by TLC. The reaction mixture was quenched with sat. aq. NH4Cl (1.0 L) and the organic product was extracted with EtOAc (2×1.5 L). The combined organic layer was dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was washed with diethyl ether and pentane and dried under reduced pressure to afford 151 g (65%) of 2-[(4-Methoxyphenyl)-methyl]-9,12-dioxa-2,4-diazadispiro[4.2.4{circumflex over ( )}{8}.2{circumflex over ( )}{5}]tetradecane-1,3-dione as an off white solid (TLC system: 10% MeOH in DCM; Rf: 0.6).


Step 3: 2-[(4-Methoxyphenyl)-methyl]-9,12-dioxa-2,4-diazadispiro[4.2.4{circumflex over ( )}{8}.2{circumflex over ( )}{5}]tetradecan-3-one

AlCl3 (144.3 g, 1082.6 mmol) was added to a solution of LiAlH4 (2M in THF) (433 mL, 866.10 mmol) in THF (4.5 L) at 0° C. under argon atmosphere and the resulting mixture was stirred at RT for 1 h. 2-[(4-Methoxyphenyl)-methyl]-9,12-dioxa-2,4-diazadispiro[4.2.4{circumflex over ( )}{8}.2{circumflex over ( )}{5}]tetradecane-1,3-dione (150 g, 433.05 mmol) was added at 0° C. The reaction mixture was stirred at RT for 16 h. The reaction completion was monitored by TLC. The reaction mixture was cooled to 0° C., quenched with sat. aq. NaHCO3 (500 mL) and filtered through celite pad. The filtrate was extracted with EtOAc (2×2.0 L). The combined organic layer was dried over anhydrous Na2SO4 and concentrated in vacuo to afford 120 g (84%) of 2-[(4-methoxyphenyl)-methyl]-9,12-dioxa-2,4-diazadispiro[4.2.4{circumflex over ( )}{8}.2{circumflex over ( )}{5}]tetradecan-3-one as an off-white solid. (TLC system: 10% MeOH in DCM, Rf: 0.5).


Step 4: 3-[(4-Methoxyphenyl)-methyl]-1,3-diazaspiro[4.5]decane-2,8-dione

A solution of 2-[(4-methoxyphenyl)-methyl]-9,12-dioxa-2,4-diazadispiro[4.2.4{circumflex over ( )}{8}.2{circumflex over ( )}{5}] tetradecan-3-one (120 g, 361.03 mmol) in 6N aq. HCl (2.4 L) was stirred at 0° C. for 2 h and then at RT for 18 h. The reaction completion was monitored by TLC. The reaction mixture was extracted with DCM (2×2.0 L). The aqueous layer was basified to pH 10 with 50% aq. NaOH and then extracted with DCM (2×2.0 L). Combined organic extracts were dried over anhydrous Na2SO4 and concentrated under reduced pressure. The solid residue was washed with hexane and dried in vacuo to afford 90 g of 3-[(4-Methoxyphenyl)-methyl]-1,3-diazaspiro[4.5]decane-2,8-dione (INT-966) as an off-white solid (TLC system: 10% MeOH in DCM; Rf: 0.4) [M+H]+ 289.11.


Synthesis of INT-971: CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-8-(3-hydroxyphenyl)-3-[(4-methoxyphenyl)-methyl]-1,3-diazaspiro [4.5]decan-2-one



embedded image


Step 1: CIS-8-(dimethylamino)-1-isobutyl-3-(4-methoxybenzyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one

In analogy to the method described for INT-951 step 1 CIS-8-Dimethylamino-8-[3-(methoxymethyloxy)-phenyl]-3-[(4-methoxyphenyl)-methyl]-1,3-diazaspiro[4.5]decan-2-one (INT-968) was converted into CIS-1-(cyclobutylmethyl)-8-(dimethylamino)-3-(4-methoxybenzyl)-8-(3-(methoxymethoxy)phenyl)-1,3-diazaspiro[4.5]decan-2-one.


Step 2: CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-8-(3-hydroxyphenyl)-3-[(4-methoxyphenyl)-methyl]-1,3-diazaspiro[4.5]decan-2-one

TFA (0.2 mL) was added to the solution of CIS-1-(cyclobutylmethyl)-8-(dimethylamino)-3-(4-methoxybenzyl)-8-(3-methoxyphenyl)-1,3-diazaspiro[4.5]decan-2-one (300 mg, 0.57 mmol) in DCM (1.5 mL) at 0° C. The reaction mixture was stirred at 0° C. for 3 h. The reaction completion was monitored by TLC. The reaction mixture was quenched with sat. aq. NaHCO3 and the organic product was extracted with DCM (3×10 mL). The combined organic extracts were dried over anhydrous Na2SO4 and concentrated under reduced pressure. Purification of the residue by preparative TLC (3% MeOH in DCM as mobile phase) yielded 50 mg (18%) of CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-8-(3-hydroxyphenyl)-3-[(4-methoxyphenyl)-methyl]-1,3-diazaspiro[4.5]decan-2-one (INT-971) as an off white solid. (TLC system: 10% MeOH in DCM;


Rf: 0.20) [M+H]+ 478.3
Synthesis of INT-974: CIS-8-Dimethylamino-8-(3-fluorophenyl)-3-[(4-methoxyphenyl)-methyl]-1,3-diazaspiro[4.5]decan-2-one



embedded image


Step 1: 8-(dimethylamino)-3-(4-methoxybenzyl)-2-oxo-1,3-diazaspiro[4.5]decane-8-carbonitrile

Dimethylamine hydrochloride (76.4 g, 936.4 mmol) was added to a solution of 3-[(4-methoxyphenyl)-methyl]-1,3-diazaspiro[4.5]decane-2,8-dione (INT-966) (90 g, 312.13 mmol) in MeOH (180 mL) at RT under argon atmosphere. The solution was stirred for 15 min and 40 wt % aq. dimethylamine (780 mL) and KCN (48.76 g, 749.11 mmol) were sequentially added. The reaction mixture was stirred for 48 h and the completion of the reaction was monitored by NMR. The reaction mixture was diluted with water (1.0 L) and the organic product was extracted with ethyl acetate (2×2.0 L). The combined organic layer was dried over anhydrous Na2SO4 and concentrated under reduced pressure to afford 90 g (85%) of 8-(dimethylamino)-3-(4-methoxybenzyl)-2-oxo-1,3-diazaspiro[4.5]decane-8-carbonitrile as an off white solid (TLC system:TLC system: 10% MeOH in DCM; Rf: 0.35, 0.30).


Step 2: CIS-8-Dimethylamino-8-(3-fluorophenyl)-3-[(4-methoxyphenyl)-methyl]-1,3-diazaspiro[4.5]decan-2-one

3-Fluorophenylmagnesium bromide (1M in THF) (220 mL, 219.17 mmol) was added dropwise to a solution of 8-(dimethylamino)-3-(4-methoxybenzyl)-2-oxo-1,3-diazaspiro[4.5]decane-8-carbonitrile (15 g, 43.83 mmol) in THF (300 mL) at 0° C. under argon atmosphere. The reaction mixture was stirred for 16 h at RT. The reaction completion was monitored by TLC. The reaction mixture was cooled to 0° C., quenched with sat. aq. NH4Cl (200 mL) and the organic product was extracted with EtOAc (2×200 mL). The combined organic layer was dried over anhydrous Na2SO4 and concentrated under reduced pressure. The reaction was carried out in 4 batches (15 g×2 and 5 g×2) and the batches were combined for purification. Purification of the crude product by flash column chromatography on silica gel (230-400 mesh) (2 times) (0-20% methanol in DCM) eluent and subsequently by washing with pentane yielded 5.6 g (11%) of CIS-8-dimethylamino-8-(3-fluorophenyl)-3-[(4-methoxyphenyl)-methyl]-1,3-diazaspiro[4.5]decan-2-one (INT-974) as an off-white solid. (TLC system: 5% MeOH in DCM in presence of ammonia; Rf: 0.1). [M+H]+ 412.2


Synthesis of INT-975: CIS-8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one



embedded image


KOtBu (1M in THF) (29.30 mL, 29.30 mmol) was added to the solution of CIS-8-Dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one INT-976 (8.0 g, 29.30 mmol) in THF (160 mL) under argon atmosphere and the reaction mixture was stirred for 30 min. 4-Methoxybenzyl bromide (4.23 mL, 29.30 mmol) was added and stirring was continued at RT for 4 h. The reaction completion was monitored by TLC. The reaction mixture was diluted with sat. aq. NH4Cl (150 mL) and the organic product was extracted with EtOAc (2×150 mL). The combined organic layer was dried over anhydrous Na2SO4 and concentrated in vacuo. The reaction was carried out in 2 batches (8 g×2) and the batches were combined for purification. Purification of the crude product by flash column chromatography on silica gel (0-10% methanol in DCM) and subsequently by washing with pentane yielded 11 g (47%) of CIS-8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-975) as a white solid. [M+H]+ 394.2


Synthesis of INT-976: CIS-8-Dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one



embedded image


Step 1: 8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4,5]decane-2,4-dione

In a sealed tube 4-dimethylamino-4-phenyl-cyclohexan-1-one (INT-965) (2 g, 9.22 mmol) was suspended in 40 mL EtOH/H2O (1:1 v/v) at RT under argon atmosphere. (NH4)2CO3 (3.62 g, 23.04 mmol) and KCN (0.6 g, 9.22 mmol) were added. The reaction mixture was stirred at 60° C. for 18 h. The reaction mixture was cooled to 0° C. and diluted with ice-water and filtered through a glass filter. The solid residue was dried under reduced pressure to afford 8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4,5]decane-2,4-dione (1.8 g, 86%) as an off white crystalline solid (TLC: 80% EtOAc in hexane; Rf: 0.25).


Step 2: 8-(dimethylamino)-8-phenyl-1, 3-diazaspiro [4, 5] decan-2-one

LiAlH4 (2M in THF) (70 mL, 139.4 mmol) was added to the solution of 8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4,5]decane-2,4-dione (10 g, 34.8 mmol) in THF/Et2O (2:1 v/v) (400 mL) at 0° C. under argon atmosphere. The reaction mixture was stirred for 4 h at 60° C. The reaction completion was monitored by TLC. The reaction mixture was cooled to 0° C., quenched with saturated Na2SO4 solution (100 mL) and filtered through Celite pad. The filtrate was dried over anhydrous Na2SO4 and concentrated in vacuo to afford 5.7 g (59%) of 8-(dimethylamino)-8-phenyl-1, 3-diazaspiro [4, 5] decan-2-one as an off white solid. (TLC system: 10% MeOH in DCM, Rf: 0.3).


Step 3: CIS-8-Dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one

A mixture of CIS- and TRANS-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4,5]decan-2-one (8 g, 29.30 mmol) was purified by preparative chiral SFC (column: Chiralcel AS-H, 60% CO2, 40% (0.5% DEA in MeOH)) to get 5 g of CIS-8-Dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-976) as a white solid. [M+H]+ 274.2.


Synthesis of INT-977: CIS-2-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl)-acetic acid; 2,2,2-trifluoro-acetic acid salt



embedded image


Step 1: CIS-2-[8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl]-acetic acid tert-butyl ester

A solution of CIS-8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-975) (5.0 g, 12.7 mmol) in THF (18 mL) was cooled to 0° C. and treated with LDA solution (2M in THF/heptane/ether, 25.4 mL, 50.8 mmol). The resulting mixture was was allowed to warm up to RT over 30 min. The solution was then cooled to 0° C. again and tert-butyl-bromoacetate (5.63 mL, 38.1 mmol) was added. The reaction mixture was stirred at RT for 16 h, quenched with water and extracted with DCM (3×). The combinded organic layers were dried over Na2SO4, filtered and concentrated inder reduced pressure. Purification of the residue by column chromatography on silica gel provided CIS-2-[8-dimethylamino-3-[(4-methoxyphenyl)-methyl]-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl]-acetic acid tert-butyl ester (4.4 g).


Step 2: cis-2-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl)-acetic acid trifluoroacetic acid salt

CIS-2-[8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl]-acetic acid tert-butyl ester (200 mg, 0.4 mmol) was dissolved in TFA (5 mL) and heated to reflux overnight. After cooling to RT all volatiles are removed in vacuo. The residue was taken up in THF (1 mL) and added dropwise to diethyl ether (20 mL). The resulting precipitate was filtered off and dried under reduced pressure to give CIS-2-(8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl)-acetic acid; 2,2,2-trifluoro-acetic acid salt (INT-977) (119 mg) as a white solid. [M+H]+ 332.2


Synthesis of INT-978: CIS-2-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl)-N,N-dimethyl-acetamide



embedded image


CIS-2-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl)-acetic acid (INT-977) trifluoroacetic acid salt (119 mg, 0.35 mmol) was dissolved in DCM (5 mL). Triethylamine (0.21 mL, 1.6 mmol), dimethylamine (0.54 mL, 1.1 mmol) and T3P (0.63 mL, 1.1 mmol) were sequentially added. The reaction mixture was stirred at RT overnight, then diluted with 1 M aq. Na2CO3 (5 mL). The aqueous layer was extracted with DCM (3×5 mL), the combined organic layers were dried over Na2SO4 and concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel to yield CIS-2-(8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl)-N,N-dimethyl-acetamide (INT-978) (39 mg) as a white solid. [M+H]+ 359.2


Synthesis of INT-982: CIS-8-Dimethylamino-1-[(1-methyl-cyclobutyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one



embedded image


Step 1: CIS-8-(dimethylamino)-3-(4-methoxybenzyl)-1-((1-methylcyclobutyl)methyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one

A solution of NaOH (2.85 g, 71.2 mmol) in DMSO (25 mL) was stirred at RT for 10 min. CIS-8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-975) (7.00 g, 17.8 mmol) was added and stirring was continued for 15 min. 1-(Bromo-methyl)-1-methyl-cyclobutane (8.7 g, 53.4 mmol) was added at 0° C. The reaction mixture was heated to 60° C. for 16 h. After cooling down to RT, water (100 mL) was added and the mixture was extracted with DCM (3×150 mL). The combined organic layers were washed with water (70 mL), brine (100 mL), dried over Na2SO4 and concentrated under reduced pressure. Purification of the residue by column chromatography on silica gel provided CIS-8-(dimethylamino)-3-(4-methoxybenzyl)-1-((1-methylcyclobutyl)methyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (6.5 g) as a light yellow solid.


Step 2: CIS-8-Dimethylamino-1-[(1-methyl-cyclobutyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one

To the solution of CIS-8-Dimethylamino-1-[(1-methyl-cyclobutyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (6.66 g, 14.0 mmol) in DCM (65 mL) was added TFA (65 mL) and the resulting mixture was stirred at RT for 16 h. The reaction mixture was concentrated under reduced pressure. The residue was taken up in DCM (100 mL) and water (60 mL) and basified with 2M aq. NaOH to pH 10. The organic layer was separated and washed with brine (40 mL), dried over MgSO4, filtered and concentrated under reduced pressure. Crystallization of the residue from EtOAc provided CIS-8-Dimethylamino-1-[(1-methyl-cyclobutyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-982) (3.41 g) as an off-white solid. [M+H]+ 356.3


Synthesis of INT-984: CIS-1-(Cyclobutyl-methyl)-8-(ethyl-methyl-amino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one



embedded image


Step 1: CIS-8-(dimethylamino)-1-isobutyl-3-(4-methoxybenzyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one

In analogy to the method described for INT-951 step 1 CIS-8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-975) was converted into CIS-8-(dimethylamino)-1-isobutyl-3-(4-methoxybenzyl)-8-phenyl-1,3-diazaspiro [4.5]decan-2-one.


Step 2: CIS-1-(Cyclobutyl-methyl)-8-(ethyl-methyl-amino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one

In analogy to the method described for INT-982 step 2 CIS-8-(dimethylamino)-1-isobutyl-3-(4-methoxybenzyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one was converted into CIS-1-(Cyclobutyl-methyl)-8-(ethyl-methyl-amino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-984).


Synthesis of INT-986: CIS-1-(Cyclobutyl-methyl)-8-(ethyl-methyl-amino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one



embedded image


Step 1: CIS-3-benzyl-1-(cyclobutylmethyl)-8-(methylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one

N-Iodosuccinimide (3.1 g, 13.92 mmol) was added to the solution of CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-8-phenyl-3-[phenyl-methyl]-1,3-diazaspiro[4.5]decan-2-one (INT-950) (4 g, 9.28 mmol) in a mixture of acetonitrile and THF (1:1 v/v, 80 mL) and the resulting mixture was stirred at RT for 16 h. The reaction mixture was basified with 2N aq. NaOH to pH-10 and the organic product was extracted with DCM (3×10 mL). The combined organic extracts were dried over anhydrous Na2SO4 and concentrated in vacuo. The residue was stirred vigorously with a mixture of 10 wt % aq. citric acid (5 mL) and DCM (10 mL) at RT for 10 min. The reaction mixture was basified with 5N aq. NaOH to pH-10 and extracted with DCM (3×10 mL). The combined organic layer was dried over anhydrous Na2SO4 and concentrated in vacuo to give 3.5 g (crude) of CIS-3-benzyl-1-(cyclobutylmethyl)-8-(methylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one as semi solid (TLC system: 10% MeOH in DCM; Rf: 0.60.).


Step 2: CIS-3-benzyl-1-(cyclobutylmethyl)-8-(ethyl(methyl)amino)-8-phenyl-1,3-diazaspiro [4.5]decan-2-one

Sodium cyanoborohydride (1.56 g, 25.17 mmol, 3 equiv.) was added to the solution of CIS-3-benzyl-1-(cyclobutylmethyl)-8-(methylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (3.5 g, 8.39 mmol), acetaldehyde (738 mg, 16.78 mmol, 2 equiv.) and acetic acid (0.5 mL) in methanol (20 mL). The reaction mixture was stirred at RT for 3 h, then quenched with sat. aq. NaHCO3 and the organic product was extracted with DCM (3×50 mL). The combined organic extracts were dried over anhydrous Na2SO4 and concentrated in vacuo. Purification of the residue by flash column chromatography on silica gel (230-400 mesh) (20-25% ethyl acetate in petroleum ether) yielded 2.3 g (62%) of CIS-3-benzyl-1-(cyclobutylmethyl)-8-(ethyl(methyl)amino)-8-phenyl-1,3-diazaspiro [4.5]decan-2-one as a solid. (TLC system: 50% EtOAc in Pet. Ether; Rf: 0.65).


Step 3: CIS-1-(Cyclobutyl-methyl)-8-(ethyl-methyl-amino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-986)

Sodium metal (1.18 g, 51.68 mmol, 10 equiv.) was added to liquid ammonia (˜25 mL) at −78° C. The resulting mixture was stirred for 10 min at −78° C. A solution of CIS-3-benzyl-1-(cyclobutylmethyl)-8-(ethyl(methyl)amino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (2.3 g, 5.16 mmol) in THF (25 mL) was added at −78° C. The reaction mixture was stirred for 15 min, then quenched with sat. aq. NH4Cl, warmed to RT and stirred for 1 h. The organic product was extracted with DCM (3×50 mL). The combined organic layer was washed with water, brine and concentrated under reduced pressure to afford 1.30 g (72%) of CIS-1-(cyclobutylmethyl)-8-(ethyl(methyl)amino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-986) as an off-white solid. (TLC system: 10% MeOH in DCM Rf: 0.15.). [M+H]+ 356.3


Synthesis of INT-987: CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one



embedded image


In analogy to the method as described for INT-982 step 2 CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-8-phenyl-3-[(4-methoxyphenyl)-methyl]-1,3-diazaspiro[4.5]decan-2-one (INT-952) was converted into CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-987).


Synthesis of INT-988: CIS-8-(dimethylamino)-1-(2-(1-methoxycyclobutyl)ethyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one



embedded image


Step 1: CIS-8-(dimethylamino)-1-[2-(1-methoxycyclobutyl)ethyl]-3-[(4-methoxyphenyl)methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one

Sodium hydroxide (78.06 mg, 4.0 equiv.) was suspended in DMSO (3.5 mL), stirred for 10 minutes, 8-(dimethylamino)-3-[(4-methoxyphenyl)methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-975) (192.0 mg, 1.0 equiv.) was added, the reaction mixture was stirred for 5 min followed by addition of 2-(1-methoxycyclobutyl)ethyl 4-methylbenzenesulfonate (416.2 mg, 3.0 equiv.) in DMSO (1.5 mL). The resulting mixture was stirred overnight at 50° C. The reaction mixture was quenched with water and extracted with DCM (3×20 mL). The combined organic phases were washed with brine, dried over Na2SO4 and concentrated under reduced pressure. The residue (283 mg yellow oil) was purified by column chromatography on silica gel (eluent DCM/EtOH 98/2 to 96/4) to give 8-(dimethylamino)-1-[2-(1-methoxycyclobutyl)ethyl]-3-[(4-methoxyphenyl)methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one 163 mg (66%).


Step 2: CIS-8-(dimethylamino)-1-(2-(1-methoxycyclobutyl)ethyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-988)

In analogy to the method described for INT-982 step 2 CIS-8-(dimethylamino)-1-[2-(1-methoxycyclobutyl)ethyl]-3-[(4-methoxyphenyl)methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one was converted into CIS-8-(dimethylamino)-1-(2-(1-methoxycyclobutyl)ethyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-988). Mass: m/z 386.3 (M+H)+.


Synthesis of INT-989: CIS-3-(2-chloropyrimidin-5-yl)-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one



embedded image


CIS-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-976) (1250 mg, 4.6 mmol), 5-bromo-2-chloro-pyrimidine (1.5 equiv., 6.7 mmol, 1327 mg), Cs2CO3 (2 equiv., 9.15 mmol, 2980 mg), XantPhos (0.15 equiv., 0.69 mmol, 397 mg) and Pd2(dba)3 (0.05 equiv., 0.23 mmol, 209 mg) were dissolved in dry 1,4-dioxane (120 equiv., 549 mmol, 47 mL) under nitrogen atmosphere and stirred at 90° C. overnight. The reaction mixture was cooled down, diluted with water (50 mL), extracted with DCM (3×70 mL), the combined organic phases were dried over Na2SO4 and concentrated under reduced pressure. The residue (2.8 g) was suspended in 10 mL DCM and stirred for 10 min. The resulting precipitate was filtered off and washed with small amount of DCM to give 1213 mg of CIS-3-(2-chloropyrimidin-5-yl)-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-989) as a white solid. The mother liquor was concentrated under reduced pressure (1428 mg), suspended in 3 mL DCM, 3 mL pentane were slowly added and the mixture was stirred for 30 min. The precipitate was filtered off, washed with small amounts of pentane and DCM to give second portion of INT-989 (215 mg) as a light yellow solid. 1H NMR (600 MHz, DMSO) δ 8.94 (s, 2H), 7.88 (s, 1H), 7.41-7.33 (m, 4H), 7.27 (tt, 1H), 3.65 (s, 2H), 2.49-2.32 (m, 2H), 1.98-1.88 (m, 2H), 1.96 (s, 6H), 1.87-1.73 (m, 2H), 1.53-1.47 (m, 2H). Mass: m/z 386.2 (M+H)+.


Synthesis of INT-991: lithium CIS-5-(8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)pyrimidine-2-carboxylate



embedded image


Methyl CIS-5-[8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]pyrimidine-2-carboxylate (INT-990) (950 mg, 2.32 mmol) was suspended in a mixture of MeOH (140 equiv., 325 mmol, 13 mL) and THF (70 equiv., 162 mmol, 13 mL). Lithium hydroxide 2M aq. sol. (1.3 mL) was added. The reaction mixture was stirred 5 days at RT. Additional 1.3 mL of lithium hydroxide 2M aq. sol. were added and the reaction mixture was stirred for 2 h at RT. The solvents were removed under reduced pressure. The residue was suspended in EtOAc (10 mL) and stirred overnight. The precipitate was filtered off (1.07 g) and washed with DCM (3 mL), pentane and dried under reduced pressure. The resulting solid (960 mg) containing INT-990 and residual lithium salts was used directly in the next steps. Mass: m/z 394.2 (M-Li).


Synthesis of INT-1008: CIS-8-ethylamino-8-phenyl-1,3-diaza-spiro[4.5]decan-2-one



embedded image


Step 1 and step 2: ethyl-(8-phenyl-1,4-dioxa-spiro[4.5]dec-8-yl)-amine hydrochloride (INT-1004)

A mixture of 1,4-dioxa-spiro[4.5]decan-8-one (25.0 g, 160.25 mmol, 1.0 eq.) and 2M solution of EtNH2 in THF (200 ml, 2.5 eq. 400.64 mmol) in EtOH (30 ml) was stirred at RT for 48 h. The reaction mixture was concentrated under argon atmosphere and the residue was diluted with ether (60 ml), and a freshly prepared PhLi solution was added [prepared by addition of 2.5M n-BuLi in THF (70.5 ml, 1.1 eq. 176.27 mmol) to a solution of bromobenzene (27.675 g, 1.1 eq. 176.275 mmol) in ether (100 ml) at −30° C. and stirred at RT for 1 h). The reaction mixture was stirred at RT for 1.5 h, quenched with saturated NH4Cl solution (100 ml) at 0° C. and extracted with ethyl acetate (2×750 ml). The combined organic layer was washed with water (3×350 ml), brine (300 ml), dried over Na2SO4 and concentrated under reduced pressure. The resulting residue was dissolved in ethyl methyl ketone (100 ml) and trimethylsilyl chloride (37.5 ml) was added at 0° C. The resulting mixture was stirred at RT for 16 h. The precipitated solid was filtered off and washed with acetone followed by THF to get ethyl-(8-phenyl-1,4-dioxa-spiro[4.5]dec-8-yl)-amine hydrochloride as an off white solid. This reaction was done in 2 batches of 25 g scale and the yield is given for 2 combined batches. Yield: 18% (17.1 g, 57.575 mmol). LCMS: m/z 262.2 (M+H)+.


Step 3: 4-ethylamino-4-phenyl-cyclohexanone (INT-1005)

To a solution of ethyl-(8-phenyl-1,4-dioxa-spiro[4.5]dec-8-yl)-amine hydrochloride (10.1 g, 34.0 mmol, 1 eq.) in water (37.5 ml) was added conc. aq. HCl (62.5 ml) at 0° C. and the resulting mixture was stirred at RT for 16 h. The reaction mixture was basified with aq. NaOH (pH ˜14) at 0° C. and extracted with DCM (2×750 ml). Organic layer was washed with water (400 ml), brine (400 ml), dried over Na2SO4 and concentrated under reduced pressure to yield 4-ethylamino-4-phenyl-cyclohexanone which was used in the next step without further purification. This reaction was carried out in another batch of 15.1 g scale and the yield is given for 2 combined batches. Yield: 92% (17.0 g, 78.34 mmol).


Step 4: cis and trans mixture of 8-ethylamino-8-phenyl-1,3-diaza-spiro[4.5]decane-2,4-dione (INT-1006 and INT-1007)

To a solution of 4-ethylamino-4-phenyl-cyclohexanone (17 g, 78.341 mmol, 1.0 eq.) in EtOH (250 ml) and water (200 ml) was added (NH4)2CO3 (18.8 g, 195.85 mmol, 2.5 eq.) and the reaction mixture was stirred at RT for 15 min. KCN (5.09 g, 78.341 mmol, 1.0 eq.) was added and stirring was continued at 60° C. for 18 h. The reaction mixture was cooled down to RT. The precipitated solid was filtered off, washed with water (250 ml), EtOH (300 ml), hexane (200 ml) and dried under reduced pressure to yield cis and trans mixture of 8-ethylamino-8-phenyl-1,3-diaza-spiro[4.5]decane-2,4-dione (13.0 g, 45.29 mmol, 58%) as a white solid. Yield: 58% (13 g, 45.296 mmol). LC-MS: m/z [M+1]+=288.2.


Step 5: CIS-8-ethylamino-8-phenyl-1,3-diaza-spiro[4.5]decane-2,4-dione (INT-1006)

To a solution of cis and trans mixture of 8-ethylamino-8-phenyl-1,3-diaza-spiro[4.5]decane-2,4-dione (12 g) in MeOH-DCM (1:1, 960 ml) was added a solution of L-tartaric acid in MeOH (25 ml) and the resulting mixture stirred at RT for 2 h and then kept in refrigerator for 16 h. The precipitated solid was filtered off and washed with MeOH-DCM (1:5, 50 ml) to get tartrate salt of 8-ethylamino-8-phenyl-1,3-diaza-spiro[4.5]decane-2,4-dione (7.5 g) as a white solid. To this solid sat. aq. NaHCO3 was added (pH-8) and the resulting mixture was extracted with 25% MeOH-DCM (2×800 ml). Combined organic layer was washed with water (300 ml), brine (300 ml), dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was triturated with 20% DCM-hexane and the resulting solid was dried under reduced pressure to afford CIS-8-ethylamino-8-phenyl-1,3-diaza-spiro[4.5]decane-2,4-dione as white solid. This step was done in 2 batches (12 g & 2.4 g) and the yield is given for 2 combined batches. Yield: 31.2% (5.0 g, 17.421 mmol). LC-MS: m/z [M+1]+=288.0.


Step 6: CIS-8-ethylamino-8-phenyl-1,3-diaza-spiro[4.5]decan-2-one (INT-1008)

To a slurry of LiAlH4 (793 mg, 20.91 mmol, 3.0 eq.) in THF (15 ml) was added a suspension of CIS-8-ethylamino-8-phenyl-1,3-diaza-spiro[4.5]decane-2,4-dione (2.0 g, 6.97 mmol, 1.0 eq.) in THF (60 ml) at 0° C. and the reaction mixture was heated to 65° C. for 16 h. The reaction mixture was cooled to 0° C., quenched with sat. aq. Na2SO4 (20 ml), stirred at RT for 1 h and filtered through celite pad. The residue was washed with 15% MeOH-DCM (500 ml). The combined filtrate was dried over anhydrous Na2SO4 and concentrated under reduced pressure to give crude product which was triturated with 15% DCM-Hexane to afford CIS-8-ethylamino-8-phenyl-1,3-diaza-spiro[4.5]decan-2-one (INT-1008) (1.6 g, 5.86 mmol, 84%) as a white solid. Yield: 84% (1.6 g, 5.86 mmol). LC-MS: m/z [M+1]+=274.2.


Synthesis of INT-1026: CIS-8-(methyl((tetrahydrofuran-3-yl)methyl)amino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one



embedded image


Step 1: 2-methyl-N-(1,4-dioxaspiro[4.5]decan-8-ylidene)propane-2-sulfinamide

Titanium ethoxide (58.45 g, 256.4 mmol) was added to a solution of 1,4-dioxaspiro[4.5]decan-8-one (20 g, 128.20 mmol) and 2-methylpropane-2-sulfinamide (15.51 g, 128.20 mmol) in THF (200 mL) at RT and the reaction mixture was stirred at RT for 18 h. The reaction mixture was cooled to 0° C. and quenched by dropwise addition of sat. aq. NaHCO3 (500 mL) over a period of 30 min. The organic product was extracted with EtOAc (3×100 mL). The combined organic extracts were dried over anhydrous Na2SO4 and concentrated in vacuo to afford 10 g (crude) of 2-methyl-N-(1,4-dioxaspiro[4.5]decan-8-ylidene)propane-2-sulfinamide as a white solid (TLC system: 30% Ethyl acetate in hexane; Rf: 0.30).


Step 2: 2-methyl-N-(8-phenyl-1,4-dioxaspiro[4.5]decan-8-yl)propane-2-sulfinamide

Phenylmagnesium bromide (1M in THF, 116 mL, 116 mmol) was added dropwise to a solution of 2-methyl-N-(1,4-dioxaspiro[4.5]decan-8-ylidene)propane-2-sulfinamide (10 g, 38.61 mmol) in THF (500 mL) at −10° C. under argon atmosphere. The reaction mixture was stirred for 2 h at −10° C. to 0° C. The reaction completion was monitored by TLC. The reaction mixture was quenched with sat. aq. NH4Cl (50 mL) at 0° C. and the organic product was extracted with EtOAc (3×100 mL). The combined organic extracts were dried over anhydrous Na2SO4 and concentrated in vacuo. The residue was purified by column chromatography (silica gel 230-400 mesh; 40-60% ethyl acetate in hexane) to yield 6.0 g (46%) of 2-methyl-N-(8-phenyl-1,4-dioxaspiro[4.5]decan-8-yl)propane-2-sulfinamide as a liquid (TLC system: 70% Ethyl acetate in hexane; Rf: 0.30).


Step 3: 8-phenyl-1,4-dioxaspiro[4.5]decan-8-amine hydrochloride

2N solution of HCl in diethyl ether (17.80 mL, 35.60 mmol) was added to a solution of 2-methyl-N-(8-phenyl-1,4-dioxaspiro[4.5]decan-8-yl)propane-2-sulfinamide (6.0 g, 17.80 mmol) in DCM (60 mL) at 0° C. The reaction mixture was stirred at RT for 2 h. The reaction mixture was concentrated in vacuo. The residue was washed with diethyl ether to yield 3 g (crude) of 8-phenyl-1,4-dioxaspiro[4.5]decan-8-amine hydrochloride as a brown solid (TLC system: 5% MeOH in DCM; Rf: 0.10).


Step 4: 8-phenyl-N-((tetrahydrofuran-3-yl)methyl)-1,4-dioxaspiro[4.5]decan-8-amine

Sodium cyanoborohydride (2.17 g, 33.45 mmol) was added to a solution of 8-phenyl-1,4-dioxaspiro[4.5]decan-8-amine hydrochloride (3.0 g, 11.15 mmol) and tetrahydrofuran-3-carbaldehyde (4.46 mL, 22.30 mmol) and acetic acid (0.05 mL) in methanol (30 mL) at 0° C. The reaction mixture was stirred at RT for 16 h. The reaction mixture was concentrated in vacuo at 30° C. and to the residue sat. aq. NaHCO3 was added. The organic product was extracted with DCM (3×30 mL). The combined organic extracts were dried over anhydrous Na2SO4 and solvent was concentrated under reduced pressure to get 3 g (crude) of 8-phenyl-N-((tetrahydrofuran-3-yl)methyl)-1,4-dioxaspiro[4.5]decan-8-amine as a semi-solid (TLC system: 10% MeOH in DCM; Rf: 0.22).


Step 5: N-methyl-8-phenyl-N-((tetrahydrofuran-3-yl)methyl)-1,4-dioxaspiro[4.5]decan-8-amine)

Sodium cyanoborohydride (1.76 g, 28.39 mmol) was added to a solution of 8-phenyl-N-((tetrahydrofuran-3-yl)methyl)-1,4-dioxaspiro[4.5]decan-8-amine (3.0 g, 9.46 mmol), 37% formaldehyde in water (7.70 mL, 94.60 mmol) and acetic acid (0.05 mL) in methanol (30 mL) at 0° C. The reaction mixture was stirred at RT for 16 h. The reaction mixture was concentrated in vacuo and to the residue sat. aq. NaHCO3 was added. The organic product was extracted with DCM (3×30 mL). The combined organic extracts were dried over anhydrous Na2SO4 and solvent was concentrated under reduced pressure. The resulting residue was purified by column chromatography (silica gel 230-400 mesh; 5-6% MeOH in DCM) to yield 2.50 g (83%) of N-methyl-8-phenyl-N-((tetrahydrofuran-3-yl)methyl)-1,4-dioxaspiro[4.5]decan-8-amine as a semi solid (TLC system: 10% MeOH in DCM; Rf: 0.25).


Step 6: 4-(methyl((tetrahydrofuran-3-yl)methyl)amino)-4-phenylcyclohexanone

5% sulfuric acid in water (25 mL) was added to N-methyl-8-phenyl-N-((tetrahydrofuran-3-yl)methyl)-1,4-dioxaspiro[4.5]decan-8-amine (2.50 g, 7.55 mmol) at 0° C. and the resulting mixture was stirred at RT for 24 h. The reaction mixture was quenched with sat. aq. NaHCO3 and the organic product was extracted with DCM (2×50 mL). The combined organic layers were dried over anhydrous Na2SO4 and concentrated in vacuo to afford 2.0 g (crude) of 4-(methyl((tetrahydrofuran-3-yl)methyl)amino)-4-phenylcyclohexanone as a thick liquid (TLC system: 10% MeOH in DCM, Rf: 0.20).


Step 7: 8-(methyl((tetrahydrofuran-3-yl)methyl)amino)-8-phenyl-1,3-diazaspiro[4.5]decane-2,4-dione

4-(methyl((tetrahydrofuran-3-yl)methyl)amino)-4-phenylcyclohexanone (1.50 g, 5.22 mmol) was suspended in 30 mL of EtOH:H2O (1:1 v/v) at RT under argon atmosphere. (NH4)2CO3 (1.9 g, 13.05 mmol) and KCN (0.34 g, 5.22 mmol) were added. The reaction mixture was heated to 70° C. for 16 h. The reaction mixture was diluted with ice-water and the organic product was extracted with DCM (2×50 mL). The combined organic layer was dried over anhydrous Na2SO4 and concentrated in vacuo to give 1.0 g (crude) of 8-(methyl((tetrahydrofuran-3-yl)methyl)amino)-8-phenyl-1,3-diazaspiro[4.5]decane-2,4-dione as a solid (TLC system: 70% Ethyl acetate in hexane; Rf: 0.18).


Step 8: CIS-8-(methyl((tetrahydrofuran-3-yl)methyl)amino)-8-phenyl-1,3-diazaspiro[4.5]decane-2,4-dione

Diastereomeric mixture of 8-(methyl((tetrahydrofuran-3-yl)methyl)amino)-8-phenyl-1,3-diazaspiro[4.5]decane-2,4-dione (1.0 g) was separated by reverse phase preparative HPLC to afford 400 mg of isomer 1 (CIS-8-(methyl((tetrahydrofuran-3-yl)methyl)amino)-8-phenyl-1,3-diazaspiro[4.5]decane-2,4-dione) and 60 mg of isomer 2 (TRANS-8-(methyl((tetrahydrofuran-3-yl)methyl)amino)-8-phenyl-1,3-diazaspiro[4.5]decane-2,4-dione) and 300 mg of mixture of both isomers. Reverse phase preparative HPLC conditions: mobile phase: 10 mM ammonium bicarbonate in H2O/acetonitrile, column: X-BRIDGE-C18 (150*30), 5 μm, gradient (T/B %): 0/35, 8/55, 8.1/98, 10/98, 10.1/35, 13/35, flow rate: 25 ml/min, diluent: mobile phase+THF.


Step 9: CIS-8-(methyl((tetrahydrofuran-3-yl)methyl)amino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-1026)

LiAlH4 (1M in THF) (4.48 mL, 4.48 mmol) was added to a solution of CIS-8-(methyl((tetrahydrofuran-3-yl)methyl)amino)-8-phenyl-1,3-diazaspiro[4.5]decane-2,4-dione (isomer-1) (0.4 g, 1.12 mmol) in THF:Et2O (2:1 v/v, 15 mL) at 0° C. under argon atmosphere. The reaction mixture was stirred at 65° C. for 16 h. The mixture was cooled to 0° C., quenched with sat. aq. Na2SO4 (1000 mL) and filtered through celite pad. The filtrate was dried over anhydrous Na2SO4 and concentrated in vacuo. The residue was purified by column chromatography (silica gel 230-400 mesh; 5-6% MeOH in DCM) to yield 0.3 g (78%) of CIS-8-(methyl((tetrahydrofuran-3-yl)methyl)amino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-1026) as an off white solid. (TLC system: 10% MeOH in DCM, Rf: 0.2). LC-MS: m/z [M+1]+=344.2.


Synthesis of INT-1031: CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-8-(3-fluorophenyl)-1,3-diazaspiro[4.5]decan-2-one



embedded image


Step 1: CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-8-(3-fluorophenyl)-3-[(4-methoxyphenyl)-methyl]-1,3-diazaspiro[4.5]decan-2-one

In analogy to the method described for INT-952 CIS-8-dimethylamino-8-(3-fluorophenyl)-3-[(4-methoxyphenyl)-methyl]-1,3-diazaspiro[4.5]decan-2-one (INT-974) was converted into CIS-1-(cyclobutyl-methyl)-8-dimethylamino-8-(3-fluorophenyl)-3-[(4-methoxyphenyl)-methyl]-1,3-diazaspiro[4.5]decan-2-one.


Step 2: CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-8-(3-fluorophenyl)-1,3-diazaspiro[4.5]decan-2-one

In analogy to the method described for INT-982 step 2 1-(cyclobutyl-methyl)-8-dimethylamino-8-(3-fluorophenyl)-3-[(4-methoxyphenyl)-methyl]-1,3-diazaspiro[4.5]decan-2-one was converted into 1-(cyclobutyl-methyl)-8-dimethylamino-8-(3-fluorophenyl)-1,3-diazaspiro[4.5]decan-2-one (INT-1031).


Synthesis of INT-1037: 8-(dimethylamino)-2-oxo-1,3-diazaspiro[4.5]decane-8-carbonitrile



embedded image


Step 1: 9,12-dioxa-2,4-diazadispiro[4.2.4{circumflex over ( )}{8}.2{circumflex over ( )}{5}]tetradecan-3-one

Lithiumaluminiumhydride (2.2 equiv., 292 mmol) was suspended in THF (400 mL) and the suspension was cooled to 0° C. 8-(Dimethylamino)-8-(m-tolyl)-1,3-diazaspiro[4.5]decan-2-one (B, 75 mg, 0,261 mmol) (step 1 of INT-965) was added portionwise at 0° C. The reaction mixture was stirred 1.5 h at 0° C., then overnight at RT and then 2 h at 40° C. The reaction mixture was cooled down to 0° C., quenched carefully with sat. aq. Na2SO4, EtOAc (400 mL) was added and the resulting mixture was stirred for 2 h and then left without stirring for 2 h at RT. The precipitate was filtered off and washed with EtOAc and MeOH. The resulting solid residue was suspended in methanol and stirred at RT overnight. The precipitate was filtered off and disposed. The filtrate was concentrated under reduced pressure, the residue was suspended thoroughly in water (50 mL) at 40° C., the precipitate was filtered off and dried under reduced pressure to yield 9,12-dioxa-2,4-diazadispiro[4.2.4{circumflex over ( )}{8}.2{circumflex over ( )}{5}]tetradecan-3-one (11.4 g, 41%). Mass: m/z 213.2 (M+H)+.


Step 2: 1,3-diazaspiro[4.5]decane-2,8-dione

In analogy to the method described for INT-1003 step 3 9,12-dioxa-2,4-diazadispiro[4.2.4{circumflex over ( )}{8}.2{circumflex over ( )}{5}]tetradecan-3-one was treated with conc. aq. HCl to be converted into 1,3-diazaspiro[4.5]decane-2,8-dione. Mass: m/z 169.1 (M+H)+.


Step 3: 8-(dimethylamino)-2-oxo-1,3-diazaspiro[4.5]decane-8-carbonitrile (INT-1037)

In analogy to the method described for INT-965 step 1 1,3-diazaspiro[4.5]decane-2,8-dione was treated with dimethyl amine and potassium cyanide to be converted into 8-(dimethylamino)-2-oxo-1,3-diazaspiro[4.5]decane-8-carbonitrile (INT-1037). Mass: m/z 223.2 (M+H)+.


Synthesis of INT-1038: CIS-8-(dimethylamino)-8-(m-tolyl)-1,3-diazaspiro[4.5]decan-2-one



embedded image


To the suspension of 8-(dimethylamino)-2-oxo-1,3-diazaspiro[4.5]decane-8-carbonitrile (200 mg, 0.90 mmol) in THF (4 mL) at RT was added dropwise 1M bromo(m-tolyl)magnesium in THF (4 equiv., 3.6 mmol, 3.6 mL) and the reaction mixture was stirred for 1 h at RT. Additional portion of 1M bromo(m-tolyl)magnesium in THF (1 equiv., 0.8 mL) was added. The reaction mixture was stirred at RT overnight, then quenched with methanol/water. Solid NH4Cl and DCM were added to the resulting mixture and the precipitate was filtered off. The organic phase of the filtrate was separated and the aqueous phase was extracted with DCM (3×). The combined organic phases were dried over anhydr. Na2SO4 and concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel (DCM/MeOH, 100/0 to 65/35) to yield CIS-8-(dimethylamino)-8-(m-tolyl)-1,3-diazaspiro[4.5]decan-2-one (INT-1038) (81 mg, 31%). Mass: m/z 288.2 (M+H)+.


Synthesis of INT-1059: TRANS-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one



embedded image


Step 1: TRANS-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decane-2,4-dione

To a stirred solution of 4-dimethylamino-4-phenyl-cyclohexanone (250.0 g, 1.15 mol, 1.0 eq.) in EtOH (2.5 L) and water (2.1 L) was added (NH4)2CO3 (276.2 g, 2.87 mol, 2.5 eq.) and the reaction mixture was stirred at RT for 15 min. KCN (74.92 g, 1.15 mol, 1.0 eq.) was added. The reaction mixture was stirred at 60° C. for 18 h and then filtered in hot condition to get white solid which was washed with water (2.5 L), ethanol (1 L) and hexane (2.5 L). The resulting solid was dried under reduced pressure to get CIS-8-dimethylamino-8-phenyl-1,3-diaza-spiro[4.5]decane-2,4-dione (223 g, 0.776 mol, 65%) as a white solid. The filtrate was collected from multiple batches (˜450 g) which contained a mixture of cis and trans isomers. The filtrate was concentrated under reduced pressure and solid obtained was filtered and washed with water (1 L) and hexane (1 L). Solid material was dried under reduced pressure to get ˜100 g of a mixture of cis and trans (major) isomers. Crude material was partially dissolved in hot MeOH (600 mL) and cooled to RT, filtered through sintered funnel, washed with MeOH (200 mL) followed by ether (150 mL) and dried to get TRANS-8-dimethylamino-8-phenyl-1,3-diaza-spiro[4.5]decane-2,4-dione (50 g, 0.174 mmol, ˜9-10%).


Step 2: TRANS-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-1059)

In analogy to the method described for INT-976 step 2 TRANS-8-dimethylamino-8-phenyl-1,3-diaza-spiro[4.5]decane-2,4-dione was treated with LiAlH4 to be converted into TRANS-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-1059). Mass: m/z 274.2 (M+H)+.


Synthesis of INT-1068 and INT-1069: CIS- and TRANS-8-(dimethylamino)-8-phenyl-1-(2,2,2-trifluoroethyl)-1,3-diazaspiro[4.5]decan-2-one



embedded image


Step 1: 1-amino-4-dimethylamino-4-phenyl-cyclohexanecarbonitrile

To a stirred solution of 4-dimethylamino-4-phenyl-cyclohexanone (50 g, 230.096 mmol) in MeOH (400 mL) was added NH4Cl (24.6 g, 460.8 mmol) followed by NH4OH (400 mL) at RT and the reaction mixture was stirred for 15 min. NaCN (22.5 g, 460.83 mmol) was added and the resulting mixture was stirred for 16 h at RT. The reaction mixture was extracted with DCM (3×750 mL). Combined organic layer was washed with water (750 mL), brine (750 mL), dried over Na2SO4 and concentrated under reduced pressure. The residue was triturated with DCM/hexane to get crude 1-amino-4-dimethylamino-4-phenyl-cyclohexanecarbonitrile (50 g, 90%) as an off white solid which was used in next step without further purification. LC-MS: m/z [M+H]+=244.2 (MW calc. 244.09).


Step 2: N-(1-cyano-4-dimethylamino-4-phenyl-cyclohexyl)-2,2,2-trifluoroacetamide

To a solution of 1-amino-4-dimethylamino-4-phenyl-cyclohexanecarbonitrile (5.0 g, 20.57 mmol, 1.0 eq.) in THF (100 ml) were added DIPEA (10.72 ml, 61.71 mmol, 3.0 eq), trifluoroacetic acid (1.89 ml, 24.69 mmol, 1.2 eq) and T3P (18.2 ml, 30.85 mmol, 1.5 eq) at 0° C. The reaction mixture was stirred at RT for 16 h, then diluted with water (100 ml) and extracted with 10% MeOH in DCM (2×250 mL). Combined organic layer was washed with brine (100 mL), dried over Na2SO4 and concentrated under reduced pressure to get crude N-(1-cyano-4-dimethylamino-4-phenyl-cyclohexyl)-2,2,2-trifluoroacetamide as a light yellow sticky material which was used in the next step without further purification. LC-MS: m/z [M+1]+=339.9 (MW calc. 339.36).


Step 3: 1-aminomethyl-N′,N′-dimethyl-4-phenyl-N-(2,2,2-trifluoroethyl)cyclohexane-1,4-diamine

To suspension of LiAlH4 (4.03 g, 106.19 mmol, 6.0 eq.) in dry THF (40 mL) was added N-(1-cyano-4-dimethylamino-4-phenyl-cyclohexyl)-2,2,2-trifluoro-acetamide (6.0 g, 17.69 mmol, 1.0 eq.) in dry THF (100 mL) dropwise at 0° C. The reaction mixture was stirred at RT for 16 h, then quenched with sat. aq. Na2SO4 at 0° C., excess THF was added and the resulting mixture was stirred at RT for 2 h. The resulting suspension was filtered through celite and the filter cake was washed with 10% MeOH in DCM (150 mL). Combined filtrate was concentrated under reduced pressure to yield crude 1-aminomethyl-N′,N′-dimethyl-4-phenyl-N-(2,2,2-trifluoro-ethyl)-cyclohexane-1,4-diamine (4.2 g, crude) as a light yellow sticky material which was directly used in the next step without further purification. LC-MS: m/z [M+1]+=330.0 (MW calc. 329.40).


Step 4: CIS- and TRANS-8-dimethylamino-8-phenyl-1-(2,2,2-trifluoro-ethyl)-1,3-diaza-spiro[4.5]decan-2-one (INT-1068 and INT-1069)

To a solution of 1-aminomethyl-N′,N′-dimethyl-4-phenyl-N-(2,2,2-trifluoro-ethyl)-cyclohexane-1,4-diamine (4.2 g, 12.76 mmol, 1.0 eq.) in toluene (60 ml) was added KOH (4.29 g, 76.56 mmol, 6.0 eq.) in water (120 ml) at 0° C. followed by addition of COCl2 (15.6 ml, 44.66 mmol, 3.5 eq., 20% in toluene) at 0° C. and stirred at RT for 16 h. Reaction mixture was basified with sat NaHCO3 solution and extracted with DCM (2×200 ml). Combined organic layer was dried over Na2SO4 and concentrated under reduced pressure to get crude product which was purified by prep HPLC to get CIS-8-dimethylamino-8-phenyl-1-(2,2,2-trifluoro-ethyl)-1,3-diaza-spiro[4.5]decan-2-one (INT-1068) (1.5 g) (major isomer, polar spot on TLC) and TRANS-8-dimethylamino-8-phenyl-1-(2,2,2-trifluoro-ethyl)-1,3-diaza-spiro[4.5]decan-2-one (INT-1069) as minor isomer (non-polar spot on TLC) (120 mg, 92.93% by HPLC) as off-white solids. CIS-isomer: LC-MS: m/z [M+1]+=356.2 (MW calc.=355.40). HPLC: 98.53%, Column: Xbridge C-18 (100×4.6), 5μ, Diluent: MeOH, Mobile phase: A) 0.05% TFA in water; B) ACN flow rate: 1 ml/min, Rt=5.17 min. 1HNMR (DMSO-d6, 400 MHz), δ (ppm)=7.43-7.27 (m, 5H), 6.84 (s, 1H), 3.30-3.25 (m, 4H), 2.66-2.63 (d, 2H, J=12.72 Hz), 1.89 (s, 6H), 1.58-1.51 (m, 2H), 1.46-1.43 (m, 2H), 1.33-1.23 (m, 2H).


For further intermediates the synthesis in analogy to previously described methods is given in the following table. The syntheses of the building blocks and intermediates have either been described previously within this application or can be performed in analogy to the herein described methods or by methods known to the person, skilled in the art. Such a person will also know which building blocks and intermediates need to be chosen for synthesis of each exemplary compound.



















in analogy
m/z


Intermediate
Chemical Name
Chemical Structure
to method
[M + H]+







INT-601
CIS-5-(-8-(dimethylamino)-8-(3-fluorophenyl)-2- oxo-1,3-diazaspiro[4.5]decan-3-yl)pyrimidine-2- carbonitrile


embedded image


INT-600 
395.1





INT-794
CIS-3-(3,4-dimethoxybenzyl)-8- (dimethylamino)-8-phenyl-1,3- diazaspiro[4.5]decan-2-one


embedded image


INT-975 
424.3





INT-796
CIS-8-Dimethylamino-3-[(4-methoxyphenyl)- methyl]-8-(3-methoxy-propyl)-1,3- diazaspiro[4.5]decan-2-one


embedded image


INT-974 
390.3





INT-797
CIS-8-(Ethyl-methyl-amino)-8-phenyl-1,3- diazaspiro[4.5]decan-2-one


embedded image


INT-976 
288.2





INT-949
CIS-8-Dimethylamino-1-ethyl-8-phenyl-1,3- diazaspiro[4.5]decan-2-one


embedded image


INT-984 
302.2





INT-950
CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-8- phenyl-3-[phenyl-methyl]-1,3- diazaspiro[4.5]decan-2-one


embedded image


INT-952 
432.3





INT-954
4-Dimethylamino-4-(5-methyl-thiophen-2-yl)- cyclohexan-1-one


embedded image


INT-965 
238.1





INT-955
4-Dimethylamino-4-thiophen-2-yl-cyclohexan-1- one


embedded image


INT-965 
224.1





INT-956
1-(1-Methyl-1H-pyrazol-3-yl)-4-oxo- cyclohexane-1-carbonitrile


embedded image


INT-958 
204.1





INT-957
4-Oxo-1-pyrazin-2-yl-cyclohexane-1-carbonitrile


embedded image


INT-958 
202.1





INT-959
4-Dimethylamino-4-(1-methyl-1H-pyrazol-3-yl)- cyclohexan-1-one


embedded image


INT-961 
222.2





INT-960
4-Dimethylamino-4-pyrazin-2-yl-cyclohexan-1- one


embedded image


INT-961 
220.1





INT-962
4-Dimethylamino-4-(3-methoxyphenyl)- cyclohexan-1-one


embedded image


INT-965 
248.2





INT-963
CIS-3-Benzyl-8-dimethylamino-8-phenyl-1,3- diazaspiro[4.5]decan-2-one


embedded image


INT-975 
364.2





INT-964
4-(Ethyl-methyl-amino)-4-phenyl-cyclohexan-1- one


embedded image


INT-965 
232.2





INT-967
CIS-8-Dimethylamino-8-[4- (methoxymethyloxy)-phenyl]-3-[(4- methoxyphenyl)-methyl]-1,3- diazaspiro[4.5]decan-2-one


embedded image


INT-974 
454.3





INT-968
CIS-8-Dimethylamino-8-[3- (methoxymethyloxy)-phenyl]-3-[(4- methoxyphenyl)-methyl]-1,3- diazaspiro[4.5]decan-2-one


embedded image


INT-974 
454.3





INT-969
CIS-1-(Cyclobutyl-methyl)-8-dimethylamino- 8-(4-hydroxyphenyl)-3-[(4-methoxyphenyl)- methyl]-1,3-diazaspiro[4.5]decan-2-one


embedded image


INT-971 
478.3





INT-970
CIS-8-Dimethylamino-8-(4-methoxyphenyl)-3- [(4-methoxyphenyl)-methyl]-1,3- diazaspiro[4.5]decan-2-one


embedded image


SC_2017
424.3





INT-972
CIS-8-Dimethylamino-8-(3-methoxyphenyl)-3- [(4-methoxyphenyl)-methyl]-1,3- diazaspiro[4.5]decan-2-one


embedded image


SC_2017
424.3





INT-973
CIS-8-Dimethylamino-8-(4-fluorophenyl)-3-[(4- methoxyphenyl)-methyl]-1,3- diazaspiro[4.5]decan-2-one


embedded image


INT-974 
412.2





INT-979
CIS-8-Dimethylamino-1-(3-methoxy-propyl)-8- phenyl-1,3-diazaspiro[4.5]decan-2-one


embedded image


INT-984 
346.2





INT-980
CIS-8-Dimethylamino-1-(2-methoxy-ethyl)-8- phenyl-1,3-diazaspiro[4.5]decan-2-one


embedded image


INT-984 
332.2





INT-981
CIS-8-Dimethylamino-8-phenyl-1-propyl-1,3- diazaspiro[4.5]decan-2-one


embedded image


INT-984 
316.2





INT-983
CIS-1-(Cyclopropyl-methyl)-8-dimethylamino-8- phenyl-1,3-diazaspiro[4.5]decan-2-one


embedded image


INT-984 
328.2





INT-985
CIS-1-(Cyclobutyl-methyl)-8-(methyl-propyl- amino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one


embedded image


INT-986 
370.3





INT-990
methyl CIS-5-(8-(dimethylamino)-2-oxo-8- phenyl-1,3-diazaspiro[4.5]decan-3-yl)pyrimidine- 2-carboxylate


embedded image


INT-989 
410.2





INT-992
CIS-3-(2-chloro-4-methylpyrimidin-5-yl)-8- (dimethylamino)-8-phenyl-1,3- diazaspiro[4.5]decan-2-one


embedded image


INT-989 
400.2





INT-993
4-benzyl-4-(dimethylamino)cyclohexanone


embedded image


INT-965 
232.3





INT-994
CIS-8-benzyl-8-(dimethylamino)-1,3- diazaspiro[4.5]decan-2-one


embedded image


INT-976 
288.2





INT-995
TRANS-8-benzyl-8-(dimethylamino)-1,3- diazaspiro[4.5]decan-2-one


embedded image


INT-976 
288.2





INT-997
CIS-8-(dimethylamino)-8-(thiophen-2-yl)-1,3- diazaspiro[4.5]decan-2-one


embedded image


INT-976 
280.1





INT-998
TRANS-8-(dimethylamino)-8-(thiophen-2-yl)- 1,3-diazaspiro[4.5]decan-2-one


embedded image


INT-976 
280.1





INT-999
4-(dimethylamino)-4-(1-methyl-1H- benzo[d]imidazol-2-yl)cyclohexanone


embedded image


INT-965 
272.2





INT-1000
CIS-8-(dimethylamino)-8-(1-methyl-1H- benzo[d]imidazol-2-yl)-1,3-diazaspiro[4.5]decan- 2-one


embedded image


INT-976 
328.2





INT-1001
TRANS-8-(dimethylamino)-8-(1-methyl-1H- benzo[d]imidazol-2-yl)-1,3-diazaspiro[4.5]decan- 2-one


embedded image


INT-976 
328.2





INT-1002
CIS-3-(2-chloropyrimidin-4-yl)-8- (dimethylamino)-8-phenyl-1,3- diazaspiro[4.5]decan-2-one


embedded image


INT-989 
386.9





INT-1009
TRANS-8-ethylamino-8-phenyl-1,3-diaza- spiro[4.5]decan-2-one


embedded image


INT-1008
274.2





INT-1024
CIS-8-(dimethylamino)-8-(3-fluorophenyl)-1,3- diazaspiro[4.5]decan-2-one


embedded image


INT-977  (step 2)
292.2





INT-1025
CIS-8-(dimethylamino)-8-(4-fluorophenyl)-1,3- diazaspiro[4.5]decan-2-one


embedded image


INT-974,  INT-977  (step 2)
292.2





INT-1027
CIS-3-(2-chloropyrimidin-5-yl)-8- (dimethylamino)-8-(thiophen-2-yl)-1,3- diazaspiro[4.5]decan-2-one


embedded image


INT-989 
392.1





INT-1039
CIS-8-(dimethylamino)-8-(3- (trifluoromethoxy)phenyl)-1,3- diazaspiro[4.5]decan-2-one


embedded image


INT-1038
358.2





INT-1040
(CIS)-8-(dimethylamino)-8-(3- (trifluoromethyl)phenyl)-1,3- diazaspiro[4.5]decan-2-one


embedded image


INT-1038
342.2





INT-1041
(CIS)-8-(dimethylamino)-8-(3-methoxyphenyl)- 1,3-diazaspiro[4.5]decan-2-one


embedded image


INT-1038
304.2





INT-1042
(CIS)-8-(5-chlorothiophen-2-yl)-8- (dimethylamino)-1,3-diazaspiro[4.5]decan-2-one


embedded image


INT-1038
314.1





INT-1043
(CIS)-8-(dimethylamino)-8-(3-fluoro-5- methylphenyl)-1,3-diazaspiro[4.5]decan-2-one


embedded image


INT-1038
306.2





INT-1044
(CIS)-8-(3-chlorophenyl)-8-(dimethylamino)-1,3- diazaspiro[4.5]decan-2-one


embedded image


INT-1038
308.2





INT-1045
(CIS)-3-(5-chloro-3-fluoropyridin-2-yl)-8- (dimethylamino)-8-phenyl-1,3- diazaspiro[4.5]decan-2-one


embedded image


INT-989 
403.2





INT-1047
(CIS)-8-(methyl(oxetan-3-ylmethyl)amino)-8- phenyl-1,3-diazaspiro[4.5]decan-2-one


embedded image


INT-1026
330.5





INT-1048
(CIS)-3-(6-chloropyridin-3-yl)-8- (dimethylamino)-8-phenyl-1,3- diazaspiro[4.5]decan-2-one


embedded image


INT-989 
385.2





INT-1049
(CIS)-3-(5-chloropyridin-2-yl)-8- (dimethylamino)-8-phenyl-1,3- diazaspiro[4.5]decan-2-one


embedded image


INT-989 
385.2





INT-1061
TRANS-1-(cyclopropyl-methyl)-8- dimethylamino-8-phenyl-1,3- diazaspiro[4.5]decan-2-one


embedded image


INT-984 
328.2





INT-1063
CIS-1-(cyclopropylmethyl)-8-(dimethylamino)-8- (3-fluorophenyl)-1,3-diazaspiro[4.5]decan-2-one


embedded image


INT-1031
346.2





INT-1066
TRANS-1-(cyclobutylmethyl)-8- (dimethylamino)-8-phenyl-1,3- diazaspiro[4.5]decan-2-one


embedded image


INT-987 
342.3





INT-1070
CIS-8-(dimethylamino)-8-phenyl-1-(3,3,3- trifluoropropyl)-1,3-diazaspiro[4.5]decan-2-one


embedded image


INT-1068
360.2





INT-1074
CIS-8-(dimethylamino)-8-(3-fluorophenyl)-1-((1- hydroxycyclobutyl)methyl)-1,3- diazaspiro[4.5]decan-2-one


embedded image


INT-1031
376.2





INT-1076
CIS-3-(2-chloro-4-methylpyrimidin-5-yl)-8- (dimethylamino)-8-(3-fluorophenyl)-1,3- diazaspiro[4.5]decan-2-one


embedded image


INT-989 
418.2





INT-1077
CIS-3-(4-chloro-2-(trifluoromethyl)pyrimidin-5- yl)-8-(dimethylamino)-8-(3-fluorophenyl)-1,3- diazaspiro[4.5]decan-2-one


embedded image


INT-989 
472.2





INT-1078
CIS-3-(4-chloro-2-cyclopropylpyrimidin-5-yl)-8- (dimethylamino)-8-(3-fluorophenyl)-1,3- diazaspiro[4.5]decan-2-one


embedded image


INT-989 
444.2









Synthesis of Exemplary Compounds
Synthesis of SC_3013: cis-5-[8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-pyrimidine-2-carbonitrile



embedded image


NaH (60% in mineral oil, 0.076 g, 3.19 mmol, 3 equiv.) was added to a solution of 5-(cis-8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)pyrimidine-2-carbonitrile INT_600 (0.4 g, 1.06 mmol) in DMF (5 mL) at 0° C. The mixture was stirred for 30 min at RT and then cooled to 0° C. (1-(Tert-butyldimethylsilyloxy)cyclobutyl)methyl 4-methylbenzenesulfonate (1.18 g, 3.19 mmol, 3 equiv.) was added dropwise over a period of 5 min and the reaction mixture was allowed to warm up to RT and further heated to 70° C. for 16 h. The reaction mixture was diluted with water (10 mL) and extracted with EtOAc (3×20 mL). The combined organic layers were dried over anhydrous Na2SO4 and the solvent was removed in vacuo. The residue was purified by silica gel flash chromatography to afford CIS-5-[8-dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-pyrimidine-2-carbonitrile (0.25 g).


Synthesis of SC_3014: cis-2-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-pyrimidine-5-carbonitrile



embedded image


cis-1-(Cyclobutylmethyl)-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one INT-987 (500 mg, 1.464 mmol), 2-chloropyrimidine-5-carbonitrile (409 mg, 2.928 mmol) and Cs2CO3 (954 mg, 2.928 mmol) in 1,4-dioxane (6 ml) were stirred under an nitrogen atmosphere for 18 h at 105° C. The reaction mixture was cooled to RT, 2N aqueous NaOH solution (3 ml) was added and stirring was continued for 10 min. The mixture was extracted first with EtOAc and then with a blend of DCM (30 ml) and methanol (5 ml). The organic layers were combined and concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel (elution with a DCM/EtOAc gradient) provided cis-2-[1-(cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-pyrimidine-5-carbonitrile SC_3014 (57 mg).


Synthesis of SC_3016: cis-2-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-pyrimidine-5-carboxylic acid amide



embedded image


cis-2-[1-(Cyclobutylmethyl)-8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]pyrimidine-5-carbonitrile SC_3014 (40 mg, 0.09 mmol) was dissolved in DMSO (1.2 mL) and K2CO3 (25 mg, 0.18 mmol) and hydrogen peroxide (30%, 0.13 mL 1.260 mmol) were added. The reaction mixture was stirred at RT for 20 h, then diluted with 2N NaOH (10 mL) and extracted with DCM (3×20 mL). The combined organic layers were dried over Na2SO4, concentrated in vacuo. The residue was purified by flash chromatography to yield cis-2-[1-(cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-pyrimidine-5-carboxylic acid amide SC_3016 (40 mg) as a white solid.


Synthesis of SC_3022: cis-1-(Cyclobutylmethyl)-8-(dimethylamino)-8-phenyl-3-[2-(trifluoromethyl)pyrimidin-5-yl]-1,3-diazaspiro[4.5]decan-2-one



embedded image


cis-1-(Cyclobutylmethyl)-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one INT-987 (240 mg, 0.7 mmol), Pd-XPhos Generation 2 (138 mg, 0.17 mmol), Cs2CO3 (457 mg, 1.4 mmol) and 5-bromo-2-(trifluoromethyl)pyrimidine (319 mg, 1.4 mmol) were suspended in anhydrous 1,4-dioxane (3 mL) under nitrogen atmosphere and the resulting mixture was stirred at 100° C. overnight. The reaction mixture was cooled to RT and water (3 mL) was added. The aqueous layer was extracted with DCM (3×10 mL), the combined organic layers were dried over Na2SO4 and concentrated in vacuo. The residue was purified by flash chromatography on silica gel to yield the title compound. Final purification using a strong cation exchange resin gave cis-1-(cyclobutylmethyl)-8-(dimethylamino)-8-phenyl-3-[2-(trifluoromethyl)pyrimidin-5-yl]-1,3-diazaspiro[4.5]decan-2-one SC_3022 (145 mg) as a white solid.


Synthesis of SC_3028: cis-4-[1-(cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-N,N-dimethyl-benzamide



embedded image


Step 1: Lithium 4-(cis-1-(cyclobutylmethyl)-8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)benzoate

Methyl 4-(cis-1-(cyclobutylmethyl)-8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro [4,5]decan-3-yl)benzoate SC_3081 (400 mg) was dissolved in methanol (5 mL) and DCM (5 mL). Lithium hydroxide solution (2 M in water, 1 mL) was added and the resulting mixture was stirred overnight at RT. All volatiles were removed in vacuo to yield lithium 4-(cis-1-(cyclobutylmethyl)-8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)benzoate (403 mg).


Step 2 cis-4-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro [4,5]decan-3-yl]-N,N-dimethyl-benzamide (SC_3028)

Lithium 4-(cis-1-(cyclobutylmethyl)-8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro [4,5]decan-3-yl)benzoate (80 mg, 0.17 mmol) was suspended in DCM (1 mL) and triethylamine (0.23 mL, 1.7 mmol) and dimethylamine (2M solution in THF, 0.17 mL) and T3P (0.20 mL, 0.34 mmol) were sequentially added. The resulting mixture was stirred for 18 h at RT. Water (10 mL) was added and the mixture was extracted with DCM (3×20 mL). The combined organic layers were dried over Na2SO4, concentrated in vacuo and the residue was purified by flash chromatography to yield cis-4-[1-(cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-N,N-dimethyl-benzamide SC_3028 (28 mg) as white solid.


Synthesis of SC_3045: cis-4-Methoxy-5-[1-(3-methoxypropyl)-8-(methylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]pyrimidine-2-carbonitrile



embedded image


N-iodosuccinimide (150 mg, 0.67 mmol) was added to a suspension of cis-5-[8-(dimethylamino)-1-(3-methoxypropyl)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-4-methoxy-pyrimidine-2-carbonitrile SC_3040 (214 mg, 0.44 mmol) in acetonitrile/THF (2/1 v/v, 10 mL) at RT and the resulting mixture was stirred for 16 h at RT. The reaction mixture was basified with 2N NaOH solution to pH-10 and the organic product was extracted with DCM (10 mL×3). The combined organic extracts were dried over anhydrous Na2SO4, the solvent was removed in vacuo and the residue was purified by preparative flash chromatography to give cis-4-methoxy-5-[1-(3-methoxypropyl)-8-(methylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]pyrimidine-2-carbonitrile SC_3045 (81 mg) as a solid.


Synthesis of SC_3064: cis-2-[3-(2-cyano-pyrimidin-5-yl)-8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl]-N-propyl-acetamide



embedded image


Sodium hydroxide (51 mg, 1.3 mmol) was added to anhydrous DMSO (4.5 mL) and stirred for 10 minutes at room temperature. cis-5-[8-(Dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]pyrimidine-2-carbonitrile INT_600 (80 mg, 0.21 mmol) was added and the resulting mixture was stirred at room temperature for 5 min and then heated to 50° C. 2-Bromo-N-propyl-acetamide (153 mg, 0.85 mmol) was added and stirring was continued at 50° C. for one hour. The reaction mixture was quenched with water (25 mL) and extracted with ethyl acetate (2×10 mL). The combined organic layers were washed with water (5 mL) and brine (5 mL), dried over Na2SO4 and concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel to yield cis-2-[3-(2-cyano-pyrimidin-5-yl)-8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl]-N-propyl-acetamide SC 3064 (22 mg) as a solid.


Synthesis of SC_3065: 5-(cis-1-(Cyclobutylmethyl)-8-(ethyl(methyl)amino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-4-methoxypyrimidine-2-carbonitrile



embedded image


Cs2CO3 (274 mg, 0.84 mmol) was added to the solution of cis-1-(cyclobutylmethyl)-8-(ethyl(methyl)amino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one INT_986 (150 mg, 0.42 mmol), Xanthphos (36 mg, 0.063 mmol), Pd2(dba)3 (19 mg, 0.0211 mmol) and 5-bromo-4-methoxypyrimidine-2-carbonitrile (135 mg, 0.633 mmol) in 1,4-dioxane (10 mL) under argon atmosphere. The mixture was flushed again with argon for 5 min and the reaction mixture was stirred at 90° C. for 5 h. The reaction mixture was cooled to room temperature. The residue was diluted with water (20 mL) and the organic product was extracted with ethyl acetate (3×10 mL). The combined organic extracts were dried over anhydrous Na2SO4 and the solvent was concentrated under reduced pressure. The residue was purified by preparative TLC (EtOAc/petroleum ether 1/9) to afford a white solid (0.15 g), which was further washed with n-pentane to give 0.1 g of 5-(cis-1-(cyclobutylmethyl)-8-(ethyl(methyl)amino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-4-methoxypyrimidine-2-carbonitrile SC_3065.


Synthesis of SC_3008: cis-2-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-5-methylsulfoylsulfonyl-benzonitrile



embedded image


cis-2-[1-(Cyclobutylmethyl)-8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-5-methylsulfanyl-benzonitrile (320 mg, 0.66 mmol, prepared from 2-iodo-5-(methylthio)benzonitrile and INT-987 analogously to SC_3022) was dissolved in a mixture of methanol (9 mL) and water (8 mL). Oxone® (807 mg, 1.3 mmol) was added at RT and the resulting mixture was stirred at RT for 18 h. Water (10 mL) was added and the mixture was extracted with DCM (3×20 mL). The combined organic layers were dried over Na2SO4, concentrated in vacuo. The residue was purified by flash chromatography on silica gel to yield cis-2-[1-(cyclobutylmethyl)-8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-5-methylsulfonyl-benzonitrile SC_3008 (66 mg) as a white solid.


Synthesis of SC_3023: cis-8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-3-(2-hydroxy-pyrimidin-5-yl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one



embedded image


Boron tribromide (1M in DCM, 0.38 mL, 0.387 mmol) was added to the solution of cis-8-dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-3-(2-methoxy-pyrimidin-5-yl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one SC_3015 (180 mg, 0.387 mmol) in DCM (2 mL) at 0° C. The reaction mixture was stirred for 30 min at 0° C. and then for 16 h at room temperature, quenched with methanol (2 mL), the solvents were removed under reduced pressure and the residue was purified by normal phase preparative HPLC to yield cis-8-dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-3-(2-hydroxy-pyrimidin-5-yl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one SC_3023 (60 mg, 34%) as a white solid. 1H NMR (400 MHz, DMSO-d6, δ in ppm): δ 8.43 (s, 2H), 7.35-7.25 (m, 5H), 5.50 (s, 1H), 3.67 (s, 2H), 3.19 (s, 2H), 2.69-2.65 (m, 2H), 2.19-2.10 (m, 4H), 1.98-1.85 (m, 8H), 1.68-1.61 (m, 1H), 1.51-1.39 (m, 5H).


Synthesis of SC_3025: cis-5-[8-Dimethylamino-1-(2-hydroxy-ethyl)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-pyrimidine-2-carbonitrile



embedded image


Step 1: 5-(cis-1-(2-(tert-Butyldimethylsilyloxy)ethyl)-8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)pyrimidine-2-carbonitrile

NaH (60% in mineral oil, 63.8 mg, 1.59 mmol) was added at 0° C. to the solution of 5-(cis-8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)pyrimidine-2-carbonitrile INT-600 (0.2 g, 0.53 mmol) in DMF (8 mL) for 10 min at 0° C. The reaction mixture was stirred at RT for 30 min, (3-bromopropoxy)(tert-butyl)dimethylsilane (252 mg, 1.06 mmol) was added dropwise over 5 min at 0° C. and the mixture was stirred for further 16 h at RT. The reaction mixture was diluted with water (15 mL) and extracted with diethyl ether (3×25 mL). The combined organic extracts were dried over anhydrous Na2SO4, the solvents were removed under reduced pressure and the residue was purified by flash chromatography on silica gel to afford 5-(cis-1-(2-(tert-butyldimethylsilyloxy)ethyl)-8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)pyrimidine-2-carbonitrile (100 mg, 34%) as a white solid.


Step 2: cis-5-[8-Dimethylamino-1-(2-hydroxy-ethyl)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-pyrimidine-2-carbonitrile (SC_3025)

1M TBAF solution in THF (0.36 mL, 0.36 mmol) was added to 5-(cis-1-(2-(tert-butyldimethylsilyloxy)ethyl)-8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)pyrimidine-2-carbonitrile (0.1 g, 0.18 mmol) in THF (5 mL) at 0° C. The reaction mixture was stirred at RT for 30 min, diluted with water (10 mL) and extracted with diethyl ether (3×25 mL). The combined organic extracts were washed with sat. aq. NaHCO3, water and brine and dried over anhydrous Na2SO4. The solvents were evaporated under reduced pressure and the residue was purified by preparative TLC (ethyl acetate/n-hexane=45:55) and then washed with n-pentane (5 mL) to give of cis-5-[8-dimethylamino-1-(2-hydroxy-ethyl)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-pyrimidine-2-carbonitrile (70 mg, 80%) as a white solid. 1H NMR (400 MHz, DMSO-d6, δ in ppm): δ 9.18 (s, 2H), 7.38-7.26 (m, 5H), 4.84 (t, 1H), 3.82 (s, 2H), 3.55-3.51 (m, 2H), 3.26-3.20 (m, 2H), 2.73-2.70 (m, 2H), 2.17-2.11 (m, 2H), 2.00 (s, 6H), 1.57-1.43 (m, 4H).


Synthesis of SC_3097: CIS-8-dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-3-(2-morpholin-4-yl-pyrimidin-5-yl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one



embedded image


starting from here until the end of the section all procedures were added


Step 1: 4-(5-bromopyrimidin-2-yl)morpholine

K2CO3 (14.2 g, 103 mmol) was added to the solution of morpholine (9.0 g, 103 mmol) in acetonitrile (900 mL) and the resulting suspension was stirred at RT for 1 h. 5-Bromo-2-chloropyrimidine (20 g, 103 mmol) was added portionwise. The reaction mixture was stirred for 16 h at 80° C., then cooled down to RT and diluted with EtOAc (100 mL) and water (50 mL). The organic product was extracted with EtOAc (2×100 mL). The combined organic layer was washed with brine (100 mL), dried over anhydrous Na2SO4 and concentrated under reduced pressure. The resulting residue was purified by column chromatography on silica gel (100-200 mesh) (20% EtOAc in petroleum ether) to afford 18.0 g (71%) of 4-(5-bromopyrimidin-2-yl)morpholine as an off white solid (TLC system: 30% EtOAc in pet ether, Rf: 0.6).


Step 2: CIS-8-dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-3-(2-morpholin-4-yl-pyrimidin-5-yl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (SC_3097)

K2CO3 (0.53 g, 3.85 mmol, 2.5 equiv.) was added to the suspension of CIS-8-(dimethylamino)-1-((1-hydroxycyclobutyl)methyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-799) (0.55 g, 1.54 mmol, 1 equiv.) and 4-(5-bromopyrimidin-2-yl)morpholine (0.37 g, 1.54 mmol, 1 equiv.) in dioxane (20 mL) and the resulting suspension was purged with nitrogen for 5 min. Copper(I) iodide (0.29 g, 1.54 mmol, 1 equiv.) and trans-1,2-diaminocyclohexane (0.35 g, 3.085 mmol, 2 equiv.) were sequentially added, the reaction vessel was sealed and the reaction mixture was stirred at 130° C. for 4 h. The reaction mixture was cooled down to RT and diluted with EtOAc (20 mL) and aq. ammonia (10 mL). The organic product was extracted with EtOAc (2×50 mL). The combined organic layer was washed with brine (50 mL), dried over anhydrous Na2SO4 and concentrated under reduced pressure. Purification of the resulting residue by column chromatography on silica gel (100-200 mesh) (60-70% EtOAc in petroleum ether) afforded 0.35 g (48%) of CIS-8-(dimethylamino)-1-((1-hydroxycyclobutyl)methyl)-3-(2-morpholin-4-yl-pyrimidin-5-yl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (SC_3097) as an off white solid (TLC system:EtOAc, Rf: 0.7). 1H NMR (DMSO-d6): δ 8.60 (s, 2H), 7.36-7.35 (m, 4H), 7.27-7.24 (m, 1H), 5.50 (s, 1H), 3.72 (s, 2H), 3.62-3.61 (m, 8H), 3.21 (s, 2H), 2.70-2.66 (m, 2H), 2.19-2.11 (m, 4H), 1.98 (s, 6H), 1.93-1.85 (m, 2H), 1.66-1.64 (m, 1H), 1.53-1.42 (m, 5H). Mass: m/z 521.3 (M+H)+.


Synthesis of SC_3099: CIS-1-[(1-hydroxy-cyclobutyl)-methyl]-8-methylamino-3-(2-morpholin-4-yl-pyrimidin-5-yl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one



embedded image


N-Iodosuccinimide (162 mg, 0.72 mmol) was added to the solution CIS-8-(dimethylamino)-1-((1-hydroxycyclobutyl)methyl)-3-(2-morpholinopyrimidin-5-yl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (SC-3097) (250 mg, 0.48 mmol) in acetonitrile (8.0 mL) and THF (8.0 mL) at 0° C. and the resulting mixture was stirred for 16 h at RT. The reaction mixture was concentrated under reduced pressure. The residue was dissolved in EtOAc (2×30 mL), the organic layer was washed with 2N aq. NaOH solution, dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by reverse phase prep. HPLC to yield 0.12 g (49%) of CIS-1-((1-hydroxycyclobutyl)methyl)-8-(methylamino)-3-(2-morpholinopyrimidin-5-yl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (SC_3099) as an off white solid (TLC system 5% MeOH in DCM Rf: 0.5.). Preparative reverse phase HPLC conditions: column: Luna-Phenyl-Hexyl-C18 (150*19 mm) 5 μm; mobile phase: 10 mM ammonium bicarbonate/acetonitrile, gradient (T/% B): 0/50, 7/85, 7.1/98, 9/98, 9.1/50, 12/50; flow Rate: 25 ml/min; diluent: mobile phase+THF. 1H NMR (DMSO-d6): δ 8.63 (s, 2H), 7.49-7.47 (m, 2H), 7.34-7.30 (t, 2H), 7.21-7.17 (m, 1H), 5.60 (s, 1H), 3.76 (s, 2H), 3.64-3.62 (m, 8H), 3.35 (m, 2H), 2.26-2.20 (m, 3H), 2.12-2.08 (m, 2H), 1.90-1.88 (m, 7H), 1.79-1.73 (m, 2H), 1.65-1.63 (m, 1H), 1.52-1.44 (m, 3H). Mass: m/z 507.3 (M+H)+.


Synthesis of SC_3100: CIS-8-dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-8-phenyl-3-(2-piperazin-1-yl-pyrimidin-5-yl)-1,3-diazaspiro[4.5]decan-2-one hydrochloride



embedded image


Step 1: tert-butyl 4-(5-bromopyrimidin-2-yl)piperazine-1-carboxylate

In analogy to the method described for SC_3097 step 1 tert-butyl piperazine-1-carboxylate was reacted with 5-bromo-2-chloropyrimidine to be converted into tert-butyl 4-(5-bromopyrimidin-2-yl)piperazine-1-carboxylate.


Step 2: tert-butyl 4-(5-((cis)-8-(dimethylamino)-1-((1-hydroxycyclobutyl)methyl)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)pyrimidin-2-yl)piperazine-1-carboxylate

K2CO3 (0.38 g, 2.8 mmol, 2.5 equiv.) was added to the suspension of CIS-8-(dimethylamino)-1-((1-hydroxycyclobutyl)methyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (0.4 g, 1.12 mmol, 1 equiv.) (INT-799) and tert-butyl 4-(5-bromopyrimidin-2-yl)piperazine-1-carboxylate (0.38 g, 1.12 mmol, 1 equiv.) in dioxane (25 mL) and the resulting mixture was purged with nitrogen for 5 min. Copper(I) iodide (0.21 g, 1.12 mmol, 1 equiv.) and trans-1,2-diaminocyclohexane (0.25 g, 2.24 mmol, 2 equiv.) were sequentially added, the reaction vessel was sealed and the reaction mixture was stirred for 10 h at 130° C. The reaction mixture was cooled down to RT and diluted with EtOAc (20 mL) and aq. ammonia (10 mL). The organic product was extracted with e EtOAc (2×50 mL). The combined organic layer was washed with brine (50 mL), dried over anhydrous Na2SO4 and concentrated under reduced pressure. Purification of the residue by column chromatography on silica gel (100-200 mesh) (60-70% EtOAc in petroleum ether) afforded 0.5 g (72%) of tert-butyl 4-(5-((cis)-8-(dimethylamino)-1-((1-hydroxycyclobutyl)methyl)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)pyrimidin-2-yl)piperazine-1-carboxylate as an off white solid (TLC system: 1:1 EtOAc/pet ether, Rf: 0.3).


Step 3: CIS-8-(dimethylamino)-1-((1-hydroxycyclobutyl)methyl)-8-phenyl-3-(2-(piperazin-1-yl)pyrimidin-5-yl)-1,3-diazaspiro[4.5]decan-2-one hydrochloride (SC_3100)

4N HCl in dioxane (2 mL) was added to tert-butyl 4-(5-(cis-8-(dimethylamino)-1-((1-hydroxycyclobutyl)methyl)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)pyrimidin-2-yl)piperazine-1-carboxylate (0.15 g, 0.24 mmol). The resulting mixture was stirred at 0° C. for 6 h and then concentrated under reduced pressure to give a pale yellow solid which was triturated with n-pentane and lyophilized with water for 16 h to yield 0.14 g of CIS-8-(dimethylamino)-1-((1-hydroxycyclobutyl)methyl)-8-phenyl-3-(2-(piperazin-1-yl)pyrimidin-5-yl)-1,3-diazaspiro[4.5]decan-2-one hydrochloride (SC_3100) as a pale yellow solid. 1H NMR (DMSO-d6): δ 10.42 (br s, 1H), 9.34 (br s, 2H), 8.63 (s, 2H), 7.70-7.68 (m, 2H), 7.54-7.50 (m, 3H), 3.88-3.86 (m, 4H), 3.77 (m, 4H), 3.16-3.11 (m, 6H), 2.52-2.49 (m, 6H), 2.47 (m, 2H), 2.10-2.07 (m, 2H), 2.00-1.95 (t, 2H), 1.87-1.81 (m, 3H), 1.70-1.68 (m, 2H), 1.58 (m, 1H). Mass: m/z 520.3 (M+H)+.


Synthesis of SC_3103: CIS-1-(cyclobutyl-methyl)-8-dimethylamino-3-[4-methyl-6-(trifluoromethyl)-pyridin-3-yl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one



embedded image


Cs2CO3 (2 g, 6.451 mmol) was added to an argon purged solution of CIS-1-(cyclobutylmethyl)-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-987) (1.1 g, 3.225 mmol, 1 equiv.), Xantphos (279 mg, 0.483 mmol, 0.15 equiv.), Pd2(dba)3 (295 mg, 0.322 mmol, 0.1 equiv.) and 5-bromo-4-methyl-2-(trifluoromethyl)pyridine (774 mg, 3.225 mmol, 1 equiv.) in 1,4-dioxane (55 mL). The mixture was purged again with argon for 15 min. The reaction mixture was stirred at 90° C. for 18 h, then cooled down to RT, filtered through Celite and washed with EtOAc (80 mL). The filtrate was concentrated under reduced pressure. The resulting residue was purified by flash chromatography (neutral alumina, 0-3% methanol in DCM) to afford 0.6 g (37%) of CIS-1-(cyclobutylmethyl)-8-(dimethylamino)-3-(4-methyl-6-(trifluoromethyl)pyridin-3-yl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (SC_3103) as an off white solid. (TLC system: 5% MeOH in DCM; Rf: 0.5). 1H NMR (DMSO-d6): δ 8.56 (s, 1H), 7.80 (s, 1H), 7.34-7.24 (m, 5H), 3.71 (s, 2H), 3.17 (d, 2H), 2.70-2.56 (m, 3H), 2.31 (s, 3H), 2.17-2.11 (m, 2H), 2.03-2.00 (m, 8H), 1.82-1.73 (m, 4H), 1.54-1.41 (m, 4H). Mass: m/z 501.3 (M+H)+.


Synthesis of SC_3105: CIS-1-(cyclopropyl-methyl)-8-dimethylamino-3-(4-methylsulfonyl-phenyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one



embedded image


NaH (60% in mineral oil) (36.80 mg, 0.92 mmol) was added portionwise to the solution of CIS-8-(dimethylamino)-3-(4-(methylsulfonyl)phenyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (200 mg, 0.46 mmol, prepared from INT-976 and 1-bromo-4-(methylsulfonyl)benzene by analogy with SC_3103) in DMF (30 mL) at 0° C. under argon atmosphere and the resulting mixture was stirred for 10 min. (Bromomethyl)cyclopropane (122 mg, 0.92 mmol) was added dropwise at 0° C., ice bath was removed and the reaction mixture was further stirred for 4 h at room temperature. The reaction progress was monitored by TLC. The reaction mixture was diluted with water (30 mL) and the precipitated solid was filtered. Purification by column chromatography (silica gel 100-200 mesh, 50-60% ethyl acetate in hexane as eluent) to get 80 mg (35%) of CIS-1-(cyclopropylmethyl)-8-(dimethylamino)-3-(4-(methylsulfonyl)phenyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (SC_3105) as off white solid (TLC system: 10% MeOH in DCM; Rf: 0.70). 1H NMR (CDCl3): δ 7.85-7.83 (d, 2H), 7.73-7.71 (d, 2H), 7.39-7.36 (m, 2H), 7.32-7.27 (m, 3H), 3.64 (s, 2H), 3.20 (d, 2H), 3.00 (s, 3H), 2.75-2.71 (m, 2H), 2.43-2.36 (m, 2H), 2.07 (s, 6H), 1.57 (m, 2H), 1.50 (m, 2H), 1.11-1.06 (m, 1H), 0.59-0.54 (m, 2H), 0.41-0.37 (m, 2H). Mass: m/z 482.2 (M+H)+.


Synthesis of SC_3109: CIS-2-[8-Dimethylamino-1-[2-(1-methoxy-cyclobutyl)-ethyl]-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-benzamide



embedded image


Step 1: CIS-2-(8-(dimethylamino)-1-(2-(1-methoxycyclobutyl)ethyl)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)benzonitrile

In analogy to the method described for SC_3103 CIS-8-(dimethylamino)-1-(2-(1-methoxycyclobutyl)ethyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one was reacted with 2-bromobenzonitrile to be converted into CIS-2-(8-(dimethylamino)-1-(2-(1-methoxycyclobutyl)ethyl)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)benzonitrile.


Step 2: CIS-2-[8-Dimethylamino-1-[2-(1-methoxy-cyclobutyl)-ethyl]-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-benzamide SC_3109

CIS-2-[8-(dimethylamino)-1-[2-(1-methoxycyclobutyl)ethyl]-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]benzonitrile (57.0 mg, 1.0 equiv.) was dissolved in DMSO (1.6 mL), hydrogen peroxide (0.167 mL, 14.0 equiv., 30 mass % in water solution) and K2CO3 (32.4 mg, 2.0 equiv.) were added and the reaction mixture was stirred at RT for 18 h. The reaction mixture was then quenched with 10 mL water, extracted with DCM (3×10 mL), the combined organic extracts were dried over Na2SO4 and concentrated under reduced pressure (24 mg crude product). The aqueous phase was concentrated to dryness (91 mg), suspended in DCM, the precipitate was filtered off and the organic solution was concentrated under reduced pressure to give additional 56 mg of the crude product. The combined crude product was purified by column chromatography on silica gel (DCM/EtOH 95/5) to give 37 mg (62%) of CIS-2-[8-dimethylamino-1-[2-(1-methoxy-cyclobutyl)-ethyl]-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-benzamide (SC_3109) as a white solid. 1H NMR (600 MHz, DMSO) δ 7.52-7.48 (s, 1H), 7.47-7.31 (m, 7H), 7.29-7.23 (m, 1H), 7.25-7.22 (s, 1H), 7.24-7.18 (m, 1H), 3.68-3.65 (s, 3H), 3.13-3.10 (s, 2H), 3.09-3.02 (m, 2H), 2.71-2.65 (m, 2H), 2.21-2.12 (m, 2H), 2.09-1.99 (m, 2H), 2.02-1.98 (s, 6H), 1.97-1.86 (m, 4H), 1.77-1.67 (m, 1H), 1.64-1.52 (m, 3H), 1.44-1.36 (td, 2H). Mass: m/z 505.32 (M+H)+.


Synthesis of SC_3112: CIS-2-(1-((1-hydroxycyclobutyl)methyl)-8-(methylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)benzonitrile



embedded image


Step 1: CIS-2-(8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)benzonitrile

In analogy to the method described for SC_3103 1-bromo-2-cyanobenzene was reacted with CIS-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-976) to be converted into CIS-2-(8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)benzonitrile.


Step 2: CIS-2-(8-(dimethylamino)-1-((1-hydroxycyclobutyl)methyl)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)benzonitrile

To a solution of CIS-2-(8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)benzonitrile (500 mg, 1.336 mmol, 1.0 equiv.) in DMSO (16 ml) was added sodium hydroxide (213 mg, 5.334 mmol, 4.0 equiv.) and the mixture was stirred at 60° C. for 30 min. A solution of 1-oxa-spiro[2.3]hexane (237 mg, 6.68 mmol, 5.0 equiv.) in DMSO (4 ml) was added at RT and the reaction mixture was stirred at 55° C. for 16 h. The reaction mixture was diluted with water (100 ml) and extracted with EtOAc (100 ml). The organic layer was washed with water (50 ml) and brine (50 ml), dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (EtOAc/Hexane, 7/3) to yield CIS-2-(8-(dimethylamino)-1-((1-hydroxycyclobutyl)methyl)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)benzonitrile (200 mg, 0.436 mmol, 32%) as an off white solid. Mass: m/z 459.4 (M+H)+


Step 3: CIS-2-(1-((1-hydroxycyclobutyl)methyl)-8-(methylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)benzonitrile (SC_3112)

In analogy to the method described for SC_3099 CIS-2-(8-(dimethylamino)-1-((1-hydroxycyclobutyl)methyl)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)benzonitrile was reacted with N-iodosuccinimide to be converted into CIS-2-(1-((1-hydroxycyclobutyl)methyl)-8-(methylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)benzonitrile (SC_3112). Yield: 29%. 1H NMR (DMSO-d6, 400 MHz), δ (ppm)=7.75 (dd, 1H, J=7.76 Hz, 1.16 Hz), 7.70-7.65 (m, 1H), 7.50 (d, 1H, J=8.16 Hz), 7.44-7.42 (m, 2H), 7.35-7.25 (m, 3H), 7.17-7.15 (m, 1H), 5.49 (s, 1H), 3.85 (s, 2H), 3.32 (s, 2H), 2.29-2.23 (m, 2H), 2.12-2.23 (m, 2H), 1.87 (bs, 6H), 1.73-1.46 (m, 6H). Mass: m/z 445.26 (M+H)+.


Synthesis of SC_3120: CIS-8-(dimethylamino)-3-(2-(3-oxopiperazin-1-yl)pyrimidin-5-yl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one



embedded image


CIS-3-(2-chloropyrimidin-5-yl)-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-989) (100 mg, 0.259 mmol) was placed into a reaction vial for microwave reactor (5 mL), the vial was flushed with nitrogen, anhydrous n-butanol (50 equiv., 13.0 mmol, 1.2 mL), diisopropylethylamine (5 equiv., 1.30 mmol, 0.224 mL) and piperazine-2-one (1.2 equiv., 0.311 mmol, 31 mg) were added, the vial was sealed and the reaction mixture was stirred for 2.5 h at 140° C. (conventional heating). The reaction mixture was cooled down, transferred into a 1-neck flask and concentrated under reduced pressure. The resulting residue (128 mg) was purified by flash chromatography on aluminium oxide (neutral) (DCM/MeOH gradient 100/0 to 97/3) to yield 65 mg (56%) CIS-8-(dimethylamino)-3-(2-(3-oxopiperazin-1-yl)pyrimidin-5-yl)-8-phenyl-1,3-diazaspiro-[4.5]decan-2-one (SC_3120). 1H NMR (600 MHz, DMSO) δ 8.60 (s, 2H), 8.01 (s, 1H), 7.46 (s, 1H), 7.43-7.30 (m, 4H), 7.27 (td, 1H), 4.09 (s, 2H), 3.91-3.75 (m, 2H), 3.62-3.40 (m, 2H), 3.30-3.09 (m, 2H), 2.61-2.51 (m, 2H), 2.44-2.25 (m, 2H), 1.97 (s, 6H), 1.93-1.80 (m, 2H), 1.55-1.41 (m, 2H). Mass: m/z 437.27 (M+H)+.


Synthesis of SC_3129: CIS-3-(5-(8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)pyrimidin-2-yl)benzonitrile



embedded image


CIS-3-(2-chloropyrimidin-5-yl)-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-989) (1 equiv., 0.47 mmol, 180 mg), Pd(PPh3)4 (0.1 equiv., 0,047 mmol, 54 mg) and (3-cyanophenyl)boronic acid (1.5 equiv., 0.70 mmol, 103 mg) were dissolved in degassed dry tetrahydrofurane (9.5 mL) and sodium carbonate 1M aq. sol. (1.9 equiv., 0.89 mmol, 0.89 mL) was added. The resulting clear reaction mixture was stirred overnight at 70° C. Additional portion of Pd(PPh3)4 (0.1 equiv., 0,047 mmol, 54 mg) was added and the reaction was stirred further 12 h at 70° C. The reaction mixture was diluted with EtOAc (50 mL), stirred for 10 min, the precipitate was filtered off and the filtrate was concentrated under reduced pressure. The resulting residue (285 mg) was purified by flash chromatography on silica gel (gradient DCM/MeOH, 100/0 to 80/20) to yield 130 mg (62%) of CIS-3-(5-(8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)pyrimidin-2-yl)benzonitrile (SC_3129). 1H NMR (600 MHz, DMSO) δ 9.13 (s, 2H), 8.60 (dp, 2H), 7.93 (dt, 1H), 7.88 (s, 1H), 7.72 (dd, 1H), 7.42-7.35 (m, 5H), 7.28 (d, 1H), 3.73 (s, 2H), 2.01-1.91 (m, 2H), 1.98 (s, 10H), 1.57-1.48 (m, 2H). Mass: m/z 453.24 (M+H)+.


Synthesis of SC_3130: CIS-8-(dimethylamino)-3-(2-(4-(methylsulfonyl)piperazin-1-yl)pyrimidin-5-yl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one



embedded image


CIS-8-(dimethylamino)-8-phenyl-3-(2-(piperazin-1-yl)pyrimidin-5-yl)-1,3-diazaspiro[4.5]decan-2-one (SC_3124) (100 mg, 0.23 mmol) was dissolved in DCM (150 equiv., 34 mmol, 2.2 mL) under nitrogen atmosphere. To the resulting solution 4-dimethylaminopyridine (0.05 equiv., 0.012 mmol, 1.4 mg) and diisopropylethylamine (3 equiv., 0.67 mmol, 0.119 mL) were added and the mixture was cooled to 0° C. Methansulfonylchloride (2 equiv., 0.46 mmol, 0.036 mL) was added, ice bath was removed and the reaction mixture was stirred for 2 h at RT. The reaction mixture was quenched with water (5 mL), diluted with DCM (10 mL), the resulting brown suspension was filtered through a glass filter, the filtrate transferred to a separating funnel, the organic phase separated and the aqueous phase extracted with DCM (2×10 mL). The combined organic phases were dried over MgSO4 and concentrated under reduced pressure. The resulting residue (81 mg) was purified by flash chromatography on aluminium oxide (gradient DCM/EtOH 97/3 to 96/4) to yield 51 mg (43%) of CIS-8-(dimethylamino)-3-(2-(4-(methylsulfonyl)piperazin-1-yl)pyrimidin-5-yl)-8-phenyl-1,3-diazaspiro-[4.5]decan-2-one (SC_3130). 1H NMR (600 MHz, DMSO) δ 8.59 (s, 2H), 7.46 (s, 1H), 7.39 (d, 1H), 7.37 (s, 3H), 7.28 (d, 1H), 3.79-3.74 (m, 4H), 3.54 (s, 2H), 3.18-3.13 (m, 4H), 2.87 (s, 3H), 2.43-2.32 (m, 2H), 1.97 (s, 6H), 1.92-1.87 (m, 2H), 1.51-1.41 (m, 2H). Mass: m/z 514.26 (M+H)+.


Synthesis of SC_3132: CIS-8-((cyclopropylmethyl)(methyl)amino)-8-phenyl-3-(2-(trifluoromethyl)pyrimidin-5-yl)-1,3-diazaspiro[4.5]decan-2-one



embedded image


Step 1: CIS-8-(methylamino)-8-phenyl-3-(2-(trifluoromethyl)pyrimidin-5-yl)-1,3-diazaspiro[4.5]decan-2-one

In analogy to the method described for SC_3099 CIS-8-(dimethylamino)-8-phenyl-3-(2-(trifluoromethyl)pyrimidin-5-yl)-1,3-diazaspiro[4.5]decan-2-one (SC_3245) was reacted with N-iodosuccinimide to be converted into CIS-8-(methylamino)-8-phenyl-3-(2-(trifluoromethyl)pyrimidin-5-yl)-1,3-diazaspiro[4.5]decan-2-one.


Step 2: CIS-1-(4-methoxybenzyl)-8-(methylamino)-8-phenyl-3-(2-(trifluoromethyl)pyrimidin-5-yl)-1,3-diazaspiro[4.5]decan-2-one

NaH (60% in mineral oil) (296.3 mg, 7.407 mmol, 1.5 equiv.) was added portionwise to the solution CIS-8-(methylamino)-8-phenyl-3-(2-(trifluoromethyl)pyrimidin-5-yl)-1,3-diazaspiro[4.5]decan-2-one (2 g, 4.938 mmol, 1 equiv.) in DMF (20 mL) at 0° C. under argon atmosphere and the resulting mixture was stirred for 10 min. 1-(Bromomethyl)-4-methoxybenzene (1.092 g, 5.432 mmol, 1.1 equiv.) was added dropwise. The reaction mixture was allowed to warm up to RT and stirred for 16 h. The reaction progress was monitored by LCMS. The reaction mixture was diluted with water (150 mL) and the organic product was extracted with EtOAc (3×60 mL). The combined organic extracts were dried over anhydrous Na2SO4 and concentrated under reduced pressure. The resulting residue was purified by flash chromatography (silica gel 230-400 mesh; 0-4% MeOH/DCM) to afford 2 g (77%) of CIS-1-(4-methoxybenzyl)-8-(methylamino)-8-phenyl-3-(2-(trifluoromethyl)pyrimidin-5-yl)-1,3-diazaspiro[4.5]decan-2-one as an off white solid (TLC system 5% MeOH in DCM Rf: 0.55).


Step 3: CIS-8-((cyclopropylmethyl)(methyl)amino)-1-(4-methoxybenzyl)-8-phenyl-3-(2-(trifluoromethyl)pyrimidin-5-yl)-1,3-diazaspiro[4.5]decan-2-one

(Bromomethyl)cyclopropane (0.461 mL, 4.762 mmol, 5 equiv.) was added dropwise to a mixture of CIS-1-(4-methoxybenzyl)-8-(methylamino)-8-phenyl-3-(2-(trifluoromethyl)pyrimidin-5-yl)-1,3-diazaspiro-[4.5]decan-2-one (500 mg, 0.952 mmol, 1 equiv.) and K2CO3 (657 mg, 4.762 mmol, 5 equiv.) in acetonitrile (20 mL) at RT under argon atmosphere. The reaction vessel was sealed and the mixture was stirred at 95° C. for 24 h. Reaction progress was monitored by LCMS. The reaction mixture was diluted with water (50 mL) and the organic product was extracted with EtOAc (2×50 mL). The combined organic extracts were dried over anhydrous Na2SO4 and concentrated under reduced pressure. The resulting residue was purified by flash chromatography (silica gel 230-400 mesh; 0-40% EtOAc/petroleum ether) to afford 220 mg (39%) of CIS-8-((cyclopropylmethyl)(methyl)amino)-1-(4-methoxybenzyl)-8-phenyl-3-(2-(trifluoromethyl)pyrimidin-5-yl)-1,3-diazaspiro[4.5]decan-2-one as an off white solid (TLC 50% EtOAc in petroleum ether, Rf: 0.65) and 230 mg of the unreacted starting material.


Step 4: CIS-8-((cyclopropylmethyl)(methyl)amino)-8-phenyl-3-(2-(trifluoromethyl)pyrimidin-5-yl)-1,3-diazaspiro[4.5]decan-2-one (SC_3132)

TFA (4.2 mL) was added drop wise to a solution of CIS-8-((cyclopropylmethyl)(methyl)amino)-1-(4-methoxybenzyl)-8-phenyl-3-(2-(trifluoromethyl)pyrimidin-5-yl)-1,3-diazaspiro[4.5]decan-2-one (210 mg, 0.363 mmol) in DCM (0.05 mL) at 0° C. under argon atmosphere. The reaction mixture was allowed to warm up to RT and stirred for 16 h. The reaction progress was monitored by LCMS. The excess of TFA was evaporated under reduced pressure and the residual amount of TFA was removed as an azeotropic mixture with DCM (2×5 mL). The crude product was purified by preparative HPLC to yield 105 mg (63%) of CIS-8-((cyclopropylmethyl)(methyl)amino)-8-phenyl-3-(2-(trifluoromethyl)pyrimidin-5-yl)-1,3-diazaspiro[4.5]decan-2-one (SC_3132) as an off white solid (TLC system 50% EtOAc in pe ether, Rf: 0.35). 1H NMR (DMSO-d6): δ 9.17 (s, 2H), 8.10 (br s, 1H), 7.35-7.33 (m, 4H), 7.25-7.22 (m, 1H), 3.72 (s, 2H), 2.43 (m, 2H), 2.13 (s, 3H), 1.97-1.82 (m, 6H), 1.49 (m, 2H), 0.75-0.71 (m, 1H), 0.41-0.39 (m, 2H), 0.06-0.01 (m, 2H). Mass: m/z=460.2 (M+H).


Synthesis of SC_3133: CIS-8-Dimethylamino-3-[2-(4-methyl-piperazine-1-carbonyl)-pyrimidin-5-yl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one



embedded image


1-Methylpiperazine (2 equiv., 0.5 mmol, 55 μL) and [5-[8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]pyrimidine-2-carbonyl]oxylithium (INT-990) (100 mg, 0.25 mmol) were suspended in DCM (1.6 mL), triethylamine (10 equiv., 2.5 mmol, 336 μL) and propylphosphonic anhydride (>50 wt. % solution in ethyl acetate) (2 equiv., 0.5 mmol, 297 μL) were sequentially added and the reaction mixture was stirred at RT for 2 h. The resulting mixture was quenched with 2M aq. NaOH (2 mL), organic phase was separated and aqueous phase was extracted with dichloromethane (3×10 mL). The combined organic extracts were dried over Na2SO4 and concentrated under reduced pressure. The residue (88 mg) was dissolved in 3 mL DCM and 6 mL pentane were slowly added. The resulting mixture was stirred for 30 min. The precipitate was filtered off and dried under reduced pressure to give 69 mg (58%) of CIS-8-dimethylamino-3-[2-(4-methyl-piperazine-1-carbonyl)-pyrimidin-5-yl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (SC_3133). 1H NMR (600 MHz, DMSO) δ 9.03 (s, 2H), 7.87 (s, 1H), 7.42-7.34 (m, 5H), 7.28 (d, 1H), 3.69 (s, 2H), 3.62 (dd, 2H), 3.17-3.12 (m, 2H), 2.57-2.51 (m, 2H), 2.36 (t, 2H), 2.25-2.21 (m, 2H), 2.21 (s, 3H), 1.98-1.89 (m, 2H), 1.96 (s, 6H), 1.56-1.46 (m, 2H). Mass: m/z 478.29 (M+H)+.


Synthesis of SC_3146: CIS-5-(8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)pyrimidine-2-carboxamide



embedded image


Methyl CIS-5-(8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)pyrimidine-2-carboxylate (INT-990) (100 mg, 0.244 mmol) was dissolved in 7N NH3 in methanol (25 equiv. NH3, 0.9 mL) in a microwave reactor vial. The reaction vessel was sealed, the reaction mixture was stirred for 5 days at RT and then concentrated under reduced pressure. The residue was purified by flash chromatography on neutral aluminum oxide (DCM/EtOH, gradient 90/10 to 74/26) to yield 38 mg (39%) of CIS-5-(8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)pyrimidine-2-carboxamide (SC_3140). 1H NMR (600 MHz, DMSO) δ 9.07 (s, 2H), 8.02 (d, 1H), 7.93 (s, 1H), 7.59-7.55 (m, 1H), 7.38 (d, 4H), 7.28 (ddd, 1H), 3.72 (s, 2H), 2.49-2.37 (m, 2H), 1.99-1.92 (m, 8H), 1.88-1.75 (m, 2H), 1.56-1.45 (m, 2H). Mass: m/z 395.22 (M+H)+.


Synthesis of SC_3146: methyl CIS-2-(4-(5-(8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)pyrimidin-2-yl)piperazin-1-yl)acetate



embedded image


CIS-8-(dimethylamino)-8-phenyl-3-(2-(piperazin-1-yl)pyrimidin-5-yl)-1,3-diazaspiro[4.5]decan-2-one (SC_3124) (200 mg, 0.46 mmol) was dissolved in dry acetonitrile (5 mL) under nitrogen atmosphere, K2CO3 (1.2 equiv., 0.55 mmol, 76 mg) and methyl-2-chloroacetate (1.5 equiv., 0.69 mmol, 0.06 mL) were sequentially added and the reaction mixture was stirred at reflux for 5 h. A new portion of methyl-2-chloroacetate (1.5 equiv., 0.69 mmol, 0.06 mL) was added and the reaction mixture was stirred at reflux overnight. The reaction mixture was concentrated under reduced pressure. The residue was suspended in DCM, the precipitate was filtered off and washed with DCM. The combined filtrate was concentrated under reduced pressure to give 106 mg of crude product. Flash chromatography on silica gel (eluent DCM/EtOH gradient 98/2 to 96/4) yielded 168 mg (72%) of methyl CIS-2-(4-(5-(8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)pyrimidin-2-yl)piperazin-1-yl)acetate (SC_3146). 1H NMR (600 MHz, DMSO) δ 8.54 (s, 2H), 7.42 (s, 1H), 7.37 (m, 4H), 7.27 (m, 1H), 3.63 (t, 7H), 3.52 (s, 2H), 3.27 (s, 2H), 2.54 (t, 4H), 2.45-2.30 (m, 2H), 1.96 (s, 6H), 1.93-1.83 (m, 4H), 1.52-1.42 (m, 2H). Mass: m/z 508.4 (M+H)+.


Synthesis of SC_3162: CIS-8-(dimethylamino)-8-phenyl-3-(2-(pyridin-2-yl)pyrimidin-5-yl)-1,3-diazaspiro[4.5]decan-2-one



embedded image


CIS-3-(2-chloropyrimidin-5-yl)-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-989) (200 mg, 0.52 mmol), tributyl(2-pyridyl)stannane (1.5 equiv., 0.78 mmol, 286 mg) and Pd(PPh3)4 (0.1 equiv., 0.052 mmol, 60 mg) were dissolved in degassed anhydrous DMF (150 equiv., 77.7 mmol, 6 mL) under nitrogen atmosphere. Cesium fluoride (2.2 equiv., 1.14 mmol, 173 mg) was added and the reaction mixture was stirred at 90° C. overnight. The resulting suspension was cooled down to RT, diluted with water (10 mL), extracted with ethylacetate (30 mL), then DCM (30 mL), the DCM phase was dried over MgSO4 and concentrated under reduced pressure to give 320 mg of crude product. Flash chromatography on silica gel (eluent DCM/0.1N NH3 in MeOH, gradient 95/5 to 70/30) yielded 72 mg (33%) of CIS-8-(dimethylamino)-8-phenyl-3-(2-(pyridin-2-yl)pyrimidin-5-yl)-1,3-diazaspiro[4.5]decan-2-one (SC_3162). 1H NMR (600 MHz, DMSO) δ 9.13 (s, 2H), 8.71-8.67 (m, 1H), 8.30 (d, 1H), 7.92 (td, 1H), 7.86 (s, 1H), 7.46 (dd, 1H), 7.43-7.35 (m, 5H), 7.31-7.25 (m, 1H), 3.73 (s, 2H), 2.48-2.33 (m, 2H), 2.00-1.78 (m, 10H), 1.57-1.47 (m, 2H). Mass: m/z 429.2 (M+H)+.


Synthesis of SC_3169: CIS-2-(2-(8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)phenoxy)acetic acid



embedded image


Step 1: CIS-2-(2-(8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)phenoxy)acetonitrile

In analogy to the method described for SC_3103 CIS-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-976) was reacted with 2-(2-bromophenoxy)acetonitrile to be converted into CIS-2-(2-(8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)phenoxy)acetonitrile.


Step 2: CIS-2-(2-(8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)phenoxy)acetic acid (SC_3169)

CIS-2-(2-(8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)phenoxy)acetonitrile (134 mg, 0.331 mmol) was dissolved in conc. aq. HCl (1.4 mL, 50 equiv.). The reaction mixture was heated to 100° C. for 2 h and cooled down to RT. The precipitate was filtered off, washed with water (2×) and dried under reduced pressure to give 31 mg (22%) of CIS-2-(2-(8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)phenoxy)acetic acid (SC_3169). 1H NMR (600 MHz, DMSO) δ 7.75-7.71 (m, 1H), 7.59-7.48 (m, 4H), 7.27 (dd, 1H), 7.15 (ddd, 1H), 6.97-6.90 (m, 2H), 4.65 (s, 2H), 3.43 (s, 2H), 2.70 (d, 2H), 2.56 (s, 6H), 2.31 (t, 2H), 1.93-1.86 (m, 2H), 1.33-1.22 (m, 2H). Mass: m/z 424.2 (M+H)+.


Synthesis of SC_3173: CIS-8-(dimethylamino)-8-phenyl-3-(2-(piperazine-1-carbonyl)pyrimidin-5-yl)-1,3-diazaspiro[4.5]decan-2-one



embedded image


Step 1: CIS-tert-butyl 4-(5-(8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)pyrimidine-2-carbonyl)piperazine-1-carboxylate

In analogy to the method described for SC_3133 lithium CIS-5-(8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)pyrimidine-2-carboxylate (INT-990) was reacted with 1-(tert-butoxycarbonyl)piperazine to be converted into CIS-tert-butyl 4-(5-(8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)pyrimidine-2-carbonyl)piperazine-1-carboxylate.


Step 2: CIS-8-(dimethylamino)-8-phenyl-3-(2-(piperazine-1-carbonyl)pyrimidin-5-yl)-1,3-diazaspiro[4.5]decan-2-one (SC_3173)

CIS-tert-butyl 4-(5-(8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)pyrimidine-2-carbonyl)piperazine-1-carboxylate (230 mg, 0.41 mmol) was dissolved in TFA (2.2 mL, 28.6 mmol, 70 equiv.). The reaction mixture was stirred at RT for 2.5 h and then concentrated under reduced pressure. The residue was dissolved in DCM and aq. sat Na2CO3 was added (until pH 10). The organic phase was separated and the aq. phase was extracted with DCM (2×). The combined organic extracts were dried over MgSO4 and concentrated under reduced pressure. Recrystallization of the residue from DCM/pentane gave 105 mg (56%) of CIS-8-(dimethylamino)-8-phenyl-3-(2-(piperazine-1-carbonyl)pyrimidin-5-yl)-1,3-diazaspiro[4.5]decan-2-one (SC_3173). 1H NMR (600 MHz, DMSO) δ 9.04 (s, 2H), 7.89 (s, 1H), 7.42-7.32 (m, 4H), 7.31-7.26 (m, 1H), 3.69 (s, 2H), 3.65 (t, 2H), 3.21 (t, 2H), 2.90 (t, 2H), 2.79-2.74 (m, 2H), 2.43 (s, 2H), 1.98 (s, 9H), 1.89-1.75 (m, 1H), 1.53-1.47 (m, 2H). Mass: m/z 464.3 (M+H)+.


Synthesis of SC_3182: CIS-8-(dimethylamino)-3-(2-(4-hydroxypiperidin-1-yl)pyrimidin-5-yl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one



embedded image


Et3N (0.39 g, 3.89 mmol) was added to the solution of CIS-3-(2-chloropyrimidin-5-yl)-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-989) (0.5 g, 1.29 mmol) and piperidin-4-ol (0.32 g, 3.24 mmol) in DMF (10 mL) at RT. The reaction mixture was stirred at 130° C. for 16 h, cooled down to RT and concentrated under reduced pressure. The residue was diluted with 10% aq. NaOH and the organic product was extracted with 1/9 v/v MeOH/DCM. The combined organic layer was dried over anhydrous Na2SO4 and concentrated in vacuo. The residue was purified by preparative TLC using 10% MeOH/DCM as eluent to afford 130 mg of CIS-8-(dimethylamino)-3-(2-(4-hydroxypiperidin-1-yl)pyrimidin-5-yl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (SC_3182) as an off-white solid (TLC system: 10% MeOH in DCM; Rf: 0.1). 1H NMR (DMSO-d6): δ 8.50 (s, 2H), 7.39-7.26 (m, 6H), 4.68 (d, 1H), 4.19-4.16 (m, 2H), 3.69-3.67 (m, 1H), 3.51 (s, 2H), 3.14 (t, 2H), 2.33 (m, 2H), 1.94-1.71 (m, 12H), 1.45 (m, 2H), 1.30-1.23 (m, 2H). Mass: m/z 451.2 (M+H)+.


Synthesis of SC_3186: CIS-8-(dimethylamino)-3-(3-methylpyridin-2-yl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one



embedded image


Compound was synthesized within a parallel array. An argon-flushed dry reaction vessel equipped with a septum was loaded with the solutions of INT-976 (0.1 M, 1 mL) and 1-bromo-2-methylbenzene (0.15 M, 1 mL) in dioxane. To the resulting mixture Cs2CO3 (200 μmol), XantPhos (10 μmol) and Pd2(dba)3 (5 μmol) were added. The reaction vessel was flushed with argon once again, sealed and the reaction mixture was shaken at 100° C. overnight. The resulting mixture was cooled down to RT and the solvent was removed under reduced pressure. The residue was taken up in 3 mL dichloromethane and 3 mL water, the organic phase was separated, the aqueous phase was extracted with dichloromethane (2×3 mL). Combined organic phases were concentrated under reduced pressure. The residue was purified by HPLC to give CIS-8-(dimethylamino)-3-(3-methylpyridin-2-yl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (SC_3186). Mass: m/z 363.2 (M+H)+.


Synthesis of SC_3208: CIS-4-(5-(8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)pyrimidin-2-yl)indolin-2-one



embedded image


CIS-3-(2-chloropyrimidin-5-yl)-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-989) (150 mg, 0.38 mmol), Pd(t-Bu3P)2 (0.1 equiv., 0.02 mmol, 10 mg) and 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)indolin-2-one (2 equiv., 0.78 mmol, 201 mg) were dissolved in degassed anhydrous THF (80 equiv., 31 mmol, 2.5 mL) and 1M aq. Na2CO3 (5.5 equiv., 2.14 mmol, 2.14 mL) was added. The resulting mixture was stirred at 60° C. for 8 h and then at RT overnight. The reaction mixture was diluted with water until precipitation occurred. The precipitate was filtered off, suspended in 30 mL DCM, filtered off again, washed with pentane (5 mL) and dried under reduced pressure to give 143 mg (76%) of CIS-4-(5-(8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)pyrimidin-2-yl)indolin-2-one (SC_3208). 1H NMR (600 MHz, DMSO) δ 10.45 (s, 1H), 9.10 (s, 2H), 7.87 (d, 1H), 7.84-7.80 (m, 1H), 7.39 (d, 5H), 7.29 (dt, 2H), 6.91 (d, 1H), 3.82 (s, 2H), 3.72 (s, 2H), 2.41 (d, 2H), 2.03-1.74 (m, 9H), 1.60-1.44 (m, 3H). Mass: m/z 484.26 (M+H)+.


Synthesis of SC_3221: CIS-8-(dimethylamino)-3-(2-((2-hydroxyethyl)amino)pyrimidin-5-yl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one



embedded image


Step 1: CIS-8-(dimethylamino)-3-(2-((2-methoxyethyl)amino)pyrimidin-5-yl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one

In analogy to the method described for SC_3103 2-methoxyethanamine was reacted with CIS-3-(2-chloropyrimidin-5-yl)-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-989) to be converted into CIS-8-(dimethylamino)-3-(2-((2-methoxyethyl)amino)pyrimidin-5-yl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one.


Step 2: CIS-8-(dimethylamino)-3-(2-((2-hydroxyethyl)amino)pyrimidin-5-yl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (SC_3221)

BBr3 (1M in DCM) (2.2 mL, 2.22 mmol) was added to the solution of CIS-8-(dimethylamino)-3-(2-((2-methoxyethyl)amino)pyrimidin-5-yl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (0.55 g, 1.06 mmol) in DCM (20 mL) at −78° C. over 15 min. The reaction mixture was stirred at RT for 4 h, then quenched with water and concentrated under reduced pressure. The residue was purified by preparative reverse phase HPLC to afford 82 mg (19%) of CIS-8-(dimethylamino)-3-(2-((2-hydroxyethyl)amino)pyrimidin-5-yl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (SC_3221) (TLC system: 10% MeOH in DCM (Ammonia atmosphere); Rf: 0.3). 1H NMR (DMSO-d6): δ 8.41 (s, 2H), 7.39-7.24 (m, 6H), 6.70 (t, 1H), 4.64 (br, s, 1H), 3.50-3.45 (m, 4H), 3.28-3.25 (m, 2H), 2.37 (br m, 2H), 1.94-1.86 (m, 10H), 1.45 (m, 2H). Mass: m/z 411.2 (M+H)+


Synthesis of SC_3224: CIS-3-(2-(1H-indazol-1-yl)pyrimidin-5-yl)-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one



embedded image


K2CO3 (0.53 g, 3.89 mmol) was added to the solution of CIS-3-(2-chloropyrimidin-5-yl)-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (500 mg, 1.29 mmol) and 1H-indazole (306 mg, 2.59 mmol) in DMF (10 mL). The reaction mixture was stirred at 140° C. for 48 h, cooled down to RT and concentrated under reduced pressure. The residue was diluted with DCM (50 mL), filtered through Celite and the filtrate was concentrated under reduced pressure. The residue was purified by flash chromatography using neutral alumina (0-10% MeOH/DCM) followed by reverse phase HPLC to afford 77 mg (13%) of CIS-3-(2-(1H-indazol-1-yl)pyrimidin-5-yl)-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (SC_3224) as off-white solid (TLC system: 10% MeOH in DCM; Rf: 0.6). 1H NMR (DMSO-d6): δ 9.10 (s, 2H), 8.57-8.55 (d, 1H), 8.41 (s, 1H), 7.89-7.87 (d, 1H), 7.82 (br s, 1H), 7.57-7.53 (t, 1H), 7.39-7.28 (m, 6H), 3.72 (s, 2H), 2.45 (m, 2H), 1.98-1.93 (m, 10H), 1.52 (m, 2H). Mass: m/z 468.2 (M+H)+.


Synthesis of SC_3235: CIS-methyl 2-(2-(8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)phenoxy)acetate



embedded image


CIS-2-(2-(8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)phenoxy)acetic acid (120 mg, 0.28 mmol) was dissolved in methanol (1.4 mL, 125 equiv.) and thionyl chloride (4 equiv., 1.13 mmol, 83 μL) was added dropwise. The reaction mixture was stirred at RT overnight, diluted with aq. sat. NaHCO3 and extracted with DCM (3×). The combined organic phases were dried over MgSO4 and concentrated under reduced pressure. The residue (112 mg) was purified by flash chromatography on silica get (gradient DCM/MeOH 97/3 to 88/12) to give 92 mg (74%) of CIS-methyl 2-(2-(8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)phenoxy)acetate (SC_3235). 1H NMR (600 MHz, DMSO) δ 7.40-7.33 (m, 4H), 7.29 (dd, 1H), 7.28-7.24 (m, 1H), 7.13 (td, 1H), 6.99-6.91 (m, 2H), 4.76 (s, 2H), 3.67 (s, 3H), 3.55 (s, 2H), 2.45-2.26 (m, 2H), 2.07 (s, 2H), 1.98 (s, 6H), 1.94-1.75 (m, 4H), 1.52-1.45 (m, 2H). Mass: m/z 438.2 (M+H)+.


Synthesis of SC_3238: CIS-2-(5-(8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)pyrimidin-2-yl)benzonitrile



embedded image


CIS-3-(2-chloropyrimidin-5-yl)-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-989) (240 mg, 0.56 mmol), [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) complex with dichloromethane (0.05 equiv., 0.028 mmol, 23 mg) and (2-cyanophenyl)boronic acid (1.125 equiv., 0.63 mmol, 92 mg) were dissolved in degassed 1,2-dimethoxyethane (100 equiv., 56 mmol, 5.8 mL) and Cs2CO3 (3.3 equiv., 1.84 mmol, 600 mg) in water (175 equiv., 98 mmol, 1.8 mL) was added. The resulting clear reaction mixture was stirred 3 days at 60° C. The reaction mixture was diluted with water (15 mL) and extracted with EtOAc (2×15 mL). Combined organic phases were dried over MgSO4 and concentrated under reduced pressure. The residue (355 mg) was purified by flash chromatography on silica get (gradient DCM/MeOH 95/5 to 70/30) to give 60 mg of product, which was further purified by HPLC to give 15.4 mg (6%) of CIS-2-(5-(8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)pyrimidin-2-yl)benzonitrile (SC_3238). 1H NMR (600 MHz, DMSO) δ 9.17 (s, 2H), 8.27 (dd, 1H), 7.94 (dd, 1H), 7.81 (td, 1H), 7.65 (td, 1H), 7.42-7.35 (m, 5H), 7.28 (ddt, 1H), 3.75 (s, 2H), 2.49-2.34 (m, 1H), 2.00-1.76 (m, 11H), 1.55-1.51 (m, 2H). Mass: m/z 453.24 (M+H)+.


Synthesis of SC_3239: CIS-3-(2-aminopyrimidin-5-yl)-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one



embedded image


Microwave reactor vial was loaded with CIS-3-(2-chloropyrimidin-5-yl)-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-989) (250 mg, 0.65 mmol), flushed with nitrogen, 7N solution of NH3 in methanol (108 equiv., 70 mmol, 10 mL) and dioxane (37 equiv., 24 mmol, 2 mL) were added, the vial was sealed and the reaction mixture was stirred at 115° C. for 12 h in the microwave reactor. The reaction mixture was then cooled down to 4° C. overnight. The precipitate formed was filtered off, washed with DCM (small amount), water (2×), ether (2×) and dried under reduced pressure to give 180 mg (76%) of CIS-3-(2-aminopyrimidin-5-yl)-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (SC_3239) as an off-white solid. 1H NMR (600 MHz, DMSO) δ 8.39 (s, 2H), 7.40-7.32 (m, 5H), 7.26 (tt, 1H), 6.25 (s, 2H), 3.51 (s, 2H), 2.37 (s, 2H), 2.07 (s, 2H), 1.96 (s, 6H), 1.94-1.68 (m, 4H), 1.47 (d, 2H). Mass: m/z 367.23 (M+H)+.


Synthesis of SC_3240: CIS-N-(5-(8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)pyrimidin-2-yl)cyclopropanecarboxamide



embedded image


CIS-3-(2-aminopyrimidin-5-yl)-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (SC_3239) (50 mg, 0.14 mmol) and 4-dimethylaminopyridine (1.3 equiv., 0.18 mmol, 22 mg) were dissolved in dry pyridine (200 equiv., 27 mmol, 2.2 mL) under nitrogen atmosphere. Cyclopropancarbonyl chloride (1.3 equiv., 0.18 mmol, 16 μL) was added in one portion and the reaction mixture was stirred at RT for 3 h. Additional portion of cyclopropancarbonyl chloride (3 equiv., 0.42 mmol, 37 μL) was added and the reaction mixture was stirred at 90° C. for 1 h. The reaction mixture was diluted with water (5 mL) and aq. sat. NaHCO3 (5 mL), extracted with DCM (3×10 mL), organic phases were washed with brine, dried over Na2SO4 and the solvent was removed under reduced pressure. The residue was suspended thoroughly in 3 mL DCM, the precipitate was filtered off, washed with ether and dried under reduced pressure to give 47 mg (79%) of CIS-N-(5-(8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)pyrimidin-2-yl)cyclopropanecarboxamide (SC_3240) as a white solid. 1H NMR (600 MHz, DMSO) δ 10.66 (s, 1H), 8.81 (s, 2H), 7.67 (s, 1H), 7.41-7.33 (m, 4H), 7.31-7.21 (m, 1H), 3.62 (s, 2H), 2.45-2.32 (m, 2H), 2.01 (td, 1H), 1.96 (s, 6H), 1.93-1.78 (m, 3H), 1.52-1.47 (m, 2H), 0.82-0.72 (m, 4H). Mass: m/z 435.3 (M+H)+.


Synthesis of SC_3242: CIS-8-(dimethylamino)-8-phenyl-3-(6-(piperazin-1-yl)pyridin-3-yl)-1,3-diazaspiro[4.5]decan-2-one



embedded image


Step 1: 4-(5-bromopyrimidin-2-yl)piperazine

In analogy to the method described for SC_3097 step 1 5-bromo-2-chloro-pyridine was reacted with piperazine to be converted into 4-(5-bromopyrimidin-2-yl)piperazine.


Step 2: CIS-8-(dimethylamino)-8-phenyl-3-(6-(piperazin-1-yl)pyridin-3-yl)-1,3-diazaspiro[4.5]decan-2-one (SC_3242)

CIS-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-976) (80 mg, 0.29 mmol), 4-(5-bromopyrimidin-2-yl)piperazine (2 equiv., 0.56 mmol, 142 mg) and potassium phosphate (4 equiv., 1.17 mmol, 248 mg) were suspended in N,N′-dimethylethylenediamine (18 equiv., 5.27 mmol, 0.6 mL) under nitrogen atmosphere. The reaction mixture was stirred at 80° C. for 2 h, diluted with water (10 mL) and extracted with DCM (3×15 mL). The combined organic phases contained a precipitate which was filtered off, washed with isopropanol and dried under reduced pressure to give 79 mg (62%) of CIS-8-(dimethyl-amino)-8-phenyl-3-(6-(piperazin-1-yl)pyridin-3-yl)-1,3-diazaspiro[4.5]decan-2-one (SC_3242). 1H NMR (600 MHz, DMSO) δ 8.15 (d, 1H), 7.85 (dd, 1H), 7.41-7.33 (m, 4H), 7.32-7.23 (m, 2H), 6.74 (d, 1H), 3.51 (s, 2H), 3.30-3.25 (m, 4H), 2.78-2.73 (m, 4H), 2.43-2.31 (m, 2H), 1.96 (s, 6H), 1.93-1.79 (m, 4H), 1.50-1.42 (m, 2H). Mass: m/z 435.3 (M+H)+.


Synthesis of SC_3275: CIS-8-(ethylamino)-1-((1-hydroxycyclobutyl)methyl)-8-phenyl-3-(2-(trifluoromethyl)pyrimidin-5-yl)-1,3-diazaspiro[4.5]decan-2-one



embedded image


CIS-8-amino-1-((1-hydroxycyclobutyl)methyl)-8-phenyl-3-(2-(trifluoromethyl)pyrimidin-5-yl)-1,3-diazaspiro[4.5]decan-2-one (70 mg, 0.15 mmol) was dissolved in anhydrous DCM (3.8 mL) under nitrogen atmosphere. Acetic acid (0.1 equiv., 0.015 mmol, 0.8 μL) and acetaldehyde (1.1 equiv., 0.16 mmol, 9 μL) were sequentially added and the resulting mixture was stirred at RT for 1 h. Sodium triacetoxyborohydride (2 equiv., 0.29 mmol, 62 mg) was added and the reaction mixture was stirred at RT overnight and then at 50° C. for 5 h. Additional amounts of acetaldehyde (1.1 equiv., 0.16 mmol, 9 μL) and sodium triacetoxyborohydride (2 equiv., 0.29 mmol, 62 mg) were added and the reaction mixture was stirred further 24 h at 50° C. The resulting mixture was cooled down to RT, quenched with aq. sat. NaHCO3 until pH>7, diluted with water and extracted with DCM (3×). The combined organic layers were dried over Na2SO4 and concentrated under reduced pressure. The residue (70 mg) was purified by flash chromatography on silica gel (DCM/EtOH gradient 99/1 to 95/5) to yield 43 mg (58%) of CIS-8-(ethylamino)-1-((1-hydroxycyclobutyl)methyl)-8-phenyl-3-(2-(trifluoromethyl)pyrimidin-5-yl)-1,3-diazaspiro[4.5]decan-2-one (SC_3275). 1H NMR (600 MHz, DMSO) δ 9.26 (s, 2H), 7.55-7.49 (m, 2H), 7.33 (t, 2H), 7.21 (d, 1H), 3.92 (s, 2H), 2.38 (td, 2H), 2.17-2.06 (m, 3H), 2.00-1.87 (m, 4H), 1.81 (td, 2H), 1.72-1.64 (m, 1H), 1.60-1.50 (m, 1H), 1.49-1.43 (m, 2H), 0.99 (t, 3H). Mass: m/z 504.3 (M+H)+


Synthesis of SC_3292 and SC_3293: enantiomer 1 and enantiomer 2 of CIS-8-(methyl((tetrahydrofuran-3-yl)methyl)amino)-8-phenyl-3-(2-(trifluoromethyl)pyrimidin-5-yl)-1,3-diazaspiro[4.5]decan-2-one



embedded image


Cs2CO3 (0.85 g, 2.61 mmol) was added to an argon purged solution of CIS-8-(methyl((tetrahydrofuran-3-yl)methyl)amino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-1026) (0.3 g, 0.87 mmol), Xanthphos (45 mg, 0.087 mmol), Pd2(dba)3 (80 mg, 0.087 mmol) and 5-bromo-2-(trifluoromethyl)pyrimidine (0.29 g, 1.30 mmol) in 1,4-dioxane (15 mL). The mixture was purged with argon for 5 min and stirred at 90° C. for 16 h. The reaction mixture was cooled to RT, diluted with EtOAc (20 mL), filtered through Celite and the filtrate was concentrated under reduced pressure. The crude product was purified by flash chromatography (silica gel 230-400 mesh; 3% MeOH in DCM) to get the compound which was further purified by reverse phase preparative HPLC to afford 0.1 g (23%) of CIS-8-(methyl((tetrahydrofuran-3-yl)methyl)amino)-8-phenyl-3-(2-(trifluoromethyl)pyrimidin-5-yl)-1,3-diazaspiro[4.5]decan-2-one (TLC system: 10% MeOH in DCM; Rf: 0.4) as a mixture of enantiomers. Reverse phase preparative HPLC conditions: mobile phase: 10 mM ammonium bicarbonate in H2O/acetonitrile; column: X-BRIDGE-C18 (150*19), 5 μm; mobile phase gradient (min/% B): 0/30, 8/82, 8.1/100, 10/100, 10.1/30, 12/30; flow rate: 19 ml/min; diluent: mobile phase+THF. Enantiomeric mixture of CIS-8-(methyl((tetrahydrofuran-3-yl)methyl)amino)-8-phenyl-3-(2-(trifluoromethyl)pyrimidin-5-yl)-1,3-diazaspiro[4.5]decan-2-one (100 mg) was separated by chiral SFC to afford 35 mg of enantiomer 1 (SC-3292) and 40 mg of enantiomer 2 (SC-3293) as off-white solids. Preparative SFC conditions: column: Chiralpak IA (250×30) mm, 5 μm; % CO2: 50.0%; % co-solvent: 50.0% (100% Methanol); total flow: 70.0 g/min; back pressure: 100.0 bar; UV: 256 nm; stack time: 13.5 min; load/inj.: 9.5 mg; no. of injections: 11. SC-3292: 1H NMR (DMSO-d6): δ 9.15 (s, 2H), 8.23 (broad s, 1H), 7.37-7.25 (m, 5H), 3.68-3.58 (m, 5H), 3.37-3.36 (m, 1H), 2.32 (m, 3H), 2.13-1.89 (m, 10H), 1.47 (m, 3H). SC-3293: 1H NMR (DMSO-d6): δ 9.15 (s, 2H), 8.23 (broad s, 1H), 7.37-7.36 (m, 4H), 7.26-7.24 (m, 1H), 3.68-3.56 (m, 5H), 3.37-3.36 (m, 1H), 2.31-2.28 (m, 3H), 2.13-1.86 (m, 10H), 1.48 (m, 3H). Mass: m/z 490.3 (M+H)+.


Synthesis of SC_3313: CIS-3-(2-(4-cyclopropyl-1H-1,2,3-triazol-1-yl)pyrimidin-5-yl)-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one



embedded image


Step 1: 5-bromo-2-(4-cyclopropyl-1H-1,2,3-triazol-1-yl)pyrimidine

2-Azido-5-bromo-pyrimidine (400 mg, 1.94 mmol) and ethynylcyclopropane (1.3 equiv., 2.522 mmol, 0.21 mL) were dissolved in tert-butanol (5 mL). The solutions of sodium ascorbate (0.1 equiv., 0.194 mmol, 38 mg) in water (2.5 mL) and copper(II) sulfate pentahydrate (0.1 equiv., 0.194 mmol, 48 mg) in water (2.5 mL) were sequentially added. The reaction mixture was stirred under ambient conditions for 18 h, then diluted with 20 mL 1M aq. NH4OH and extracted with EtOAc (3×30 mL). The combined organic extracts were washed with brine, dried over Na2SO4 and concentrated under reduced pressure. Crude product (510 mg) was purified by flash chromatography on silica gel (DCM/EtOH 99/1) to yield 143 mg of 5-bromo-2-(4-cyclopropyl-1H-1,2,3-triazol-1-yl)pyrimidine as a white solid. Mass: m/z 266.0 (M+H)+.


Step 2: CIS-3-(2-(4-cyclopropyl-1H-1,2,3-triazol-1-yl)pyrimidin-5-yl)-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (SC_3313)

In analogy to the method described for SC_3103 CIS-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-976) was reacted with 5-bromo-2-(4-cyclopropyl-1H-1,2,3-triazol-1-yl)pyrimidine to be converted into CIS-3-(2-(4-cyclopropyl-1H-1,2,3-triazol-1-yl)pyrimidin-5-yl)-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (SC_3313). 1H NMR (600 MHz, DMSO) δ 9.09 (d, 2H), 8.50 (d, 1H), 7.91 (s, 1H), 7.42-7.34 (m, 2H), 7.38 (s, 3H), 7.31-7.25 (m, 1H), 3.72 (s, 2H), 2.48-2.31 (m, 2H), 2.10-2.01 (m, 1H), 1.99-1.77 (m, 10H), 1.58-1.46 (m, 2H), 1.00-0.91 (m, 2H), 0.84 (tt, 2H). Mass: m/z 459.3 (M+H)+.


Synthesis of SC_3319: CIS-8-(methyl((tetrahydrofuran-3-yl)methyl)amino)-8-phenyl-3-(2-(trifluoromethyl)pyrimidin-5-yl)-1,3-diazaspiro[4.5]decan-2-one



embedded image


Cs2CO3 (145 mg, 0.45 mmol, 2 equiv.), CIS-8-(dimethylamino)-8-(3-fluorophenyl)-1,3-diazaspiro[4.5]decan-2-one (INT-1024) (65 mg, 0.223 mmol, 1 equiv.), Xanthphos (19 mg, 0.033 mmol, 0.15 equiv.), Pd2(dba)3 (10 mg, 0.011 mmol, 0.05 equiv.) and 5-bromo-1-methyl-3-(trifluoromethyl)pyrazole (102 mg, 0.446 mmol, 2 equiv.) were loaded into a microwave reactor vial (2-5 mL), the vial was sealed and flushed with nitrogen (3×). 1,4-Dioxane (1.5 mL) was added via syringe and the reaction mixture was stirred at 110° C. in the microwave reactor for 10 h. The resulting mixture was cooled down to RT, solution of Xanthphos (19 mg, 0.033 mmol, 0.15 equiv.) and Pd2(dba)3 (10 mg, 0.011 mmol, 0.05 equiv.) in 1,4 dioxane (1 mL) was added, and the reaction mixture was stirred at 130° C. in the microwave reactor for further 10 h. The resulting suspension was cooled to RT, quenched with water and extracted with DCM (3×). The combined organic layer was dried over Na2SO4 and concentrated under reduced pressure. The resulting residue was purified by flash chromatography (gradient 0% to 16% MeOH in DCM) to yield 41 mg (42%) of CIS-8-(methyl((tetrahydrofuran-3-yl)methyl)amino)-8-phenyl-3-(2-(trifluoromethyl)pyrimidin-5-yl)-1,3-diazaspiro[4.5]decan-2-one (SC_3319). 1H NMR (600 MHz, DMSO) δ 7.71 (s, 1H), 7.41 (q, 1H), 7.21-7.12 (m, 2H), 7.09 (td, 1H), 6.63 (s, 1H), 3.75 (s, 2H), 3.55 (s, 2H), 2.42-2.27 (m, 2H), 1.99-1.89 (m, 8H), 1.88-1.73 (m, 2H), 1.56-1.49 (m, 2H). Mass: m/z 440.2 (M+H)+.


Synthesis of SC_3340: CIS-2-(3-(8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)pyridin-4-yl)acetamide



embedded image


Step 1: CIS-2-(3-(8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)pyridin-4-yl)acetonitrile

In analogy to the method described for SC_3097 step 2 CIS-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-976) was reacted with (3-bromo-pyridin-4-yl)-acetonitrile to be converted into CIS-2-(3-(8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)pyridin-4-yl)acetonitrile.


Step 2: CIS-2-(3-(8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)pyridin-4-yl)acetamide (SC_3340)

To a solution of CIS-2-(3-(8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)pyridin-4-yl)acetonitrile (600 mg, 1.54 mmol, 1.0 equiv.) in EtOH (50 ml) was added NaOH (247 mg, 6.16 mmol, 4.0 equiv.). The reaction mixture was stirred at reflux for 16 h and then concentrated under reduced pressure. The resulting residue was purified by column chromatography (neutral alumina; 4% MeOH in DCM) and finally by preparative HPLC (column: Gemini NX-C18 (50×4.6), 3 μm, diluent: DMSO, mobile phase: gradient 0.05% HCOOH in water/ACN flow rate: 1 ml/min) to yield CIS-2-(3-(8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)pyridin-4-yl)acetamide (SC_3340) (40 mg, 0,098 mmol, 4% yield after two steps) as an off white solid. 1HNMR (DMSO, 400 MHz) δ 8.40 (s, 1H), 8.32 (d, 1H, J=4.92 Hz), 7.49 (s, 1H), 7.36-7.24 (m, 7H), 6.99 (s, 1H), 3.49-3.46 (m, 4H), 2.32 (bs, 2H), 1.94-1.77 (m, 10H), 1.52 (bs, 2H). Mass: m/z 408.2 (M+H)+.


Synthesis of SC_3352: CIS-8-(dimethylamino)-3-(2-hydroxybenzo[d]oxazol-7-yl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one



embedded image


Step 1: CIS-7-(8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-3-((2-(trimethylsilyl)ethoxy)methyl)benzo [d]oxazol-2(3H)-one

In analogy to the method described for SC_3103 CIS-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-976) was reacted with 7-bromo-3-(2-trimethylsilanyl-ethoxymethyl)-3H-benzooxazol-2-one (prepared from 7-bromobenzo[d]oxazol-2(3H)-one and trimethylsilylethoxymethylchloride following a standart procedure) to be converted into CIS-7-(8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-3-((2-(trimethylsilyl)ethoxy)methyl)benzo[d]oxazol-2(3H)-one. Mass: m/z 537.2 (M+H)+.


Step 2: CIS-8-(dimethylamino)-3-(2-hydroxybenzo[d]oxazol-7-yl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (SC_3352)

To a solution of CIS-7-[8-dimethylamino-2-oxo-8-phenyl-1-(2-trimethylsilanyl-ethoxymethyl)-1,3-diaza-spiro[4.5]dec-3-yl]-3H-benzooxazol-2-one (350 mg, 0.65 mmol, 1.0 eq) in 1,4-dioxane (2 mL) was added 4M HCl in dioxane (6 mL) dropwise at 0° C. The reaction mixture was stirred at RT for 48 h and then concentrated under reduced pressure. The residue was taken in DCM (200 mL) and washed with sat. aq. NaHCO3 (100 mL). Organic layer was dried over Na2SO4 and concentrated under reduced pressure to get the crude product which was purified by column chromatography (neutral alumina; 2% MeOH/DCM) to yield CIS-7-(8-dimethylamino-2-oxo-8-phenyl-1,3-diaza-spiro[4.5]dec-3-yl)-3H-benzooxazol-2-one (SC_3352) (85 mg, 0.21 mmol, 32%) as an off white solid. 1HNMR (DMSO-d6, 400 MHz at 100° C.), δ (ppm)=11.19 (bs, 1H), 7.37-7.23 (m, 6H), 7.14 (s, 1H), 7.04 (t, 1H, J=8.06), 6.76 (d, 1H, J=7.68 Hz), 3.69 (s, 2H), 2.38-2.26 (m, 2H), 2.08-1.76 (m, 10H), 1.56-1.51 (m, 2H). Mass: m/z 407.1 (M+H)+.


Synthesis of SC_3354: CIS-4-(5-(8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)pyrimidin-2-yl)benzamide trifluoroacetate salt



embedded image


3-(2-chloropyrimidin-5-yl)-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT 989) (200 mg, 0.52 mmol, 1 equiv.), 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide (129 mg, 0.52 mmol, 1 equiv.), Pd2(dba)3 (95 mg, 0.10 mmol, 0.2 equiv.), 2-dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl (X-Phos) (99 mg, 0.21 mmol, 0.4 equiv.) were loaded into microwave reactor vessel and flushed with nitrogen (2×). Anhydrous 1,4-dioxane (9 mL) and sodium carbonate (213 mg, 2.07 mmol, 4 equiv.) were sequentially added. The reaction mixture was stirred 8 h at 120° C. in the microwave reactor and then concentrated under reduced pressure. The residue was suspended in EtOAc/water (1/1, v/v) and filtered through a glass filter. The solid residue was dissolved in MeOH/DCM/TFA, filtered through Celite pad and the filtrate was concentrated under reduced pressure to give 75 mg (25%) of CIS-4-(5-(8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)pyrimidin-2-yl)benzamide trifluoroacetate salt (SC_3354). 1H NMR (600 MHz, DMSO) δ 9.05 (s, 2H), 8.42 (s, 1H), 8.34 (d, 2H), 8.03 (s, 1H), 7.98 (d, 2H), 7.74-7.65 (m, 2H), 7.58 (t, 2H), 7.56-7.52 (m, 1H), 7.40 (s, 1H), 3.58 (s, 2H), 2.70 (d, 2H), 2.60 (s, 6H), 2.25 (t, 2H), 1.91 (d, 2H), 1.39 (t, 2H). Mass: m/z 471.3 (M+H)+.


Synthesis of SC_3357: CIS-8-(dimethylamino)-3-(1H-indol-3-yl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one



embedded image


Step 1: CIS-8-(dimethylamino)-8-phenyl-3-(1-tosyl-1H-indol-3-yl)-1,3-diazaspiro[4.5]decan-2-one

In analogy to the method described for SC_3103 CIS-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-976) was reacted with 3-bromo-1-(toluene-4-sulfonyl)-1H-indole to be converted into CIS-8-(dimethylamino)-8-phenyl-3-(1-tosyl-1H-indol-3-yl)-1,3-diazaspiro[4.5]decan-2-one. Mass: m/z 543.1 (M+H)+.


Step 2: CIS-8-(dimethylamino)-3-(1H-indol-3-yl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (SC_3357)

To a solution of 8-dimethylamino-8-phenyl-3-[1-(toluene-4-sulfonyl)-1H-indol-3-yl]-1,3-diaza-spiro[4.5]decan-2-one (275 mg, 0.51 mmol, 1.0 eq.) in EtOH (24 mL) was added 10N aq. NaOH (1.2 mL) at RT. The reaction mixture was heated to reflux for 1.5 h, then concentrated, diluted with water (50 mL) and extracted with EtOAc (150 mL). Organic layer was dried over Na2SO4 and concentrated under reduced pressure. The residue was purified by column chromatography (neutral alumina; 2% MeOH/DCM) to afford CIS-8-dimethylamino-3-(1H-indol-3-yl)-8-phenyl-1,3-diaza-spiro[4.5]decan-2-one (SC_3357) (130 mg, 0.33 mmol, 65%) as light brown solid. 1H NMR (DMSO-d6, 400 MHz at 100° C.), δ (ppm)=10.55 (bs, 1H), 7.62-7.60 (d, 1H, J=7.96 Hz), 7.37-7.23 (m, 7H), 7.04 (t, 1H, J=7.48 Hz), 6.92 (t, 1H, J=7.44 Hz), 6.71 (bs, 1H), 3.61 (s, 2H), 2.38-2.33 (m, 2H), 2.04-1.82 (m, 10H), 1.59-1.54 (m, 2H). Mass: m/z 389.3 (M+H)+.


Synthesis of SC_3379: CIS-3-(1-acetyl-1H-indol-3-yl)-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one



embedded image


To a solution of 8-dimethylamino-3-(1H-indol-3-yl)-8-phenyl-1,3-diaza-spiro[4.5]decan-2-one (SC_3357) (150 mg, 0.38 mmol, 1.0 eq.) in DCM (6 mL) were added NaOH (39 mg, 0.96 mmol, 2.5 eq.) and Bu4NHSO4 (129 mg, 0.38 mmol, 1.0 eq.) at 0° C. and the reaction mixture was stirred for 30 min followed by addition of acetyl chloride (54 μl, 0.76 mmol, 2.0 eq.). The reaction mixture was stirred at RT for 16 h, then diluted with DCM (150 ml) and washed with water (50 mL) and brine (50 mL). Organic layer was dried over Na2SO4 and concentrated under reduced pressure. The residue was purified by column chromatography (neutral alumina; 1% MeOH/DCM) followed by prep HPLC to afford 3-(1-acetyl-1H-indol-3-yl)-8-dimethylamino-8-phenyl-1,3-diaza-spiro[4.5]decan-2-one (SC_3379) as off white solid. Note: Two batches of same reactions were done and yield was calculated accordingly. Yield: 13% (45 mg, 0.1 mmol). 1HNMR (DMSO-d6, 400 MHz at 100° C.), δ (ppm)=8.34-8.32 (d, 1H, J=7.88 Hz), 7.90 (d, 1H, J=7.36 Hz), 7.67 (s, 1H), 7.37-7.10 (m, 8H), 3.71 (s, 2H), 2.57 (s, 3H), 2.38-2.32 (m, 2H), 2.04-1.88 (m, 10H), 1.61-1.59 (m, 2H). Mass: m/z 431.2 (M+H)+.


Synthesis of SC_3388: CIS-8-(dimethylamino)-8-(3-hydroxyphenyl)-3-(4-methyl-6-(trifluoromethyl)pyridin-3-yl)-1,3-diazaspiro[4.5]decan-2-one



embedded image


CIS-8-(dimethylamino)-8-(3-methoxyphenyl)-3-[4-methyl-6-(trifluoromethyl)-3-pyridyl]-1,3-diazaspiro[4.5]decan-2-one (SC_3368) (42 mg, 0.091 mmol) was dissolved in DCM (2 mL) and the solution was cooled to 0° C. Boron tribromide (1M sol. in DCM, 4 equiv., 0.36 mmol, 0.36 mL) was added in one portion. The reaction mixture was allowed to stir at RT overnight, then quenched with methanol and diluted with water. The resulting mixture was extracted with DCM (2×), the combined organic phases weres dried over Na2SO4 and concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel (eluent gradient DCM/EtOH) to yield 16 mg (39%) of CIS-8-(dimethylamino)-8-(3-hydroxyphenyl)-3-(4-methyl-6-(trifluoromethyl)pyridin-3-yl)-1,3-diazaspiro[4.5]decan-2-one (SC_3388). 1H NMR (600 MHz, DMSO) δ 8.57 (s, 1H), 7.80 (s, 1H), 7.52 (s, 1H), 7.14 (t, 1H), 6.77 (d, 1H), 6.74 (s, 1H), 6.66 (dd, 1H), 3.61 (s, 2H), 2.32 (s, 3H), 2.31-2.19 (m, 2H), 2.01-1.89 (m, 8H), 1.88-1.70 (m, 2H), 1.54 (t, 2H). Mass: m/z 449.2 (M+H)+.


Synthesis of SC_3396: CIS-4-(8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)indolin-2-one



embedded image


Step 1: CIS-4-(8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-1-(4-methoxybenzyl)indoline-2,3-dione

In analogy to the method described for SC_3242 CIS-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-976) was reacted with 4-bromo-1-(4-methoxy-benzyl)-1H-indole-2,3-dione to be converted into CIS-4-(8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-1-(4-methoxybenzyl)indoline-2,3-dione. Mass: m/z 539.2 (M+H)+.


Step 2: CIS-4-(8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-1-(4-methoxybenzyl)indolin-2-one

To a solution of CIS-4-(8-dimethylamino-2-oxo-8-phenyl-1,3-diaza-spiro[4.5]dec-3-yl)-1-(4-methoxy-benzyl)-1H-indole-2,3-dione (600 mg, 1.11 mmol, 1.0 eq) in EtOH (9 mL) was added hydrazine hydrate (9 mL) at RT. The reaction mixture was stirred at reflux for 16 h, then concentrated, diluted with water (50 mL) and extracted with EtOAc (200 mL). Organic layer was dried over Na2SO4, filtered and concentrated under reduced pressure. The resulting residue was purified by column chromatography (neutral alumina, 0.5% MeOH/DCM) to afford 8-dimethylamino-3-[1-(4-methoxy-benzyl)-2-oxo-2,3-dihydro-1H-indol-4-yl]-8-phenyl-1,3-diaza-spiro[4.5]decan-2-one (275 mg, 0.52 mmol, 47%) as a brown solid. Mass: m/z 525.2 (M+H)+.


Step 3: CIS-4-(8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)indolin-2-one (SC_3396)

A solution of CIS-8-dimethylamino-3-[1-(4-methoxy-benzyl)-2-oxo-2,3-dihydro-1H-indol-4-yl]-8-phenyl-1,3-diaza-spiro[4.5]decan-2-one (275 mg, 0.52 mmol, 1.0 eq.) in TFA (4 mL) was stirred at 90° C. in a sealed tube for 16 h. The reaction mixture was cooled to RT, concentrated under reduced pressure, diluted with water (50 mL), basified with sat. aq. NaHCO3 and extracted with EtOAc (200 mL). The organic phase was washed with brine (50 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The resulting residue was purified by column chromatography (neutral alumina, 5% MeOH in DCM) to afford CIS-8-dimethylamino-3-(2-oxo-2,3-dihydro-1H-indol-4-yl)-8-phenyl-1,3-diaza-spiro[4.5]decan-2-one (SC_3396) (60 mg, 0.14 mmol, 28%) as an off-white solid. 1H NMR (DMSO-d6, 400 MHz, 100° C.): δ (ppm)=9.98 (bs, 1H), 7.36-7.22 (m, 5H), 7.09 (t, 1H, J=7.94 Hz), 6.95-6.88 (m, 2H), 6.59 (d, 1H, J=7.52 Hz), 3.57 (s, 2H), 3.49 (s, 2H), 2.36-2.31 (m, 2H), 2.03 (s, 6H), 1.97-1.85 (m, 4H), 1.55-1.51 (m, 2H). Mass: m/z 405.3 (M+H)+.


The following compounds were prepared in analogy and by combining previously described methods:





















in analogy
m/z


Example
Chemical Name
Reactant I
Reactant II
to method
[M + H]+







SC_3001
cis-5-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-
INT-987
5-bromopyrimidine-2-
SC-3022
445.3



phenyl-1,3-diazaspiro[4.5]decan-3-yl]-pyrimidine-2-

carbonitrile





carbonitrile






SC_3002
cis-5-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-
INT-987
5-bromopyrazine-2-
SC-3022
445.3



phenyl-1,3-diazaspiro[4.5]decan-3-yl]-pyrazine-2-carbonitrile

carbonitrile




SC_3003
cis-5-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-
INT-987
5-bromo-4-





phenyl-1,3-diazaspiro[4.5]decan-3-yl]-4-methoxy-pyrimidine-

methoxypyrimidine-2-
SC-3022
475.3



2-carbonitrile

carbonitrile




SC_3004
cis-5-[8-Dimethylamino-1-(2-methoxy-ethyl)-2-oxo-8-phenyl-
INT-980
5-bromopyrimidine-2-
SC-3022
435.2



1,3-diazaspiro[4.5]decan-3-yl]-pyrimidine-2-carbonitrile

carbonitrile




SC_3005
cis-5-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-
SC_3001

SC_3016
463.3



phenyl-1,3-diazaspiro[4.5]decan-3-yl]-pyrimidine-2-carboxylic







acid amide






SC_3006
cis-5-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-
INT-987
5-bromo-2-(methylthio)-
SC-3022
523.2



phenyl-1,3-diazaspiro[4.5]decan-3-yl]-2-methylsulfonyl-

pyrimidine-4-carbonitrile
(step 1);




pyrimidine-4-carbonitrile


SC_3008







(step 2)



SC_3007
cis-5-[1-(2-Methoxy-ethyl)-8-methylamino-2-oxo-8-phenyl-
SC_3004

SC_3045
421.2



1,3-diazaspiro[4.5]decan-3-yl]-pyrimidine-2-carbonitrile






SC_3008
cis-2-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-
INT-987
2-iodo-5-
SC-3022
521.3



phenyl-1,3-diazaspiro[4.5]decan-3-yl]-5-methylsulfonyl-

(methylthio)benzonitrile
(step 1);




benzonitrile

(step 1)
SC_3008







(step 2)



SC_3009
cis-2-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-
SC_3090

SC_3016
461.3



phenyl-1,3-diazaspiro[4.5]decan-3-yl]-benzamide






SC_3010
cis-3-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-
SC_3072

SC_3016
461.3



phenyl-1,3-diazaspiro[4.5]decan-3-yl]-benzamide






SC_3011
cis-5-[8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-2-
SC_3013

SC_3016
479.3



oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-pyrimidine-2-







carboxylic acid amide






SC_3012
cis-5-[1-(Cyclobutyl-methyl)-8-methylamino-2-oxo-8-phenyl-
SC_3003

SC_3045
461.3



1,3-diazaspiro[4.5]decan-3-yl]-4-methoxy-pyrimidine-2-







carbonitrile






SC_3013
cis-5-[8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-2-
INT-600

SC_3013
461.3



oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-pyrimidine-2-







carbonitrile






SC_3014
cis-2-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-
INT-987
2-chloropyrimidine-5-
SC_3014
445.3



phenyl-1,3-diazaspiro[4.5]decan-3-yl]-pyrimidine-5-

carbonitrile





carbonitrile






SC_3015
cis-8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-3-(2-
INT-976
5-bromo-2-
SC_3013
466.3



methoxy-pyrimidin-5-yl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-

methoxypyrimidine





one

(step 1);







1-(tert-butyldimethyl-







silyloxy)cyclobutyl)methyl







4-methylbenzene-sulfonate







(step 2)




SC_3016
cis-2-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-
SC_3014

SC_3016
463.3



phenyl-1,3-diazaspiro[4.5]decan-3-yl]-pyrimidine-5-carboxylic







acid amide






SC_3017
cis-4-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-
SC_3081
methanamine
SC_3028
475.3



phenyl-1,3-diazaspiro[4.5]decan-3-yl]-N-methyl-benzamide






SC_3018
cis-5-(8-Dimethylamino-2-oxo-8-phenyl-1-propyl-1,3-
INT-600
1-bromopropane
SC_3013
419.2



diazaspiro[4.5]decan-3-yl)-pyrimidine-2-carbonitrile






SC_3019
cis-5-[8-Dimethylamino-1-(3-methoxy-propyl)-2-oxo-8-
INT-600
1-bromo-3-methoxypropane
SC-3013
449.3



phenyl-1,3-diazaspiro[4.5]decan-3-yl]-pyrimidine-2-







carbonitrile






SC_3020
cis-5-[1-(Cyclopropyl-methyl)-8-dimethylamino-2-oxo-8-
INT-600
(bromomethyl)cyclopropane
SC-3013
431.2



phenyl-1,3-diazaspiro[4.5]decan-3-yl]-pyrimidine-2-







carbonitrile






SC_3021
cis-4-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-
SC_3081
ammonia
SC-3028
461.3



phenyl-1,3-diazaspiro[4.5]decan-3-yl]-benzamide






SC_3022
cis-1-(Cyclobutyl-methyl)-8-dimethylamino-8-phenyl-342-
INT-987
5-bromo-2-
SC_3022
488.3



(trifluoromethyl)-pyrimidin-5-yl]-1,3-diazaspiro[4.5]decan-2-

(trifluoromethyl)pyrimidine





one






SC_3023
cis-8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-3-(2-
SC_3015

SC_3023
452.3



hydroxy-pyrimidin-5-yl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-







one






SC_3024
cis-5-[8-Dimethylamino-1-(2-methyl-propyl)-2-oxo-8-phenyl-
INT-600
1-bromo-2-methylpropane
SC_3013
433.3



1,3-diazaspiro[4.5]decan-3-yl]-pyrimidine-2-carbonitrile






SC_3025
cis-5-[8-Dimethylamino-1-(2-hydroxy-ethyl)-2-oxo-8-phenyl-
INT-600
(3-bromopropoxy)(tert-
SC-3025
421.2



1,3-diazaspiro[4.5]decan-3-yl]-pyrimidine-2-carbonitrile

butyl)dimethylsilane




SC_3026
cis-5-[1-(Cyclobutyl-methyl)-8-methylamino-2-oxo-8-phenyl-
SC_3078

SC_3045
444.3



1,3-diazaspiro[4.5]decan-3-yl]-4-methyl-pyridine-2-







carbonitrile






SC_3027
cis-1-(Cyclobutyl-methyl)-3-(5-methoxy-pyrazin-2-yl)-8-
SC_3075

SC_3045
436.3



methylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one






SC_3028
cis-4-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-
SC_3081

SC_3028
489.3



phenyl-1,3-diazaspiro[4.5]decan-3-yl]-N,N-dimethyl-







benzamide






SC_3029
cis-4-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-
SC_3081

SC_3028
533.3



phenyl-1,3-diazaspiro[4.5]decan-3-yl]-N-ethyl-N-(2-hydroxy-







ethyl)-benzamide






SC_3030
cis-2-[1-(Cyclobutyl-methyl)-8-methylamino-2-oxo-8-phenyl-
SC_3008

SC_3045
507.2



1,3-diazaspiro[4.5]decan-3-yl]-5-methylsulfonyl-benzonitrile






SC_3031
cis-1-(Cyclobutyl-methyl)-8-methylamino-3-[2-
SC_3084

SC_3031
550.2



methylsulfonyl-4-(trifluoromethyl)-phenyl]-8-phenyl-1,3-







diazaspiro[4.5]decan-2-one






SC_3032
cis-4-[1-(Cyclobutyl-methyl)-8-methylamino-2-oxo-8-phenyl-
SC_3089

SC_3032
579.3



1,3-diazaspiro[4.5]decan-3-yl]-N,N-dimethyl-3-







(trifluoromethyl)-benzenesulfonic acid amide






SC_3033
cis-4-[1-(Cyclobutyl-methyl)-8-(ethyl-methyl-amino)-2-oxo-8-
INT-797
4-bromobenzonitrile
SC_3013
457.3



phenyl-1,3-diazaspiro[4.5]decan-3-yl]-benzonitrile

(step 1);







(bromomethyl)cyclobutane







(step 2)




SC_3034
cis-1-(Cyclobutyl-methyl)-8-(ethyl-methyl-amino)-8-phenyl-3-
INT-797
5-bromo-2-
SC-3013
502.3



[2-(trifluoromethyl)-pyrimidin-5-yl]-1,3-diazaspiro[4.5]decan-

(trifluoromethyl)pyrimidine





2-one

(step 1);







(bromomethyl)cyclobutane







(step 2)




SC_3035
cis-5-[1-(Cyclobutyl-methyl)-8-(ethyl-methyl-amino)-2-oxo-8-
INT-797
5-bromopyrimidine-2-
SC_3013
459.3



phenyl-1,3-diazaspiro[4.5]decan-3-yl]-pyrimidine-2-

carbonitrile (step 1);





carbonitrile

(bromomethyl)cyclobutane







(step 2)




SC_3036
cis-5-[8-Dimethylamino-1-[(1-methyl-cyclobutyl)-methyl]-2-
INT-982
5-bromopyrimidine-2-
SC_3022
459.3



oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-pyrimidine-2-

carbonitrile





carbonitrile






SC_3037
cis-2-[3-(2-Cyano-pyrimidin-5-yl)-8-dimethylamino-2-oxo-8-
INT-978
5-bromopyrimidine-2-
SC_3065
462.3



phenyl-1,3-diazaspiro[4.5]decan-1-yl]-N,N-dimethyl-

carbonitrile





acetamide






SC_3038
cis-1-(Cyclobutyl-methyl)-8-methylamino-8-phenyl-342-
SC_3022

SC_3038
474.2



(trifluoromethyl)-pyrimidin-5-yl]-1,3-diazaspiro[4.5]decan-2-







one






SC_3039
cis-5-[8-Dimethylamino-8-(3-fluorophenyl)-1-(4-methoxy-
INT-601
1-bromo-4-methoxybutane
SC_3064
481.3



butyl)-2-oxo-1,3-diazaspiro[4.5]decan-3-yl]-pyrimidine-2-







carbonitrile






SC_3040
cis-5-[8-Dimethylamino-143-methoxy-propyl)-2-oxo-8-
INT-979
5-bromo-4-
SC_3022
479.3



phenyl-1,3-diazaspiro[4.5]decan-3-yl]-4-methoxy-pyrimidine-

methoxypyrimidine-2-





2-carbonitrile

carbonitrile




SC_3041
cis-5-[1-[(1-Cyano-cyclobutyl)-methyl]-8-dimethylamino-2-
INT_600
(1-cyanocyclobutyl)methyl
SC_3013
470.3



oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-pyrimidine-2-

4-methylbenzenesulfonate





carbonitrile






SC_3042
cis-N-(Cyclobutyl-methyl)-5-[1-(cyc lobutyl-methyl)-8-
INT-601
(bromomethyl)cyclobutane
SC_3064
549.3



dimethylamino-8-(3-fluorophenyl)-2-oxo-1,3-







diazaspiro[4.5]decan-3-yl]-pyrimidine-2-carboxylic acid amide






SC_3043
cis-5-[1-(3-Methoxy-propyl)-8-methylamino-2-oxo-8-phenyl-
SC_3019

SC_3043
435.2



1,3-diazaspiro[4.5]decan-3-yl]-pyrimidine-2-carbonitrile






SC_3044
cis-5-[8-Dimethylamino-8-(3-fluorophenyl)-1-methyl-2-oxo-
INT_600
iodomethane
SC_3013
409.2



1,3-diazaspiro[4.5]decan-3-yl]-pyrimidine-2-carbonitrile






SC_3045
cis-4-Methoxy-5-[1-(3-methoxy-propyl)-8-methylamino-2-
SC_3040

SC_3045
465.3



oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-pyrimidine-2-







carbonitrile






SC_3046
cis-4-[8-Dimethylamino-1-(2-methoxy-ethyl)-2-oxo-8-phenyl-
INT-980
4-bromopyrimidine-2-
SC_3022
435.2



1,3-diazaspiro[4.5]decan-3-yl]-pyrimidine-2-carbonitrile

carbonitrile




SC_3047
cis-5-[8-Dimethylamino-1-(2-methoxy-ethyl)-2-oxo-8-phenyl-
INT-980
5-bromo-4-
SC_3022
465.3



1,3-diazaspiro[4.5]decan-3-yl]-4-methoxy-pyrimidine-2-

methoxypyrimidine-2-





carbonitrile

carbonitrile




SC_3048
cis-4-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-
INT-987
4-bromopyrimidine-2-
SC_3022
445.3



phenyl-1,3-diazaspiro[4.5]decan-3-yl]-pyrimidine-2-

carbonitrile





carbonitrile






SC_3049
cis-1-(Cyclobutyl-methyl)-8-dimethylamino-3-(6-
INT-987
4-bromo-6-(methylthio)-
SC_3022
466.3



methylsulfanyl-pyrimidin-4-yl)-8-phenyl-1,3-

pyrimidine





diazaspiro[4.5]decan-2-one






SC_3050
cis-2-[3-(2-Cyano-pyrimidin-4-yl)-8-dimethylamino-2-oxo-8-
SC_3022
4-bromopyrimidine-2-
SC_3022
462.3



phenyl-1,3-diazaspiro[4.5]decan-1-yl]-N,N-dimethyl-

carbonitrile





acetamide






SC_3051
cis-6-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-
INT-987
6-bromopyrimidine-4-
SC_3022
445.3



phenyl-1,3-diazaspiro[4.5]decan-3-yl]-pyrimidine-4-

carbonitrile





carbonitrile






SC_3052
cis-2-(8-Dimethylamino-2-oxo-3,8-diphenyl-1,3-
INT-987
bromobenzene
SC_3022
435.3



diazaspiro[4.5]decan-1-yl)-N,N-dimethyl-acetamide






SC_3053
cis-1-(Cyclobutyl-methyl)-8-dimethylamino-3,8-diphenyl-1,3-
INT-987
bromobenzene
SC_3022
418.3



diazaspiro[4.5]decan-2-one






SC_3054
cis-248-Dimethylamino-1-(2-methoxy-ethyl)-2-oxo-8-phenyl-
INT-980
5-chloropyrimidine-2-
SC_3022
435.2



1,3-diazaspiro[4.5]decan-3-yl]-pyrimidine-5-carbonitrile

carbonitrile




SC_3055
cis-8-Dimethylamino-1-(2-methoxy-ethyl)-3,8-diphenyl-1,3-
INT-980
bromobenzene
SC_3022
408.3



diazaspiro[4.5]decan-2-one






SC_3056
cis-5-[8-Dimethylamino-1-(2-methoxy-ethyl)-2-oxo-8-phenyl-
INT-980
5-bromo-4-
SC_3022
448.3



1,3-diazaspiro[4.5]decan-3-yl]-4-methyl-pyridine-2-

methylpicolinonitrile





carbonitrile






SC_3057
cis-N,N-Dimethyl-2-(8-methylamino-2-oxo-3,8-diphenyl-1,3-
SC_3052

SC_3045
421.3



diazaspiro[4.5]decan-1-yl)-acetamide






SC_3058
cis-5-[1-[(1-Cyano-cyclobutyl)-methyl]-8-methylamino-2-oxo-
SC_3041

SC_3058
456.2



8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-pyrimidine-2-







carbonitrile






SC_3059
cis-5-[1-[(1-Cyano-cyclobutyl)-methyl]-8-(ethyl-methyl-
INT-797
5-bromopyrimidine-2-
SC_3013
484.3



amino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-

carbo-nitrile (step 1);





pyrimidine-2-carbonitrile

1-(bromo-







methyl)cyclobutane-







carbonitrile







(step 2)




SC_3060
CIS-4-[8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-
INT-987
4-bromobenzonitrile
SC_3013
459.3



2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-benzonitrile

(step 1); (1-(tert-







butyldimethylsilyloxy)







cyclobutyl)methyl 4-







methylbenzene-sulfonate







(2 step)




SC_3061
cis-3-[8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-2-
INT-987
3-bromobenzonitrile (step
SC_3013
459.3



oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-benzonitrile

1); (1-(tert-







butyldimethylsilyloxy)cyclo







butyl)methyl 4-







methylbenzene-sulfonate







(step 2)




SC_3063
cis-5-[1-[(1-Cyano-cyclobutyl)-methyl]-8-dimethylamino-2-
INT-987
5-bromopicolinonitrile (step
SC_3013
469.3



oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-pyridine-2-

1); 1-(bromomethyl)cyclo-





carbonitrile

butanecarbonitrile (step 2)




SC_3064
cis-2-[3-(2-Cyano-pyrimidin-5-yl)-8-dimethylamino-2-oxo-8-
INT-600
2-bromo-N-propylacetamide
SC_3064
476.3



phenyl-1,3-diazaspiro[4.5]decan-1-yl]-N-propyl-acetamide






SC_3065
cis-5-[1-(Cyclobutyl-methyl)-8-(ethyl-methyl-amino)-2-oxo-8-
INT-986
5-bromo-4-
SC_3065
489.3



phenyl-1,3-diazaspiro[4.5]decan-3-yl]-4-methoxy-pyrimidine-

methoxypyrimidine-2-





2-carbonitrile

carbonitrile




SC_3066
cis-4-[1-(Cyclobutyl-methyl)-8-methylamino-2-oxo-8-phenyl-
SC_3080

SC_3066
459.3



1,3-diazaspiro[4.5]decan-3-yl]-3-methoxy-benzonitrile






SC_3067
cis-5-[8-Dimethylamino-1-(3-methoxy-propyl)-2-oxo-8-
INT-979
5-bromo-6-
SC_3022
478.3



phenyl-1,3-diazaspiro[4.5]decan-3-yl]-6-methoxy-pyridine-2-

methoxypicolinonitrile





carbonitrile






SC_3068
cis-4-[8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-2-
SC_3060

SC_3016
477.3



oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-benzamide






SC_3069
cis-5-[8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-2-
INT-976
5-bromopicolinonitrile (step
SC_3013
460.3



oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-pyridine-2-

1); 1-(tert-butyldimethyl-





carbonitrile

silyloxy)cyclobutyl)methyl







4-methylbenzene-sulfonate







(step 2)




SC_3070
cis-5-[8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-2-
INT-976
5-bromopicolinonitrile (step
SC_3013
562.3



oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-N-[(1-hydroxy-

1); 1-(tert-butyldimethyl-





cyclobutyl)-methyl]-pyridine-2-carboxylic acid amide

silyloxy)cyclobutyl)methyl







4-methylbenzene-sulfonate







(step 2)




SC_3071
cis-2-[8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-2-
INT-976
2-bromobenzonitrile (step
SC_3013
459.3



oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-benzonitrile

1); 1-(tert-butyldimethyl-







silyloxy)cyclobutyl)methyl







4-methylbenzene-sulfonate







(step 2)




SC_3072
cis-3-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-
INT-987
3-iodobenzonitrile
SC_3022
443.3



phenyl-1,3-diazaspiro[4.5]decan-3-yl]-benzonitrile






SC_3073
cis-1-(Cyclobutyl-methyl)-8-dimethylamino-8-phenyl-3-[2-
INT-987
5-bromo-2-
SC_3022
488.3



(trifluoromethyl)-pyrimidin-5-yl]-1,3-diazaspiro[4.5]decan-2-

(trifluoromethyl)pyrimidine





one






SC_3074
cis-5-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-
INT-987
methyl 5-bromo-4-methyl-
SC_3022
491.3



phenyl-1,3-diazaspiro[4.5]decan-3-yl]-4-methyl-pyridine-2-

picolinate





carboxylic acid methyl ester






SC_3075
cis-1-(Cyclobutyl-methyl)-8-dimethylamino-3-(5-methoxy-
INT-987
2-bromo-5-methoxypyrazine
SC_3022
450.3



pyrazin-2-yl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one






SC_3076
cis-1-(Cyclobutyl-methyl)-8-dimethylamino-3-(2-methoxy-
INT-987
5-bromo-2-
SC_3022
450.3



pyrimidin-5-yl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one

methoxypyrimidine




SC_3077
cis-4-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-
INT-987
4-iodobenzonitrile
SC_3022
443.3



phenyl-1,3-diazaspiro[4.5]decan-3-yl]-benzonitrile






SC_3078
cis-5-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-
INT-987
5-bromo-4-
SC_3022
458.3



phenyl-1,3-diazaspiro[4.5]decan-3-yl]-4-methyl-pyridine-2-

methylpicolinonitrile





carbonitrile






SC_3079
cis-1-(Cyclobutyl-methyl)-8-dimethylamino-3-(5-fluoro-
INT-987
2-bromo-5-fluoropyrimidine
SC_3022
438.3



pyrimidin-2-yl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one






SC_3080
cis-4-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-
INT-987
4-bromo-3-
SC_3022
473.3



phenyl-1,3-diazaspiro[4.5]decan-3-yl]-3-methoxy-benzonitrile

methoxybenzonitrile




SC_3081
cis-4-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-
INT-987
methyl 4-iodobenzoate
SC_3022
476.3



phenyl-1,3-diazaspiro[4.5]decan-3-yl]-benzoic acid methyl







ester






SC_3082
cis-1-(Cyclobutyl-methyl)-8-dimethylamino-8-phenyl-3-(2-
INT-987
4-iodo-2-(pyrrolidin-1-
SC_3022
489.3



pyrrolidin-1-yl-pyrimidin-4-yl)-1,3-diazaspiro[4.5]decan-2-one

yl)pyrimidine




SC_3083
cis-1-(Cyclobutyl-methyl)-8-dimethylamino-8-phenyl-3-(5-
INT-987
2-(5-bromothiophen-2-
SC_3022
501.3



pyridin-2-yl-thiophen-2-yl)-1,3-diazaspiro[4.5]decan-2-one

yl)pyridine




SC_3084
cis-1-(Cyclobutyl-methyl)-8-dimethylamino-3[2-
INT-987
1-bromo-2-
SC_3022
564.2



methylsulfonyl-4-(trifluoromethyl)-phenyl]-8-phenyl-1,3-

(methylsulfonyl)-4-





diazaspiro[4.5]decan-2-one

(trifluoromethyl)benzene




SC_3085
cis-1-(Cyclobutyl-methyl)-8-dimethylamino-8-phenyl-346-
INT-987
5-bromo-2-
SC_3022
487.3



(trifluoromethyl)-pyridin-3-yl]-1,3-diazaspiro[4.5]decan-2-one

(trifluoromethyl)pyridine




SC_3086
cis-1-(Cyclobutyl-methyl)-3-(2,4-dimethoxy-phenyl)-8-
INT-987
1-bromo-2,4-
SC_3022
478.3



dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one

dimethoxybenzene




SC_3087
cis-2-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-
INT 987
2-iodo-4-(methylthio)-
SC_3022/
521.3



phenyl-1,3-diazaspiro[4.5]decan-3-yl]-4-methylsulfonyl-

benzonitrile (SC_3022)
SC_3008




benzonitrile






SC_3088
cis-5-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-
INT-987
5-bromo-2-
SC_3022
461.3



phenyl-1,3-diazaspiro[4.5]decan-3-yl]-2-fluoro-benzonitrile

fluorobenzonitrile




SC_3089
cis-4-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-
INT-987
4-bromo-N,N-dimethyl-3-
SC_3022
593.3



phenyl-1,3-diazaspiro[4.5]decan-3-yl]-N,N-dimethyl-3-

(trifluoromethyl)





(trifluoromethyl)-benzenesulfonic acid amide

benzenesulfonamide




SC_3090
cis-2-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-
INT-987
2-bromobenzonitrile
SC_3022
443.3



phenyl-1,3-diazaspiro[4.5]decan-3-yl]-benzonitrile






SC_3091
cis-1-(Cyclobutyl-methyl)-8-dimethylamino-3-(2-methyl-
INT-987
6-bromo-2-
SC_3022
473.3



imidazo[1,2-alpyrazin-6-yl)-8-phenyl-1,3-

methylimidazo[1,2-





diazaspiro[4.5]decan-2-one

a]pyrazine




SC_3092
cis-1-(Cyclobutyl-methyl)-8-dimethylamino-3-(4-
INT-987
(4-
SC_3022/
496.3



methylsulfonyl-phenyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-

iodophenyl)(methyl)sulfane
SC_3008




one






SC_3093
cis-2-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-
INT-987
2-bromo-5-
SC_3022
473.3



phenyl-1,3-diazaspiro[4.5]decan-3-yl]-5-methoxy-benzonitrile

methoxybenzonitrile




SC_3094
cis-1-(Cyclobutyl-methyl)-8-dimethylamino-3,8-diphenyl-1,3-
INT-987
bromobenzene
SC_3022
418.3



diazaspiro[4.5]decan-2-one






SC_3096
cis-1-(Cyclobutyl-methyl)-8-dimethylamino-8-phenyl-3-
INT-987
2-bromopyrazine
SC_3022
420.3



pyrazin-2-yl-1,3-diazaspiro[4.5]decan-2-one





























in analogy to

m/z


Example
Chemical name
Reactant I
Reactant II
method

1H NMR data

(M + H)+





















SC_3098
cis-8-Dimethylamino-1-[(1-
INT-799
5-bromo-2-(4-
SC_3097
1H NMR (DMSO-d6): δ 8.56 (s, 2H),
534.4



hydroxy-cyclobutyl)-methyl]-3-[2-

methylpiperazin-1-

7.36-7.35 (m, 4H), 7.27-7.24 (m, 1H), 5.52 (s,



(4-methyl-piperazin-1-yl)-

yl)pyrimidine

1H), 3.71 (s, 2H), 3.64 (m, 4H), 3.21 (s, 2H),



pyrimidin-5-yl]-8-phenyl-1,3-



2.69-2.67 (m, 2H), 2.32 (m, 4H),



diazaspiro[4.5]decan-2-one



2.19-2.11 (m, 7H), 1.98 (s, 6H), 1.92-1.86 (m, 2H),







1.66-1.64 (m, 1H), 1.52-1.42 (m, 5H).


SC_3101
cis-1-[(1-Hydroxy-cyclobutyl)-
SC_3098

SC_3099
1H NMR (DMSO-d6): δ 8.58 (s, 2H),
520.4



methyl]-8-methylamino-3-[2-(4-



7.48 (d, 2H), 7.32 (t, 2H), 7.19 (t, 1H), 5.61 (s,



methyl-piperazin-1-yl)-pyrimidin-



1H), 3.75 (s, 2H), 3.66-3.64 (m, 4H), 3.30 (s,



5-yl]-8-phenyl-1,3-



2H), 2.35-2.32 (m, 4H), 2.25-2.19 (m, 5H),



diazaspiro[4.5]decan-2-one



2.12-2.07 (m, 2H), 1.90-1.88 (m, 7H),







1.79-1.73 (m, 2H), 1.65-1.63 (m, 1H),







1.50-1.44 (m, 3H)


SC_3102
cis-1-[(1-Hydroxy-cyclobutyl)-
SC_3100

SC_3099
1H NMR (DMSO-d6): δ 9.51 (br s, 2H),
506.3



methyl]-8-methylamino-8-phenyl-



9.15 (br s, 2H), 8.65 (s, 2H), 7.69-7.68 (m,



3-(2-piperazin-1-yl-pyrimidin-5-



2H), 7.50-7.41 (m, 3H), 3.88-3.86 (m, 4H),



yl)-1,3-diazaspiro[4.5]decan-2-one



3.79 (m, 2H), 3.65 (m, 2H), 3.16-3.13 (m,



dihydrochloride



4H), 2.64-2.62 (m, 2H), 2.38-2.33 (m, 2H),







2.16-2.04 (m, 7H), 1.90-1.84 (m, 2H),







1.76-1.70 (m, 3H), 1.60-1.58 (m, 1H).


SC_3104
cis-1-(Cyclobutyl-methyl)-8-
SC_3103

SC_3099
1H NMR (DMSO-d6): δ 8.59 (s, 1H),
487.3



methylamino-3-[4-methyl-6-



7.81 (s, 1H), 7.44 (d, 2H), 7.30 (t, 2H), 7.17 (t,



(trifluoromethyl)-pyridin-3-yl]-8-



1H), 3.76 (s, 2H), 3.21 (d, 2H), 2.61-2.57 (m,



phenyl-1,3-diazaspiro[4.5]decan-2-



1H), 2.32 (s, 3H), 2.29-2.17 (m, 3H),



one



2.03-1.97 (m, 2H), 1.91-1.88 (m, 5H),







1.84-1.67 (m, 6H), 1.51-1.48 (m, 2H).


SC_3106
cis-1-(Cyclopropyl-methyl)-8-
SC_3105

SC_3099
1H NMR (DMSO-d6): δ 7.90-7.88 (d, 2H),
468.2



methylamino-3-(4-methylsulfonyl-



7.82-7.80 (d, 2H), 7.50-7.48 (d, 2H),



phenyl)-8-phenyl-1,3-



7.35-7.32 (m, 2H), 7.22-7.19 (m, 1H), 3.80 (s,



diazaspiro[4.5]decan-2-one



2H), 3.14-3.10 (m, 5H), 2.29-2.23 (m, 3H),







1.91-1.79 (m, 7H), 1.42-1.39 (m, 2H),







1.05-1.04 (m, 1H), 0.50-0.47 (m, 2H),







0.34-0.32 (m, 2H).


SC_3107
cis-1-(Cyclopropyl-methyl)-8-
INT-983
1-bromo-2-fluoro-4-
SC3103 (step
1H NMR (DMSO-d6): δ 7.85 (t, 1H),
500.2



dimethylamino-3-(2-fluoro-4-

(methylsulfonyl)benzene
1), SC_3105
7.79-7.76 (m, 1H), 7.72-7.69 (m, 1H),



methylsulfonyl-phenyl)-8-phenyl-

(step 1),
(step 2)
7.37-7.33 (m, 4H), 7.27-7.24 (m, 1H), 3.81 (s, 2H),



1,3-diazaspiro[4.5]decan-2-one

(Bromomethyl)cyclopropane

3.24 (s, 3H), 3.07 (d, 2H), 2.71-2.68 (m, 2H),





(step 2)

2.28-2.22 (m, 2H), 1.99 (s, 6H),







1.53-1.42 (m, 4H), 1.00-0.99 (m, 1H), 0.53-0.49 (m,







2H), 0.34-0.30 (m, 2H).


SC_3108
cis-2-[8-Dimethylamino-1-[(1-
SC_3071

SC_3016
1H NMR (600 MHz, DMSO) δ
477.3



hydroxy-cyclobutyl)-methyl]-2-



7.59-7.55 (s, 1H), 7.47-7.39 (m, 2H), 7.39-7.31 (m,



oxo-8-phenyl-1,3-



5H), 7.30-7.21 (m, 3H), 3.77-3.73 (s,



diazaspiro[4.5]decan-3-yl]-



2H), 3.21-3.17 (s, 1H), 2.72-2.66 (d, 2H),



benzamide; formic acid



2.17-2.09 (m, 5H), 2.02-1.99 (s, 6H),







1.95-1.86 (m, 2H), 1.71-1.60 (m, 3H),







1.49-1.37 (m, 3H)


SC_3109
cis-2-[-Dimethylamino-1-[2-(1-
INT988
2-bromobenzonitrile
SC_3097 (step
1H NMR (600 MHz, DMSO) δ
505.3



methoxy-cyclobutyl)-ethyl]-2-oxo-


1), SC_3109
7.52-7.48 (s, 1H), 7.47-7.31 (m, 7H), 7.29-7.23 (m,



8-phenyl-1,3-diazaspiro[4.5]decan-


(step 2)
1H), 7.25-7.22 (s, 1H), 7.24-7.18 (m,



3-yl]-benzamide



1H), 3.68-3.65 (s, 3H), 3.13-3.10 (s, 2H),







3.09-3.02 (m, 2H), 2.71-2.65 (m, 2H),







2.21-2.12 (m, 2H), 2.09-1.99 (m, 2H),







2.02-1.98 (s, 6H), 1.97-1.86 (m, 4H),







1.77-1.67 (m, 1H), 1.64-1.52 (m, 3H),







1.44-1.36 (td, 2H).


SC_3110
cis-8-Dimethylamino-1-[2-(1-
INT-988
5-bromo2-methyl-
SC_3103
1H NMR (600 MHz, DMSO) δ
478.3



methoxy-cyclobutyl)-ethyl]-3-(2-

pyrimidine

8.94-8.90 (s, 2H), 7.41-7.34 (d, 4H),



methyl-pyrimidin-5-yl)-8-phenyl-



7.32-7.24 (ddd, 1H), 3.76-3.72 (s, 2H),



1,3-diazaspiro[4.5]decan-2-one



3.15-3.08 (m, 5H), 2.72-2.65 (m, 2H), 2.57-2.52 (s,







3H), 2.25-2.16 (m, 2H), 2.11-2.02 (m,







2H), 2.03-1.99 (s, 6H), 1.99-1.86 (m,







4H), 1.78-1.68 (tq, 1H), 1.65-1.51 (m,







3H), 1.50-1.44 (d, 2H).


SC_3111
cis-5-[1-[(1-Hydroxy-cyclobutyl)-
INT-799
5-bromo-2-
SC_3103 (step
1H NMR (600 MHz, DMSO) δ
447.3



methyl]-8-methylamino-2-oxo-8-

cyanopyrimidine
1), SC_3099
9.24-9.20 (s, 2H), 7.53-7.48 (m, 2H), 7.37-7.31 (t,



phenyl-1,3-diazaspiro[4.5]decan-3-


(step 2)
2H), 7.25-7.19 (t, 1H), 3.93-3.89 (s, 2H),



yl]-pyrimidine-2-carbonitrile



3.42-3.36 (m, 2H), 2.35-2.26 (td, 2H),







2.18-2.10 (tt, 2H), 2.09-2.04 (s, 1H),







1.97-1.88 (m, 2H), 1.93-1.90 (s, 6H),







1.86-1.77 (td, 2H), 1.72-1.62 (s, 1H),







1.59-1.54 (d, 1H), 1.48-1.43 (d, 2H).


SC_3113
cis-4-[1-[(1-Hydroxy-cyclobutyl)-
INT-976
1-bromo-4-cyano-2-
SC_3112
1HNMR (DMSO-d6, 400 MHz), δ (ppm) = 7.54 (s,
475.3



methyl]-8-methylamino-2-oxo-8-

methoxybenzene

1H), 7.50 (d, 1H, J = 8.16 Hz),



phenyl-1,3-diazaspiro[4.5]decan-3-

(step 1)

7.46-7.39 (m, 3H), 7.30 (t, 2H, J = 7.48 Hz),



yl]-3-methoxy-benzonitrile



7.18 (t, 1H, J = 7.16 Hz), 5.59 (s, 1H), 3.85 (s,







3H), 3.73 (s, 2H), 3.30 (s, 2H, merged with







DMSO-water), 2.32-2.08 (m, 4H),







1.91-1.87 (m, 7H), 1.68-1.47 (m, 6H).


SC_3114
cis-4-[8-Ethylamino-1-[(1-hydroxy-
INT-
4-Bromo-3-methoxy-
SC_3112 (step
1HNMR (DMSO-d6, 400 MHz), δ (ppm) = 7.54 (s,
489.1



cyclobutyl)-methyl]-2-oxo-8-
1008
benzonitrile (step 1)
1, step 2)
1H), 7.51-7.45 (m, 3H), 7.40 (d, 1H,



phenyl-1,3-diazaspiro[4.5]decan-3-



J = 8.24 Hz), 7.29 (t, 2H, J = 7.58 Hz),



yl]-3-methoxy-benzonitrile



7.17 (t, 1H, J = 7.12 (Hz), 5.60 (s, 1H), 3.85 (s,







3H), 3.73 (s, 2H), 3.21 (s, 2H, merged with







DMSO-H2O), 2.32-2.27 (m, 2H), 2.08 (bs,







5H), 1.96-1.87 (m, 4H), 1.68-1.46 (m, 6H),







0.97 (t, 3H, J = 4.0 Hz).


SC_3115
cis-2-[8-Ethylamino-1-[(1-hydroxy-
INT-
2-bromo-benzonitrile
SC_3112 (step
1HNMR (DMSO-d6, 400 MHz), δ (ppm) = 7.82 (d, 1H,
458.9



cyclobutyl)-methyl]-2-oxo-8-
1008
(step 1)
1, step 2)
J = 7.56 Hz), 7.71 (t, 1H, J = 6.98 Hz),



phenyl-1,3-diazaspiro[4.5]decan-3-



7.53-7.47 (m, 3H), 7.37-7.27 (m,



yl]-benzonitrile



3H), 7.19-7.17 (m, 1H), 5.55 (s, 1H), 3.87 (s,







2H), 3.38 (s, 2H), 2.36-2.32 (m, 2H),







2.10 (bs, 4H), 1.94-1.86 (m. 4H), 1.75-1.48 (6H),







0.98 (bs, 3H).


SC_3116
cis-5-[1-[(1-Hydroxy-cyclobutyl)-
INT-799
5-bromo-4-methoxy-
SC_3103 (step
1HNMR (DMSO-d6, 400 MHz, at 100° C.),
477.2



methyl]-8-methylamino-2-oxo-8-

pyrimidine-2-
1), SC_3099
δ (ppm) = 8.79 (s, 1H), 7.46 (d, 2H, J = 7.84 Hz),



phenyl-1,3-diazaspiro[4.5]decan-3-

carbonitrile (step 1)
(step 2)
7.32 (t, 2H, J = 7.12 Hz), 7.19 (t, 1H, J = 7.28 Hz),



yl]-4-methoxy-pyrimidine-2-



5.09 (bs, 1H), 4.05 (s, 3H),



carbonitrile



3.85 (s, 2H), 3.38 (s, 2H), 2.31-2.15 (m, 4H),







1.98 (m, 7H), 1.74-1.51 (m, 6H).


SC_3117
cis-2-[8-Dimethylamino-1-(oxetan-
SC_3274
toluene-4-sulfonic
SC_3105 (step
1HNMR (DMSO-d6, 400 MHz), δ (ppm) = 7.52 (s,
463.4



3-yl-methyl)-2-oxo-8-phenyl-1,3-

acid oxetan-3-
1), SC_3016
1H), 7.43-7.33 (m, 6H),



diazaspiro[4.5]decan-3-yl]-

ylmethyl ester (step
(step 2)
7.30-7.17 (m, 4H), 4.63 (t, 2H, J = 6.9 Hz), 4.39 (t, 2H,



benzamide

1)

J = 6.08 Hz), 3.64 (s, 2H), 3.38 (d, 2H, J = 7.32 Hz),







3.21-3.15 (m, 1H), 2.70-2.66 (m,







2H), 2.08-1.98 (m, 8H), 1.54-1.35 (m, 4H).


SC_3118
cis-4-Methoxy-5-(8-methylamino-
INT-976
5-bromo-4-methoxy-
SC_3103 (step
1HNMR (DMSO-d6, 400 MHz), δ (ppm) = 8.80 (s,
393.0



2-oxo-8-phenyl-1,3-

pyrimidine-2-
1), SC_3099
1H), 7.86 (bs, 1H), 7.43 (d, 2H, J = 7.84 Hz),



diazaspiro[4.5]decan-3-yl)-

carbonitrile (step 1)
(step 2)
7.32 (t, 2H, J = 7.32 Hz),



pyrimidine-2-carbonitrile



7.21-7.18 (m, 1H), 4.02 (s, 3H), 3.83 (s, 2H),







2.07-2.00 (m, 3H), 1.90-1.74 (m, 7H), 1.48 (d, 2H, J = 13.8 Hz).


SC_3119
cis-2-(8-Methylamino-2-oxo-8-
INT-976
2-bromo-benzonitrile
SC_3103 (step
1HNMR (DMSO-d6, 400 MHz) δ 7.51 (bs,
379.4



phenyl-1,3-diazaspiro[4.5]decan-3-

(step 1)
1), SC_3099
1H), 7.43-7.37 (m, 4H), 7.33-2.29 (m, 3H, J = 8.28 Hz),



yl)-benzamide


(step 2),
7.22-7.16 (m, 3H), 6.93 (bs, 1H),






SC_3016 (step
3.64 (s, 2H), 2.03-1.97 (m, 2H), 1.86 (bs,






3)
5H), 1.73-1.58 (m, 4H).


SC_3121
cis-3-(2-Cyclopropyl-pyrimidin-5-
INT-976
5-bromo-2-
SC_3103
1H NMR (600 MHz, DMSO) δ 8.80 (s, 2H),
392.3



yl)-8-dimethylamino-8-phenyl-1,3-

cyclopropyl-

7.67 (s, 1H), 7.41-7.32 (m, 4H),



diazaspiro[4.5]decan-2-one

pyrimidine

7.31-7.22 (ddt, 1H), 3.60 (s, 2H), 2.42-2.36 (m,







2H), 2.18-2.08 (m, 1H), 1.98-1.85 (m,







4H), 1.96 (s, 6H), 1.47 (s, 2H),







0.98-0.91 (m, 2H), 0.93-0.86 (m, 2H).


SC_3122
cis-8-Dimethylamino-3-[4-methyl-
INT-976
5-bromo-4-methyl-2-
SC_3103
1H NMR (600 MHz, DMSO) δ 8.57 (s, 1H),
433.2



6-(trifluoromethyl)-pyridin-3-yl]-8-

(trifluoromethyl)pyridine

7.79 (s, 1H), 7.52 (s, 1H), 7.40-7.32 (m,



phenyl-1,3-diazaspiro[4.5]decan-2-



4H), 7.30-7.22 (tt, 1H), 3.61 (s, 2H),



one



2.39-2.30 (m, 5H), 1.96 (s, 6H), 2.00-1.91 (m,







2H), 1.84 (s, 2H), 1.57-1.53 (s, 2H).


SC_3123
cis-8-Dimethylamino-3-(2-
INT-976
1-bromo-2-
SC_3103
1H NMR (600 MHz, DMSO) δ
428.2



methylsulfonyl-phenyl)-8-phenyl-

methylsulfonyl-

7.98-7.92 (dd, 1H), 7.81-7.74 (td, 1H),



1,3-diazaspiro[4.5]decan-2-one

benzene

7.61-7.54 (td, 1H), 7.52-7.46 (m, 2H),







7.41-7.31 (m, 2H), 7.35 (s, 2H), 7.29-7.22 (tt, 1H),







3.49 (s, 2H), 3.25 (s, 3H), 2.37 (s, 2H),







1.99-1.96 (m, 1H), 1.98-1.94 (s, 6H),







1.95-1.91 (d, 1H), 1.83-1.79 (m, 2H),







1.58-1.55 (s, 2H).


SC_3124
cis-8-Dimethylamino-8-phenyl-3-
INT-989
Piperazine-2-one
SC_3120
1H NMR (600 MHz, DMSO) δ 8.52 (s, 2H),
436.3



(2-piperazin-1-yl-pyrimidin-5-yl)-



7.41-7.31 (m, 5H), 3.59-3.54 (m, 4H),



1,3-diazaspiro[4.5]decan-2-one



3.52 (s, 2H), 2.76-2.70 (m, 4H), 2.55 (s,







3H), 2.49-2.33 (m, 2H), 1.96 (s, 6H),







1.93-1.83 (m, 4H), 1.51-1.43 (s, 2H).


SC_3125
trans-2-(8-Ethylamino-2-oxo-8-
SC_3127

SC_3016
1HNMR (DMSO-d6, 400 MHz), δ (ppm) = 7.56-7.20 (m,
393.1



phenyl-1,3-diazaspiro[4.5]decan-3-



12H), 3.60 (s, 2H),



yl)-benzamide



2.08-1.92 (m, 6H), 1.69 (bs, 2H), 1.56 (bs, 2H), 0.93 (t,







3H).


SC_3126
cis--2-(8-Ethylamino-2-oxo-8-
SC_3128

SC_3016

1HNMR (DMSO-d6, 400 MHz), δ (ppm) = 7.51-2.38 (m,

393.4



phenyl-1,3-diazaspiro[4.5]decan-3-



5H), 7.32-7.30 (m, 3H),



yl)-benzamide



7.22-7.18 (m, 3H), 6.93 (s, 1H), 3.63 (s, 2H),







2.07-1.98 (m, 4H), 1.86-1.72 (m, 4H),







1.60-1.57 (m, 2H), 0.93 (t, 3H).


SC_3127
cis-2-(8-Ethylamino-2-oxo-8-
INT-
2-bromo-benzonitrile
SC_3103
1HNMR (DMSO-d6, 400 MHz), δ (ppm) = 7.77 (d,
375.1



phenyl-1,3-diazaspiro[4.5]decan-3-
1009


1H, J = 6.8 Hz), 7.69-7.65 (m, 1H),



yl)-benzonitrile



7.51 (d, 1H, J = 8.4 Hz), 7.44 (d, 2H, J = 7.6 Hz),







7.39 (s, 1H), 7.34-7.28 (m, 3H), 7.17 (t,







1H, 7.2 Hz), 3.77 (s, 2H), 2.10-2.04 (m, 4H),







1.91-1.88 (m, 2H), 1.80-1.74 (m, 3H),







1.61-1.58 (m, 2H), 0.94 (t, 3H, J = 6.8 Hz).


SC_3128
cis-2-(8-Ethylamino-2-oxo-8-
INT-
2-bromo-benzonitrile
SC_3103

1HNMR (DMSO-d6, 400 MHz), δ (ppm) = 7.89 (bs,

375.1



phenyl-1,3-diazaspiro[4.5]decan-3-
1008


1H), 7.79 (d, 1H, J = 7.6), 7.69 (t,



yl)-benzonitrile



1H, J = 7.6 Hz), 7.54-7.50 (m, 3H),







7.36-7.30 (m, 3H), 7.18 (t, 1H, J = 7.2 Hz),







3.73 (s, 2H), 2.08-1.92 (m, 7H), 1.71 (bs, 2H),







1.59 (bs, 2H,), 0.93 (t, 3H, J = 6.4 Hz).


SC_3131
cis-3-[5-(8-Dimethylamino-2-oxo-
SC_3129

SC_3016
1H NMR (600 MHz, DMSO) δ 9.11 (s, 2H),
471.3



8-phenyl-1,3-diazaspiro[4.5]decan-



8.79 (t, 1H), 8.43 (dt, 1H), 8.09 (s, 1H),



3-yl)-pyrimidin-2-yl]-benzamide



7.94 (dt, 1H), 7.84 (s, 1H), 7.56 (t, 1H),







7.41-7.35 (m, 4H), 7.28 (ddd, 1H), 3.72 (s, 2H),







2.00-1.84 (m, 2H), 1.98 (s, 6H), 1.53 (s,







2H).


SC_3134
trans-4-(8-Ethylamino-2-oxo-8-
INT-
4-Bromo-3-methoxy-
SC_3103
1HNMR (DMSO-d6, 400 MHz), δ (ppm) = 7.71 (bs,
405.3



phenyl-1,3-diazaspiro[4.5]decan-3-
1009
benzonitrile

1H), 7.56-7.49 (m, 4H), 7.37 (d,



yl)-3-methoxy-benzonitrile



1H, J = 6.6 Hz), 7.31 (t, 2H, J = 7.10 Hz),







7.19-7.17 (m, 1H), 3.87 (s, 3H), 3.62 (s,







2H), 2.06-1.90 (m, 7H), 1.69-1.53 (m, 4H),







0.92 (t, 3H, J = 6.70 Hz).


SC_3135
cis-4-(8-Ethylamino-2-oxo-8-
INT-
4-Bromo-3-methoxy-
SC_3103
1HNMR (DMSO-d6, 400 MHz), δ (ppm) = 7.52-7.50 (m,
405.2



phenyl-1,3-diazaspiro[4.5]decan-3-
1008
benzonitrile

2H), 7.44-7.43 (m, 2H),



yl)-3-methoxy-benzonitrile



736 (d, 1H, J = 8.04 Hz), 7.30-7.19 (m, 4H),







3.83 (s, 3H), 3.63 (s, 2H), 2.05-1.72 (m, 8H),







1.53-1.50 (m, 2H), 0.92 (t, 3H).


SC_3136
cis-3-[2-(4-Acetyl-piperazin-1-yl)-
SC_3124
acetyl chloride
SC_3130

478.3



pyrimidin-5-yl]-8-dimethylamino-



8-phenyl-1,3-diazaspiro[4.5]decan-



2-one


SC_3137
cis-8-Dimethylamino-8-phenyl-3-
INT-989
pyridine-4-boronic
SC_3129
1H NMR (600 MHz, DMSO) δ 9.16 (s, 2H),
429.2



(2-pyridin-4-yl-pyrimidin-5-yl)-1,3-

acid

8.70 (d, 1H), 8.18 (s, 1H), 7.91 (s, 1H),



diazaspiro[4.5]decan-2-one



7.42-7.35 (m, 4H), 7.28 (tt, 1H), 3.73 (s, 2H),







2.49-2.37 (m, 2H), 1.98 (s, 6H),







2.01-1.87 (m, 2H), 1.58-1.47 (m, 2H).


SC_3138
cis-8-Dimethylamino-8-phenyl-3-
INT-989
pyridine-3-boronic
SC_3129
1H NMR (600 MHz, DMSO) δ 9.43 (dd,
429.2



(2-pyridin-3-yl-pyrimidin-5-yl)-1,3-

acid

1H), 9.13 (s, 2H), 8.65 (dd, 1H),



diazaspiro[4.5]decan-2-one



8.58 (dt, 1H), 7.52 (ddd, 1H), 7.42-7.36 (m, 4H),







7.28 (ddd, 1H), 3.72 (s, 2H), 1.98 (s, 6H),







2.02-1.89 (m, 4H), 1.57-1.46 (m, 4H).


SC_3139
cis-5-(8-Dimethylamino-2-oxo-8-
INT-991
2-aminoethanol
SC_3133
1H NMR (600 MHz, DMSO) δ 9.08 (s, 2H),
439.3



phenyl-1,3-diazaspiro[4.5]decan-3-



8.59 (t, 1H), 7.94 (s, 1H), 7.43-7.30 (m,



yl)-N-(2-hydroxy-ethyl)-



5H), 7.30-7.21 (m, 1H), 3.72 (s, 2H),



pyrimidine-2-carboxylic acid amide



3.51 (q, 2H), 2.49-2.37 (m, 2H), 2.00-1.90 (m,







10H), 1.89-1.74 (m, 2H), 1.57-1.48 (m,







2H), 1.38-1.32 (m, 1H).


SC_3141
cis-8-Dimethylamino-3-[2-
INT-976
4-[5-bromo-4-
SC_3103
1H NMR (600 MHz, DMSO) δ 8.59 (d, 1H),
505.3



morpholin-4-yl-4-(trifluoromethyl)-

(trifluoromethyl)pyrimidin-

7.39-7.35 (m, 5H), 7.27 (d, 1H), 3.73 (t,



pyrimidin-5-yl]-8-phenyl-1,3-

2-

4H), 3.67 (q, 4H), 3.28-3.22 (m, 1H),



diazaspiro[4.5]decan-2-one

yl]morpholine

2.41-2.28 (m, 2H), 1.98 (s, 6H), 1.94-1.80 (m,







3H), 1.53-1.42 (m, 2H).


SC_3142
cis-4-[5-(8-Dimethylamino-2-oxo-
INT-989
4-
SC_3129
1H NMR (600 MHz, DMSO) δ 9.15 (s, 2H),
453.2



8-phenyl-1,3-diazaspiro[4.5]decan-

cyanophenylboronic

8.49-8.43 (m, 2H), 7.99-7.92 (m, 2H),



3-yl)-pyrimidin-2-yl]-benzonitrile

acid

7.89 (s, 1H), 7.38 (m, 4H), 7.28 (td, 1H),







3.73 (s, 2H), 2.48-2.35 (m, 1H),







2.03-1.90 (m, 10H), 1.55-1.48 (m, 2H).


SC_3143
cis-5-(8-Ethylamino-2-oxo-8-
INT-
5-Bromo-4-methoxy-
SC_3103
(DMSO-d6, 400 MHz), δ (ppm) = 8.79 (s,
407.2



phenyl-1,3-diazaspiro[4.5]decan-3-
1008
pyrimidine-2-

1H), 7.60 (s, 1H), 7.41 (d, 2H, J = 7.72 Hz),



yl)-4-methoxy-pyrimidine-2-

carbonitrile

7.28 (t, 2H, J = 7.54 Hz), 7.16 (t, 1H, J = 7.32 Hz),



carbonitrile



3.97 (s, 3H), 3.72 (s, 2H), 2.02 (bs,







4H), 1.90-1.69 (m, 5H), 1.51-1.48 (m, 2H),







0.89 (t, 3H, J = 6.56 Hz).


SC_3144
trans-5-(8-Ethylamino-2-oxo-8-
INT-
5-Bromo-4-methoxy-
SC_3103
1HNMR (DMSO-d6, 400 MHz), δ (ppm) =
407.3



phenyl-1,3-diazaspiro[4.5]decan-3-
1009
pyrimidine-2-

8.87 (s, 1H), 8.10 (bs, 1H), 7.50 (d, 2H, J = 7.52 Hz),



yl)-4-methoxy-pyrimidine-2-

carbonitrile

7.31 (t, 2H, J = 7.20 Hz), 7.18 (t,



carbonitrile



1H, J = 6.88 Hz), 4.04 (s, 3H), 3.74 (s, 2H),







2.07-1.95 (m, 6H), 1.70-1.54 (m, 4H),







0.93 (t, 3H, J = 6.62 Hz).


SC_3145
cis-8-Dimethylamino-3-[2-
INT-991
morpholine
SC_3133
1H NMR (600 MHz, DMSO) δ 9.04 (s, 2H),
478.3



(morpholine-4-carbonyl)-



7.88 (s, 1H), 7.42-7.30 (m, 5H),



pyrimidin-5-yl]-8-phenyl-1,3-



7.30-7.22 (m, 1H), 3.75-3.58 (m, 6H), 3.51 (t,



diazaspiro[4.5]decan-2-one



2H), 3.20 (t, 2H), 2.50-2.33 (m, 2H),







1.99-1.90 (m, 8H), 1.89-1.74 (m, 2H),







1.54-1.44 (m, 2H).


SC_3147
cis-8-Dimethylamino-3-[2-
INT-976
1-bromo-2-
SC_3103
1H NMR (600 MHz, DMSO) δ 7.47 (d, 1H),
442.2



(methylsulfonyl-methyl)-phenyl]-8-

(methylsulfonylmethyl)benzene

7.42-7.31 (m, 6H), 7.30-7.22 (m, 3H),



phenyl-1,3-diazaspiro[4.5]decan-2-



4.50 (s, 2H), 3.56 (s, 2H), 2.88 (s, 3H),



one



2.42-2.28 (m, 2H), 2.07 (s, 2H), 1.98-1.90 (m,







8H), 1.89-1.69 (m, 2H), 1.61-1.48 (d,







2H).


SC_3148
cis-8-Dimethylamino-3-(4-methyl-
INT-992
morpholine
SC_3120
1H NMR (600 MHz, DMSO) δ 8.14 (s, 1H),
451.3



2-morpholin-4-yl-pyrimidin-5-yl)-



7.40-7.32 (m, 4H), 7.26 (td, 1H), 7.21 (s,



8-phenyl-1,3-diazaspiro[4.5]decan-



1H), 3.69-3.60 (m, 8H), 3.38 (s, 2H),



2-one



2.41-2.27 (m, 2H), 2.20 (s, 3H), 1.97 (s, 6H),







1.95-1.76 (m, 4H), 1.54-1.45 (s, 2H).


SC_3149
cis-8-Dimethylamino-3-[2-(1,1-
INT-989
thiomorpholine-1,1-
SC_3120
1H NMR (600 MHz, DMSO) δ 8.63 (s, 2H),
485.2



dioxo-[1,4]thiazinan-4-yl)-

dioxide hydrochloride

7.50 (br s, 1H), 7.41-7.33 (m, 4H), 7.27 (td,



pyrimidin-5-yl]-8-phenyl-1,3-



1H), 4.17-4.12 (m, 4H), 3.55 (s, 2H),



diazaspiro[4.5]decan-2-one



3.12-3.06 (m, 4H), 2.47-2.27 (m, 2H),







2.04-1.74 (m, 10H), 1.51-1.42 (m, 2H).


SC_3150
cis-8-Dimethylamino-3-(4-fluoro-
INT-976
3-bromo-4-fluoro-
SC_3103
1H NMR (600 MHz, DMSO) δ 8.70 (d, 1H),
369.2



pyridin-3-yl)-8-phenyl-1,3-

pyridine

8.36 (dd, 1H), 7.54 (s, 1H), 7.36 (td, 5H),



diazaspiro[4.5]decan-2-one



7.26 (s, 1H), 3.61 (s, 2H), 2.44-2.28 (m,







2H), 2.01-1.74 (m, 10H), 1.92 (d, 2H),







1.56-1.45 (m, 2H).


SC_3151
cis-5-(8-Dimethylamino-2-oxo-8-
INT-991
2-
SC_3133
1H NMR (600 MHz, DMSO) δ 9.03 (d, 2H),
453.2



phenyl-1,3-diazaspiro[4.5]decan-3-

(methylamino)ethanol

7.86 (s, 1H), 7.40-7.23 (m, 5H), 3.69 (s,



yl)-N-(2-hydroxy-ethyl)-N-methyl-



2H), 3.61 (q, 1H), 3.50 (t, 1H), 3.45 (d, 1H),



pyrimidine-2-carboxylic acid amide



3.17 (t, 1H), 3.01 and 2.83 (both s, together







3H, amide rotamers), 2.49-2.36 (m, 2H),







2.00-1.89 (m, 8H), 1.89-1.73 (m, 2H),







1.55-1.47 (m, 2H).


SC_3152
cis-5-(8-Dimethylamino-2-oxo-8-
INT-976
5-bromo-2-
SC_3103
1H NMR (600 MHz, DMSO) δ 8.24 (s, 1H),
461.3



phenyl-1,3-diazaspiro[4.5]decan-3-

morpholino-pyridine-

7.67-7.30 (m, 5H), 7.29 (s, 1H),



yl)-2-morpholin-4-yl-

4-carbonitrile

3.70-3.65 (m, 4H), 3.51-3.44 (m, 4H), 2.37-2.22 (m,



isonicotinonitrile



2H), 2.10-1.87 (m, 10H), 1.53-1.31 (m,







2H).


SC_3153
cis-4-(8-Dimethylamino-2-oxo-8-
SC_3272

SC_3016
1H NMR (600 MHz, DMSO) δ 7.79 (d, 2H),
393.2



phenyl-1,3-diazaspiro[4.5]decan-3-



7.62 (d, 2H), 7.41-7.34 (m, 4H), 7.27 (td,



yl)-benzamide



1H), 7.13-7.09 (m, 1H), 3.62 (s, 2H),







2.46-2.35 (m, 2H), 1.97 (s, 6H), 1.93-1.76 (m,







4H), 1.51-1.45 (m, 2H).


SC_3154
cis-8-Dimethylamino-3-(2-fluoro-
INT-976
1-bromo-2-fluoro-4-
SC_3103
1H NMR (600 MHz, DMSO) δ
446.2



4-methylsulfonyl-phenyl)-8-

methylsulfonyl-

7.89-7.83 (m, 1H), 7.76 (dd, 1H), 7.70 (dd, 1H),



phenyl-1,3-diazaspiro[4.5]decan-2-

benzene

7.40-7.32 (m, 5H), 7.29-7.23 (m, 1H), 3.69 (s,



one



2H), 3.23 (s, 3H), 2.43-2.30 (m, 2H),







1.96 (s, 6H), 1.94-1.88 (m, 2H), 1.53-1.47 (m,







2H).


SC_3155
cis-4-(8-Dimethylamino-2-oxo-8-
INT-976
4-bromo-3-fluoro-
SC_3103
1H NMR (600 MHz, DMSO) δ
393.2



phenyl-1,3-diazaspiro[4.5]decan-3-

benzonitrile

7.85-7.79 (m, 2H), 7.73 (s, 1H), 7.62 (dd, 1H),



yl)-3-fluoro-benzonitrile



7.40-7.31 (m, 4H), 7.26 (tt, 1H), 3.69 (s, 2H),







2.40-2.31 (m, 2H), 1.95 (s, 6H), 1.94-1.87 (m,







2H), 1.87-1.75 (m, 2H), 1.52-1.46 (m,







2H).


SC_3156
cis-4-(8-Dimethylamino-2-oxo-8-
INT-976
4-bromo-3,5-difluoro-
SC_3103
1H NMR (600 MHz, DMSO) δ 7.85 (d, 2H),
411.2



phenyl-1,3-diazaspiro[4.5]decan-3-

benzonitrile

7.61 (s, 1H), 7.39-7.31 (m, 4H), 7.25 (tt,



yl)-3,5-difluoro-benzonitrile



1H), 3.53 (s, 2H), 2.42-2.33 (m, 2H),







1.98-1.89 (m, 8H), 1.82-1.78 (m, 2H),







1.54-1.47 (m, 2H).


SC_3157
cis-8-Dimethylamino-3-(2-
INT-989
methanol instead of
SC_3120
1H NMR (600 MHz, DMSO) δ 8.76 (s, 2H),
382.2



methoxy-pyrimidin-5-yl)-8-phenyl-

n-butanol as a solvent

7.41-7.33 (m, 5H), 7.27 (ddt, 1H), 3.86 (s,



1,3-diazaspiro[4.5]decan-2-one



3H), 3.60 (s, 2H), 2.47-2.30 (m, 2H),







2.01-1.74 (m, 10H), 1.52-1.45 (m, 2H).


SC_3158
cis-3-[2-(Benzylamino)-pyrimidin-
INT-989
benzylamine
SC_3120
1H NMR (600 MHz, DMSO) δ 8.43 (s, 2H),
457.3



5-yl]-8-dimethylamino-8-phenyl-



7.50-7.45 (m, 1H), 7.46-7.33 (m, 5H),



1,3-diazaspiro[4.5]decan-2-one



7.31-7.23 (m, 4H), 7.19 (tq, 1H), 4.46 (d,







2H), 4.02 (s, 1H), 3.50 (s, 2H),







2.41-2.31 (m, 2H), 1.97 (s, 6H), 1.88 (s, 2H),







1.49-1.41 (m, 2H).


SC_3159
cis-8-Dimethylamino-3-[2-(4-
INT-989
(4-
SC_3129
1H NMR (600 MHz, DMSO) δ 9.07 (s, 2H),
446.2



fluorophenyl)-pyrimidin-5-yl]-8-

fluorophenyl)boronic

8.37-8.30 (m, 2H), 7.83 (s, 1H),



phenyl-1,3-diazaspiro[4.5]decan-2-

acid

7.44-7.35 (m, 4H), 7.34-7.25 (m, 3H), 3.69 (s,



one



2H), 2.47-2.30 (m, 2H), 2.08-1.80 (m,







10H), 1.55-1.46 (m, 2H).


SC_3160
trans-8-Benzyl-8-dimethylamino-3-
INT-995
4-(5-bromopyrimidin-
SC_3103
1H NMR (600 MHz, DMSO) δ 8.57 (s, 2H),
451.3



(2-morpholin-4-yl-pyrimidin-5-yl)-

2-yl)morpholine

7.60 (s, 1H), 7.27 (t, 2H), 7.22-7.15 (m,



1,3-diazaspiro[4.5]decan-2-one



3H), 3.68-3.62 (m, 4H), 3.64-3.57 (m,







4H), 3.49 (s, 2H), 2.66 (s, 2H), 2.22 (s, 6H),







1.80-1.70 (m, 4H), 1.51-1.43 (m, 4H).


SC_3161
cis-8-Benzyl-8-dimethylamino-3-
INT-994
4-(5-bromopyrimidin-
SC_3103
1H NMR (600 MHz, DMSO) δ 8.45 (s, 2H),
451.3



(2-morpholin-4-yl-pyrimidin-5-yl)-

2-yl)morpholine

7.27 (t, 2H), 7.22-7.15 (m, 3H), 7.11 (s,



1,3-diazaspiro[4.5]decan-2-one



1H), 3.68-3.56 (m, 8H), 2.64 (s, 2H),







2.26 (s, 6H), 1.87-1.77 (m, 4H), 1.42 (d, 2H),







1.15 (dt, 2H).


SC_3163
cis-4-(8-Dimethylamino-2-oxo-8-
SC_3156

SC_3016
1H NMR (600 MHz, DMSO) δ 8.08 (s, 1H),
429.2



phenyl-1,3-diazaspiro[4.5]decan-3-



7.65-7.58 (m, 2H), 7.48 (br s, 1H),



yl)-3,5-difluoro-benzamide



7.39-7.31 (m, 4H), 7.28-7.22 (m, 1H), 3.49 (s,







2H), 2.40-2.32 (m, 2H), 1.96 (s, 6H),







1.95-1.90 (m, 2H), 1.87-1.77 (m, 2H),







1.54-1.49 (m, 2H).


SC_3164
cis-4-(8-Dimethylamino-2-oxo-8-
SC_3155

SC_3016
1H NMR (600 MHz, DMSO) δ 7.95 (s, 1H),
411.2



phenyl-1,3-diazaspiro[4.5]decan-3-



7.72-7.64 (m, 2H), 7.61 (t, 1H),



yl)-3-fluoro-benzamide



7.54-7.50 (m, 1H), 7.40-7.32 (m, 5H), 7.26 (tt, 1H),







3.62 (s, 2H), 2.41-2.31 (m, 2H), 1.96 (s,







6H), 1.93-1.88 (m, 2H), 1.86-1.75 (m,







2H), 1.53-1.45 (m, 2H).


SC_3165
cis-8-Benzyl-8-dimethylamino-3-
INT-994
5-bromo-2-
SC_3103
1H NMR (600 MHz, DMSO) δ 9.07 (s, 2H),
434.2



[2-(trifluoromethyl)-pyrimidin-5-

(trifluoromethyl)pyrimidine

7.77 (s, 1H), 7.29 (t, 2H), 7.24-7.17 (m,



yl]-1,3-diazaspiro[4.5]decan-2-one



3H), 3.55 (s, 2H), 2.66 (s, 2H), 2.26 (s, 6H),







1.86 (dt, 4H), 1.44 (d, 2H), 1.25-1.17 (m,







2H).


SC_3166
trans-8-Benzyl-8-dimethylamino-3-
INT-995
5-bromo-2-
SC_3103
1H NMR (600 MHz, DMSO) δ 9.16 (s, 2H),
434.2



[2-(trifluoromethyl)-pyrimidin-5-

(trifluoromethyl)pyrimidine

8.28 (s, 1H), 7.27 (t, 2H), 7.22-7.16 (m,



yl]-1,3-diazaspiro[4.5]decan-2-one



3H), 3.67 (s, 2H), 2.66 (s, 2H), 2.24 (s, 6H),







1.84-1.72 (m, 4H), 1.49 (q, 4H).


SC_3167
cis-8-Dimethylamino-8-thiophen-2-
INT-997
5-bromo-2-
SC_3103
1H NMR (600 MHz, DMSO) δ 9.19 (d, 2H),
426.1



yl-3-[2-(trifluoromethyl)-

(trifluoromethyl)pyrimidine

7.97 (s, 1H), 7.43 (t, 1H), 7.07 (dd, 1H),



pyrimidin-5-yl]-1,3-



6.97 (d, 1H), 3.78 (s, 2H), 2.40-2.27 (m, 2H),



diazaspiro[4.5]decan-2-one



2.04 (s, 6H), 1.96 (t, 2H), 1.90-1.79 (m,







2H), 1.60-1.52 (m, 2H).


SC_3168
trans-8-Dimethylamino-8-thiophen-
INT-998
5-bromo-2-
SC_3103
1H NMR (600 MHz, DMSO) δ 9.20 (s, 2H),
426.1



2-yl-3-[2-(trifluoromethyl)-

(trifluoromethyl)pyrimidine

8.00 (s, 1H), 7.45 (dd, 1H), 7.09 (dd, 1H),



pyrimidin-5-yl]-1,3-



7.02-6.97 (m, 1H), 3.81 (s, 2H), 2.12 (d,



diazaspiro[4.5]decan-2-one



4H), 2.03 (s, 6H), 1.85 (t, 2H),







1.62-1.54 (m, 2H).


SC_3170
cis-8-Dimethylamino-8-phenyl-3-
INT-989
piperidine
SC_3120
1H NMR (DMSO-d6): δ 8.49 (s, 2H),
435.3



(2-piperidin-1-yl-pyrimidin-5-yl)-



7.39-7.24 (m, 6H), 3.65-3.63 (m, 4H), 3.50 (s,



1,3-diazaspiro[4.5]decan-2-one



2H), 2.36-2.32 (m, 2H), 1.95-1.86 (m, 10H),







1.61-1.56 (m, 2H), 1.50-1.44 (m, 6H).


SC_3171
cis-8-Dimethylamino-8-phenyl-3-
INT-989
pyrrolidine
SC_3120
1H NMR (CDCl3): δ 8.43 (s, 2H),
421.3



(2-pyrrolidin-1-yl-pyrimidin-5-yl)-



7.41-7.38 (m, 2H), 7.32-7.30 (m, 3H), 5.05 (br s, 1H),



1,3-diazaspiro[4.5]decan-2-one



3.53 (t, 4H), 3.45 (s, 2H), 2.30-2.06 (m,







10H), 1.99-1.96 (m, 6H), 1.62-1.58 (m, 2H).


SC_3172
cis-8-Dimethylamino-8-phenyl-3-
INT-989
pyrimidin-5-
SC_3129
1H NMR (600 MHz, DMF) δ 9.56 (s, 2H),
430.2



(2-pyrimidin-5-yl-pyrimidin-5-yl)-

ylboronic acid

9.27 (s, 1H), 9.17 (s, 2H), 8.35 (s, 1H),



1,3-diazaspiro[4.5]decan-2-one



7.89 (d, 2H), 7.63 (dq, 3H), 3.73 (s, 2H), 3.04 (d,







2H), 2.81 (s, 6H), 2.57 (td, 2H), 2.06 (d, 2H),







1.58 (td, 2H).


SC_3174
trans-8-Benzyl-8-dimethylamino-3-
INT-995
5-bromo-4-methyl-2-
SC_3103
1H NMR (600 MHz, DMSO) δ 8.57 (s, 1H),
447.2



[4-methyl-6-(trifluoromethyl)-

(trifluoromethyl)pyridine

7.80 (s, 1H), 7.67 (s, 1H), 7.27 (t, 2H),



pyridin-3-yl]-1,3-



7.23-7.15 (m, 3H), 3.58 (d, 2H), 2.67 (s, 2H),



diazaspiro[4.5]decan-2-one



2.31 (s, 3H), 2.22 (d, 6H), 1.82-1.72 (m,







4H), 1.56 (dd, 2H), 1.48 (td, 2H).


SC_3175
cis-5-(8-Dimethylamino-2-oxo-8-
SC_3152

SC_3016

480.6



phenyl-1,3-diazaspiro[4.5]decan-3-



yl)-2-morpholin-4-yl-pyridine-4-



carboxylic acid amide


SC_3176
cis-8-Dimethylamino-3-[2-(3,5-
INT-989
(3,5-
SC_3129
1H NMR (600 MHz, DMSO) δ 9.05 (s, 2H),
447.2



dimethyl-isoxazol-4-yl)-pyrimidin-

dimethylisoxazol-4-

7.80 (s, 1H), 7.43-7.34 (m, 4H), 7.28 (tt,



5-yl]-8-phenyl-1,3-

yl)boronic acid

1H), 3.68 (s, 2H), 2.69 (s, 3H), 2.47 (s, 3H),



diazaspiro[4.5]decan-2-one



2.43-2.35 (m, 2H), 2.01-1.79 (m, 10H),







1.50 (s, 2H).


SC_3177
cis-3-[2-(Benzothiazol-6-yl)-
INT-989
1,3-benzothiazol-6-
SC_3129
1H NMR (600 MHz, DMSO) δ 9.46 (s, 1H),
485.2



pyrimidin-5-yl]-8-dimethylamino-

ylboronic acid

9.12 (s, 2H), 9.07 (s, 1H), 8.49 (d, 1H),



8-phenyl-1,3-diazaspiro[4.5]decan-



8.16 (d, 1H), 7.84 (s, 1H), 7.39 (d, 4H), 7.29 (d,



2-one



1H), 3.73 (s, 2H), 2.42 (d, 2H), 1.97 (d,







10H), 1.54 (d, 2H).


SC_3178
cis-8-Dimethylamino-3-[2-fluoro-
INT-976
1-bromo-2-fluoro-4-
SC_3103
1H NMR (600 MHz, DMSO) δ 7.80 (t, 1H),
436.2



4-(trifluoromethyl)-phenyl]-8-

(trifluoromethyl)benzene

7.65 (dd, 1H), 7.53 (dd, 1H), 7.40-7.32 (m,



phenyl-1,3-diazaspiro[4.5]decan-2-



4H), 7.29-7.23 (m, 1H), 3.66 (s, 2H),



one



2.36 (s, 2H), 1.97-1.88 (m, 8H), 1.85-1.75 (m,







2H), 1.53-1.46 (m, 2H).


SC_3179
cis-8-Dimethylamino-3-(6-
INT-976
4-(5-bromo-2-
as SC_3097
1H NMR (600 MHz, DMSO) δ 8.20 (d, 1H),
436.3



morpholin-4-yl-pyridin-3-yl)-8-

pyridyl)morpholine
step 2
7.89 (dd, 1H), 7.37 (p, 5H), 7.27 (d, 1H),



phenyl-1,3-diazaspiro[4.5]decan-2-



6.79 (d, 1H), 3.71-3.66 (m, 4H), 3.53 (s,



one



2H), 2.43-2.32 (m, 2H), 1.96 (s, 7H),







1.91-1.85 (m, 5H), 1.49-1.42 (m, 2H).


SC_3180
cis-8-Dimethylamino-8-phenyl-3-
INT-976
4-bromo-2-
SC_3103
1H NMR (DMSO-d6): δ 7.89-7.87 (m, 2H),
433.2



(2-phenyl-thiazol-4-yl)-1,3-

phenylthiazole

7.55 (br s, 1H), 7.43-7.35 (m, 8H),



diazaspiro[4.5]decan-2-one



7.29-7.26 (m, 1H), 3.82 (s, 2H), 2.45 (br m, 2H),







1.96-1.79 (m, 10H), 1.53-1.50 (m, 2H).


SC_3181
cis-8-Dimethylamino-8-phenyl-3-
INT-989
tetrahydro-2H-pyran-
SC_3103
1H NMR (DMSO-d6): δ 8.42 (s, 2H),
451.3



[2-(tetrahydro-pyran-4-ylamino)-

4-amine

7.39-7.35 (m, 5H), 7.27-7.24 (m, 1H), 6.83 (d,



pyrimidin-5-yl]-1,3-



1H), 3.84-3.79 (m, 3H), 3.50 (s, 2H),



diazaspiro[4.5]decan-2-one



3.38-3.35 (m, 2H), 2.36-2.32 (m, 2H),







1.94-1.77 (m, 12H), 1.50-1.40 (m, 4H).


SC_3183
cis-8-Dimethylamino-8-phenyl-3-
INT-976
2-bromo-4-
SC_3103
1H NMR (DMSO-d6): δ 8.09 (br s, 1H),
433.2



(4-phenyl-thiazol-2-yl)-1,3-

phenylthiazole

7.87 (d, 2H), 7.51 (s, 1H), 7.37-7.24 (m, 8H),



diazaspiro[4.5]decan-2-one



3.87 (s, 2H), 2.43 (m, 2H), 1.96-1.84 (m,







10H), 1.54 (m, 2H).


SC_3184
cis-8-Dimethylamino-8-phenyl-3-
INT-976
1H-pyrrolo[2,3-
SC_3103
1H NMR (DMSO-d6): δ 9.07 (s, 2H),
468.2



[2-(1H-pyrrolo[2,3-b]pyridin-1-yl)-

b]pyridine

8.35-8.33 (m, 1H), 8.10-8.04 (m, 2H), 7.83 (br s,



pyrimidin-5-yl]-1,3-



1H), 7.41-7.37 (m, 4H), 7.29-7.21 (m, 2H),



diazaspiro[4.5]decan-2-one



6.72-6.71 (d, 1H), 3.71 (s, 2H), 2.49 (m, 2H),







1.97 (m, 10H), 1.52 (m, 2H).


SC_3185
cis-8-Dimethylamino-8-phenyl-3-
INT-989
(3,4,5-
SC_3129
1H NMR (600 MHz, DMSO) δ 9.11 (s, 2H),
481.2



[2-(3,4,5-trifluoro-phenyl)-

trifluorophenyl)boronic

8.12-8.03 (m, 2H), 7.89 (s, 1H),



pyrimidin-5-yl]-1,3-

acid

7.42-7.34 (m, 4H), 7.28 (dq, 1H), 3.71 (s, 2H),



diazaspiro[4.5]decan-2-one



2.48-2.35 (m, 2H), 1.99-1.79 (m, 10H),







1.58-1.47 (m, 2H).


SC_3187
cis-8-Dimethylamino-3-m-tolyl-8-
INT-976
1-bromo-3-
SC_3186

363.2



phenyl-1,3-diazaspiro[4.5]decan-2-

methylbenzene



one


SC_3188
cis-8-Dimethylamino-8-phenyl-3-p-
INT-976
1-bromo-4-
SC_3186

363.2



tolyl-1,3-diazaspiro[4.5]decan-2-

methylbenzene



one


SC_3189
cis-8-Dimethylamino-8-phenyl-3-
INT-976
1-bromo-4-
SC_3186

417.2



[4-(trifluoromethyl)-phenyl]-1,3-

trifluoromethylbenzene



diazaspiro[4.5]decan-2-one


SC_3190
cis-8-Dimethylamino-8-phenyl-3-
INT-976
1-bromo-3-
SC_3186

433.2



[3-(trifluoromethyloxy)-phenyl]-

(trifluoromethoxy)benzene



1,3-diazaspiro[4.5]decan-2-one


SC_3191
cis-8-Dimethylamino-8-phenyl-3-
INT-976
1-bromo-4-
SC_3186

433.2



[4-(trifluoromethyloxy)-phenyl]-

(trifluoromethoxy)benzene



1,3-diazaspiro[4.5]decan-2-one


SC_3192
cis-2-(8-Dimethylamino-2-oxo-8-
INT-976
methyl 2-
SC_3186

407.2



phenyl-1,3-diazaspiro[4.5]decan-3-

bromobenzoate



yl)-benzoic acid methyl ester


SC_3193
cis-3-(8-Dimethylamino-2-oxo-8-
INT-976
methyl 3-
SC_3186

407.2



phenyl-1,3-diazaspiro[4.5]decan-3-

bromobenzoate



yl)-benzoic acid methyl ester


SC_3194
cis-4-(8-Dimethylamino-2-oxo-8-
INT-976
methyl 4-
SC_3186

407.2



phenyl-1,3-diazaspiro[4.5]decan-3-

bromobenzoate



yl)-benzoic acid methyl ester


SC_3195
cis-3-(1,3-Benzodioxol-5-yl)-8-
INT-976
5-
SC_3186

393.2



dimethylamino-8-phenyl-1,3-

bromobenzo[d][1,3]dioxole



diazaspiro[4.5]decan-2-one


SC_3196
cis-8-Dimethylamino-8-phenyl-3-
INT-976
5-bromoquinoline
SC_3186

400.2



quinolin-5-yl-1,3-



diazaspiro[4.5]decan-2-one


SC_3197
cis-3-(2,3-Dihydro-1H-indol-6-yl)-
INT-976
6-bromoindoline
SC_3186

390.2



8-dimethylamino-8-phenyl-1,3-



diazaspiro[4.5]decan-2-one


SC_3198
cis-5-(8-Dimethylamino-2-oxo-8-
INT-976
methyl 5-bromo-4-
SC_3186

422.2



phenyl-1,3-diazaspiro[4.5]decan-3-

methylpicolinate



yl)-4-methyl-pyridine-2-carboxylic



acid methyl ester


SC_3199
cis-8-Dimethyl amino-3-(6-
INT-976
5-bromo-2-methoxy-
SC_3186

394.2



methoxy-4-methyl-pyridin-3-yl)-8-

4-methylpyridine



phenyl-1,3-diazaspiro[4.5]decan-2-



one


SC_3200
cis-8-Dimethylamino-3-[2-methyl-
INT-976
5-bromo-1-methyl-3-
SC_3186

421.2



5-(trifluoromethyl)-2H-pyrazol-3-

(trifluoromethyl)-1H-



yl]-8-phenyl-1,3-

pyrazole



diazaspiro[4.5]decan-2-one


SC_3201
cis-8-Dimethylamino-3-(3-
INT-976
2-bromo-3-
SC_3186

380.2



methoxy-pyridin-2-yl)-8-phenyl-

methoxypyridine



1,3-diazaspiro[4.5]decan-2-one


SC_3202
cis-8-Dimethylamino-8-phenyl-3-
INT-976
2-bromo-5-
SC_3186

418.2



[5-(trifluoromethyl)-pyridin-2-yl]-

trifluoromethylpyridine



1,3-diazaspiro[4.5]decan-2-one


SC_3203
cis-5-(8-Dimethylamino-2-oxo-8-
INT-976
3-bromo-5-
SC_3186

375.2



phenyl-1,3-diazaspiro[4.5]decan-3-

cyanopyridine



yl)-nicotinonitrile


SC_3204
cis-8-Dimethylamino-3-(3-methyl-
INT-976
2-bromo-3-
SC_3186

364.2



pyridin-2-yl)-8-phenyl-1,3-

methylpyridine



diazaspiro[4.5]decan-2-one


SC_3205
cis-8-Dimethylamino-3-(6-
INT-976
5-bromo-2-
SC_3186

380.2



methoxy-pyridin-3-yl)-8-phenyl-

methoxypyridine



1,3-diazaspiro[4.5]decan-2-one


SC_3206
cis-8-Dimethylamino-8-phenyl-3-
INT-976
1-bromo-3-
SC_3186

417.2



[3-(trifluoromethyl)phenyl]-1,3-

trifluoromethylbenzene



diazaspiro[4.5]decan-2-one


SC_3207
cis-3-(1,3-Benzodioxol-4-yl)-8-
INT-976
4-
SC_3186

393.2



dimethylamino-8-phenyl-1,3-

bromobenzo[d][1,3]dioxole



diazaspiro[4.5]decan-2-one


SC_3209
cis-8-Dimethylamino-3-[2-(3,5-
INT-976
3,5-dimethyl-1H-
SC_3103
1H NMR (DMSO-d6): δ 9.00 (s, 2H),
446.2



dimethyl-1H-pyrazol-1-yl)-

pyrazole

7.81 (br s, 1H), 7.38-7.27 (m, 5H), 6.07 (s, 1H),



pyrimidin-5-yl]-8-phenyl-1,3-



3.69 (s, 2H), 2.45 (m, 5H), 2.17 (s, 3H),



diazaspiro[4.5]decan-2-one



1.96-1.91 (m, 10H), 1.51 (br m, 2H).


SC_3210
cis-8-Dimethylamino-3-[2-(3-
INT-989
rac-piperidin-3-ol
SC_3182
1H NMR (DMSO-d6): 8.48 (s, 2H),
451.2



hydroxy-piperidin-1-yl)-pyrimidin-



7.39-7.35 (m, 5H), 7.27-7.24 (m, 1H), 4.82 (d,



5-yl]-8-phenyl-1,3-



1H), 4.39-4.36 (m, 1H), 4.24-4.21 (m, 1H),



diazaspiro[4.5]decan-2-one



3.51 (s, 2H), 3.41-3.36 (m, 1H),







2.92-2.87 (m, 1H), 2.77-2.72 (m, 1H), 2.42-2.32 (m,







2H), 2.00-1.66 (m, 12H), 1.46-1.39 (m, 2H),







1.34 (t, 2H).


SC_3211
cis-8-Dimethylamino-3-[2-(3-
INT-989
rac-piperidin-3-ol
SC_3182
1H NMR (DMSO-d6): 8.48 (s, 2H), 7.35 (m,
451.3



hydroxy-piperidin-1-yl)-pyrimidin-



5H), 7.25 (m, 1H), 4.82 (d, 1H),



5-yl]-8-phenyl-1,3-



4.39-4.37 (m, 1H), 4.24-4.21 (m, 1H), 3.51 (s, 2H),



diazaspiro[4.5]decan-2-one



3.40-3.39 (m, 1H), 2.90-2.87 (m, 1H),







2.77-2.72 (m, 1H), 2.37 (m, 2H), 2.00-1.66 (m,







12H), 1.45 (m, 2H), 1.34 (t, 2H).


SC_3212
cis-8-Dimethylamino-3-[2-[4-(2-
INT-989
2-piperazin-1-
SC_3120
1H NMR (600 MHz, DMSO) δ 8.53 (s, 2H),
480.3



hydroxy-ethyl)-piperazin-1-yl]-

ylethanol

7.37 (p, 5H), 7.27 (d, 1H), 3.62 (t, 4H),



pyrimidin-5-yl]-8-phenyl-1,3-



3.53 (q, 4H), 2.49-2.27 (m, 7H), 1.96 (s, 6H),



diazaspiro[4.5]decan-2-one



1.94-1.73 (m, 4H), 1.51-1.40 (m, 2H).


SC_3213
cis-2-[4-[5-(8-Dimethylamino-2-
SC_3146

INT-991
1H NMR (600 MHz, DMSO) δ 8.53 (s, 2H),
494.3



oxo-8-phenyl-1,3-



7.57 (s, 1H), 7.42 (d, 4H), 7.33 (d, 1H),



diazaspiro[4.5]decan-3-yl)-



3.68 (t, 4H), 3.19 (s, 2H), 2.62 (t, 4H), 2.37 (d,



pyrimidin-2-yl]-piperazin-1-yl]-



2H), 2.20-1.96 (m, 8H), 1.88 (t, 2H),



acetic acid



1.43 (t, 2H).


SC_3214
cis-8-Dimethylamino-3-[2-(1-
INT-989
1-methyl-4-(4,4,5,5-
SC_3208
1H NMR (600 MHz, DMSO + 2 vol % TFA)
484.3



methyl-1H-pyrrolo[2,3-b]pyridin-4-

tetramethyl-1,3,2-

δ 9.85 (s, 1H), 9.13 (s, 2H), 8.41 (d, 2H),



yl)-pyrimidin-5-yl]-8-phenyl-1,3-

dioxaborolan-2-yl)-

7.99 (s, 1H), 7.72 (s, 2H), 7.66-7.46 (m,



diazaspiro[4.5]decan-2-one

2,3-

4H), 7.30 (s, 1H), 3.88 (s, 2H), 3.60 (s, 6H),





dihydropyrrolo[2,3-

2.77-2.71 (m, 2H), 2.30-2.26 (m, 2H),





b]pyridine

1.94-1.89 (m, 2H), 1.75 (s, 3H),







1.41-1.35 (m, 2H).


SC_3215
cis-8-Benzyl-8-dimethylamino-3-
INT-994
5-bromo-4-methyl-2-
SC_3103
1H NMR (600 MHz, DMSO) δ 8.52 (s, 1H),
447.2



[4-methyl-6-(trifluoromethyl)-

(trifluoromethyl)pyridine

7.76 (s, 1H), 7.23 (dd, 2H), 7.19-7.11 (m,



pyridin-3-yl]-1,3-



4H), 2.62 (s, 2H), 2.27 (s, 6H), 2.25 (s, 3H),



diazaspiro[4.5]decan-2-one



1.86 (td, 2H), 1.80 (dt, 2H), 1.57-1.49 (m,







2H), 1.09 (td, 2H).


SC_3216
trans-8-Dimethylamino-3-[4-
INT-998
5-bromo-4-methyl-2-
SC_3103
1H NMR (600 MHz, DMSO) δ 8.61 (s, 1H),
439.2



methyl-6-(trifluoromethyl)-pyridin-

(trifluoromethyl)pyridine

7.83 (s, 1H), 7.53-7.49 (m, 1H), 7.45 (dd,



3-yl]-8-thiophen-2-yl-1,3-



1H), 7.09 (dd, 1H), 6.99 (dd, 1H), 3.70 (s,



diazaspiro[4.5]decan-2-one



2H), 2.35 (s, 3H), 2.19-2.05 (m, 4H),







2.02 (s, 6H), 1.93-1.85 (m, 2H), 1.64 (dt, 2H).


SC_3217
cis-8-Dimethylamino-3-[4-methyl-
INT-997
5-bromo-4-methyl-2-
SC_3103
1H NMR (600 MHz, DMSO) δ 8.58 (s, 1H),
439.2



6-(trifluoromethyl)-pyridin-3-yl]-8-

(trifluoromethyl)pyridine

7.80 (s, 1H), 7.45 (s, 1H), 7.42 (dd, 1H),



thiophen-2-yl-1,3-



7.05 (dd, 1H), 6.95 (dd, 1H), 3.67 (s, 2H),



diazaspiro[4.5]decan-2-one



2.33 (s, 3H), 2.32-2.25 (m, 2H), 2.04 (s,







6H), 2.00-1.92 (m, 2H), 1.89-1.76 (m,







2H), 1.62 (dt, 2H).


SC_3218
cis-8-Dimethylamino-3-[2-(1,1-
INT-976
4-[5-bromo-4-
SC_3103
1H NMR (600 MHz, DMSO) δ 8.65 (s, 1H),
553.2



dioxo-[1,4]thiazinan-4-yl)-4-

(trifluoromethyl)pyrimidin-

7.42 (s, 1H), 7.41-7.31 (m, 5H), 7.25 (tt,



(trifluoromethyl)-pyrimidin-5-yl]-

2-yl]-1,4-

1H), 4.23 (t, 4H), 3.22 (t, 4H),



8-phenyl-1,3-diazaspiro[4.5]decan-

thiazinane 1,1-

2.40-2.26 (m, 2H), 1.97-1.88 (m, 8H),



2-one

dioxide (prepared as

1.87-1.75 (m, 2H), 1.54-1.42 (m, 2H).





SC_3097 step 1)


SC_3219
cis-8-Dimethylamino-8-(1-methyl-
INT-
5-bromo-2-
SC_3103
1H NMR (600 MHz, DMSO) δ 9.14 (s, 2H),
474.2



1H-benzoimidazol-2-yl)-3-[2-
1000
(trifluoromethyl)pyrimidine

8.65 (s, 1H), 7.63 (d, 1H), 7.51 (d, 1H),



(trifluoromethyl)-pyrimidin-5-yl]-



7.25 (ddd, 1H), 7.19 (ddd, 1H), 4.02 (s, 3H),



1,3-diazaspiro[4.5]decan-2-one



3.61 (s, 2H), 2.26 (d, 2H), 2.18 (s, 6H),







2.16-2.09 (m, 2H), 1.87 (s, 2H), 1.78 (d, 2H).


SC_3220
cis-8-Dimethylamino-8-(1-methyl-
INT-
5-bromo-4-methyl-2-
SC_3103
1H NMR (600 MHz, DMSO) δ 8.56 (s, 1H),
487.3



1H-benzoimidazol-2-yl)-3-[4-
1000
(trifluoromethyl)pyridine

8.10 (s, 1H), 7.80 (s, 1H), 7.60 (d, 1H),



methyl-6-(trifluoromethyl)-pyridin-



7.50 (d, 1H), 7.23 (ddd, 1H), 7.17 (td, 1H),



3-yl]-1,3-diazaspiro[4.5]decan-2-



4.02 (s, 3H), 3.50 (s, 2H), 2.34-2.25 (m, 5H),



one



2.19-2.09 (m, 8H), 1.90-1.74 (m, 4H).


SC_3222
cis-3-[2-(Benzyl-methyl-amino)-
INT-976
N-benzyl-5-bromo-N-
SC_3103
1H NMR (DMSO-d6): δ 8.52 (s, 2H),
471.2



pyrimidin-5-yl]-8-dimethylamino-

methylpyrimidin-2-

7.39-7.33 (m, 5H), 7.30-7.17 (m, 6H), 4.81 (s,



8-phenyl-1,3-diazaspiro[4.5]decan-

amine

2H), 3.52 (s, 2H), 3.03 (s, 3H), 2.45-2.32 (m,



2-one



2H), 1.95-1.86 (m, 10H), 1.47-1.43 (m, 2H).


SC_3223
cis-5-(8-Dimethylamino-2-oxo-8-
INT-976
ethyl 5-
SC_3103 (step
1H NMR (DMSO-d6): δ 9.04 (s, 2H),
585.3



phenyl-1,3-diazaspiro[4.5]decan-3-

bromopyrimidine-2-
1), INT-991
8.24-8.23 (m, 1H), 7.42-7.39 (m, 2H),



yl)-N-[2-[2-[2-(2-methoxy-ethoxy)-

carboxylate (step 1),
(step 2),
7.32-7.31 (m, 3H), 5.70 (s, 1H), 3.70-3.60 (m, 16H),



ethoxy]-ethoxy]-ethyl]-pyrimidine-

2,5,8,11-
SC_3133 (step
3.54-3.52 (m, 2H), 3.35 (s, 3H),



2-carboxylic acid amide

tetraoxatridecan-13-
3)
2.21-2.00 (m, 12H), 1.66-1.64 (m, 2H).





amine (step 3)


SC_3225
cis-8-Dimethylamino-3-[2-[(2-
INT-989
2-
SC_3182
1H NMR (DMSO-d6): δ 8.46 (s, 2H),
425.2



hydroxy-ethyl)-methyl-amino]-

(methylamino)ethanol

7.39-7.33 (m, 5H), 7.27-7.24 (m, 1H), 4.62 (t,



pyrimidin-5-yl]-8-phenyl-1,3-



1H), 3.61-3.50 (m, 6H), 3.08 (s, 3H),



diazaspiro[4.5]decan-2-one



2.36-2.33 (m, 2H), 1.95-1.86 (m, 10H),







1.47-1.45 (m, 2H).


SC_3226
cis-3-(8-Dimethylamino-2-oxo-8-
INT-976
5-bromo-4-methyl-2-
SC_3103 (step

487.3



phenyl-1,3-diazaspiro[4.5]decan-3-

(trifluoromethyl)pyridine
1), SC_3016



yl)-benzamide


(step 2)


SC_3227
cis-8-Dimethylamino-3-[3-fluoro-
INT-976
2-bromo-3-fluoro-5-
SC_3186

417.1



5-(trifluoromethyl)-pyridin-2-yl]-8-

(trifluoromethyl)pyridine



phenyl-1,3-diazaspiro[4.5]decan-2-



one


SC_3228
cis-8-Dimethylamino-3-(5-methyl-
INT-976
2-bromo-5-
SC_3186

459.1



pyrazin-2-yl)-8-phenyl-1,3-

methylpyrazine



diazaspiro[4.5]decan-2-one


SC_3229
cis-8-Dimethylamino-3-(5-fluoro-
INT-976
4-bromo-5-
SC_3186

433.2



pyrimidin-4-yl)-8-phenyl-1,3-

fluoropyrimidine



diazaspiro[4.5]decan-2-one


SC_3230
cis-8-Dimethylamino-3-(5-fluoro-
INT-976
2-bromo-5-
SC_3186

458.1



pyrimidin-2-yl)-8-phenyl-1,3-

fluoropyrimidine



diazaspiro[4.5]decan-2-one


SC_3231
cis-8-Dimethylamino-8-phenyl-3-
INT-976
2-bromopyrazine
SC_3186

471.1



pyrazin-2-yl-1,3-



diazaspiro[4.5]decan-2-one


SC_3232
cis-3-([2,1,3]Benzoxadiazol-5-yl)-
INT-976
5-
SC_3186

444.1



8-dimethylamino-8-phenyl-1,3-

bromobenzo[c][1,2,5]-



diazaspiro[4.5]decan-2-one

oxadiazole


SC_3233
cis-2-[2-(8-Dimethylamino-2-oxo-
SC_3169
ammonium chloride
SC_3133
1H NMR (600 MHz, DMSO) δ 7.73 (s, 1H),
423.2



8-phenyl-1,3-diazaspiro[4.5]decan-



7.40-7.32 (m, 4H), 7.31 (s, 1H), 7.26 (dd,



3-yl)-phenoxy]-acetamide



1H), 7.18 (td, 1H), 6.98-6.91 (m, 2H),







4.50 (s, 2H), 3.52 (s, 2H), 2.42-2.29 (m, 2H),







2.01-1.71 (m, 10H), 1.55-1.48 (m, 2H).


SC_3234
cis-8-Dimethylamino-8-phenyl-3-
INT-976
4-(5-bromothiophen-
SC_3103
1H NMR (DMSO-d6): δ 8.45-8.43 (d, 2H),
433.2



(5-pyridin-4-yl-thiophen-2-yl)-1,3-

2-yl)pyridine

7.87 (br s, 1H), 7.54-7.53 (d, 1H),



diazaspiro[4.5]decan-2-one



7.49-7.48 (m, 2H), 7.38-7.27 (m, 5H), 6.35-6.34 (d,







2H), 3.64 (s, 2H), 2.42 (m, 2H),







1.96-1.90 (m, 10H), 1.51-1.49 (m, 2H).


SC_3236
cis-8-Dimethylamino-3-(2-
INT-
morpholine
SC_3120
1H NMR (600 MHz, DMSO) δ 8.07 (d, 1H),
437.3



morpholin-4-yl-pyrimidin-4-yl)-8-
1002


7.93 (s, 1H), 7.37 (dt, 5H), 7.27 (t, 1H),



phenyl-1,3-diazaspiro[4.5]decan-2-



3.65 (s, 2H), 3.58 (s, 8H), 2.40-2.27 (m, 2H),



one



1.94 (s, 6H), 1.92-1.80 (m, 4H), 1.43 (d,







2H).


SC_3237
cis-3-[2-(3,4-Difluoro-phenyl)-
INT-989
(3,4-
SC_3129
1H NMR (600 MHz, DMSO) δ 9.08 (s, 2H),
463.2



pyrimidin-5-yl]-8-dimethylamino-

difluorophenyl)boronic

8.22-8.12 (m, 2H), 7.54 (dt, 1H),



8-phenyl-1,3-diazaspiro[4.5]decan-

acid

7.41-7.37 (m, 4H), 7.29 (s, 1H), 3.70 (s, 2H),



2-one



2.06-1.75 (m, 12H), 1.50 (d, 2H).


SC_3241
cis-2-[4-[5-(8-Dimethylamino-2-
SC_3213
ammonium chloride
SC_3133
1H NMR (600 MHz, DMSO) δ 8.53 (s, 2H),
493.3



oxo-8-phenyl-1,3-



7.38 (d, 5H), 7.27 (s, 1H), 7.23 (s, 1H),



diazaspiro[4.5]decan-3-yl)-



7.11 (s, 1H), 3.67 (t, 4H), 3.54-3.50 (m, 2H),



pyrimidin-2-yl]-piperazin-1-yl]-



2.89 (s, 2H), 2.47 (t, 4H), 2.39-2.35 (m,



acetamide



2H), 1.96 (s, 7H), 1.93-1.82 (m, 3H),







1.48-1.44 (m, 2H).


SC_3243
cis-8-Dimethylamino-3-[6-(4-
INT-976
1-(5-bromo-2-
SC_3242 (step
1H NMR (600 MHz, DMSO) δ 8.16 (d, 1H),
449.3



methyl-piperazin-1-yl)-pyridin-3-

pyridyl)-4-methyl-
2)
7.86 (dd, 1H), 7.41-7.33 (m, 4H), 7.32 (s,



yl]-8-phenyl-1,3-

piperazine

1H), 7.27 (t, 1H), 6.78 (d, 1H), 3.51 (s, 2H),



diazaspiro[4.5]decan-2-one



2.55-2.45 (m, 4H), 2.42-2.27 (m, 6H),







2.21 (s, 3H), 1.96 (s, 6H), 1.93-1.73 (m,







4H), 1.46 (t, 2H).


SC_3244
cis-8-Dimethylamino-3-[2-(1,1-
INT-976
4-(5-bromo-4-methyl-
SC_3103
1H NMR (600 MHz, DMSO) δ 8.20 (s, 1H),
499.3



dioxo-[1,4]thiazinan-4-yl)-4-

pyrimidin-2-yl)-1,4-

7.36 (h, 4H), 7.30-7.17 (m, 2H),



methyl-pyrimidin-5-yl]-8-phenyl-

thiazinane 1,1-

4.23-4.17 (m, 4H), 3.13 (t, 4H), 2.44-2.28 (m,



1,3-diazaspiro[4.5]decan-2-one

dioxide

2H), 2.24 (s, 3H), 1.97 (s, 6H), 1.91 (d, 4H),







1.55-1.44 (m, 2H).


SC_3245
cis-8-Dimethylamino-8-phenyl-3-
INT-976
5-bromo-2-
SC_3103
1H NMR (600 MHz, DMSO) δ 9.17 (s, 2H),
419.2



[2-(trifluoromethyl)-pyrimidin-5-

(trifluoromethyl)-

8.03 (s, 1H), 7.38 (s, 4H), 7.28 (tt, 1H),



yl]-1,3-diazaspiro[4.5]decan-2-one

pyrimidine

3.73 (s, 2H), 2.49-2.35 (m, 2H), 1.97 (s, 6H),







1.97-1.92 (m, 2H), 1.90-1.73 (m, 2H),







1.55-1.49 (m, 2H).


SC_3246
cis-2-[8-Dimethylamino-1-(3-
INT-979
2-chloropyrimidine-
SC_3103
1H NMR (600 MHz, DMSO) δ 9.02 (s, 2H),
449.3



methoxy-propyl)-2-oxo-8-phenyl-

5-carbonitrile

7.40-7.31 (m, 5H), 3.86 (s, 2H), 3.26 (s,



1,3-diazaspiro[4.5]decan-3-yl]-



3H), 3.29-3.19 (m, 2H), 2.73-2.67 (m,



pyrimidine-5-carbonitrile



2H), 2.16 (td, 2H), 2.00 (s, 7H), 1.83 (dt,







2H), 1.50-1.40 (m, 5H).


SC_3247
cis-8-Dimethylamino-3-[2-(4-
INT-989
1-Methylpiperazin
SC_3120
1H NMR (600 MHz, DMSO) δ 8.54 (s, 2H),
450.3



methyl-piperazin-1-yl)-pyrimidin-



7.48-7.33 (m, 5H), 7.31-7.21 (m, 1H),



5-yl]-8-phenyl-1,3-



3.63 (dd, 4H), 2.45-2.29 (m, 6H), 2.20 (s,



diazaspiro[4.5]decan-2-one



3H), 1.96 (s, 6H), 1.94-1.78 (m, 4H),







1.51-1.42 (m, 2H).


SC_3248
cis-8-Dimethylamino-1-[(1-
SC_3245
[1-[tert-
INT-988 (step
1H NMR (600 MHz, DMSO) δ 9.24 (s, 2H),
504.3



hydroxy-cyclobutyl)-methyl]-8-

butyl(dimethyl)silyl]-
1)
7.38 (d, 4H), 7.27 (p, 1H), 3.89 (s, 2H),



phenyl-3-[2-(trifluoromethyl)-

oxycyclobutyl]methyl

2.73-2.67 (m, 2H), 2.26 (ddd, 2H), 2.19 (tt, 2H),



pyrimidin-5-yl]-1,3-

4-

2.08 (s, 1H), 2.00 (s, 6H), 1.92 (qd, 2H),



diazaspiro[4.5]decan-2-one

methylbenzenesulfonate

1.73-1.64 (m, 1H), 1.60-1.50 (m, 3H),







1.50-1.45 (m, 2H).


SC_3249
cis-2-[1-(3-Methoxy-propyl)-8-
SC_3246

SC_3099
1H NMR (600 MHz, DMSO) δ 9.05 (s, 2H),
435.3



methylamino-2-oxo-8-phenyl-1,3-



7.49-7.44 (m, 2H), 7.34 (t, 2H), 7.21 (t,



diazaspiro[4.5]decan-3-yl]-



1H), 3.90 (s, 2H), 3.26 (s, 3H), 2.23 (td, 2H),



pyrimidine-5-carbonitrile



2.07 (s, 1H), 1.91 (d, 5H), 1.86-1.78 (m,







2H), 1.73 (tt, 2H), 1.42 (d, 2H).


SC_3250
cis-8-Dimethylamino-8-phenyl-3-
INT-976
5-bromo-2-
SC_3103
1H NMR (600 MHz, DMSO) δ 8.88 (d, 1H),
419.3



[6-(trifluoromethyl)-pyridin-3-yl]-

(trifluoromethyl)pyridine

8.24 (dd, 1H), 7.86 (s, 1H), 7.78 (d, 1H),



1,3-diazaspiro[4.5]decan-2-one



7.41-7.34 (m, 4H), 7.27 (t, 1H), 3.69 (s,







2H), 2.42 (s, 2H), 1.97 (s, 6H),







1.96-1.74 (m, 4H), 1.53-1.47 (m, 2H).


SC_3251
cis-5-(8-Dimethylamino-2-oxo-8-
INT-976
5-bromopyridine-2-
SC_3103
1H NMR (600 MHz, DMSO) δ 8.92 (d, 1H),
376.2



phenyl-1,3-diazaspiro[4.5]decan-3-

carbonitrile

8.15 (dd, 1H), 7.95 (br s, 1H), 7.90 (d, 1H),



yl)-pyridine-2-carbonitrile



7.41-7.34 (m, 4H), 7.27 (t, 1H), 3.69 (s,







2H), 2.44-2.40 (m, 2H), 1.97 (s, 6H),







1.96-1.89 (m, 3H), 1.90-1.70 (m, 1H),







1.53-1.46 (m, 2H).


SC_3252
cis-8-Dimethylamino-3-(2-
INT-989
morpholine
SC_3120
1H NMR (600 MHz, DMSO) δ 8.57 (s, 2H),
437.3



morpholin-4-yl-pyrimidin-5-yl)-8-



7.46-7.42 (m, 1H), 7.40-7.34 (m, 4H),



phenyl-1,3-diazaspiro[4.5]decan-2-



7.27 (td, 1H), 3.64 (dd, 4H), 3.59 (dd, 4H),



one



3.54 (s, 2H), 2.46-2.29 (m, 2H), 1.96 (s,







7H), 1.93-1.73 (m, 3H), 1.50-1.44 (m,







2H).


SC_3253
ci s-8-Dimethylamino-3-(2-methyl-
INT-976
5-bromo-2-methyl-
SC_3103
1H NMR (600 MHz, DMSO) δ 8.86 (s, 2H),
366.3



pyrimidin-5-yl)-8-phenyl-1,3-

pyrimidine

7.69 (s, 1H), 7.41-7.33 (m, 5H),



diazaspiro[4.5]decan-2-one



7.31-7.19 (m, 1H), 3.62 (s, 2H), 2.53 (s, 3H),







2.48-2.31 (m, 2H), 1.97 (s, 6H), 1.95-1.77 (m,







4H), 1.52-1.46 (m, 2H).


SC_3254
cis-8-Dimethylamino-1-[(2-
SC_3253
2-methoxybenzyl
SC_3105
1H NMR (DMSO-d6): δ 8.90 (s, 2H),
486.2



methoxyphenyl)-methyl]-3-(2-

bromide

7.39-7.34 (m, 3H), 7.28-7.22 (m, 4H),



methyl-pyrimidin-5-yl)-8-phenyl-



6.95-6.87 (m, 2H), 4.58 (s, 2H), 3.89 (s, 3H), 3.63 (s,



1,3-diazaspiro[4.5]decan-2-one



2H), 2.68-2.64 (m, 5H), 2.35-2.28 (m, 2H),







2.01 (s, 6H), 1.49-1.43 (m, 4H).


SC_3255
cis-1-[(1-Hydroxy-cyclobutyl)-
SC_3248

SC_3099
1H NMR (600 MHz, DMSO) δ 9.26 (s, 2H),
490.3



methyl]-8-methylamino-8-phenyl-



7.51 (d, 2H), 7.34 (t, 2H), 7.22 (t, 1H),



3-[2-(trifluoromethyl)-pyrimidin-5-



3.92 (s, 2H), 3.41 (s, 1H), 2.31 (td, 2H), 2.15 (td,



yl]-1,3-diazaspiro[4.5]decan-2-one



2H), 2.07 (d, 1H), 1.93 (d, 7H), 1.83 (dt,







2H), 1.67 (t, 1H), 1.56 (q, 1H), 1.47 (d, 2H).


SC_3256
cis-8-Dimethylamino-1-[(1-
SC_3253
[1-[tert-
INT-988 (step
1H NMR (600 MHz, DMSO) δ 8.92 (s, 2H),
450.3



hydroxy-cyclobutyl)-methyl]-3-(2-

butyl(dimethyl)silyl]-
1)
7.37 (d, 4H), 7.27 (td, 1H), 3.79 (s, 2H),



methyl-pyrimidin-5-yl)-8-phenyl-

oxycyclobutyl]methyl

3.27 (s, 1H), 2.72-2.65 (m, 2H), 2.54 (s, 3H),



1,3-diazaspiro[4.5]decan-2-one

4-

2.25-2.19 (m, 2H), 2.16 (tt, 2H), 2.07 (s,





methylbenzenesulfonate

2H), 2.00 (s, 6H), 1.95-1.86 (m, 2H),







1.67 (qd, 1H), 1.55 (td, 2H), 1.51-1.42 (m, 3H).


SC_3257
cis-1-[(1-Hydroxy-cyclobutyl)-
SC_3260

SC_3099
1H NMR (600 MHz, DMSO) δ 9.07 (s, 2H),
422.3



methyl]-8-methylamino-8-phenyl-



8.81 (s, 1H), 7.53-7.48 (m, 2H), 7.33 (t,



3-pyrimidin-5-yl-1,3-



2H), 7.24-7.18 (m, 1H), 3.86 (s, 2H),



diazaspiro[4.5]decan-2-one



2.29 (td, 2H), 2.14 (tt, 2H), 2.07 (s, 1H),







1.96-1.87 (m, 8H), 1.82 (td, 2H), 1.71-1.62 (m,







1H), 1.54 (dp, 1H), 1.49-1.43 (m, 2H).


SC_3258
cis-5-(8-Dimethylamino-2-oxo-8-
INT-976
5-bromo-4-methyl-
SC_3103
1H NMR (600 MHz, DMSO) δ 8.57 (s, 1H),
390.2



phenyl-1,3-diazaspiro[4.5]decan-3-

pyridine-2-

7.92 (s, 1H), 7.61-7.57 (m, 1H),



yl)-4-methyl-pyridine-2-

carbonitrile

7.42-7.32 (m, 4H), 7.25 (tt, 1H), 3.63 (s, 2H),



carbonitrile



2.38 (d, 2H), 2.28 (s, 3H), 2.00-1.90 (m, 9H),







1.90-1.72 (m, 1H), 1.59-1.49 (m, 2H).


SC_3259
cis-8-Dimethylamino-3-(2-methyl-
SC_3253
2-
SC_3105
1H NMR (DMSO-d6): δ 8.94 (s, 2H),
457.2



pyrimidin-5-yl)-8-phenyl-1-

(bromomethyl)pyridine

8.52-8.51 (m, 1H), 7.77-7.74 (m, 1H),



(pyridin-2-yl-methyl)-1,3-



7.45-7.42 (d, 1H), 7.38-7.22 (m, 6H), 4.47 (s, 2H),



diazaspiro[4.5]decan-2-one



3.84 (s, 2H), 2.66-2.63 (m, 2H), 2.54 (s, 3H),







2.06-2.03 (m, 2H), 1.92 (s, 6H),







1.57-1.42 (m, 4H).


SC_3260

INT-976
5-bromopyrimidine
SC_3103
1H NMR (600 MHz, DMSO) δ 8.98 (s, 2H),
352.2







8.76 (s, 1H), 7.78 (s, 1H), 7.41-7.34 (m,







4H), 7.31-7.24 (m, 1H), 3.65 (s, 2H),







2.49-2.34 (m, 2H), 1.97 (s, 6H), 1.95-1.76 (m,







4H), 1.50 (t, 2H).


SC_3261
cis-8-Dimethylamino-1-[(1-
SC_3260
[1-[tert-
INT-988 (step
1H NMR (600 MHz, DMSO) δ 9.04 (s, 2H),
436.3



hydroxy-cyclobutyl)-methyl]-8-

butyl(dimethyl)silyl]-
1)
8.80 (s, 1H), 7.37 (d, 4H), 7.27 (p, 1H),



phenyl-3-pyrimidin-5-yl-1,3-

oxycyclobutyl]methyl

3.83 (s, 2H), 3.28 (s, 1H), 2.72-2.65 (m, 2H),



diazaspiro[4.5]decan-2-one

4-

2.23 (td, 1H), 2.17 (tt, 1H), 2.07 (s, 2H),





methylbenzenesulfonate

2.00 (s, 6H), 1.91 (dt, 2H), 1.72-1.63 (m, 1H),







1.60-1.45 (m, 5H).


SC_3262
cis-8-Amino-1-[(1-hydroxy-
SC_3255

SC_3099
1H NMR (600 MHz, DMSO) δ 9.29 (s, 2H),
476.2



cyclobutyl)-methyl]-8-phenyl-3-[2-



7.68-7.63 (m, 2H), 7.33 (t, 2H),



(trifluoromethyl)-pyrimidin-5-yl]-



7.26-7.18 (m, 1H), 3.97 (s, 2H), 3.45 (s, 2H), 2.43 (td,



1,3-diazaspiro[4.5]decan-2-one



2H), 2.14 (tt, 2H), 1.99 (td, 2H),







1.96-1.90 (m, 2H), 1.71-1.54 (m, 4H),







1.52-1.47 (m, 2H).


SC_3263
cis-8-Dimethylamino-3-(3-
INT-976
1-bromo-3-fluoro-
SC_3103
1H NMR (600 MHz, DMSO) δ
368.2



fluorophenyl)-8-phenyl-1,3-

benzene

7.58-7.50 (m, 2H), 7.41-7.33 (m, 4H),



diazaspiro[4.5]decan-2-one



7.33-7.23 (m, 3H), 6.77-6.71 (m, 1H), 3.58 (s, 2H),







2.48-2.31 (m, 2H), 1.97 (s, 6H),







1.92-1.80 (m, 4H), 1.47 (t, 2H).


SC_3264
cis-8-Dimethylamino-3-(3-
INT-976
1-bromo-3-
SC_3103
1H NMR (600 MHz, DMSO) δ 8.13 (t, 1H),
428.2



methylsulfonyl-phenyl)-8-phenyl-

methylsulfonylbenzene

7.88 (d, 1H), 7.65 (s, 1H), 7.53 (t, 1H),



1,3-diazaspiro[4.5]decan-2-one



7.47 (dt, 1H), 7.41-7.35 (m, 4H), 7.28 (qd, 1H),







3.66 (s, 2H), 3.16 (s, 3H), 2.49-2.36 (m,







2H), 1.97 (s, 6H), 1.96-1.74 (m, 4H),







1.53-1.47 (m, 2H).


SC_3265
cis-8-Dimethylamino-3-(4-
INT-976
1-bromo-4-
SC_3103
1H NMR (600 MHz, DMSO) δ
428.2



methylsulfonyl-phenyl)-8-phenyl-

methylsulfonylbenzene

7.83-7.70 (m, 5H), 7.41-7.34 (m, 4H), 7.27 (tt, J = 7.1,



1,3-diazaspiro[4.5]decan-2-one



1.9 Hz, 1H), 3.65 (s, 2H), 3.12 (s, 3H),







2.49-2.31 (m, 2H), 1.97 (s, 6H),







1.95-1.75 (m, 4H), 1.49 (t, J = 8.6 Hz, 2H).


SC_3266
cis-8-Dimethylamino-8-phenyl-3-
INT-976
3-bromopyridazine
SC_3103
1H NMR (600 MHz, DMSO) δ 8.82 (dd, J = 4.6,
352.2



pyridazin-3-yl-1,3-



1.4 Hz, 1H), 8.45 (dd, J = 9.2, 1.4 Hz,



diazaspiro[4.5]decan-2-one



1H), 7.95 (br s, 1H), 7.55 (dd, J = 9.2, 4.5 Hz,







1H), 7.42-7.34 (m, 4H), 7.28 (t, J = 6.8 Hz,







1H), 3.83 (s, 2H), 2.47-2.29 (m, 1H),







1.97 (s, 10H), 1.54-1.48 (m, 2H).


SC_3267
cis-3-Methoxy-4-(8-methylamino-
INT-976
4-bromo-3-methoxy-
SC_3103 (for
1HNMR (DMSO-d6, 400 MHz), δ (ppm) = 7.50-7.50 (m,
391.2



2-oxo-8-phenyl-1,3-

benzonitrile (step 1)
step 1),
2H), 7.42-7.31 (m, 5H),



diazaspiro[4.5]decan-3-yl)-


SC_3099 (for
7.18 (bs, 2H), 3.83 (s, 3H), 3.64 (s, 2H),



benzonitrile


step 2)
2.05-21.99 (m, 2H), 1.85 (bs, 5H), 1.70 (bs, 2H),







1.53-1.50 (m, 2H).


SC_3268
cis-8-Dimethylamino-3-(2-
INT-976
1-bromo-2-
SC_3103
1H NMR (600 MHz, DMSO) δ 7.46 (td, J = 8.0,
368.2



fluorophenyl)-8-phenyl-1,3-

luorobenzene

1.6 Hz, 1H), 7.40-7.32 (m, 5H),



diazaspiro[4.5]decan-2-one



7.26 (td, J = 6.7, 3.3 Hz, 1H), 7.24-7.12 (m,







3H), 3.53 (s, 2H), 2.37-2.33 (m, 2H),







1.96 (s, 6H), 1.95-1.74 (m, 4H), 1.49 (t, J = 9.3 Hz,







2H).


SC_3269
cis-8-Dimethylamino-8-phenyl-3-
INT-976
5-bromo-2-phenyl-
SC_3103
1H NMR (600 MHz, DMSO) δ 9.07 (s, 2H),
428.3



(2-phenyl-pyrimidin-5-yl)-1,3-

pyrimidine

8.34-8.28 (m, 2H), 7.82 (s, 1H),



diazaspiro[4.5]decan-2-one



7.52-7.42 (m, 4H), 7.39 (s, 1H), 7.38 (s, 3H),







7.28 (t, J = 4.8 Hz, 1H), 3.70 (s, 2H),







2.43-2.39 (m, 2H), 2.06-1.72 (m, 10H), 1.52 (d, J = 10.8 Hz,







2H).


SC_3270
cis-8-Methylamino-1-(oxetan-3-yl-
SC_3245
oxetan-3-ylmethyl 4-
SC_3099 (for
1H NMR (DMSO-d6): δ 9.24 (s, 2H),
476.2



methyl)-8-phenyl-3-[2-

methylbenzenesulfonate
step1),
7.49 (d, 2H), 7.34 (t, 2H), 7.21 (t, 1H),



(trifluoromethyl)-pyrimidin-5-yl]-

(step 2)
SC_3105 (for
4.66-4.62 (m, 2H), 4.44 (t, 2H), 3.87 (s, 2H), 3.55 (d,



1,3-diazaspiro[4.5]decan-2-one


step 2)
2H), 3.28-3.23 (m, 1H), 2.36 (m, 1H),







2.20-2.14 (m, 2H), 1.95-1.91 (m, 5H),







1.84-1.77 (m, 2H), 1.43-1.40 (m, 2H).


SC_3271
cis-1-(Cyclopropyl-methyl)-8-
SC_3245
(bromomethyl)-
SC_3099 (for
1H NMR (DMSO-d6): δ 9.26 (s, 2H),
460.1



methylamino-8-phenyl-3-[2-

cyclopropane
step1),
7.50 (d, 2H), 7.35 (t, 2H), 7.22 (t, 1H), 3.89 (s,



(trifluoromethyl)-pyrimidin-5-yl]-


SC_3105 (for
2H), 3.13 (d, 2H), 2.29-2.23 (m, 3H),



1,3-diazaspiro[4.5]decan-2-one


step 2)
1.92-1.82 (m, 7H), 1.47-1.44 (m, 2H),







1.08-1.05 (m, 1H), 0.52-0.48 (m, 2H),







0.36-0.36-0.32 (m, 2H).


SC_3272
cis-4-(8-Dimethylamino-2-oxo-8-
INT-976
4-bromobenzonitrile
SC_3103
1H NMR (600 MHz, DMSO) δ
375.2



phenyl-1,3-diazaspiro[4.5]decan-3-



7.82-7.71 (m, 3H), 7.72-7.67 (m, 2H),



yl)-benzonitrile



7.41-7.33 (m, 4H), 7.30-7.23 (m, 1H), 3.63 (s, 2H),







2.45-2.39 (m, 2H), 1.97 (s, 6H),







1.95-1.72 (m, 4H), 1.51-1.44 (m, 2H).


SC_3273
cis-8-Dimethylamino-3-(4-
INT-976
1-bromo-4-fluoro-
SC_3103

368.2



fluorophenyl)-8-phenyl-1,3-

benzene



diazaspiro[4.5]decan-2-one


SC_3274
cis-2-(8-Dimethylamino-2-oxo-8-
INT-976
2-bromobenzonitrile
SC_3103
1H NMR (600 MHz, DMSO) δ 7.77 (dd, J = 7.5,
375.2



phenyl-1,3-diazaspiro[4.5]decan-3-



1.6 Hz, 1H), 7.66 (ddd, J = 8.3, 7.5, 1.6 Hz,



yl)-benzonitrile



1H), 7.60 (s, 1H), 7.48 (dd, J = 8.3, 1.1 Hz,







1H), 7.39-7.34 (m, 4H), 7.32 (td, J = 7.5,







1.1 Hz, 1H), 7.26 (tt, J = 7.5, 1.6 Hz,







1H), 3.68 (s, 2H), 2.46-2.30 (m, 2H),







2.01-1.75 (m, 10H), 1.59-1.50 (m, 2H).


SC_3276
cis-1-[(1-Hydroxy-cyclobutyl)-
SC_3256

SC_3099
1H NMR (600 MHz, DMSO) δ 8.94 (s, 2H),
436.3



methyl]-8-methylamino-3-(2-



7.53-7.47 (m, 2H), 7.39-7.30 (m, 2H),



methyl-pyrimidin-5-yl)-8-phenyl-



7.24-7.17 (m, 1H), 3.83 (s, 2H),



1,3-diazaspiro[4.5]decan-2-one



3.54-3.36 (m, 2H), 2.56 (s, 3H), 2.28 (td, 2H),







2.18-2.09 (m, 2H), 1.97-1.86 (m, 7H),







1.81 (td, 2H), 1.71-1.61 (m, 1H),







1.59-1.47 (m, 1H), 1.49-1.42 (m, 2H).


SC_3277
cis-8-Dimethyl amino-3-[2-
INT-976
4-[(5-
SC_3103
1H NMR (600 MHz, DMSO) δ 8.93 (s, 2H),



(morpholin-4-yl-methyl)-

bromopyrimidin-2-

7.87-7.65 (m, 1H), 7.42-7.34 (m, 4H),



pyrimidin-5-yl]-8-phenyl-1,3-

yl)methyl]morpholine

7.28 (dq, 1H), 3.66-3.62 (m, 2H), 3.61 (s,



diazaspiro[4.5]decan-2-one



2H), 3.54 (t, 4H), 2.43 (t, 4H), 1.98 (s, 6H),







1.96-1.74 (m, 4H), 1.52-1.46 (m, 2H).


SC_3278
cis-8-Dimethylamino-3-[2-(methyl-
INT-989
N-methyltetrahydro-
SC_3120
1H NMR (DMSO-d6): δ 8.50 (s, 2H),
465.2



tetrahydro-pyran-4-yl-amino)-

2H-pyran-4-amine

7.39-7.35 (m, 5H), 7.27-7.24 (m, 1H),



pyrimidin-5-yl]-8-phenyl-1,3-



4.74-4.67 (m, 1H), 3.94-3.90 (m, 2H), 3.50 (s, 2H),



diazaspiro[4.5]decan-2-one



3.39 (t, 2H), 2.93 (s, 3H), 2.35 (m, 2H),







1.99-1.71 (m, 12H), 1.50-1.44 (m, 4H).


SC_3279
cis-5-[8-Dimethylamino-1-[(1-
INT-990
(1-(tert-
SC_3105 (step
1H NMR (DMSO-d6): δ 9.12 (s, 2H),
669.4



hydroxy-cyclobutyl)-methyl]-2-

butyldimethylsilyloxy)cyclobutyl)methyl
1), SC_3133
8.63 (t, 1H), 7.36-7.33 (m, 4H), 7.26-7.23 (m,



oxo-8-phenyl-1,3-

4-
(step 2)
1H), 5.25 (s, 1H), 3.85 (s, 2H), 3.52-3.34 (m,



diazaspiro[4.5]decan-3-yl]-N-[2-[2-

methylbenzenesulfonate

16H), 3.35 (m, 2H), 3.19 (s, 3H),



[2-(2-methoxy-ethoxy)-ethoxy]-

(step 1), 2,5,8,11-

2.69-2.66 (m, 2H), 2.25-2.13 (m, 4H), 1.97 (s, 6H),



ethoxy]-ethyl]-pyrimidine-2-

tetraoxatridecan-13-

1.92-1.87 (m, 2H), 1.57-1.44 (m, 6H).



carboxylic acid amide

amine (step 2)


SC_3280
cis-1-(Cyclopropyl-methyl)-3-(2-
INT-976
1-bromo-2-fluoro-4-
SC_3103 (for
1H NMR (DMSO-d6): δ 7.86 (t, 1H),
486.2



fluoro-4-methylsulfonyl-phenyl)-8-

(methylsulfonyl)benzene
step 1),
7.81-7.77 (m, 1H), 7.73-7.70 (m, 1H), 7.45 (d,



methylamino-8-phenyl-1,3-

(step 1),
SC_3105 (step
2H), 7.31 (t, 2H), 7.19 (t, 1H), 3.85 (s, 2H),



diazaspiro[4.5]decan-2-one

(Bromomethyl)cyclopropane
2), SC_3099
3.24 (s, 3H), 3.09 (d, 2H), 2.29-2.22 (m, 3H),





(step 2)
(step 3)
1.93-1.90 (m, 5H), 1.74-1.68 (m, 2H),







1.49-1.46 (m, 2H), 1.04 (m, 1H), 0.51-0.46 (m,







2H), 0.34-0.30 (m, 2H).


SC_3281
cis-2-[[5-(8-Dimethylamino-2-oxo-
INT-989
2-
SC_3120
1H NMR (DMSO-d6): δ 8.48 (s, 2H),
438.2



8-phenyl-1,3-diazaspiro[4.5]decan-

(methylamino)acetamide

7.39-7.35 (m, 5H), 7.27-7.25 (m, 2H), 6.89 (s,



3-yl)-pyrimidin-2-yl]-methyl-

hydrochloride

1H), 4.08 (s, 2H), 3.51 (s, 2H), 3.07 (s, 3H),



amino]-acetamide



2.36-2.33 (m, 2H), 1.94-1.86 (m, 10H),







1.45 (m, 2H).


SC_3282
cis-2-[[5-(8-Dimethylamino-2-oxo-
INT-976
tert-butyl (5-
SC_3103 (for
1H NMR (DMSO-d6): δ 8.45 (s, 2H),
424.2



8-phenyl-1,3-diazaspiro[4.5]decan-

bromopyrimidin-2-
step 1),
7.39-7.33 (m, 5H), 7.27-7.22 (m, 2H), 6.92 (s,



3-yl)-pyrimidin-2-yl]amino]-

yl)(cyanomethyl)carbamate
SC_3100 step 3
1H), 6.86 (t, 1H), 3.74 (d, 2H), 3.51 (s, 2H),



acetamide

(step 1)
(for step 2)
2.46-2.28 (m, 2H), 1.95-1.86 (m, 10H),







1.45 (m, 2H).


SC_3283
cis-1-(Cyclopropyl-methyl)-8-
SC_3284

SC_3099
1H NMR (DMSO-d6): δ 8.61 (s, 1H),
473.3



methylamino-3-[4-methyl-6-



7.82 (s, 1H), 7.46-7.44 (m, 2H), 7.30 (t, 2H),



(trifluoromethyl)-pyridin-3-yl]-8-



7.18 (t, 1H), 3.80 (s, 2H), 3.08 (d, 2H),



phenyl-1,3-diazaspiro[4.5]decan-2-



2.33-2.25 (m, 6H), 1.92-1.89 (m, 5H), 1.72 (t, 2H),



one



1.56-1.53 (m, 2H), 1.04 (m, 1H),







0.51-0.46 (m, 2H), 0.33-0.30 (m, 2H).


SC_3284
cis-1-(Cyclopropyl-methyl)-8-
INT-984
5-bromo-4-methyl-2-
SC_3103
1H NMR (DMSO-d6): δ 8.59 (s, 1H),
487.3



dimethylamino-3-[4-methyl-6-

(trifluoromethyl)pyridine

7.82 (s, 1H), 7.35-7.34 (m, 4H), 7.27-7.23 (m,



(trifluoromethyl)-pyridin-3-yl]-8-



1H), 3.75 (s, 2H), 3.06 (d, 2H), 2.71-2.68 (m,



phenyl-1,3-diazaspiro[4.5]decan-2-



2H), 2.33-2.24 (m, 5H), 2.00 (m, 6H),



one



1.59-1.56 (m, 2H), 1.46 (t, 2H), 1.02-0.99 (m,







1H), 0.53-0.48 (m, 2H), 0.33-0.30 (m, 2H).


SC_3285
cis-N-[5-(8-Dimethylamino-2-oxo-
SC_3239
thiophene-2-carbonyl
SC_3240
1H NMR (600 MHz, DMSO) δ 8.90 (s, 2H),
477.2



8-phenyl-1,3-diazaspiro[4.5]decan-

chloride

8.08-8.04 (m, 1H), 7.84 (dd, 1H), 7.71 (s,



3-yl)-pyrimidin-2-yl]-thiophene-2-



1H), 7.38 (d, 5H), 7.27 (td, 1H), 7.19 (dd,



carboxylic acid amide



1H), 3.66 (s, 2H), 2.48-2.34 (m, 2H),







1.99-1.75 (m, 10H), 1.54-1.48 (m, 2H).


SC_3286
cis-N-[5-(8-Dimethylamino-2-oxo-
SC_3239
benzoyl chloride
SC_3240
1H NMR (600 MHz, DMSO) δ 10.84 (s,
471.3



8-phenyl-1,3-diazaspiro[4.5]decan-



1H), 8.91 (s, 2H), 7.98-7.93 (m, 2H),



3-yl)-pyrimidin-2-yl]-benzamide



7.62-7.55 (m, 1H), 7.50 (t, 2H), 7.39 (d, 4H),







7.28 (dt, 1H), 3.67 (s, 2H), 2.48-2.32 (m,







2H), 2.05-1.76 (m, 10H), 1.55-1.49 (m,







2H).


SC_3287
cis-8-Dimethylamino-8-phenyl-3-
INT-976
2-bromo-5-
SC_3103
1H NMR (DMSO-d6): δ 7.80-7.70 (br s,
432.2



(5-phenyl-thiophen-2-yl)-1,3-

phenylthiophene

1H), 7.52 (d, 2H), 7.38-7.28 (m, 7H),



diazaspiro[4.5]decan-2-one



7.20-7.17 (m, 2H), 6.27 (d, 1H), 3.61 (s, 2H),







2.49 (m, 2H), 1.95-1.91 (m, 10H), 1.48 (m, 2H).


SC_3288
cis-1-(Cyclopropyl-methyl)-8-
INT-984
1-bromo-2-
SC_3103
1H NMR (CDCl3): δ 7.49 (d, 1H),
496.3



dimethylamino-3-[2-

(methylsulfonylmethyl)benzene

7.41-7.22 (m, 8H), 4.45 (s, 2H), 3.64 (s, 2H), 3.15 (d,



(methylsulfonyl-methyl)-phenyl]-8-



2H), 2.79 (s, 3H), 2.71-2.67 (m, 2H), 2.37 (t,



phenyl-1,3-diazaspiro[4.5]decan-2-



2H), 2.06 (s, 6H), 1.67-1.64 (m, 2H),



one



1.55-1.44 (m, 2H), 1.10-1.06 (m, 1H),







0.57-0.52 (m, 2H), 0.39-0.35 (m, 2H).


SC_3289
cis-1-(Cyclopropyl-methyl)-8-
SC_3288

SC_3099
1H NMR (DMSO-d6): δ 7.49-7.37 (m, 5H),
482.3



methylamino-3-[2-(methylsulfonyl-



7.32-7.30 (m, 3H), 7.19-7.15 (m, 1H),



methyl)-phenyl]-8-phenyl-1,3-



4.49 (s, 2H), 3.71 (s, 2H), 3.05 (d, 2H), 2.87 (s,



diazaspiro[4.5]decan-2-one



3H), 2.26-2.20 (m, 3H), 1.91-1.87 (m, 5H),







1.71-1.56 (m, 4H), 1.03-1.01 (m, 1H),







0.49-0.45 (m, 2H), 0.31-0.28 (m, 2H).


SC_3290
cis-8-Dimethylamino-8-(3-
INT-
1-bromo-2-
SC_3103
1H NMR (600 MHz, DMSO) δ 7.46 (dd,
460.3



fluorophenyl)-3-[2-
1024
(methylsulfonylmethyl)benzene

1H), 7.39 (td, 2H), 7.33 (dd, 1H),



(methylsulfonyl-methyl)-phenyl]-



7.31-7.21 (m, 1H), 7.18 (d, 1H), 7.15 (dd, 1H),



1,3-diazaspiro[4.5]decan-2-one



7.08 (td, 1H), 4.50 (s, 2H), 3.56 (s, 2H), 2.88 (s,







3H), 2.42-2.24 (m, 2H), 1.99-1.89 (m,







8H), 1.88-1.75 (m, 2H), 1.60-1.48 (m,







2H).


SC_3291
cis-8-Dimethylamino-8-(4-
INT-
1-bromo-2-
SC_3103
1H NMR (600 MHz, DMSO) δ 7.46 (dd,
460.3



fluorophenyl)-3-[2-
1025
(methylsulfonylmethyl)benzene

1H), 7.43-7.34 (m, 3H), 7.33 (dd, 1H),



(methylsulfonyl-methyl)-phenyl]-



7.28 (td, 2H), 7.16 (t, 2H), 4.49 (s, 2H), 3.55 (s,



1,3-diazaspiro[4.5]decan-2-one



2H), 2.88 (s, 3H), 2.35-2.32 (m, 2H),







1.95 (s, 6H), 1.94-1.88 (m, 2H), 1.88-1.65 (m,







2H), 1.59-1.47 (m, 2H).


SC_3294
cis-8-Dimethylamino-8-(3-
INT-
4-(5-bromo-4-methyl-
SC_3103
1H NMR (600 MHz, DMSO) δ 8.13 (s, 1H),
469.3



fluorophenyl)-3-(4-methyl-2-
1024
pyrimidin-2-

7.40 (td, 1H), 7.22-7.11 (m, 4H), 7.08 (td,



morpholin-4-yl-pyrimidin-5-yl)-

yl)morpholine

1H), 3.69-3.60 (m, 8H), 2.34-2.31 (m,



1,3-diazaspiro[4.5]decan-2-one



2H), 2.20 (s, 3H), 1.96 (s, 6H),







1.96-1.70 (m, 4H), 1.56-1.43 (m, 2H).


SC_3295
cis-3-[6-(4-Acetyl-piperazin-1-yl)-
INT-976
1-[4-(5-bromo-4-
SC_3103
1HNMR (DMSO-d6, 400 MHz at 100° C.), δ
491.3



4-methyl-pyridin-3-yl]-8-

methyl-pyridin-2-yl)-

(ppm) = 7.88 (s, 1H), 7.35-7.22 (m, 5H),



dimethylamino-8-phenyl-1,3-

piperazin-1-yl]-

6.73 (s, 1H), 6.64 (s, 1H), 3.53-3.50 (m, 8H),



diazaspiro[4.5]decan-2-one

ethanone

3.38 (s, 2H), 2.33-2.30 (m, 2H), 2.14 (s, 3H),







2.03-1.88 (m, 13H), 1.56-1.51 (m, 2H).


SC_3296
cis-3-[2-(4-Acetyl-piperazin-1-yl)-
INT-976
1-[4-(5-bromo-4-
SC_3103
1H-NMR (DMSO-d6, 400 MHz at 100° C.),
492.3



4-methyl-pyrimidin-5-yl]-8-

methyl-pyrimidin-2-

δ (ppm) = 8.11 (s, 1H), 7.35-7.24 (m, 5H),



dimethylamino-8-phenyl-1,3-

yl)-piperazin-1-yl]-

6.88 (s, 1H), 3.73 (bs, 4H), 3.52 (bs, 4H),



diazaspiro[4.5]decan-2-one

ethanone

3.38 (s, 2H), 2.33 (bs, 2H), 2.22 (s, 3H),







2.03-1.87 (m, 13H), 1.56-1.53 (m, 2H).


SC_3297
cis-8-Dimethylamino-3-(4-methyl-
INT-976
5-bromo-2-chloro-4-
SC_3103 (for
1H-NMR (DMSO-d6, 400 MHz at 100° C.),
442.3



6-pyridin-4-yl-pyridin-3-yl)-8-

methyl-pyridine (step
step 1),
δ (ppm) = 8.65 (d, 2H, J = 5.92 Hz), 8.50 (s,



phenyl-1,3-diazaspiro[4.5]decan-2-

1), 4-pyridinylboronic
SC_3129 (for
1H), 7.96 (d, 2H, J = 5.96 Hz), 7.91 (s, 1H),



one

acid (step 2)
step 2)
7.36-7.23 (m, 5H), 7.07 (s, 1H), 3.57 (s, 2H),







2.38-2.33 (m, 5H), 2.04 (s, 6H),







2.00-1.88 (m, 4H), 1.61-1.57 (m, 2H).


SC_3298
cis-3-[2-(4-Acetyl-piperazin-1-yl)-
INT-976
1-[4-(5-bromo-4-
SC_3103
1H-NMR (DMSO-d6, 400 MHz at 100° C.),
546.3



4-(trifluoromethyl)-pyrimidin-5-

trifluoromethyl-

δ (ppm) = 8.52 (s, 1H), 7.35-7.22 (m, 5H),



yl]-8-dimethylamino-8-phenyl-1,3-

pyrimidin-2-yl)-

7.07 (s, 1H), 3.79-3.78 (t, 4H, 5.08 Hz),



diazaspiro[4.5]decan-2-one

piperazin-1-yl]-

3.57 (t, 4H, 5.26 Hz), 3.39 (s, 2H), 2.36-2.32 (m,





ethanone

2H), 2.04-1.85 (m, 13H), 1.54-1.50 (m, 2H).


SC_3299
cis-8-Dimethylamino-3-[2-(3-oxo-
INT-976
4-(5-bromo-4-
SC_3103
1HNMR (DMSO-d6, 400 MHz), δ (ppm) = 8.55 (s,
518.2



piperazin-1-yl)-4-(trifluoromethyl)-

trifluoromethyl-

1H), 7.77 (bs, 1H), 7.35-7.23 (m,



pyrimidin-5-yl]-8-phenyl-1,3-

pyrimidin-2-yl)-

5H), 7.09 (s, 1H), 4.20 (s, 2H), 3.92 (t, 2H, J = 5.04 Hz),



diazaspiro[4.5]decan-2-one

piperazin-2-one

3.39 (s, 2H), 3.33 (bs, 2H),







2.36-2.33 (m, 2H), 2.03-1.85 (m, 10H),







1.54-1.39 (m, 2H).


SC_3300
cis-8-Dimethylamino-3-
INT-976
4-bromo-isoquinoline
SC_3103
1HNMR (DMSO-d6, 400 MHz at 100° C.), δ
401.2



isoquinolin-4-yl-8-phenyl-1,3-



(ppm) = 9.16 (s, 1H), 8.41 (s, 1H), 8.13 (d,



diazaspiro[4.5]decan-2-one



1H, J = 8.12 Hz), 7.91 (d, 1H, J = 8.64 Hz),







7.71 (t, 1H, J = 7.58 Hz), 7.67 (t, 1H, J = 7.46 Hz),







7.36-7.23 (m, 5H), 7.14 (s, 1H),







3.67 (s, 2H), 2.41-2.36 (m, 2H),







2.10-1.89 (m, 10H), 1.68-1.64 (m, 2H).


SC_3301
cis-8-Dimethylamino-3-
INT-976
5-bromo-isoquinoline
SC_3103
1HNMR (DMSO-d6, 400 MHz at 100° C.), δ
401.2



isoquinolin-5-yl-8-phenyl-1,3-



(ppm) = 9.29 (s, 1H), 8.48 (d, 1H, J = 5.92 Hz)



diazaspiro[4.5]decan-2-one



7.98-7.96 (m, 1H), 7.70-7.64 (m, 3H),







7.36-7.23 (m, 5H), 7.13 (s, 1H), 3.65 (s, 2H),







2.41-2.36 (m, 2H), 2.10-1.90 (m, 10H),







1.68-1.63 (m, 2H).


SC_3302
cis-8-Dimethylamino-8-phenyl-3-
INT-976
4-bromo-1H-
SC_3103
1H NMR (600 MHz, DMSO) δ 11.42 (s,
390.2



(1H-pyrrolo[2,3-b]pyridin-4-yl)-

pyrrolo[2,3-

1H), 7.99 (d, 1H), 7.66 (br s, 1H),



1,3-diazaspiro[4.5]decan-2-one

b]pyridine

7.43-7.33 (m, 5H), 7.27 (t, 1H), 7.22 (t, 1H),







6.65-6.60 (m, 1H), 3.91 (s, 2H), 2.45-2.27 (m,







2H), 1.98-1.82 (m, 10H), 1.56-1.49 (m,







2H).


SC_3303
cis-8-Dimethylamino-8-phenyl-3-
INT-976
4-bromo-2-(pyridin-
SC_3103
1H NMR (DMSO-d6): δ 8.62 (d, 2H),
434.1



(2-pyridin-4-yl-thiazol-4-yl)-1,3-

4-yl)thiazole

7.82 (d, 2H), 7.61 (broad s, 1H), 7.54 (s, 1H),



diazaspiro[4.5]decan-2-one



7.40-7.37 (m, 4H), 7.29-7.27 (m, 1H),







3.84 (s, 2H), 2.49 (m, 2H), 1.96-1.79 (m, 10H),







1.51 (m, 2H).


SC_3304
cis-8-[Methyl-(tetrahydro-furan-3-
INT-
4-(5-bromopyrimidin-
step 2 of
1H NMR (DMSO-d6): δ 8.56 (s, 2H),
507.3



yl-methyl)-amino]-3-(2-morpholin-
1026
2-yl)morpholine
SC_3097 (for
7.65 (broad s, 1H), 7.36-7.23 (m, 5H),



4-yl-pyrimidin-5-yl)-8-phenyl-1,3-


synthesis),
3.66-3.55 (m, 10H), 3.49 (s, 2H), 3.38 (m, 1H),



diazaspiro[4.5]decan-2-one


SC_3292 and
2.32-2.26 (m, 3H), 2.11-1.94 (m, 6H),



(enantiomer 1)


SC_3293 (for
1.86-1.82 (m, 3H), 1.50-1.41 (m, 3H).






separation of






enantiomers)


SC_3305
cis-8-[Methyl-(tetrahydro-furan-3-
INT-
4-(5-bromopyrimidin-
step 2 of
1H NMR (DMSO-d6): δ 8.56 (s, 2H),
507.2



yl-methyl)-amino]-3-(2-morpholin-
1026
2-yl)morpholine
SC_3097 (for
7.66 (broad s, 1H), 7.35-7.24 (m, 5H),



4-yl-pyrimidin-5-yl)-8-phenyl-1,3-


synthesis),
3.63-3.49 (m, 12H), 3.31 (m, 1H), 2.27 (m, 3H),



diazaspiro[4.5]decan-2-one


SC_3292 and
2.11-1.84 (m, 10H), 1.42 (m, 3H).



(enantiomer 2)


SC_3293 (for






separation of






enantiomers)


SC_3306
cis-3-[2-(Azetidin-1-yl)-pyrimidin-
INT-976
2-azetidin-1-yl-5-
step 2 of
1HNMR (DMSO-d6, 400 MHz at 100° C.), δ
407.2



5-yl]-8-dimethylamino-8-phenyl-

bromo-pyrimidine
SC_3242
(ppm) = 8.48 (s, 2H), 7.36-7.26 (m, 5H),



1,3-diazaspiro[4.5]decan-2-one



7.07 (s, 1H), 3.99 (t, 4H, J = 7.18 Hz),







3.50 (s, 2H), 2.35-2.26 (m, 4H), 2.03 (s, 6H),







1.95-1.91 (m, 2H), 1.52-1.50 (m, 2H).


SC_3307
cis-3-[2-(3,3-Difluoro-azetidin-1-
INT-976
5-bromo-2-(3,3-
step 2 of
1HNMR (DMSO-d6, 400 MHz at 100° C.), δ
443.2



yl)-pyrimidin-5-yl]-8-

difluoro-azetidin-1-
SC_3242
(ppm) = 8.62 (s, 2H), 7.37-7.25 (m, 5H),



dimethylamino-8-phenyl-1,3-

yl)-pyrimidine

7.20 (s, 1H), 4.38 (t, 4H, J = 12.40 Hz),



diazaspiro[4.5]decan-2-one



3.55 (s, 2H), 2.36-233 (m, 2H), 2.03 (s, 6H)







1.97-1.89 (m, 4H), 1.53-1.51 (m, 2H).


SC_3308
cis-8-Dimethylamino-3-[6-
INT-976
4-(5-bromo-3-
SC_3103
1HNMR (DMSO-d6, 400 MHz at 100° C.), δ
504.3



morpholin-4-yl-5-(trifluoromethyl)-

trifluoromethyl-

(ppm) = 8.63 (s, 1H), 8.38 (s, 1H),



pyridin-3-yl]-8-phenyl-1,3-

pyridin-2-yl)-

7.37-7.25 (m, 6H), 3.71 (bs, 4H), 3.65 (s, 2H),



diazaspiro[4.5]decan-2-one

morpholine

3.03 (bs, 4H), 2.37-2.32 (m, 2H), 2.03 (s, 6H),







1.98-1.88 (m, 4H), 1.55-1.52 (m, 2H).


SC_3309
cis-8-Methylamino-3-[6-
SC_3308

SC_3099
1HNMR (DMSO-d6, 400 MHz at 100° C.), δ
490.4



morpholin-4-yl-5-(trifluoromethyl)-



(ppm) = 8.68 (s, 1H), 8.42 (s, 1H), 7.48 (d,



pyridin-3-yl]-8-phenyl-1,3-



2H, J = 8.12 Hz), 7.33 (t, 2H, J = 7.62 Hz),



diazaspiro[4.5]decan-2-one



7.20 (t, 1H, J = 7.38 Hz), 7.14 (s, 1H),







3.75-3.71 (m, 6H), 3.03 (t, 4H, J = 8.88 Hz),







2.08-2.02 (m, 2H), 1.95-1.79 (m, 8H),







1.58-1.55 (m, 2H).


SC_3310
cis-8-Dimethylamino-8-phenyl-3-
INT-976
2-bromo-5-
SC_3103
1H NMR (600 MHz, DMSO) δ
435.2



[5-(trifluoromethyloxy)-pyridin-2-

(trifluoromethoxy)-

8.32-8.26 (m, 2H), 7.86-7.82 (m, 1H), 7.79 (dd, 1H),



yl]-1,3-diazaspiro[4.5]decan-2-one

pyridine

7.41-7.33 (m, 4H), 7.27 (t, 1H), 3.71 (s,







2H), 2.46-2.33 (m, 2H), 1.96 (s, 6H),







1.94-1.72 (m, 4H), 1.47 (t, 2H).


SC_3311
cis-8-Dimethylamino-3-(5-
INT-976
2-bromo-5-
SC_3103
1H NMR (600 MHz, DMSO) δ 8.66 (dd,
429.2



methylsulfonyl-pyridin-2-yl)-8-

methylsulfonylpyridine

1H), 8.39 (dd, 1H), 8.14 (dd, 1H), 8.06 (s,



phenyl-1,3-diazaspiro[4.5]decan-2-



1H), 7.42-7.33 (m, 4H), 7.28 (t, 1H),



one



3.77 (s, 2H), 3.21 (s, 3H), 2.46-2.32 (m, 2H),







2.03-1.68 (m, 10H), 1.52-1.46 (m, 2H).


SC_3312
cis-6-(8-Dimethylamino-2-oxo-8-
INT-976
6-bromopyridine-3-
SC_3103
1H NMR (600 MHz, DMSO) δ 8.66 (d, 1H),
376.2



phenyl-1,3-diazaspiro[4.5]decan-3-

carbonitrile

8.34 (d, 1H), 8.08 (dd, 1H), 7.41-7.33 (m,



yl)-nicotinonitrile



4H), 7.28 (t, 1H), 3.74 (s, 2H),







2.46-2.30 (m, 2H), 1.96 (s, 6H), 1.94-1.73 (m, 4H),







1.51-1.44 (m, 2H).


SC_3314
cis-8-Dimethylamino-3-[4-methyl-
INT-976
4-(5-bromo-4-methyl-
SC_3103
1HNMR (DMSO-d6, 400 MHz at 100° C.), δ
464.2



2-(3-oxo-piperazin-1-yl)-pyrimidin-

pyrimidin-2-yl)-

(ppm) = 8.14 (s, 1H), 7.65 (bs, 1H),



5-yl]-8-phenyl-1,3-

piperazin-2-one

7.34-7.23 (m, 5H), 6.89 (s, 1H), 4.16 (s, 2H),



diazaspiro[4.5]decan-2-one



3.88 (bs, 2H), 3.39 (s, 2H), 3.29 (bs, 2H),







2.33 (bs, 2H), 2.24 (s, 3H), 2.03-1.87 (m, 10H),







1.53 (bs, 2H).


SC_3315
cis-5-(8-Dimethylamino-2-oxo-8-
SC_3312

SC_3016
1H NMR (600 MHz, DMSO) δ 8.80 (d, 1H),
394.2



phenyl-1,3-diazaspiro[4.5]decan-3-



8.10 (dd, 1H), 7.95-7.89 (m, 2H), 7.79 (s,



yl)-pyridine-2-carboxylic acid



1H), 7.42-7.35 (m, 5H), 7.28 (s, 1H),



amide



3.67 (s, 2H), 2.48-2.28 (m, 2H), 1.95 (d, 10H),







1.53-1.46 (m, 2H).


SC_3316
cis-3-[4-(Azetidin-1-yl)-2-methyl-
INT-976
4-azetidin-1-yl-5-
step 2 of
1HNMR (DMSO-d6, 400 MHz at 100° C.), δ
421.2



pyrimidin-5-yl]-8-dimethylamino-

bromo-2-methyl-
SC_3242
(ppm) = 7.85 (s, 1H), 7.34-7.23 (m, 5H),



8-phenyl-1,3-diazaspiro[4.5]decan-

pyrimidine

6.93 (s, 1H), 4.11 (t, 4H, J = 7.40 Hz),



2-one



3.33 (s, 2H), 2.33-2.30 (m, 7H), 2.02 (s, 6H),







1.96-1.87 (m, 4H), 1.53-1.48 (m, 2H).


SC_3317
cis-2-(8-Dimethylamino-2-oxo-8-
INT-976
2-bromobenzonitrile
SC_3103 (step
1H NMR (600 MHz, DMSO) δ 7.50 (s, 1H),
393.2



phenyl-1,3-diazaspiro[4.5]decan-3-


1), SC_3016
7.42 (dd, 1H), 7.42-7.32 (m, 5H), 7.31 (d,



yl)-benzamide


(step 2)
1H), 7.26 (t, 1H), 7.23-7.13 (m, 3H),







3.53 (s, 2H), 2.41-2.27 (m, 2H), 1.96 (s, 6H),







1.90 (t, 2H), 1.86-1.68 (m, 2H),







1.52-1.48 (m, 2H).


SC_3318
cis-8-Dimethylamino-3-[2-
INT-997
1-bromo-2-
SC_3103
1H NMR (600 MHz, DMSO) δ 7.47 (dd,
448.2



(methylsulfonyl-methyl)-phenyl]-8-

(methylsulfonylmethyl)-

1H), 7.43-7.36 (m, 2H), 7.34 (dd, 1H),



thiophen-2-yl-1,3-

benzene

7.29 (ddd, 1H), 7.19 (s, 1H), 7.05 (ddd, 1H),



diazaspiro[4.5]decan-2-one



6.94 (d, 1H), 4.50 (s, 2H), 3.61 (s, 2H), 2.89 (s,







3H), 2.35-2.21 (m, 2H), 2.04 (s, 6H),







1.98-1.90 (m, 2H), 1.86-1.70 (m, 2H),







1.66-1.59 (m, 2H).


SC_3320
cis-8-Dimethylamino-3-(4-methyl-
INT-997
4-(5-bromo-4-methyl-
SC_3319
1H NMR (600 MHz, DMSO) δ 8.15 (d, 1H),
457.2



2-morpholin-4-yl-pyrimidin-5-yl)-

pyrimidin-2-

7.41 (dt, 1H), 7.13 (s, 1H), 7.05 (ddd, 1H),



8-thiophen-2-yl-1,3-

yl)morpholine

6.94 (dd, 1H), 3.71-3.60 (m, 8H), 3.44 (s,



diazaspiro[4.5]decan-2-one



2H), 2.32-2.24 (m, 2H), 2.21 (s, 3H),







2.04 (s, 6H), 1.98-1.88 (m, 2H), 1.87-1.75 (m,







2H), 1.62-1.54 (m, 2H).


SC_3321
cis-8-Dimethylamino-3-(6-
INT-976
5-bromo-2-
SC_3103
1H NMR (600 MHz, DMSO) δ 8.89 (d, J = 2.6 Hz,
429.2



methylsulfonyl-pyridin-3-yl)-8-

methylsulfonylpyridine

1H), 8.28 (dd, J = 8.9, 2.6 Hz, 1H),



phenyl-1,3-diazaspiro[4.5]decan-2-



7.93 (d, 1H), 7.42-7.34 (m, 4H),



one



7.31-7.25 (m, 1H), 3.71 (s, 2H), 3.18 (s, 3H),







2.48-2.33 (m, 2H), 2.04-1.76 (m, 10H),







1.54-1.48 (m, 2H).


SC_3322
cis-8-Dimethylamino-8-phenyl-3-
INT-976
tert-butyl 5-
SC_3103 (for
1H NMR (600 MHz, DMSO) δ 11.45 (s,
390.2



(1H-pyrrolo[2,3-b]pyridin-5-yl)-

bromopyrrolo[2,3-
step 1),
1H), 8.38 (s, 1H), 8.00 (d, 1H),



1,3-diazaspiro[4.5]decan-2-one

b]pyridine-1-
SC_3173 (for
7.85-7.81 (m, 1H), 7.70-7.66 (m, 2H),





carboxylate (step 1)
step 2)
7.57-7.53 (m, 3H), 7.41 (t, 1H), 6.35 (dd, 1H), 3.54 (s,







2H), 2.75-2.41 (m, 8H, overlapps with







solvent residual peak), 2.30-2.26 (m, 2H),







1.89 (d, 2H), 1.41-1.37 (m, 2H).


SC_3323
cis-N-[5-(8-Dimethylamino-2-oxo-
SC_3239
acetyl chloride
SC_3240
1H NMR (600 MHz, DMSO) δ 10.36 (s,
409.2



8-phenyl-1,3-diazaspiro[4.5]decan-



1H), 8.82 (s, 2H), 8.40 (s, rotamer), 7.67 (s,



3-yl)-pyrimidin-2-yl]-acetamide



1H), 7.44-7.31 (m, 4H), 7.27 (td, 1H),



(enantiomer 1)



3.62 (s, 2H), 2.46-2.30 (m, 2H), 2.11 (s, 3H),







2.08 (s, rotamer), 1.96 (s, 6H), 1.97 (s,







rotamer), 1.95-1.75 (m, 4H),







1.52-1.47 (m, 2H).


SC_3324
cis-3-[2-(4-Methyl-piperazin-1-yl)-
INT-
5-bromo-2-(4-
step 2 of
1H NMR (DMSO-d6): δ 8.52 (s, 2H),
518.3



pyrimidin-5-yl]-8-[methyl-
1026
methylpiperazin-1-
SC_3097 (for
7.64 (broad s, 1H), 7.36-7.23 (m, 5H),



(tetrahydro-furan-3-yl-methyl)-

yl)pyrimidine
synthesis),
3.66-3.55 (m, 7H), 3.48 (s, 2H), 3.37-3.36 (m, 1H),



amino]-8-phenyl-1,3-


SC_3292 and
2.33-2.13 (m, 11H), 2.01-1.82 (m, 9H),



diazaspiro[4.5]decan-2-one


SC_3293 (for
1.50-1.41 (m, 3H).



(enantiomer 2)


separation of






enantiomers)


SC_3325
cis-3-[2-(4-Methyl-piperazin-1-yl)-
INT-
5-bromo-2-(4-
step 2 of
1H NMR (DMSO-d6): δ 8.52 (s, 2H),
518.3



pyrimidin-5-yl]-8-[methyl-
1026
methylpiperazin-1-
SC_3097 (for
7.64 (broad s, 1H), 7.36-7.24 (m, 5H),



(tetrahydro-furan-3-yl-methyl)-

yl)pyrimidine
synthesis),
3.66-3.55 (m, 7H), 3.48 (s, 2H), 3.36 (m, 1H),



amino]-8-phenyl-1,3-


SC_3292 and
2.34-2.13 (m, 10H), 2.01-1.83 (m, 10H),



diazaspiro[4.5]decan-2-one


SC_3293 (for
1.50-1.41 (m, 3H).






separation of






enantiomers)


SC_3326
cis-8-Dimethylamino-3-(4,6-
INT-976
4-(5-bromo-4,6-
SC_3103

465.3



dimethyl-2-morpholin-4-yl-

dimethyl-pyrimidin-



pyrimidin-5-yl)-8-phenyl-1,3-

2-yl)morpholine



diazaspiro[4.5]decan-2-one


SC_3327
cis-8-Dimethylamino-3-(2-
INT-
morpholine
SC_3120
1H NMR (600 MHz, DMSO) δ 8.58 (s, 2H),
443.2



morpholin-4-yl-pyrimidin-5-yl)-8-
1027


7.43 (dd, 1H), 7.40-7.32 (m, 1H), 7.07 (dd,



thiophen-2-yl-1,3-



1H), 6.96 (dd, 1H), 3.67-3.61 (m, 4H),



diazaspiro[4.5]decan-2-one



3.62-3.57 (m, 6H), 2.31-2.27 (m, 2H), 2.04 (s,







6H), 1.91 (t, 2H), 1.86-1.82 (m, 2H),







1.56-1.50 (m, 2H).


SC_3328
cis-6-(8-Dimethylamino-2-oxo-8-
SC_3312

SC_3016
1H NMR (600 MHz, DMSO) δ 8.71 (d, J = 2.3 Hz,
394.2



phenyl-1,3-diazaspiro[4.5]decan-3-



1H), 8.24 (d, J = 8.9 Hz, 1H),



yl)-pyridine-3-carboxylic acid



8.12 (dd, J = 9.0, 2.4 Hz, 1H), 7.95 (s, 1H),



amide



7.86 (s, 1H), 7.36 (dq, J = 13.7, 6.6, 5.6 Hz, 5H),







7.27 (t, J = 7.2 Hz, 1H), 3.74 (s, 2H),







2.41-2.37 (m, 2H), 1.96 (s, 6H), 1.94-1.87 (m,







2H), 1.86-1.80 (m, 2H), 1.51-1.44 (m,







2H).


SC_3329
cis-8-Dimethylamino-3-[2-methyl-
INT-997
5-bromo-1-methyl-3-
SC_3319
1H NMR (600 MHz, DMSO) δ
428.2



5-(trifluoromethyl)-2H-pyrazol-3-

(trifluoromethyl)pyrazole

7.66-7.63 (m, 1H), 7.42 (dd, 1H), 7.06 (dd, 1H),



yl]-8-thiophen-2-yl-1,3-



6.95 (dd, 1H), 6.64 (s, 1H), 3.75 (s, 3H), 3.60 (s,



diazaspiro[4.5]decan-2-one



2H), 2.30-2.26 (m, 2H), 2.04 (s, 6H),







1.98-1.90 (m, 2H), 1.83-1.79 (m, 2H),







1.64-1.57 (m, 2H).


SC_3330
cis-8-Dimethylamino-3-[2-[(2-
INT-
2-
SC_3120
1H NMR (600 MHz, DMSO) δ 8.48 (s, 2H),
431.2



hydroxy-ethyl)-methyl-amino]-
1027
(methylamino)ethanol

7.43 (d, 1H), 7.30 (s, 1H), 7.07 (dd, 1H),



pyrimidin-5-yl]-8-thiophen-2-yl-



6.96 (d, 1H), 3.61 (dd, 2H), 3.58-3.51 (m,



1,3-diazaspiro[4.5]decan-2-one



4H), 3.09 (s, 3H), 2.34-2.22 (m, 2H),







2.04 (s, 6H), 1.96-1.76 (m, 4H), 1.56-1.50 (m,







2H).


SC_3331
cis-8-Dimethylamino-3-[2-(2-oxo-
INT-
4-(4,4,5,5-
SC_3208
1H NMR (600 MHz, DMSO) δ 10.46 (s,
489.2



1,3-dihydro-indol-4-yl)-pyrimidin-
1027
tetramethyl-1,3,2-

1H), 9.12 (s, 2H), 7.87 (d, 1H),



5-yl]-8-thiophen-2-yl-1,3-

dioxaborolan-2-

7.47-7.42 (m, 1H), 7.31 (t, 1H), 7.08 (dd, 1H),



diazaspiro[4.5]decan-2-one

yl)indolin-2-one

6.98 (dd, 1H), 6.92 (d, 1H), 3.83 (s, 2H), 3.77 (s,







2H), 2.35-2.30 (m, 2H), 2.05 (s, 6H),







1.96 (t, 2H), 1.88 (s, 2H), 1.60-1.54 (m, 2H).


SC_3332
cis-8-Dimethylamino-3-[4-methyl-
INT-976
4-(5-bromo-4-methyl-
step 2 of
1H-NMR (DMSO-d6, 400 MHz at 100° C.), δ
463.2



6-(3-oxo-piperazin-1-yl)-pyridin-3-

pyridin-2-yl)-
SC_3097
(ppm) = 7.89 (s, 1H), 7.62 (bs, 1H),



yl]-8-phenyl-1,3-

piperazin-2-one

7.35-7.22 (m, 5H), 6.73 (s, 1H), 6.62 (s, 1H),



diazaspiro[4.5]decan-2-one



3.96 (s, 2H), 3.68 (t, 2H, J = 5.2 Hz), 3.39 (s, 2H),







3.30 (bs, 2H), 2.35-2.30 (m, 2H), 2.15 (s,







3H), 2.03-1.86 (m, 10H), 1.56-1.51 (m, 2H).


SC_3333
cis-8-Dimethylamino-3-(4-methyl-
INT-976
5-bromo-2-chloro-4-
SC_3103 (for
1H-NMR (DMSO-d6, 400 MHz at 100° C.),
442.3



6-pyridin-2-yl-pyridin-3-yl)-8-

methyl-pyridine (step
step 1),
δ (ppm) = 8.64 (d, 1H, J = 4.0 Hz), 8.45 (s,



phenyl-1,3-diazaspiro[4.5]decan-2-

1), 2-
SC_3162 (for
1H), 8.31 (d, 1H, J = 8.68 Hz), 8.22 (s, 1H),



one

tributylstannanyl-
step 2)
7.88 (t, 1H, J = 7.04 Hz), 7.39-7.35 (m, 5H),





pyridine (step 2)

7.26-7.23 (m, 1H), 7.03 (s, 1H), 3.57 (s, 2H),







2.39-2.33 (m, 5H), 2.04 (s, 6H),







2.01-1.88 (m, 4H), 1.61-1.57 (m, 2H).


SC_3334
cis-8-Dimethylamino-3-(4-
INT-976
3-bromo-4-
SC_3103 (for
1HNMR at 100° C. (DMSO-d6, 400 MHz), δ
429.3



methylsulfonyl-pyridin-3-yl)-8-

methylsulfanyl-
step 1),
(ppm) = 8.77-8.72 (m, 2H), 7.85-7.84 (m,



phenyl-1,3-diazaspiro[4.5]decan-2-

pyridine (step 1)
SC_3008 (for
1H), 7.35-7.23 (m, 6H), 3.60 (s, 2H),



one


step 2)
3.31 (s, 3H), 2.36 (bs, 2H), 2.03-1.82 (m, 10H),







1.60-1.58 (m, 2H).


SC_3335
cis-3-(Benzothiazol-7-yl)-8-
INT-976
7-bromo-
SC_3103

407.1



dimethylamino-8-phenyl-1,3-

benzothiazole



diazaspiro[4.5]decan-2-one


SC_3336
cis-8-Dimethylamino-8-(4-
INT-
4-(5-bromo-4-methyl-
SC_3319
1H NMR (600 MHz, DMSO) δ 8.13 (s, 1H),
469.3



fluorophenyl)-3-(4-methyl-2-
1025
pyrimidin-2-

7.41-7.35 (m, 2H), 7.22-7.13 (m, 3H),



morpholin-4-yl-pyrimidin-5-yl)-

yl)morpholine

3.69-3.60 (m, 8H), 2.35-2.31 (m, 2H),



1,3-diazaspiro[4.5]decan-2-one



2.20 (s, 3H), 1.94 (s, 6H), 1.93-1.74 (m,







4H), 1.53-1.43 (m, 2H).


SC_3337
cis-2-[8-Dimethylamino-3[4-
SC_3122
2-chloro-N,N-
INT-988 (step
1H NMR (600 MHz, DMSO) δ 8.59 (s, 1H),
518.3



methyl-6-(trifluoromethyl)-pyridin-

dimethyl-acetamide
1)
7.82 (s, 1H), 7.37-7.32 (m, 4H), 7.25 (ddd,



3-yl]-2-oxo-8-phenyl-1,3-



1H), 4.00 (s, 2H), 3.80 (s, 2H), 3.07 (s, 3H),



diazaspiro[4.5]decan-1-yl]-N,N-



2.87 (s, 3H), 2.71-2.64 (m, 2H), 2.55 (s,



dimethyl-acetamide



3H), 2.34 (s, 3H), 2.03 (td, 2H), 1.98 (s, 6H),







1.67-1.58 (m, 2H), 1.49-1.40 (m, 2H).


SC_3338
cis-8-Dimethylamino-3-[2-(2-
INT-989
2-methyl-4-(4,4,5,5-
SC_3208
1H NMR (600 MHz, DMSO) δ 9.57 (s, 1H),
497.3



methyl-1-oxo-2,3-dihydro-isoindol-

tetramethyl-1,3,2-

9.08 (s, 2H), 8.52 (d, 1H), 8.43 (s, 1H),



4-yl)-pyrimidin-5-yl]-8-phenyl-1,3-

dioxaborolan-2-

7.77 (d, 1H), 7.72 (d, 2H), 7.63 (t, 1H), 7.59 (t,



diazaspiro[4.5]decan-2-one

yl)isoindolin-1-one

2H), 7.55 (t, 1H), 4.86 (s, 2H), 3.59 (s, 2H),







3.13 (s, 3H), 2.72 (d, 2H), 2.61 (s, 6H),







2.25 (td, 2H), 1.91 (d, 2H), 1.43-1.35 (m, 2H).


SC_3339
cis-2-[[5-(8-Dimethylamino-2-oxo-
INT-976
(5-bromo-2-methyl-
step 2 of

1HNMR at 100° C. (DMSO-d6, 400 MHz), δ

438.4



8-phenyl-1,3-diazaspiro[4.5]decan-

pyrimidin-4-
SC_3242 (for
(ppm) = 7.93 (s, 1H), 7.36-7.22 (m, 5H),



3-yl)-2-methyl-pyrimidin-4-

ylamino)-acetonitrile
step 1),
7.12 (s, 1H), 6.91 (bs, 2H), 6.58 (bs, 1H),



yl]amino]-acetamide

(step 1)
SC_3016 (for
3.94 (d, 2H), 3.46 (s, 2H), 2.35-2.32 (m, 5H),






step 2)
2.03-1.97 (m, 8H), 1.91-1.84 (m, 2H),







1.61-1.56 (m, 2H).


SC_3341
cis-8-Dimethylamino-3-[4-
INT-976
3-bromo-4-
step 2 of
1HNMR at 100° C. (DMSO-d6, 400 MHz), δ
443.4



(methylsulfonyl-methyl)-pyridin-3-

methanesulfonylmethyl-
SC_3097
(ppm) = 8.53 (s, 1H), 8.43 (d, 1H, J = 4.88 Hz),



yl]-8-phenyl-1,3-

pyridine

7.48 (d, 1H, J = 4.88 Hz), 7.36-7.23 (m,



diazaspiro[4.5]decan-2-one



5H), 7.15 (s, 1H), 4.55 (s, 2H), 3.64 (s, 2H),







2.95 (s, 3H), 2.38-2.33 (m, 2H), 2.04 (s, 6H),







1.99-1.83 (m, 4H), 1.62-1.57 (m, 2H).


SC_3342
cis-8-Dimethylamino-3-[6-(4-
INT-976
4-(5-bromo-2-
SC_3242 (step
1H NMR (600 MHz, CDCl3) δ 8.09 (d, 1H),
463.3



methyl-3-oxo-piperazin-1-yl)-

pyridyl)-1-methyl-
2)
8.00 (dd, 1H), 7.45-7.39 (m, 2H),



pyridin-3-yl]-8-phenyl-1,3-

piperazin-2-one

7.37-7.28 (m, 3H), 6.61 (d, 1H), 5.71 (s, 1H),



diazaspiro[4.5]decan-2-one



4.04 (s, 2H), 3.87-3.82 (m, 2H), 3.51 (s, 2H),







3.45 (t, 2H), 3.03 (s, 3H), 2.32-2.02 (m,







10H), 2.02-1.94 (m, 2H), 1.64-1.53 (m,







2H).


SC_3343
cis-8-Dimethylamino-3-(2,4-
INT-976
5-bromo-2,4-
SC_3103
1H NMR (600 MHz, DMSO) δ 8.46 (s, 1H),
380.3



dimethyl-pyrimidin-5-yl)-8-phenyl-

dimethyl-pyrimidine

7.45-7.33 (m, 5H), 7.28-7.24 (m, 1H),



1,3-diazaspiro[4.5]decan-2-one



3.51 (s, 2H), 2.54 (s, 3H), 2.41-2.28 (m,







5H), 2.03-1.77 (m, 10H), 1.56-1.49 (m,







2H).


SC_3344
cis-8-Dimethylamino-3-[2-(1-oxo-
INT-989
4-(4,4,5,5-
SC_3208
1H NMR (600 MHz, DMSO) δ 9.06 (s, 2H),
483.3



2,3-dihydro-isoindol-4-yl)-

tetramethyl-1,3,2-

8.67 (s, 1H), 8.52 (d, 1H), 8.39 (s, 1H),



pyrimidin-5-yl]-8-phenyl-1,3-

dioxaborolan-2-

7.75 (dd, 3H), 7.66-7.51 (m, 4H), 4.75 (s, 2H),



diazaspiro[4.5]decan-2-one; 2,2,2-

yl)isoindolin-1-one

3.58 (s, 2H), 3.18 (s, 2H), 2.75 (d, 2H),



trifluoro-acetic acid



2.60 (s, 6H), 2.27 (t, 2H), 1.91 (d, 2H), 1.39 (t,







2H).


SC_3345
cis-8-Dimethylamino-3-[6-[(2-
INT-976
2-[[5-bromo-3-
SC_3103
1H NMR (600 MHz, DMSO) δ
492.3



hydroxy-ethyl)-methyl-amino]-5-

(trifluoromethyl)-2-

8.55-8.51 (m, 1H), 8.35 (d, 1H), 7.62 (s, 1H), 7.37 (td,



(trifluoromethyl)-pyridin-3-yl]-8-

pyridyl]-methyl-

4H), 7.27 (td, 1H), 3.63 (s, 2H), 3.50 (td,



phenyl-1,3-diazaspiro[4.5]decan-2-

amino]ethanol

2H), 3.20 (t, 2H), 2.78 (s, 3H),



one



2.43-2.36 (m, 2H), 1.96 (s, 6H), 1.95-1.75 (m, 4H),







1.48 (t, 2H).


SC_3346
cis-8-Dimethylamino-8-phenyl-3-
INT-976
3,3,3-trifluoroprop-1-
SC_3313
1H NMR (600 MHz, DMSO) δ 9.56 (d, 1H),
487.3



[2-[4-(trifluoromethyl)-1H-

yne, 2-azido-5-

9.16 (s, 2H), 7.99 (s, 1H), 7.42-7.35 (m,



[1,2,3]triazol-1-yl]-pyrimidin-5-yl]-

bromo-pyrimidine

4H), 7.31-7.25 (m, 1H), 3.75 (s, 2H),



1,3-diazaspiro[4.5]decan-2-one



2.49-2.34 (m, 2H), 2.05-1.75 (m, 10H),







1.60-1.47 (m, 2H).


SC_3347
cis-8-Dimethylamino-3-[2-(4-
INT-976
3-methylbut-1-yne, 2-
SC_3313
1H NMR (600 MHz, DMSO) δ 9.10 (s, 2H),
461.3



isopropyl-1H-[1,2,3]triazol-1-yl)-

azido-5-bromo-

8.50 (d, 1H), 7.91 (s, 1H), 7.42-7.35 (m,



pyrimidin-5-yl]-8-phenyl-1,3-

pyrimidine

5H), 7.28 (td, 1H), 3.73 (s, 2H), 3.08 (hept,



diazaspiro[4.5]decan-2-one



1H), 2.44 (s, 2H), 2.01-1.76 (m, 10H),







1.59-1.48 (m, 2H), 1.30 (d, 6H).


SC_3348
cis-8-Dimethylamino-3-[6-(1,1-
INT-976
1,4-thiazinane 1,1-
SC_3242
1H NMR (600 MHz, DMSO) δ 8.23 (d, 1H),
484.2



dioxo-[1,4]thiazinan-4-yl)-pyridin-

dioxide, 5-bromo-2-

7.93 (dd, 1H), 7.41-7.33 (m, 5H), 7.27 (t,



3-yl]-8-phenyl-1,3-

chloro-pyridine (step

1H), 6.98 (d, 1H), 3.97 (t, 4H), 3.53 (s, 2H),



diazaspiro[4.5]decan-2-one

1)

3.04 (t, 4H), 2.43-2.28 (m, 2H), 1.96 (s,







6H), 1.92-1.72 (m, 4H), 1.51-1.40 (m,







2H).


SC_3349
cis-5-(8-Dimethylamino-2-oxo-8-
INT-976
5-bromo-2-
SC_3242
1H NMR (600 MHz, DMSO-d6) δ 8.66 (d, J = 2.9 Hz,
461.3



phenyl-1,3-diazaspiro[4.5]decan-3-

chloropyridine-3-

1H), 8.25 (d, J = 2.8 Hz, 1H),



yl)-2-morpholin-4-yl-nicotinonitrile

carbonitrile,

7.60 (s, 1H), 7.41-7.33 (m, 4H), 7.30-7.24 (m,





morpholine

1H), 3.74-3.69 (m, 4H), 3.60 (s, 2H),







2.48-2.29 (m, 2H), 1.96 (s, 6H), 1.94-1.68 (m,







4H), 1.52-1.41 (m, 2H).


SC_3350
cis-8-Dimethylamino-3-(1-
INT-976
5-bromo-1-
SC_3103
1H NMR (600 MHz, DMSO) δ 8.64 (d, 1H),
468.2



methylsulfonyl-1H-pyrrolo[2,3-

methylsulfonyl-

8.28 (d, 1H), 7.65 (dd, 1H), 7.57 (s, 1H),



b]pyridin-5-yl)-8-phenyl-1,3-

pyrrolo[2,3-

7.38 (dd, 4H), 7.28 (dt, 1H), 6.72 (dd, 1H),



diazaspiro[4.5]decan-2-one

b]pyridine

3.68 (s, 2H), 3.65 (s, 3H), 2.48-2.29 (m,







2H), 1.98 (s, 10H), 1.53-1.44 (m, 2H).


SC_3351
cis-8-Dimethylamino-3-(1H-indol-
INT-976
4-bromo-1-(toluene-
SC_3357
1H-NMR (DMSO-d6, 400 MHz at 100° C.),
389.3



4-yl)-8-phenyl-1,3-

4-sulfonyl)-1H-indole

δ (ppm) = 10.77 (bs, 1H), 7.37 (bs, 4H),



diazaspiro[4.5]decan-2-one

(step 1)

7.24-7.18 (m, 3H), 7.02-6.94 (m, 2H),







6.81 (bs, 1H), 6.41 (s, 1H), 3.66 (s, 2H),







2.36-2.33 (m, 2H), 2.05-1.96 (m, 10H), 1.60-156 (m,







2H).


SC_3353
cis-8-Dimethylamino-3-[2-fluoro-
INT-976
1-bromo-2-fluoro-4-
SC_3103
1H NMR (600 MHz, DMSO) δ 7.62 (t, 1H),
452.2



4-(trifluoromethyloxy)-phenyl]-8-

(trifluoromethoxy)-

7.50-7.46 (m, 1H), 7.40 (dd, 1H),



phenyl-1,3-diazaspiro[4.5]decan-2-

benzene

7.38-7.31 (m, 4H), 7.25 (t, 1H), 7.21 (d, 1H),



one



3.57 (s, 2H), 2.38 (d, 2H), 1.97-1.88 (m, 8H),







1.84-1.79 (m, 2H), 1.53-1.46 (m, 2H).


SC_3355
cis-8-Dimethylamino-3-(1-methyl-
INT-976
4-bromo-1-methyl-
SC_3103
1H NMR (600 MHz, DMSO) δ 8.04 (d, 1H),
404.3



1H-pyrrolo[2,3-b]pyridin-4-yl)-8-

pyrrolo[2,3-

7.70 (s, 1H), 7.47 (d, 1H), 7.41-7.33 (m,



phenyl-1,3-diazaspiro[4.5]decan-2-

b]pyridine

4H), 7.31-7.24 (m, 2H), 6.65 (d, 1H),



one



3.91 (s, 2H), 3.74 (s, 3H), 2.44-2.25 (m, 2H),







2.08-1.74 (m, 10H), 1.52 (t, 2H).


SC_3356
cis-3-(1-Acetyl-1H-indol-4-yl)-8-
SC_3351
acetyl chloride
SC_3379
1H-NMR (DMSO-d6, 400 MHz at 100° C.),
431.2



dimethylamino-8-phenyl-1,3-



δ (ppm) = 8.12 (d, 1H, J = 8.28 Hz), 7.68 (d,



diazaspiro[4.5]decan-2-one



1H, J = 3.64 Hz), 7.36-7.22 (m, 6H), 7.16 (d,







1H, J = 7.80 Hz), 7.01 (s, 1H), 6.69 (d, 1H, J = 3.8 Hz),







3.66 (s, 2H), 2.62 (s, 3H),







2.38-2.33 (m, 2H), 2.05-1.92 (m, 10H),







1.61-1.56 (m, 2H).


SC_3358
cis-6-(8-Dimethylamino-2-oxo-8-
INT-976
6-chloro-5-methyl-
SC_3103
1H NMR (600 MHz, DMSO) δ 8.64 (s, 1H),
390.2



phenyl-1,3-diazaspiro[4.5]decan-3-

pyridine-3-

8.12 (s, 1H), 7.76 (s, 1H), 7.39-7.34 (m,



yl)-5-methyl-nicotinonitrile

carbonitrile

4H), 7.27 (s, 1H), 3.71 (s, 2H),







2.43-2.15 (m, 5H), 2.11-1.70 (m, 10H), 1.52 (s, 2H).


SC_3359
cis-6-(8-Dimethylamino-2-oxo-8-
INT-976
6-chloro-5-fluoro-
SC_3103
1H NMR (600 MHz, DMSO) δ 8.64 (d, 1H),
394.2



phenyl-1,3-diazaspiro[4.5]decan-3-

pyridine-3-

8.30 (dd, 1H), 7.95 (s, 1H), 7.40-7.31 (m,



yl)-5-fluoro-nicotinonitrile

carbonitrile

4H), 7.29-7.23 (m, 1H), 3.72 (s, 2H),







2.36-2.33 (m, 2H), 1.96 (s, 6H), 1.94-1.79 (m,







4H), 1.52 (t, 2H).


SC_3361
cis-6-(8-Dimethylamino-2-oxo-8-
SC_3358

SC_3016
1H NMR (600 MHz, DMSO) δ 8.64 (d, 1H),
408.2



phenyl-1,3-diazaspiro[4.5]decan-3-



8.06-8.02 (m, 2H), 7.54 (s, 1H), 7.44 (s,



yl)-5-methyl-pyridine-3-carboxylic



1H), 7.38-7.30 (m, 4H), 7.27-7.21 (m,



acid amide



1H), 3.67 (s, 2H), 2.37-2.26 (m, 5H),







2.05-1.75 (m, 10H), 1.51 (t, 2H).


SC_3362
cis-6-(8-Dimethylamino-2-oxo-8-
SC_3359

SC_3016
1H NMR (600 MHz, DMSO) δ
412.2



phenyl-1,3-diazaspiro[4.5]decan-3-



8.65-8.61 (m, 1H), 8.13 (s, 1H), 8.04 (dd, 1H), 7.76 (s,



yl)-5-fluoro-pyridine-3-carboxylic



1H), 7.59 (s, 1H), 7.39-7.30 (m, 4H),



acid amide



7.28-7.21 (m, 1H), 3.70 (s, 2H), 2.41-2.23 (m,







2H), 1.96-1.76 (m, 10H), 1.50 (t, 2H).


SC_3363
cis-8-Dimethylamino-3-[4-methyl-
INT-
5-bromo-4-methyl-2-
SC_3319
1H NMR (600 MHz, DMSO) δ 8.56 (s, 1H),
447.2



6-(trifluoromethyl)-pyridin-3-yl]-8-
1038
(trifluoromethyl)pyridine

7.80 (s, 1H), 7.52 (s, 1H), 7.24 (t, 1H),



m-tolyl-1,3-diazaspiro[4.5]decan-2-



7.17-7.11 (m, 2H), 7.06 (d, 1H), 3.60 (s, 2H),



one



2.39-2.25 (m, 8H), 2.01-1.78 (m, 10H),







1.58-1.48 (m, 2H).


SC_3364
cis-3-(8-Dimethylamino-2-oxo-8-
INT-976
3-bromopyridine-4-
SC_3242
1H NMR (600 MHz, DMSO) δ 8.79 (s, 1H),
376.2



phenyl-1,3-diazaspiro[4.5]decan-3-

carbonitrile

8.50 (d, 1H), 7.84-7.80 (m, 1H), 7.37 (td,



yl)-isonicotinonitrile



4H), 7.26 (td, 1H), 3.79 (s, 2H),







2.43-2.36 (m, 2H), 1.97 (s, 7H), 1.96-1.91 (m, 2H),







1.88-1.81 (m, 2H), 1.61-1.45 (m, 2H).


SC_3365
cis-8-Dimethylamino-3-[3-fluoro-
INT-
4-(4,4,5,5-
SC_3354
1H NMR (600 MHz, DMSO) δ 10.51 (s,
500.2



5-(2-oxo-1,3-dihydro-indol-4-yl)-
1045
tetramethyl-1,3,2-

1H), 8.39 (d, 1H), 7.96 (dd, 1H),



pyridin-2-yl]-8-phenyl-1,3-

dioxaborolan-2-

7.41-7.32 (m, 4H), 7.28 (dt, 2H), 7.08 (d, 1H), 6.88 (d,



diazaspiro[4.5]decan-2-one

yl)indolin-2-one (step

1H), 3.71 (s, 2H), 3.67 (s, 2H),





2)

2.44-2.22 (m, 2H), 1.98-1.87 (m, 11H),







1.58-1.46 (m, 2H).


SC_3366
cis-8-Dimethylamino-3-[4-methyl-
INT-
5-bromo-4-methyl-2-
SC_3319
1H NMR (600 MHz, DMSO) δ 8.55 (s, 1H),
517.2



6-(trifluoromethyl)-pyridin-3-yl]-8-
1039
(trifluoromethyl)pyridine

7.79 (s, 1H), 7.51 (t, 2H), 7.38 (dd, 1H),



[3-(trifluoromethyloxy)-phenyl]-



7.26 (d, 2H), 3.62 (s, 2H), 2.40-2.34 (m, 2H),



1,3-diazaspiro[4.5]decan-2-one



2.31 (s, 3H), 2.01-1.77 (m, 10H),







1.58-1.49 (m, 2H).


SC_3367
cis-8-Dimethylamino-3-[4-methyl-
INT-
5-bromo-4-methyl-2-
SC_3319
1H NMR (600 MHz, DMSO) δ 8.55 (s, 1H),
501.2



6-(trifluoromethyl)-pyridin-3-yl]-8-
1040
(trifluoromethyl)pyridine

7.79 (s, 1H), 7.69-7.56 (m, 5H), 7.52 (s,



[3-(trifluoromethyl)phenyl]-1,3-



1H), 3.61 (s, 2H), 2.44-2.36 (m, 2H),



diazaspiro[4.5]decan-2-one



2.31 (s, 3H), 2.02-1.80 (m, 10H),







1.60-1.47 (m, 2H).


SC_3368
cis-8-Dimethylamino-8-(3-
INT-
5-bromo-4-methyl-2-
SC_3319
1H NMR (600 MHz, DMSO) δ 8.56 (s, 1H),
463.2



methoxyphenyl)-3-[4-methyl-6-
1041
(trifluoromethyl)pyridine

7.80 (s, 1H), 7.51 (s, 1H), 7.31-7.25 (m,



(trifluoromethyl)-pyridin-3-yl]-1,3-



1H), 6.92 (dt, 1H), 6.87-6.82 (m, 2H),



diazaspiro[4.5]decan-2-one



3.75 (s, 3H), 3.61 (s, 2H), 2.35-2.30 (m, 5H),







1.98 (s, 7H), 1.96-1.90 (m, 2H),







1.88-1.80 (m, 2H), 1.60-1.49 (m, 2H).


SC_3369
cis-8-(5-Chloro-thiophen-2-yl)-8-
INT-
5-bromo-4-methyl-2-
SC_3319
1H NMR (600 MHz, DMSO) δ 8.56 (s, 1H),
473.1



dimethylamino-3-[4-methyl-6-
1042
(trifluoromethyl)pyridine

7.79 (s, 1H), 7.39 (s, 1H), 7.04-7.00 (m,



(trifluoromethyl)-pyridin-3-yl]-1,3-



1H), 6.80 (d, 1H), 3.64 (s, 2H), 2.31 (s, 3H),



diazaspiro[4.5]decan-2-one



2.22-2.15 (m, 2H), 2.04 (s, 6H),







1.95-1.87 (m, 2H), 1.83-1.77 (m, 2H),







1.63-1.57 (m, 2H).


SC_3370
cis-8-Dimethylamino-8-(3-
INT-
5-bromo-4-methyl-2-
SC_3319
1H NMR (600 MHz, DMSO) δ 8.56 (s, 1H),
451.2



fluorophenyl)-3-[4-methyl-6-
1024
(trifluoromethyl)pyridine

7.80 (s, 1H), 7.51 (s, 1H), 7.41 (td, 1H),



(trifluoromethyl)-pyridin-3-yl]-1,3-



7.21-7.12 (m, 2H), 7.12-7.06 (m, 1H), 3.61 (s,



diazaspiro[4.5]decan-2-one



2H), 2.38-2.30 (m, 5H), 1.97 (s, 6H),







1.96-1.90 (m, 2H), 1.90-1.73 (m, 2H),







1.61-1.45 (m, 2H).


SC_3371
cis-8-Dimethylamino-3-(2-
INT-989
methylamine
SC_3239
1H NMR (600 MHz, DMSO + TFA) δ
381.2



methylamino-pyrimidin-5-yl)-8-



8.69 (s, 2H), 8.29 (s, 1H), 7.68 (d, 2H), 7.52 (dt,



phenyl-1,3-diazaspiro[4.5]decan-2-



3H), 2.90 (s, 3H), 2.68 (d, 2H), 2.59 (s, 6H),



one



2.24 (t, 2H), 1.86 (d, 2H), 1.39-1.31 (m,







2H)


SC_3372
cis-8-(5-Chloro-thiophen-2-yl)-8-
INT-
4-(5-bromo-4-methyl-
SC_3242
1H NMR (600 MHz, DMSO) δ 8.15 (d, 1H),
491.2



dimethylamino-3-(4-methyl-2-
1042
pyrimidin-2-

7.15 (s, 1H), 7.05 (d, 1H), 6.82 (d, 1H),



morpholin-4-yl-pyrimidin-5-yl)-

yl)morpholine

3.70-3.61 (m, 8H), 3.44 (s, 2H), 2.31-2.12 (m,



1,3-diazaspiro[4.5]decan-2-one



5H), 2.06 (s, 6H), 1.93-1.85 (m, 2H),







1.82-1.69 (m, 2H), 1.64-1.49 (m, 2H).


SC_3373
cis-N-[5-(8-Dimethylamino-2-oxo-
SC_3371
Cyclopropancarbonyl
SC_3240
1H NMR (600 MHz, DMSO) δ 8.97 (s, 2H),
449.3



8-phenyl-1,3-diazaspiro[4.5]decan-

chlorid

7.83-7.73 (m, 1H), 7.41-7.34 (m, 4H),



3-yl)-pyrimidin-2-yl]-N-methyl-



7.30-7.24 (m, 1H), 3.66 (s, 2H), 3.27 (s,



cyclopropanecarboxylic acid amide



3H), 2.47-2.29 (m, 2H), 1.99-1.87 (m,







10H), 1.49 (t, 2H), 0.88-0.80 (m, 2H),







0.70 (dt, 2H).


SC_3374
cis-N-[5-(8-Dimethylamino-2-oxo-
SC_3371
2,5-dimethylpyrazole-
SC_3240
1H NMR (600 MHz, DMSO) δ 8.83 (s, 2H),
503.3



8-phenyl-1,3-diazaspiro[4.5]decan-

3-carbonyl chloride

7.77 (s, 1H), 7.41-7.32 (m, 4H), 7.27 (td,



3-yl)-pyrimidin-2-yl]-N,2,5-



1H), 5.48 (s, 1H), 3.80 (s, 3H), 3.61 (s, 2H),



trimethyl-2H-pyrazole-3-carboxylic



3.40 (s, 3H), 2.46-2.31 (m, 2H), 1.96 (s,



acid amide



3H), 1.96 (s, 6H), 1.94-1.74 (m, 5H),







1.52-1.42 (m, 2H).


SC_3375
cis-3-[4,6-Bis(trifluoromethyl)-
INT-976
5-bromo-2,4-
SC_3103
1H NMR (600 MHz, DMSO) δ 8.98 (s, 1H),
487.2



pyridin-3-yl]-8-dimethylamino-8-

bis(trifluoromethyl)pyridine

8.20 (s, 1H), 7.79 (s, 1H), 7.40-7.32 (m,



phenyl-1,3-diazaspiro[4.5]decan-2-



4H), 7.26 (td, 1H), 3.62 (s, 2H),



one



2.44-2.24 (m, 2H), 1.98-1.91 (m, 8H), 1.86 (s, 2H),







1.53 (t, 2H).


SC_3376
cis-8-Dimethylamino-3-[2-[(2-
INT-976
2-[(6-bromo-
SC_3242
1HNMR at 100° C. (DMSO-d6, 400 MHz), δ
475.1



hydroxy-ethyl)-methyl-amino]-

quinazolin-2-yl)-

(ppm) = 8.99 (s, 1H), 8.28 (d, 1H, J = 9.24 Hz),



quinazolin-6-yl]-8-phenyl-1,3-

methyl-amino]-

7.63 (s, 1H), 7.43-7.26 (m, 6H),



diazaspiro[4.5]decan-2-one

ethanol

7.13 (s, 1H), 4.31 (bs, 1H), 3.78-3.76 (m, 2H),







3.66 (bs, 4H), 3.24 (s, 3H), 2.43-2.38 (m,







2H), 2.05-1.90 (m, 10H), 1.56-1.54 (m, 2H).


SC_3377
cis-8-Dimethylamino-3-(2-
INT-976
6-bromo-2-
SC_3242
1HNMR at 100° C. (DMSO-d6, 400 MHz), δ
487.2



morpholin-4-yl-quinazolin-6-yl)-8-

morpholin-4-yl-

(ppm) = 9.05 (s, 1H), 8.34 (d, 1H), 7.68 (s,



phenyl-1,3-diazaspiro[4.5]decan-2-

quinazoline

1H), 7.48 (d, 1H, J = 9.4 Hz), 7.38-7.27 (m,



one



5H), 7.18 (s, 1H), 3.81-3.67 (m, 10H),







2.40-2.38 (m, 2H), 2.05-1.90 (m, 10H),







1.57-1.54 (m, 2H).


SC_3378
cis-8-[Methyl-(oxetan-3-yl-
INT-
2-trifluoromethyl-5-
SC_3103
1H NMR (DMSO-d6): δ 9.21-9.15 (s, 2H),
476.2



methyl)-amino]-8-phenyl-3-[2-
1047
bromopyrimidine

8.19-8.18 (broad s, 1H), 7.41-7.34 (m, 4H),



(trifluoromethyl)-pyrimidin-5-yl]-



7.27-7.25 (m, 1H), 4.58-4.56 (m, 2H),



1,3-diazaspiro[4.5]decan-2-one



4.18 (s, 1H), 3.69 (s, 2H), 3.05-2.99 (m, 1H),







2.41-2.36 (m, 4H), 1.91 (m, 7H), 1.47 (s,







2H).


SC_3380
cis-8-Dimethylamino-8-phenyl-3-
INT-976
6-bromo-quinazoline
SC_3103
1HNMR at 100° C. (DMSO-d6, 400 MHz), δ
402.2



quinazolin-6-yl-1,3-



(ppm) = 9.35 (s, 1H), 9.10 (s, 1H), 8.65 (d, 1H,



diazaspiro[4.5]decan-2-one



J = 9.04) 7.91-7.89 (m, 2H), 7.39-7.27 (m,







5H), 3.75 (s, 2H), 2.42-2.32 (m, 2H), 2.05 (s,







6H), 2.00-1.92 (m, 4H), 1.56 (bs, 2H).


SC_3381
cis-5-(8-Dimethylamino-2-oxo-8-
INT-976
5-bromo-2-chloro-
SC_3103 (for
1H NMR (600 MHz, DMSO) δ 8.88 (s, 1H),
507.3



phenyl-1,3-diazaspiro[4.5]decan-3-

pyridine-4-
step 1),
8.24 (s, 1H), 7.85 (s, 1H), 7.52-7.46 (m,



yl)-2-(2-oxo-1,3-dihydro-indol-4-

carbonitrile
SC_3129 (for
1H), 7.41-7.29 (m, 6H), 7.27 (td, 1H),



yl)-isonicotinonitrile

(step 1), 4-(4,4,5,5-
step 2)
6.92 (d, 1H), 3.84 (s, 2H), 3.78 (s, 2H),





tetramethyl-1,3,2-

2.48-2.30 (m, 2H), 1.99-1.93 (m, 8H),





dioxaborolan-2-

1.92-1.74 (m, 2H), 1.58-1.54 (m, 2H).





yl)indolin-2-one





(step 2)


SC_3382
cis-N-[5-(8-Dimethylamino-2-oxo-
SC_3371
tetrahydropyran-4-
SC_3240
1H NMR (600 MHz, DMSO) δ 8.97 (s, 2H),
493.3



8-phenyl-1,3-diazaspiro[4.5]decan-

carbonyl chloride

7.80 (s, 1H), 7.42-7.34 (m, 4H),



3-yl)-pyrimidin-2-yl]-N-methyl-



7.31-7.25 (m, 1H), 3.79 (ddd, 2H), 3.67 (s, 2H),



tetrahydro-pyran-4-carboxylic acid



3.25 (s, 2H), 3.17 (td, 2H), 3.04-2.96 (m,



amide



1H), 2.49-2.34 (m, 2H), 1.97 (s, 6H),







1.95-1.74 (m, 4H), 1.68-1.53 (m, 4H),







1.54-1.48 (m, 2H).


SC_3383
cis-N-[5-(8-Dimethylamino-2-oxo-
SC_3371
pivaloyl chloride
SC_3240
1H NMR (600 MHz, DMSO) δ 8.98 (s, 2H),
465.3



8-phenyl-1,3-diazaspiro[4.5]decan-



7.42-7.34 (m, 4H), 7.30-7.26 (m, 1H),



3-yl)-pyrimidin-2-yl]-N,2,2-



3.69 (s, 2H), 3.14 (s, 3H), 2.46-2.41 (m,



trimethyl-propionamide



2H), 1.99-1.87 (m, 10H), 1.54-1.45 (m,







2H), 0.97 (s, 9H).


SC_3384
cis-8-Dimethylamino-3-[2-(1-
INT-989
1-methyl-4-(4,4,5,5-
SC_3208
1H NMR (600 MHz, CDCl3) δ 9.05 (s, 2H),
497.3



methyl-2-oxo-1,3-dihydro-indol-4-

tetramethyl-1,3,2-

8.08 (d, 1H), 7.47-7.39 (m, 3H),



yl)-pyrimidin-5-yl]-8-phenyl-1,3-

dioxaborolan-2-

7.38-7.31 (m, 3H), 6.91 (d, 1H), 5.46 (s, 1H),



diazaspiro[4.5]decan-2-one

yl)indolin-2-one

4.04 (s, 2H), 3.64 (s, 2H), 3.27 (s, 3H),







2.35-2.14 (m, 4H), 2.10 (s, 6H), 2.08-2.01 (m,







3H), 1.73-1.64 (m, 2H), 1.28 (s, 0H).


SC_3385
cis-8-Dimethylamino-3-(2-
INT-976
6-bromo-1-(tert-
SC_3242 (for
1HNMR at 100° C. (DMSO-d6, 400 MHz), δ
475.2



morpholin-4-yl-1H-benzoimidazol-

butylsilanyl-
step 1), step 2
(ppm) = 10.94 (bs, 1H), 7.50 (bs, 1H),



5-yl)-8-phenyl-1,3-

methoxymethyl)-2-
of SC_3352
7.39-7.27 (m, 5H), 7.06 (m, 2 H), 6.84 (bs, 1H),



diazaspiro[4.5]decan-2-one

morpholin-4-yl-1H-
(for step 2)
3.72 (t, 4H, 4.56 Hz), 3.55 (s, 2H), 3.45 (t,





benzoimidazole (step

4H, 4.56 Hz), 2.372.24 (m, 2H),





1)

1.95-1.81 (m, 10H), 1.52-1.50 (m, 2H)


SC_3386
cis-8-Dimethylamino-8-(3-fluoro-
INT-
5-bromo-4-methyl-2-
SC_3319
1H NMR (600 MHz, DMSO) δ 8.57 (s, 1H),
465.2



5-methyl-phenyl)-3-[4-methyl-6-
1043
(trifluoromethyl)pyridine

7.80 (s, 1H), 7.51 (s, 1H), 6.99 (s, 1H),



(trifluoromethyl)-pyridin-3-yl]-1,3-



6.96-6.89 (m, 2H), 3.61 (s, 2H), 2.34 (s, 3H),



diazaspiro[4.5]decan-2-one



2.32 (s, 3H), 2.07 (s, 1H), 1.97 (s, 6H),







1.96-1.89 (m, 2H), 1.88-1.78 (m, 2H), 1.54 (d,







2H).


SC_3387
cis-8-Dimethylamino-3-[6-(2-oxo-
INT-
4-(4,4,5,5-
SC_3129
1H NMR (600 MHz, DMSO) δ 8.83 (d, 1H),
482.3



1,3-dihydro-indol-4-yl)-pyridin-3-
1048
tetramethyl-1,3,2-

8.11 (dd, 1H), 7.77 (d, 1H), 7.64 (s, 1H),



yl]-8-phenyl-1,3-

dioxaborolan-2-

7.43-7.34 (m, 5H), 7.31-7.24 (m, 2H),



diazaspiro[4.5]decan-2-one

yl)indolin-2-one

6.84 (d, 1H), 3.73 (s, 2H), 3.68 (s, 2H),







2.45-2.31 (m, 2H), 1.99-1.79 (m, 10H),







1.51 (t, 2H).


SC_3389
cis-3-[6-(Azetidin-1-yl)-5-
INT-976
5-bromo-2-chloro-3-
SC_3103 (for
1H NMR (600 MHz, DMSO) δ 8.40 (d, 1H),
453.2



(trifluoromethyl)-pyridin-3-yl]-8-

(trifluoromethyl)pyridine
step 1),
8.21 (d, 1H), 7.47 (s, 1H), 7.41-7.33 (m,



dimethylamino-8-phenyl-1,3-

(step 1), azetidine
SC_3120 (for
4H), 7.30-7.24 (m, 1H), 4.03 (t, 4H),



diazaspiro[4.5]decan-2-one

(step 2)
step 2, 160° C.)
3.58 (s, 2H), 2.47-2.29 (m, 2H), 2.25 (p, 2H),







1.96 (s, 6H), 1.89 (s, 4H), 1.47 (t, 2H).


SC_3390
cis-3-[1-(Cyclopropyl-methyl)-8-
SC_3364
bromomethylcyclopropane
INT-952
1H NMR (600 MHz, DMSO) δ 8.82 (s, 1H),
430.3



dimethylamino-2-oxo-8-phenyl-



8.51 (dd, 1H), 7.81 (d, 1H), 7.40-7.33 (m,



1,3-diazaspiro[4.5]decan-3-yl]-



4H), 7.29-7.23 (m, 1H), 3.93 (s, 2H),



isonicotinonitrile



3.10 (d, 2H), 2.76-2.70 (m, 2H), 2.29 (ddd, 2H),







2.02 (s, 6H), 1.58 (d, 2H), 1.52-1.44 (m,







2H), 1.01 (ddt, 1H), 0.55-0.49 (m, 2H),







0.37-0.31 (m, 2H).


SC_3391
cis-3-[3,5-Bis(trifluoromethyl)-
INT-976
2-chloro-3,5-
SC_3103
1H NMR (600 MHz, DMSO) δ 9.04 (d, 1H),
487.2



pyridin-2-yl]-8-dimethylamino-8-

bis(trifluoromethyl)pyridine

8.58 (d, 1H), 7.96 (s, 1H), 7.41-7.32 (m,



phenyl-1,3-diazaspiro[4.5]decan-2-



4H), 7.29-7.23 (m, 1H), 3.75 (s, 2H),



one



2.41-2.25 (m, 2H), 1.98-1.89 (m, 10H),







1.52 (t, 2H).


SC_3392
cis-8-Dimethylamino-3-(5-fluoro-
INT-976
4-(5-bromo-3-fluoro-
SC_3103
1H NMR (600 MHz, CDCl3) δ 8.13 (dd,
454.3



6-morpholin-4-yl-pyridin-3-yl)-8-

2-pyridyl)morpholine

1H), 7.76 (d, 1H), 7.42 (t, 2H), 7.33 (dd,



phenyl-1,3-diazaspiro[4.5]decan-2-



3H), 5.84 (s, 1H), 3.84 (t, 4H), 3.52 (s, 2H),



one



3.37 (t, 4H), 2.29-2.12 (m, 4H), 2.08 (s,







6H), 2.01-1.94 (m, 2H), 1.60 (t, 2H).


SC_3393
cis-8-(3-Chlorophenyl)-8-
INT-
5-bromo-4-methyl-2-
SC_3319
1H NMR (600 MHz, DMSO) δ 8.57 (s, 1H),
467.2



dimethylamino-3-[4-methyl-6-
1044
(trifluoromethyl)pyridine

7.80 (s, 1H), 7.55-7.49 (m, 1H),



(trifluoromethyl)-pyridin-3-yl]-1,3-



7.43-7.37 (m, 1H), 7.38-7.29 (m, 3H), 3.61 (s,



diazaspiro[4.5]decan-2-one



2H), 2.40-2.24 (m, 5H), 1.99-1.90 (m,







8H), 1.90-1.76 (m, 2H), 1.60-1.47 (m,







2H).


SC_3394
cis-8-Dimethylamino-3-[5-(2-oxo-
INT-
4-(4,4,5,5-
SC_3354
1H NMR (600 MHz, DMSO) δ 8.41 (d, 1H),
482.3



1,3-dihydro-indol-4-yl)-pyridin-2-
1049
tetramethyl-1,3,2-

8.26 (d, 1H), 7.92 (dd, 1H), 7.75 (s, 1H),



yl]-8-phenyl-1,3-

dioxaborolan-2-

7.41-7.32 (m, 5H), 7.30-7.23 (m, 2H),



diazaspiro[4.5]decan-2-one

yl)indolin-2-one

7.01 (d, 1H), 6.83 (d, 1H), 3.75 (s, 2H),







3.61 (s, 2H), 2.46-2.30 (m, 2H), 1.96 (s, 6H),







1.94-1.88 (m, 2H), 1.86-1.82 (m, 2H),







1.48 (t, 2H).


SC_3395
cis-8-Dimethylamino-8-phenyl-3-
INT-976
2-bromo-5-
SC_3103
1H NMR (600 MHz, DMSO) δ 8.69 (s, 1H),
426.2



[5-(trifluoromethyl)-

(trifluoromethyl)-

7.42-7.34 (m, 4H), 7.28 (t, 1H), 3.89 (s,



[1,3,4]thiadiazol-2-yl]-1,3-

1,3,4-thiadiazole

2H), 2.45-2.31 (m, 2H), 2.07-1.88 (m,



diazaspiro[4.5]decan-2-one



8H), 1.88-1.84 (m, 2H), 1.60-1.53 (m,







2H).


SC_3397
cis-8-Dimethylamino-3-[2-[(2-
INT-976
2-{[6-bromo-1-(2-
SC_3242 (for
1HNMR (DMSO-d6, 400 MHz at 100° C.), δ
463.3



hydroxy-ethyl)-methyl-amino]-1H-

trimethylsilanyl-
step 1), step 2
(ppm) = 10.62 (bs, 1H), 7.48-7.24 (m, 6H),



benzoimidazol-5-yl]-8-phenyl-1,3-

ethoxymethyl)-1H-
of SC_3352
7.01-6.91 (m, 2H,), 6.76 (s, 1H), 4.58 (bs,



diazaspiro[4.5]decan-2-one

benzoimidazol-2-yl]-
(for step 2)
1H), 3.66 (t, 2H, J = 5.62 Hz), 3.54-3.50 (m,





methyl-amino}-

4H), 3.09 (s, 3H), 2.37-2.32 (m, 2H), 2.04 (s,





ethanol (step 1)

6H), 1.96-1.91 (m, 4H), 1.52-1.40 (m, 2H).


SC_3398
cis-8-Dimethylamino-3-(5-methyl-
INT-976
4-(5-bromo-3-methyl-
SC_3103
1H NMR (600 MHz, DMSO) δ 8.23 (s, 1H),
450.3



6-morpholin-4-yl-pyridin-3-yl)-8-

2-pyridyl)morpholine

7.83 (s, 1H), 7.46-7.33 (m, 5H),



phenyl-1,3-diazaspiro[4.5]decan-2-



7.30-7.24 (m, 1H), 3.71 (t, 4H), 3.55 (s, 2H),



one



2.93 (t, 4H), 2.41-2.37 (m, 2H), 1.96 (s, 6H),







1.91-1.82 (m, 4H), 1.49-1.44 (m, 2H).


SC_3399
cis-1-(Cyclopropyl-methyl)-8-
SC_3409
bromomethylcyclopropane
SC_3105
1HNMR (DMSO-d6, 400 MHz), δ (ppm) = 8.68-8.68 (d,
501.4



dimethylamino-8-(3-fluorophenyl)-



1H, J = 2.32 Hz), 8.42-8.40 (d,



3-(5-methylsulfonyl-pyridin-2-yl)-



1H, J = 9.04 Hz), 8.18-8.15 (m, 1H),



1,3-diazaspiro[4.5]decan-2-one



7.44-7.38 (m, 1H), 7.20-7.08 (m, 3H), 3.90 (s,







2H), 3.22 (s, 3H), 3.11-3.10 (d, 2H, J = 6.68 Hz),







2.71-2.68 (d, 2H, J = 13.6 Hz),







2.27-2.21 (m, 2H), 2.00 (s, 6H), 1.53-1.44 (m,







4H), 1.02-0.99 (m, 1H), 0.54-0.50 (m, 2H),







0.36-0.35 (m, 2H).


SC_3400
cis-1-(Cyclopropyl-methyl)-8-(3-
SC_3399

SC_3099
1HNMR (DMSO-d6, 400 MHz), δ (ppm) = 8.72-8.71 (d,
487.2



fluorophenyl)-8-methylamino-3-(5-



1H, J = 2.28 Hz), 8.42-8.40 (d,



methylsulfonyl-pyridin-2-yl)-1,3-



1H, J = 9.04 Hz), 8.18-8.15 (m, 1H),



diazaspiro[4.5]decan-2-one



7.40-7.31 (m, 3H), 7.05-7.01 (m, 1H), 3.93 (s,







2H), 3.23 (s, 3H), 3.14-3.13 (d, 2H, J = 6.76 Hz),







2.42 (bs, 1H), 2.28-2.23 (m, 2H),







1.96-1.88 (m, 5H), 1.79-1.73 (m, 2H),







1.44-1.41 (d, 2H, J = 12.2 Hz), 1.06-1.02 (m, 1H),







0.52-0.47 (m, 2H), 0.36-0.33 (m, 2H).


SC_3401
cis-1-(Cyclobutyl-methyl)-8-(3-
SC_3404
bromomethylcyclobutane
SC_3105 (for
1HNMR at 100° C. (DMSO-d6, 400 MHz), δ
492.1



fluorophenyl)-8-methylamino-3-[2-

(step 1)
step 1),
(ppm) = 9.23 (s, 2H), 7.38-7.26 (m, 3H),



(trifluoromethyl)-pyrimidin-5-yl]-


SC_3099 (for
7.00 (t, 1H, J = 8.1 Hz), 3.86 (s, 2H),



1,3-diazaspiro[4.5]decan-2-one


step 2)
3.30-3.28 (d, 2H, J = 7.24 Hz), 2.68-2.65 (m, 1H),







2.27-2.16 (m, 3H), 2.06-1.78 (m, 13H),







1.46-1.43 (m, 2H).


SC_3402
cis-1-(Cyclopropyl-methyl)-8-
SC_3404
bromomethylcyclopropane
SC_3105
1HNMR (DMSO-d6, 400 MHz), δ (ppm) = 9.21 (s,
492.0



dimethylamino-8-(3-fluorophenyl)-



2H), 7.45-7.39 (m, 1H),



3-[2-(trifluoromethyl)-pyrimidin-5-



7.22-7.18 (m, 2H), 7.14-7.09 (m, 1H), 3.84 (s, 2H),



yl]-1,3-diazaspiro[4.5]decan-2-one



3.09 (d, 2H, J = 6.4 Hz), 2.70 (d, 2H, J = 9.6 Hz),







2.32-2.21 (m, 2H), 2.01 (s, 6H),







1.59-1.46 (m, 4H), 1.01-1.00 (m, 1H),







0.54-0.49 (m, 2H), 0.35-0.33 (m, 2H).


SC_3403
cis-1-(Cyclopropyl-methyl)-8-(3-
SC_3402

SC_3099
1HNMR (DMSO-d6, 400 MHz), δ (ppm) = 9.25 (s,
478.4



fluorophenyl)-8-methylamino-3-[2-



2H), 7.41-7.30 (m, 3H), 7.04 (t, 1H,



(trifluoromethyl)-pyrimidin-5-yl]-



J = 6.8 Hz),



1,3-diazaspiro[4.5]decan-2-one



3.89 (s, 2H), 3.12 (d, 2H, J = 6.8 Hz),







2.41 (bs, 1H), 2.27-2.22 (m, 2H), 1.93-1.78 (m,







7H), 1.46-1.43 (m, 2H), 1.08-1.03 (m,







1H), 0.51-0.47 (m, 2H), 0.33-0.29 (m, 2H).


SC_3404
cis-8-Dimethylamino-8-(3-
INT-
2-trifluoromethyl-5-
SC_3242
1HNMR at 100° C. (DMSO-d6, 400 MHz), δ
437.9



fluorophenyl)-3-[2-
1024
bromopyrimidine

(ppm) = 9.15 (s, 2H), 7.75 (s, 1H),



(trifluoromethyl)-pyrimidin-5-yl]-



7.44-7.38 (m, 1H), 7.21-7.04 (m, 3H), 3.73 (s, 2H),



1,3-diazaspiro[4.5]decan-2-one



2.38-2.37 (m, 2H), 2.05 (s, 6H),







2.01-1.85 (m, 4H), 1.57-1.53 (m, 2H).


SC_3405
cis-1-(Cyclopropyl-methyl)-8-
SC_3319
bromomethylcyclopropane
SC_3105
1HNMR at 100° C. (DMSO-d6, 400 MHz), δ
494.3



dimethylamino-8-(3-fluorophenyl)-



(ppm) = 7.39-7.36 (m, 1H), 7.19-7.05 (m,



3-[2-methyl-5-(trifluoromethyl)-



3H), 6.56 (s, 1H), 3.78-3.67 (m, 5H),



2H-pyrazol-3-yl]-1,3-



3.10-3.08 (d, 2H, J = 6.12 Hz), 2.64-2.60 (d, 2H, J = 13.32 Hz),



diazaspiro[4.5]decan-2-one



2.37-2.26 (m, 2H), 2.09 (s, 6H),







1.61-1.49 (m, 4H), 1.10-1.02 (m, 1H),







0.54-0.52 (m, 2H), 0.36-0.33 (m, 2H).


SC_3406
cis-1-(Cyclopropyl-methyl)-8-(3-
SC_3405

SC_3099
1HNMR at 100° C. (DMSO-d6, 400 MHz), δ
480.0



fluorophenyl)-8-methylamino-3-[2-



(ppm) = 7.39-7.24 (m, 3H), 6.99-6.96 (m,



methyl-5-(trifluoromethyl)-2H-



1H), 6.58 (s, 1H), 3.78-3.71 (m, 5H),



pyrazol-3-yl]-1,3-



3.11-3.10 (d, 2H, J = 5.40 Hz), 2.30-2.23 (m, 2H),



diazaspiro[4.5]decan-2-one



1.99-1.92 (m, 5H), 1.79-1.72 (m, 2H),







1.58-1.56 (m, 2H), 1.10-1.00 (m, 1H),







0.54-0.52 (m, 2H), 0.36-0.33 (m, 2H).


SC_3407
cis-8-Methylamino-3-(4-methyl-2-
SC_3148

SC_3099

437.3



morpholin-4-yl-pyrimidin-5-yl)-8-



phenyl-1,3-diazaspiro[4.5]decan-2-



one


SC_3408
cis-3-[5-(Azetidin-1-yl)-3-methyl-
INT-
5-(azetidin-1-yl)-2-
SC_3103
1H NMR (600 MHz, DMSO) δ
438.3



pyridin-2-yl]-8-dimethylamino-8-
1024
chloro-3-methyl-

7.44-7.36 (m, 2H), 7.20-7.05 (m, 4H), 6.69 (d, 1H),



(3-fluorophenyl)-1,3-

pyridine

3.82 (t, 4H), 3.51 (s, 2H), 2.36-2.26 (m,



diazaspiro[4.5]decan-2-one



4H), 2.15 (s, 3H), 1.96 (s, 6H),







1.94-1.76 (m, 4H), 1.49 (t, 2H).


SC_3409
cis-8-Dimethylamino-8-(3-
INT-
2-bromo-5-
SC_3103
1H NMR (600 MHz, DMSO) δ 8.67 (dd,
447.2



fluorophenyl)-3-(5-methylsulfonyl-
1024
methylsulfonyl-

1H), 8.39 (dd, 1H), 8.14 (dd, 1H), 8.04 (s,



pyridin-2-yl)-1,3-

pyridine

1H), 7.42 (td, 1H), 7.19 (d, 1H), 7.15 (dt,



diazaspiro[4.5]decan-2-one



1H), 7.11 (td, 1H), 3.78 (s, 2H), 3.21 (s, 3H),







2.41-2.37 (m, 2H), 1.97 (s, 6H),







1.94-1.75 (m, 4H), 1.54-1.45 (m, 2H).


SC_3410
cis-3-(6-(azetidin-1-yl)-4-
INT-976
2-(azetidin-1-yl)-5-
SC_3103



fluoropyridin-3-yl)-8-

bromo-4-



(dimethylamino)-8-phenyl-1,3-

fluoropyridine



diazaspiro[4.5]decan-2-one


SC_3411
cis-3-(6-(azetidin-1-yl)pyridin-3-
INT-
2-(azetidin-1-yl)-5-
SC_3103



yl)-8-(dimethylamino)-8-(3-
1024
bromopyridine



fluorophenyl)-1,3-



diazaspiro[4.5]decan-2-one


SC_3412
cis-3-(1-(cyclopropanecarbonyl)-3-
INT-
(5-bromo-3-
SC_3103



(trifluoromethyl)-1H-pyrazol-5-yl)-
1024
(trifluoromethyl)-1H-



8-(dimethylamino)-8-(3-

pyrazol-1-



fluorophenyl)-1,3-

yl)(cyclopropyl)methanone



diazaspiro[4.5]decan-2-one


SC_3413
cis-8-(dimethylamino)-8-(3-
INT-
2-(5-bromo-3-
SC_3242



fluorophenyl)-3-(1-(2-
1024
(trifluoromethyl)-1H-



hydroxyethyl)-3-(trifluoromethyl)-

pyrazol-1-yl)ethanol



1H-pyrazol-5-yl)-1,3-



diazaspiro[4.5]decan-2-one


SC_3414
cis-3-(1-(cyclopropylmethyl)-3-
INT-
5-bromo-1-
SC_3242

480.2



(trifluoromethyl)-1H-pyrazol-5-yl)-
1024
(cyclopropylmethyl)-



8-(dimethylamino)-8-(3-

3-(trifluoromethyl)-



fluorophenyl)-1,3-

1H-pyrazole



diazaspiro[4.5]decan-2-one


SC_3415
cis-8-(dimethylamino)-8-(3-
INT-
5-bromo-1-
SC_3242



fluorophenyl)-3-(1-
1024
(methylsulfonyl)-3-



(methylsulfonyl)-3-

(trifluoromethyl)-1H-



(trifluoromethyl)-1H-pyrazol-5-yl)-

pyrazole



1,3-diazaspiro[4.5]decan-2-one


SC_3416
cis-1-(cyclopropylmethyl)-8-
SC_3415
bromomethylcyclopropane
SC_3105



(dimethylamino)-8-(3-



fluorophenyl)-3-(1-



(methylsulfonyl)-3-



(trifluoromethyl)-1H-pyrazol-5-yl)-



1,3-diazaspiro[4.5]decan-2-one


SC_3417
cis-2-(5-(8-(dimethylamino)-8-(3-
INT-
2-(5-bromo-3-
SC_3242



fluorophenyl)-2-oxo-1,3-
1024
(trifluoromethyl)-1H-



diazaspiro[4.5]decan-3-yl)-3-

pyrazol-1-yl)-N,N-



(trifluoromethyl)-1H-pyrazol-1-yl)-

dimethylacetamide



N,N-dimethylacetamide


SC_3418
cis-2-(5-(1-(cyclopropylmethyl)-8-
SC_3417
bromomethylcyclopropane
SC_3105



(dimethylamino)-8-(3-



fluorophenyl)-2-oxo-1,3-



diazaspiro[4.5]decan-3-yl)-3-



(trifluoromethyl)-1H-pyrazol-1-yl)-



N,N-dimethylacetamide


SC_3419
cis-8-(dimethylamino)-3-(1-methyl-
INT-976
5-bromo-1-methyl-
SC_3103

404.3



1H-pyrrolo[2,3-b]pyridin-5-yl)-8-

1H-pyrrolo[2,3-



phenyl-1,3-diazaspiro[4.5]decan-2-

b]pyridine



one


SC_3420
cis-8-(dimethylamino)-3-(3-fluoro-
INT-976
5-bromo-3-fluoro-1-
SC_3352

408.2



1H-pyrrolo[2,3-b]pyridin-5-yl)-8-

((2-



phenyl-1,3-diazaspiro[4.5]decan-2-

(trimethylsilyl)ethoxy)methyl)-



one

1H-





pyrrolo[2,3-





b]pyridine (step 1)


SC_3421
cis-8-(dimethylamino)-8-phenyl-3-
INT-976
4-bromo-1-((2-
SC_3352

390.2



(1H-pyrrolo[2,3-c]pyridin-4-yl)-

(trimethylsilyl)ethoxy)methyl)-



1,3-diazaspiro[4.5]decan-2-one

1H-





pyrrolo[2,3-





c]pyridine


SC_3422
cis-8-(dimethylamino)-8-phenyl-3-
INT-989
4-(4,4,5,5-
SC_3354

430.2



(2-(pyridazin-4-yl)pyrimidin-5-yl)-

tetramethyl-1,3,2-



1,3-diazaspiro[4.5]decan-2-one

dioxaborolan-2-





yl)pyridazine


SC_3423
cis-8-(dimethylamino)-3-(2-(2-oxo-
INT-989
(2-oxo-1,2-
SC_3354

445.2



1,2-dihydropyridin-4-yl)pyrimidin-

dihydropyridin-4-



5-yl)-8-phenyl-1,3-

yl)boronic acid



diazaspiro[4.5]decan-2-one


SC_3424
cis-8-(dimethylamino)-8-(3-
INT-
3,5-dibromo-1-
SC_3103 (for



fluorophenyl)-3-(1-methyl-3-
1024
methyl-1H-pyrazole
step 1),



(thiophen-2-yl)-1H-pyrazol-5-yl)-

(step 1), thiophen-2-
SC_3354 (for



1,3-diazaspiro[4.5]decan-2-one

ylboronic acid (step
step 2)





2)


SC_3425
cis-8-(dimethylamino)-8-(3-
INT-
3,5-dibromo-1-
SC_3103 (for



fluorophenyl)-3-(1-methyl-3-
1024
methyl-1H-pyrazole
step 1),



morpholino-1H-pyrazol-5-yl)-1,3-

(step 1), morpholine
SC_3103 (for



diazaspiro[4.5]decan-2-one

(step 2)
step 2)


SC_3426
cis-8-(dimethylamino)-8-phenyl-1-
INT-
2-trifluoromethyl-5-
SC_3103

502.2



(2,2,2-trifluoroethyl)-3-(2-
1068
bromopyrimidine



(trifluoromethyl)pyrimidin-5-yl)-



1,3-diazaspiro[4.5]decan-2-one


SC_3427
cis-8-(dimethylamino)-8-phenyl-3-
INT-
2-trifluoromethyl-5-
SC_3103



(2-(trifluoromethyl)pyrimidin-5-
1070
bromopyrimidine



yl)-1-(3,3,3-trifluoropropyl)-1,3-



diazaspiro[4.5]decan-2-one


SC_3428
cis-3-(4-methyl-6-
SC_3122

SC_3099



(trifluoromethyl)pyridin-3-yl)-8-



(methylamino)-8-phenyl-1,3-



diazaspiro[4.5]decan-2-one


SC_3429
cis-3-(1-methyl-3-
SC_3200

SC_3099



(trifluoromethyl)-1H-pyrazol-5-yl)-



8-(methylamino)-8-phenyl-1,3-



diazaspiro[4.5]decan-2-one


SC_3430
cis-8-(dimethylamino)-8-(3-
INT-
3-bromo-4-
SC_3103



fluorophenyl)-3-(4-
1024
(methylsulfonyl)pyridine



(methylsulfonyl)pyridin-3-yl)-1,3-



diazaspiro[4.5]decan-2-one


SC_3431
cis-8-(dimethylamino)-3-(1-ethyl-
INT-
5-bromo-1-ethyl-3-
SC_3242



3-(trifluoromethyl)-1H-pyrazole-5-
1024
(trifluoromethyl)-1H-



yl)-8-(3-fluorophenyl)-1,3-

pyrazole



diazaspiro[4.5]decan-2-one


SC_3432
cis-3-(1-cyclopropyl-3-
INT-
5-bromo-1-
SC_3242



(trifluoromethyl)-1H-pyrazol-5-yl)-
1024
cyclopropyl-3-



8-(dimethylamino)-8-(3-

(trifluoromethyl)-1H-



fluorophenyl)-1,3-

pyrazole



diazaspiro[4.5]decan-2-one


SC_3433
cis-8-(dimethylamino)-8-(3-
INT-
5-bromo-1-(oxetan-3-
SC_3242



fluorophenyl)-3-(1-(oxetan-3-
1024
ylmethyl)-3-



ylmethyl)-3-(trifluoromethyl)-1H-

(trifluoromethyl)-1H-



pyrazol-5-yl)-1,3-

pyrazole



diazaspiro[4.5]decan-2-one


SC_3434
cis-8-(dimethylamino)-8-(3-
INT-
5-bromo-1-(2-
SC_3242



fluorophenyl)-3-(1-(2-
1024
(methylsulfonyl)ethyl)-



(methylsulfonyl)ethyl)-3-

3-(trifluoromethyl)-



(trifluoromethyl)-1H-pyrazol-5-yl)-

1H-pyrazole



1,3-diazaspiro[4.5]decan-2-one


SC_3435
cis-8-(dimethylamino)-8-(3-
INT-
methylamine
SC_3239



fluorophenyl)-3-(4-methyl-2-
1076



(methylamino)pyrimidin-5-yl)-1,3-



diazaspiro[4.5]decan-2-one


SC_3436
cis-3-(2-cyclopropoxy-4-
INT-
cyclopropanol
SC_3224

440.3



methylpyrimidin-5-yl)-8-
1076



(dimethylamino)-8-(3-



fluorophenyl)-1,3-



diazaspiro[4.5]decan-2-one


SC_3437
cis-N-(5-(8-(dimethylamino)-8-(3-
INT-
N-(5-bromo-4-
SC_3103

481.3



fluorophenyl)-2-oxo-1,3-
1024
methylpyrimidin-2-



diazaspiro[4.5]decan-3-yl)-4-

yl)-N-



methylpyrimidin-2-yl)-N-

methylcyclopropanecarboxamide



methylcyclopropanecarboxamide


SC_3438
cis-N-(5-(8-(dimethylamino)-8-(3-
INT-
N-(5-bromo-4-
SC_3103

497.3



fluorophenyl)-2-oxo-1,3-
1024
methylpyrimidin-2-



diazaspiro[4.5]decan-3-yl)-4-

yl)-N-



methylpyrimidin-2-yl)-N-

methylpivalamide



methylpivalamide


SC_3439
cis-3-(4-(azetidin-1-yl)-2-
INT-
azetidine
SC_3120

493.2



(trifluoromethyl)pyrimidin-5-yl)-8-
1077



(dimethylamino)-8-(3-



fluorophenyl)-1,3-



diazaspiro[4.5]decan-2-one


SC_3440
cis-8-(dimethylamino)-8-(3-
INT-
oxetan-3-ylmethanol
SC_3224

524.2



fluorophenyl)-3-(4-(oxetan-3-
1077



ylmethoxy)-2-



(trifluoromethyl)pyrimidin-5-yl)-



1,3-diazaspiro[4.5]decan-2-one


SC_3441
cis-3-(2-cyclopropyl-4-(2,2,2-
INT-
2,2,2-trifluoroethanol
SC_3224

508.2



trifluoroethoxy)pyrimidin-5-yl)-8-
1078



(dimethylamino)-8-(3-



fluorophenyl)-1,3-



diazaspiro[4.5]decan-2-one


SC_3442
cis-3-(2-cyclopropyl-4-((2-
INT-
2-
SC_3120

483.3



hydroxyethyl)(methyl)amino)pyrimidin-
1078
(methylamino)ethanol



5-yl)-8-(dimethylamino)-8-(3-



fluorophenyl)-1,3-



diazaspiro[4.5]decan-2-one









Chemical Structures of all Examples




embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image




embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


Pharmacological Investigations


Functional investigation on the human mu-opioid receptor (hMOP), human kappa-opioid receptor (hKOP), human delta-opioid receptor (hDOP), and human nociceptin/orphanin FQ peptide receptor (hNOP)


Human Mu-Opioid Peptide (hMOP) Receptor Binding Assay


The hMOP receptor binding assay was performed as homogeneous SPA-assay (scintillation proximity assay) using the assay buffer 50 mM TRIS-HCl (pH 7.4) supplemented with 0.052 mg/ml bovine serum albumin (Sigma-Aldrich Co. St. Louis. Mo.). The final assay volume (250 l/well) included 1 nM of [N-allyl-2.3-3H]naloxone as ligand (PerkinElmer Life Sciences. Inc. Boston. Mass. USA). and either test compound in dilution series or 25 μM unlabelled naloxone for determination of unspecific binding. The test compound was diluted with 25% DMSO in H2O to yield a final 0.5% DMSO concentration. which also served as a respective vehicle control. The assay was started by adding wheat germ agglutinin coated SPA beads (GE Healthcare UK Ltd. Buckinghamshire. UK) which had been preloaded with hMOP receptor membranes (PerkinElmer Life Sciences. Inc. Boston. Mass. USA). After incubation for 90 minutes at RT and centrifugation for 20 minutes at 500 rpm the signal rate was measured by means of a 1450 Microbeta Trilux β-counter (PerkinElmer Life Sciences/Wallac. Turku. Finland). Half-maximal inhibitory concentration (IC50) values reflecting 50% displacement of [3H]naloxone-specific receptor binding were calculated by nonlinear regression analysis and Ki values were calculated by using the Cheng-Prusoff equation. (Cheng and Prusoff. 1973).


Human Kappa-Opioid Peptide (hKOP) Receptor Binding Assay


The hKOP receptor binding assay is run as homogeneous SPA-assay (scintillation proximity assay) using the assay buffer 50 mM TRIS-HCl (pH 7.4) supplemented with 0.076 mg BSA/ml. The final assay volume of 250 μl per well includes 2 nM of [3H]U69,593 as ligand, and either test compound in dilution series or 100 μM unlabelled naloxone for determination of unspecific binding. The test compound is diluted with 25% DMSO in H2O to yield a final 0.5% DMSO concentration which serves as respective vehicle control, as well. The assays are started by the addition of wheat germ agglutinin coated SPA beads (1 mg SPA beads/250 μl final assay volume per well) which has been preloaded for 15 minutes at room temperature with hKOP receptor membranes (14.8 μg/250 μl final assay volume per well). After short mixing on a mini-shaker, the microtiter plates are covered with a lid and the assay plates are incubated for 90 minutes at room temperature. After this incubation, the microtiter plates are sealed with a topseal and centrifuged for 20 minutes at 500 rpm. The signal rate is measured after a short delay of 5 minutes by means of a 1450 Microbeta Trilux β-counter (PerkinElmer Life Sciences/Wallac, Turku, Finland). Half-maximal inhibitory concentration (IC50) values reflecting 50% displacement of [3H]U69.593-specific receptor binding are calculated by nonlinear regression analysis and Ki values are calculated by using the Cheng-Prusoff equation, (Cheng and Prusoff, 1973).


Human Delta-Opioid Peptide (hDOP) Receptor Binding Assay


The hDOP receptor binding assay is performed as homogeneous SPA-assay using the assay buffer 50 mM TRIS-HCl, 5 mM MgCl2 (pH 7.4). The final assay volume (250 μl/well) includes 1 nM of [Tyrosyl-3,5-3H]2-D-Ala-deltorphin II as ligand, and either test compound in dilution series or 10 μM unlabelled naloxone for determination of unspecific binding. The test compound is diluted with 25% DMSO in H2O to yield a final 0.5% DMSO concentration which serves as respective vehicle control, as well. The assays are started by the addition of wheat germ agglutinin coated SPA beads (1 mg SPA beads/250 μl final assay volume per well) which has been preloaded for 15 minutes at room temperature with hDOP receptor membranes (15.2 μg/250 μl final assay volume per well). After short mixing on a mini-shaker, the microtiter plates are covered with a lid and the assay plates are incubated for 120 minutes at room temperature and centrifuged for 20 minutes at 500 rpm. The signal rate is measured by means of a 1450 Microbeta Trilux β-counter (PerkinElmer Life Sciences/Wallac, Turku, Finland). Half-maximal inhibitory concentration (IC50) values reflecting 50% displacement of [Tyrosyl-3,5-3H]2-D-Ala-deltorphin II-specific receptor binding are calculated by nonlinear regression analysis and Ki values are calculated by using the Cheng-Prusoff equation, (Cheng and Prusoff, 1973).


Human Nociceptin/Orphanin FQ Peptide (hNOP) Receptor Binding Assay


The hNOP receptor binding assay was performed as homogeneous SPA-assay (scintillation proximity assay) using the assay buffer 50 mM TRIS-HCl. 10 mM MgCl2. 1 mM EDTA (pH 7.4). The final assay volume (250 μl/well) included 0.5 nM of [leucyl-3H]nociceptin as ligand (PerkinElmer Life Sciences. Inc. Boston. Mass. USA). and either test compound in dilution series or 1 μM unlabelled nociceptin for determination of unspecific binding. The test compound was diluted with 25% DMSO in H2O to yield a final 0.5% DMSO concentration. which also served as a respective vehicle control. The assay was started by adding wheat germ agglutinin coated SPA beads (GE Healthcare UK Ltd. Buckinghamshire. UK) which had been preloaded with hMOP receptor membranes (PerkinElmer Life Sciences. Inc. Boston. Mass. USA). After incubation for 60 minutes at RT and centrifugation for 20 minutes at 500 rpm the signal rate was measured by means of a 1450 Microbeta Trilux β-counter (PerkinElmer Life Sciences/Wallac. Turku. Finland). Half-maximal inhibitory concentration (IC50) values reflecting 50% displacement of [3H]nociceptin-specific receptor binding were calculated by nonlinear regression analysis and Ki values were calculated by using the Cheng-Prusoff equation. (Cheng and Prusoff. 1973).


















hNOP Ki
hMOP Ki




[nM] or %
[nM] or %




inhibition
inhibition



Example
at 1 μM
at 1 μM




















SC_3001
0.3
120



SC_3002
1.3
250



SC_3003
0.4
350



SC_3004
19.5
515



SC_3005
0.7
12



SC_3006
1.1
46



SC_3007
85.8
705



SC_3008
0.6
23



SC_3009
1.1
41



SC_3010
2.7
18



SC_3011
4.4
4.4



SC_3012
2.2
120



SC_3013
1.4
39



SC_3014
0.8
29.5



SC_3015
2.6
32.5



SC_3016
4.2
45



SC_3017
2
30



SC_3018
5.2
101.5



SC_3019
10.2
135



SC_3020
10.8
290



SC_3021
1.8
14.5



SC_3022
0.4
37.2



SC_3023
7.7
36



SC_3024
1
145



SC_3025
236.7
1530



SC_3026
4.6
300



SC_3027
5
136



SC_3028
0.6
10.4



SC_3029
1.8
7.3



SC_3030
2.2
59



SC_3031
4.1
45.5



SC_3032
11
245



SC_3033
107
38%@10 μM



SC_3034
12.2
730



SC_3035
6.6
1055



SC_3036
1.4
220



SC_3037
33.5
775



SC_3038
1
76



SC_3039
13
380



SC_3040
4
335



SC_3041
0.9
79.5



SC_3042
4.1
136.5



SC_3043
70
655



SC_3044
230
10920



SC_3045
55.5
520



SC_3046
13.9
63



SC_3047
10.1
2105



SC_3048
1
38.5



SC_3049
25
940



SC_3050
85
28



SC_3051
3.6
170



SC_3052
160
355



SC_3053
73.5
1200



SC_3054
16.5
29.5



SC_3055
94.5
215



SC_3056
9.8
49.5



SC_3057
955
245



SC_3058
5
7.8



SC_3059
11.4
320



SC_3060
3
65



SC_3061
4.7
54.5



SC_3063
0.7
38



SC_3064
119
365



SC_3065
6.2
1990



SC_3066
2.2
96



SC_3067
41.5
99.5



SC_3068
5.9
50.5



SC_3069
2.6
49



SC_3070
2.8
12.5



SC_3071
8.2
170



SC_3072
5.9
235



SC_3073
1
110



SC_3074
1.6
55



SC_3075
8.1
260



SC_3076
0.6
35.3



SC_3077
3.2
325



SC_3078
0.6
77.5



SC_3079
1.6
38.5



SC_3080
1.6
90.5



SC_3081
8
1320



SC_3082
39
1110



SC_3083
12
117.3



SC_3084
1.8
22



SC_3085
1.6
107



SC_3086
1.1
43.5



SC_3087
2.8
99



SC_3088
3.1
770



SC_3089
3.3
235



SC_3090
1.3
67



SC_3091
2.3
24



SC_3092
2.2
330



SC_3093
1.1
47



SC_3094
5.4
45.5



SC_3096
14
250



SC_3097
17
18



SC_3098
2
6



SC_3099
13
19



SC_3100
1
1



SC_3101
1
3



SC_3102
2
1



SC_3103
7
1



SC_3104





SC_3105
2
97



SC_3106
8
165



SC_3107
2
115



SC_3108
5
26



SC_3109
8
19



SC_3110
6
20



SC_3111
8
37



SC_3112
36
120



SC_3113
24
26



SC_3114
245
460



SC_3115
265
915



SC_3116
6
170



SC_3117
92
1380



SC_3118
80
 5%



SC_3119
22%
10%



SC_3120
26
4950



SC_3121
44
30%



SC_3122
21
32%



SC_3123
82
2260



SC_3124
5
1090



SC_3125
3%@10 μM
52%@10 μM



SC_3126
 0%
 0%



SC_3127
 0%
3945



SC_3128
 0%
 1%



SC_3129
6
2180



SC_3130
13
4530



SC_3131
4
3090



SC_3132
540
 6%



SC_3133
19
6515



SC_3134
3%@10 μM
40%@10 μM



SC_3135
 1%
 1%



SC_3136
16
5840



SC_3137
5
4235



SC_3138
28
 7%



SC_3139
59
1690



SC_3140
119
2355



SC_3141
34
7855



SC_3142
9
3750



SC_3143
 0%
 4%



SC_3144
 0%
3590



SC_3145
46
1635



SC_3146
18
7675



SC_3147
27
3325



SC_3148
14
4575



SC_3149
18
6900



SC_3150
105
16%



SC_3151
115
3490



SC_3152
24
4775



SC_3153
77
2220



SC_3154
17
3575



SC_3155
34
3495



SC_3156
45
6375



SC_3157
35
5690



SC_3158
19
2540



SC_3159
13
19%



SC_3160
 4%
5730



SC_3161
 2%
13%



SC_3162
5
1325



SC_3163
28
2095



SC_3164
30
880



SC_3165
 4%
17%



SC_3166
 3%
1640



SC_3167
18
3745



SC_3168
11
5



SC_3169
635
3445



SC_3170
7
3610



SC_3171
15
2010



SC_3172
130
 7%



SC_3173
10
2525



SC_3174
 3%
1265



SC_3175





SC_3176
13
3740



SC_3177
8
4630



SC_3178
6
6700



SC_3179
15
3950



SC_3180
125
2250



SC_3181
22
5490



SC_3182
11
2990



SC_3183
165
1415



SC_3184
19
7645



SC_3185
335
15%



SC_3186
33
2210



SC_3187
87
2240



SC_3188
25
1060



SC_3189
57
3470



SC_3190
42
28%



SC_3191
27
20%



SC_3192
140
4270



SC_3193
100
2480



SC_3194
28
5120



SC_3195
15
1240



SC_3196
22
1595



SC_3197
44
1680



SC_3198
22
5885



SC_3199
19
4020



SC_3200
7
13%



SC_3201
115
3885



SC_3202
25
3210



SC_3203
68
1225



SC_3204
110
14%



SC_3205
20
2465



SC_3206
27
2445



SC_3207
39
1505



SC_3208
2
3285



SC_3209





SC_3210





SC_3211





SC_3212
9
2005



SC_3213
52
18%



SC_3214
7
19%



SC_3215
 0%
14%



SC_3216
11
14



SC_3217
23
2155



SC_3218
83
15%



SC_3219
 0%
 1%



SC_3220
10%@10 μM
24%@10 μM



SC_3221
33
1935



SC_3222
6
1910



SC_3223
155
6150



SC_3224
10
1695



SC_3225
13
2520



SC_3226





SC_3227
16
3785



SC_3228
67
3135



SC_3229
105
3625



SC_3230
145
2485



SC_3231
120
2420



SC_3232
15
3475



SC_3233
38
1390



SC_3234
4
1350



SC_3235
30
1095



SC_3236
285
18%



SC_3237
20
17%



SC_3238
4
25%



SC_3239
35
2410



SC_3240
28
17%



SC_3241
8
4610



SC_3242
5
675



SC_3243
6
695



SC_3244
27
4265



SC_3245
67




SC_3246
11
1025



SC_3247
16
1220



SC_3248
4
41



SC_3249
740
855



SC_3250
52




SC_3251
185
4550



SC_3252
30




SC_3253
205




SC_3254
22
240



SC_3255
23
150



SC_3256
12
61



SC_3257
150
240



SC_3258
58
7125



SC_3259
45
180



SC_3260
570
nd



SC_3261
10
63



SC_3262
540
3060



SC_3263
66
800



SC_3264
145
130



SC_3265
38
2405



SC_3266
245
1055



SC_3267
460




SC_3268
41
1625



SC_3269
13
5580



SC_3270
305
31



SC_3271
34
245



SC_3272
115
4175



SC_3273





SC_3274
63
1880



SC_3275
155
124



SC_3276
24
130



SC_3277
37
13%



SC_3278
12
7035



SC_3279
17
78



SC_3280
6
300



SC_3281
19
2580



SC_3282
37
3510



SC_3283
12
1030



SC_3284
5
305



SC_3285
15
20%



SC_3286
18
5895



SC_3287
119
18%



SC_3288
15
115



SC_3289
84
430



SC_3290
16
6605



SC_3291
350
15%



SC_3292
 4%
 0%



SC_3293
 3%
 0%



SC_3294
9
12%



SC_3295
28
2975



SC_3296
10
4530



SC_3297
8
4270



SC_3298
20
17%



SC_3299
23
5705



SC_3300
22
565



SC_3301
33
2320



SC_3302
31
1025



SC_3303
450
21%



SC_3304
 9%
 4%



SC_3305
10%
 0%



SC_3306
9
4555



SC_3307
13
5345



SC_3308
2
2575



SC_3309
17
6910



SC_3310
7
23%



SC_3311
14
27%







SC_3312
23
1830



SC_3313
10
2400



SC_3314
9
4090



SC_3315
14
5325



SC_3316
255
5430



SC_3317
56
6045



SC_3318
35
1235



SC_3319
4
15%



SC_3320
11
1955



SC_3321
13
5715



SC_3322
12
1150



SC_3323
27
5530



SC_3324
12%
 5%



SC_3325
53%@10 μM
20%@10 μM



SC_3326





SC_3327
17
3360



SC_3328
31
3295



SC_3329
13
4285



SC_3330
14
1505



SC_3331
2
5265



SC_3332
19
2055



SC_3333
5
1580



SC_3334
17
4005



SC_3335
30
2305



SC_3336
240
13%



SC_3337
10
1970



SC_3338
36
 7%



SC_3339
10
6830



SC_3340
150
5750



SC_3341
15
3460



SC_3342
21
3845



SC_3343
27
16%



SC_3344
1
13%



SC_3345
4
1800



SC_3346
12
2580



SC_3347
15
4845



SC_3348
25
4090



SC_3349
8
3980



SC_3350
7
1485



SC_3351
20
2205



SC_3352
37
2160



SC_3353
53
15%



SC_3354
2
23%



SC_3355
52
4785



SC_3356
9
4805



SC_3357
13
555



SC_3358
51
7020



SC_3359
66
3520



SC_3360
7
2870



SC_3361
27
5095



SC_3362
28
29%



SC_3363
33
 8%



SC_3364
32
4685



SC_3365
2
1655



SC_3366
1285
14%



SC_3367
1220
 8%



SC_3368
195
11%



SC_3369
51
3105



SC_3370
4
14%



SC_3371
350
 9%



SC_3372
125
3535



SC_3373
19
18%



SC_3374
55
10%



SC_3375
13
12%



SC_3376
37
1720



SC_3377
22
980



SC_3379
11
635



SC_3380
102
5415



SC_3381
3
1235



SC_3382
29
13%



SC_3383
10
17%



SC_3384
6
11%



SC_3385
33
925



SC_3386
14
 0%



SC_3387
2
1245



SC_3388
29
185



SC_3389
2
1970



SC_3390
18
465



SC_3391
53
10%



SC_3392
7
4490



SC_3393
88
13%



SC_3394
6
735



SC_3395
14
4990



SC_3396
44
1730



SC_3397
48
560



SC_3398
9
5640



SC_3399
5
45%



SC_3400
8
635



SC_3401
1
455



SC_3402
7
3630



SC_3403
9
1440



SC_3404
10
 5%



SC_3405
12
925



SC_3406
24
805



SC_3407
77
13%



SC_3408
7
18%



SC_3409
11
25%










Protocol for [35S]GTPγS Functional NOP/MOP/KOP/DOP Assays


Cell membrane preparations of CHO-K1 cells transfected with the human MOP receptor (Art.-No. RBHOMM) or the human DOP receptor (Art.-No. RBHODM), and HEK293 cells transfected with the human NOP receptor (Art.-No. RBHORLM) or the human KOP receptor (Art.-No. 6110558) are available from PerkinElmer (Waltham, Mass.). Membranes from CHO-K1 cells transfected with the human nociceptin/orphanin FQ peptide (hNOP) receptor (Art.-No. 93-0264C2, DiscoveRx Corporation, Freemont, Calif.) are also used. [35S]GTPγS (Art.-No. NEG030H;


Lot-No. #0112, #0913, #1113 calibrated to 46.25 TBq/mmol) is available from PerkinElmer (Waltham, Mass.).


The [35S]GTPγS assays are carried out essentially as described by Gillen et al (2000). They are run as homogeneous scintillation proximity (SPA) assays in microtiter luminescence plates, where each well contains 1.5 mg of WGA-coated SPA-beads. To test the agonistic activity of test compounds on recombinant hNOP, hMOP, hDOP, and hKOP receptor expressing cell membranes from CHO-K1 or HEK293 cells, 10 or 5 μg membrane protein per assay are incubated with 0.4 nM [35S]GTPγS and serial concentrations of receptor-specific agonists in buffer containing 20 mM HEPES pH 7.4, 100 mM NaCl, 10 mM MgCl2, 1 mM EDTA, 1 mM dithiothreitol, 1.28 mM NaN3, and 10 μM GDP for 45 min at room temperature. The microtiter plates are then centrifuged for 10 min at 830 to sediment the SPA beads. The microtiter plates are sealed and the bound radioactivity [cpm] is determined after a delay of 15 min by means of a 1450 Microbeta Trilux (PerkinElmer, Waltham, Mass.).


The unstimulated basal binding activity (UBSobs [cpm]) is determined from 12 unstimulated incubates and is set as 100% basal binding. For determination of the potency and the efficacy, the arithmetic mean of the observed total [35S]GTPγS binding (TBobs [cpm]) of all incubates (duplicates) stimulated by the receptor-specific agonists (i.e. N/OFQ, SNC80, DAMGO, or U69,593) are transformed in percent total binding (TBobs [%]) relative to the basal binding activity (i.e. 100% binding). The potency (EC50) of the respective agonist and its maximal achievable total [35S]GTPγS binding (TBcalc [%]) above its calculated basal binding (UBScalc [%]) are determined from its transformed data (TBobs [%]) by means of nonlinear regression analysis with XLfit for each individual concentration series. Then the difference between the calculated unstimulated [35S]GTPγS binding (UBScalc [%]) and the maximal achievable total [35S]GTPγS binding (TBcalc [%]) by each tested agonist is determined (i.e. B1calc [%]). This difference (B1calc[%]) as a measure of the maximal achievable enhancement of [35S]GTPγS binding by a given agonist is used to calculate the relative efficacy of test compounds versus the maximal achievable enhancement by a receptor-specific full agonist, e.g. N/OFQ (B1calc-N/OFQ [%]) which is set as 100% relative efficacy for the hNOP receptor. Likewise, the percentage efficacies of test compounds at the hDOP, hMOP, or hKOP receptor are determined versus the calculated maximal enhancement of [35S]GTPγS binding by the full agonists SNC80 (B1calc-SNC80 [%]), DAMGO (B1calc-DAMGO [%]) and U69,593 (B1calc-U69,593 [%]) which are set as 100% relative efficacy at each receptor, respectively.


The foregoing description and examples have been set forth merely to illustrate the invention and are not intended to be limiting. Since modifications of the described embodiments incorporating the spirit and substance of the invention may occur to persons skilled in the art, the invention should be construed broadly to include all variations within the scope of the appended claims and equivalents thereof.

Claims
  • 1. A compound according to general formula (I)
  • 2. The compound according to claim 1, wherein R11, R12, R13, R14, R15, R16, R17, R18, R19, and R20 independently of one another mean —H, —F, —OH, or —C1-C6-alkyl.
  • 3. The compound according to claim 1, wherein R1 means —H; and R2 means —C1-C6-alkyl, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted.
  • 4. The compound according to claim 1, wherein R1 means —CH3; and R2 means —C1-C6-alkyl, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted.
  • 5. The compound according to claim 1, wherein R1 means —H or —CH3; and wherein R2 means —CH2-cycloalkyl, —CH2-cyclobutyl, —CH2-cyclopentyl, —CH2-oxetanyl or —CH2— tetrahydrofuranyl.
  • 6. The compound according to claim 1, wherein R1 and R2 together with the nitrogen atom to which they are attached form a ring and mean —(CH2)3-6—.
  • 7. The compound according to claim 1, wherein R3 means —C1-C6-alkyl, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted.
  • 8. The compound according to claim 1, wherein R3 means a 6-14-membered aryl moiety, unsubstituted, mono- or polysubstituted.
  • 9. The compound according to claim 1, wherein R3 means a 5-14-membered heteroaryl moiety, unsubstituted, mono- or polysubstituted.
  • 10. The compound according to claim 1, wherein R4 means —H.
  • 11. The compound according to claim 1, wherein R4 means —C1-C6-alkyl, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted.
  • 12. The compound according to claim 1, wherein R4 means a 3-12-membered cycloalkyl moiety, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein the 3-12-membered cycloalkyl moiety is connected through —C1-C6-alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted.
  • 13. The compound according to claim 1, wherein R4 means a 3-12-membered heterocycloalkyl moiety, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said 3-12-membered heterocycloalkyl moiety is connected through —C1-C6-alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted.
  • 14. The compound according to claim 1, wherein R4 means a 6-14-membered aryl moiety, unsubstituted, mono- or polysubstituted; wherein said 6-14-membered aryl moiety is connected through —C1-C6-alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted.
  • 15. The compound according to claim 1, wherein R4 means a 5-14-membered heteroaryl moiety, unsubstituted, mono- or polysubstituted; wherein said 5-14-membered heteroaryl moiety is connected through —C1-C6-alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted.
  • 16. The compound according to claim 1, wherein R5 means -phenyl, unsubstituted, mono- or polysubstituted.
  • 17. The compound according to claim 1, wherein R5 means a monocyclic 5-6-membered heteroaryl moiety, unsubstituted, mono- or polysubstituted.
  • 18. The compound according to claim 1, wherein R5 means a bicyclic 9-10-membered heteroaryl moiety, unsubstituted, mono- or polysubstituted.
  • 19. The compound according to claim 17, wherein R5 means -1,2-benzodioxole, -pyrazinyl, -pyridazinyl, -pyridinyl, -pyrimidinyl, -thienyl, -imidazolyl, -benzimidazolyl, -thiazolyl, -1,3,4-thiadiazolyl, -benzothiazolyl, -oxazolyl, -benzoxazolyl, -pyrazolyl, -quinolinyl, -isoquinolinyl, -quinazolinyl, -indolyl, -indolinyl, -benzo[c][1,2,5]oxadiazolyl, -imidazo[1,2-a]pyrazinyl, or -1H-pyrrolo[2,3-b]pyridinyl, in each case unsubstituted, mono- or polysubstituted.
  • 20. The compound according to claim 1, which has a structure according to any of general formulas (II-A) to (VIII-C):
  • 21. The compound according to claim 1, wherein R5 is selected from the group consisting of:
  • 22. The compound according to claim 1, wherein R1 means —H or —CH3;R2 means —C1-C6-alkyl, linear or branched, saturated, unsubstituted; cyclopropyl connected through —CH2—; or tetrahydropyranyl connected through —CH2—;R3 means -phenyl, benzyl, -thienyl or -pyridinyl, in each case unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —CN, —CH3, —CH2CH3, —CH2F, —CHF2, —CF3, —OCF3, —OH, —OCH3, —C(═O)NH2, C(═O)NHCH3, —C(═O)N(CH3)2, —NH2, —NHCH3, —N(CH3)2, —NHC(═O)CH3, —CH2OH, SOCH3 and SO2CH3; orR4 means—H;—C1-C6-alkyl, linear or branched, saturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —C1, —Br, —I, —CN, —OH, —O—C1-C4-alkyl, —C(═O)NH—C1-C6-alkyl, —C(═O)N(C1-C6-alkyl)2 or —C(═O)NRR′ wherein R and R′ together with the nitrogen atom to which they are attached form a ring and mean —(CH2)3-5—;3-6-membered cycloalkyl, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br, —I, —CN, —OH, and —O—C1-C4-alkyl, wherein said 3-6-membered cycloalkyl is connected through —C1-C6-alkylene;3-6-membered heterocycloalkyl, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br, —I, —CN, —OH, and —O—C1-C4-alkyl, wherein said 3-6-membered heterocycloalkyl is connected through —C1-C6-alkylene;-phenyl, unsubstituted or monosubstituted with —OCH3; wherein said -phenyl isconnected through —C1-C6-alkylene-; or-pyridyl, unsubstituted, mono- or polysubstituted; wherein said -pyridyl is connected through —C1-C6-alkylene-;R5 means-phenyl, -1,2-benzodioxole, -pyrazinyl, -pyridazinyl, -pyridinyl, -pyrimidinyl, -thienyl, -imidazolyl, -benzimidazolyl, -thiazolyl, -1,3,4-thiadiazolyl, -benzothiazolyl, -oxazolyl, -benzoxazolyl, -pyrazolyl, -quinolinyl, -isoquinolinyl, -quinazolinyl, -indolyl, -indolinyl, -benzo[c][1,2,5]oxadiazolyl, -imidazo[1,2-a]pyrazinyl, or -1H-pyrrolo[2,3-b]pyridinyl, in each case unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F; —Cl; —Br; —I;—CN; —C1-C4-alkyl; —C1-C4-alkyl-OH; —CF3; —C1-C4-alkyl-CF3; —C1-C4-alkyl-C(═O)NH2; —C1-C4-alkyl-C(═O)NHC1-C6-alkyl; —C1-C4-alkyl-C(═O)N(C1-C6-alkyl)2; —C1-C4-alkyl-S(═O)2—C1-C4-alkyl;—C(═O)—C1-C4-alkyl; —C(═O)OH; —C(═O)O—C1-C4-alkyl; —C(═O)NH2; —C(═O)NHC1-C4-alkyl; —C(═O)N(C1-C4-alkyl)2; —C(═O)NH(C1-C4-alkyl-OH); —C(═O)N(C1-C4-alkyl)(C1-C4-alkyl-OH); —C(═O)NH—(CH2CH2O)1-30—CH3;—NH2; —NHC1-C4-alkyl; —N(C1-C4-alkyl)2; —NHC1-C4-alkyl-OH; —NCH3C1-C4-alkyl-OH; —NH—C1-C4-alkyl-C(═O)NH2; —NCH3—C1-C4-alkyl-C(═O)NH2; —NHC(═O)—C1-C4-alkyl; —NCH3C(═O)—C1-C4-alkyl;—OH; —O—C1-C4-alkyl; —OCF3; —O—C1-C4-alkyl-CO2H; —O—C1-C4-alkyl-C(═O)O—C1-C4-alkyl; —O—C1-C4-alkyl-CONH2;—S—C1-C4-alkyl; —S(═O)C1-C4-alkyl; —S(═O)2C1-C4-alkyl; and —S(═O)2N(C1-C4-alkyl)2;-3-12-membered cycloalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said 3-12-membered cycloalkyl is optionally connected through —CH2—, —O—, —NH—, —NCH3—, —NH—(CH2)1-3—, —NCH3(CH2)1-3—, —(C═O)—, —NHC(═O)—, —NCH3C(═O)—, —C(═O)NH—(CH2)1-3—, —C(═O)NCH3—(CH2)1-3—;-3-12-membered heterocycloalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said 3-12-membered heterocycloalkyl is optionally connected through —CH2—, —O—, —NH—, —NCH3—, —NH—(CH2)1-3—, —NCH3(CH2)1-3—, —(C═O)—, —NHC(═O)—, —NCH3C(═O)—, —C(═O)NH—(CH2)1-3—, —C(═O)NCH3—(CH2)1-3—;-6-14-membered aryl, unsubstituted, mono- or polysubstituted; wherein said 6-14-membered aryl is optionally connected through —CH2—, —O—, —NH—, —NCH3—, —NH—(CH2)1-3—, —NCH3(CH2)1-3—, —(C═O)—, —NHC(═O)—, —NCH3C(═O)—, —C(═O)NH—(CH2)1-3—, —C(═O)NCH3—(CH2)1-3—; or-5-14-membered heteroaryl, unsubstituted, mono- or polysubstituted; wherein said 5-14-membered heteroaryl is optionally connected through —CH2—, —O—, —NH—, —NCH3—, —NH—(CH2)1-3—, —NCH3(CH2)1-3—, —(C═O)—, —NHC(═O)—, —NCH3C(═O)—, —C(═O)NH—(CH2)1-3—, —C(═O)NCH3—(CH2)1-3—;andR11, R12, R13, R14, R15, R16, R17, R18, R19, and R20 mean —H.
  • 23. The compound according to claim 1, which has a structure according to general formula (I′)
  • 24. The compound according to claim 1, which has a structure according to general formula (IX) or (X)
  • 25. The compound according to claim 1, which has a structure according to general formula
  • 26. The compound according to claim 1, which is selected from the group consisting of cis-5-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-pyrimidine-2-carbonitrile;cis-5-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-pyrazine-2-carbonitrile;cis-5-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-4-methoxy-pyrimidine-2-carbonitrile;cis-5-[8-Dimethylamino-1-(2-methoxy-ethyl)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-pyrimidine-2-carbonitrile;cis-5-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-pyrimidine-2-carboxylic acid amide;cis-5-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-2-methylsulfonyl-pyrimidine-4-carbonitrile;cis-5-[1-(2-Methoxy-ethyl)-8-methylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-pyrimidine-2-carbonitrile;cis-2-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-5-methylsulfonyl-benzonitrile;cis-2-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-benzamide;cis-3-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-benzamide;cis-5-[8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-pyrimidine-2-carboxylic acid amide;cis-5-[1-(Cyclobutyl-methyl)-8-methylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-4-methoxy-pyrimidine-2-carbonitrile;cis-5-[8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-pyrimidine-2-carbonitrile;cis-2-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-pyrimidine-5-carbonitrile;cis-8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-3-(2-methoxy-pyrimidin-5-yl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-2-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-pyrimidine-5-carboxylic acid amide;cis-4-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-N-methyl-benzamide;cis-5-(8-Dimethylamino-2-oxo-8-phenyl-1-propyl-1,3-diazaspiro[4.5]decan-3-yl)-pyrimidine-2-carbonitrile;cis-5-[8-Dimethylamino-1-(3-methoxy-propyl)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-pyrimidine-2-carbonitrile;cis-5-[1-(Cyclopropyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-pyrimidine-2-carbonitrile;cis-4-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-benzamide;cis-1-(Cyclobutyl-methyl)-8-dimethylamino-8-phenyl-3-[2-(trifluoromethyl)-pyrimidin-5-yl]-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-3-(2-hydroxy-pyrimidin-5-yl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-5-[8-Dimethylamino-1-(2-methyl-propyl)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-pyrimidine-2-carbonitrile;cis-5-[8-Dimethylamino-1-(2-hydroxy-ethyl)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-pyrimidine-2-carbonitrile;cis-5-[1-(Cyclobutyl-methyl)-8-methylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-4-methyl-pyridine-2-carbonitrile;cis-1-(Cyclobutyl-methyl)-3-(5-methoxy-pyrazin-2-yl)-8-methylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-4-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-N,N-dimethyl-benzamide;cis-4-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-N-ethyl-N-(2-hydroxy-ethyl)-benzamide;cis-2-[1-(Cyclobutyl-methyl)-8-methylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-5-methylsulfonyl-benzonitrile;cis-1-(Cyclobutyl-methyl)-8-methylamino-3-[2-methylsulfonyl-4-(trifluoromethyl)-phenyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-4-[1-(Cyclobutyl-methyl)-8-methylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-N,N-dimethyl-3-(trifluoromethyl)-benzenesulfonic acid amide;cis-4-[1-(Cyclobutyl-methyl)-8-(ethyl-methyl-amino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-benzonitrile;cis-1-(Cyclobutyl-methyl)-8-(ethyl-methyl-amino)-8-phenyl-3-[2-(trifluoromethyl)-pyrimidin-5-yl]-1,3-diazaspiro[4.5]decan-2-one;cis-5-[1-(Cyclobutyl-methyl)-8-(ethyl-methyl-amino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-pyrimidine-2-carbonitrile;cis-5-[8-Dimethylamino-1-[(1-methyl-cyclobutyl)-methyl]-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-pyrimidine-2-carbonitrile;cis-2-[3-(2-Cyano-pyrimidin-5-yl)-8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl]-N,N-dimethyl-acetamide;cis-1-(Cyclobutyl-methyl)-8-methylamino-8-phenyl-3-[2-(trifluoromethyl)-pyrimidin-5-yl]-1,3-diazaspiro[4.5]decan-2-one;cis-5-[8-Dimethylamino-8-(3-fluorophenyl)-1-(4-methoxy-butyl)-2-oxo-1,3-diazaspiro[4.5]decan-3-yl]-pyrimidine-2-carbonitrile;cis-5-[8-Dimethylamino-1-(3-methoxy-propyl)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-4-methoxy-pyrimidine-2-carbonitrile;cis-5-[1-[(1-Cyano-cyclobutyl)-methyl]-8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-pyrimidine-2-carbonitrile;cis-N-(Cyclobutyl-methyl)-5-[1-(cyclobutyl-methyl)-8-dimethylamino-8-(3-fluorophenyl)-2-oxo-1,3-diazaspiro[4.5]decan-3-yl]-pyrimidine-2-carboxylic acid amide;cis-5-[1-(3-Methoxy-propyl)-8-methylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-pyrimidine-2-carbonitrile;cis-5-[8-Dimethylamino-8-(3-fluorophenyl)-1-methyl-2-oxo-1,3-diazaspiro[4.5]decan-3-yl]-pyrimidine-2-carbonitrile;cis-4-Methoxy-5-[1-(3-methoxy-propyl)-8-methylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-pyrimidine-2-carbonitrile;cis-4-[8-Dimethylamino-1-(2-methoxy-ethyl)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-pyrimidine-2-carbonitrile;cis-5-[8-Dimethylamino-1-(2-methoxy-ethyl)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-4-methoxy-pyrimidine-2-carbonitrile;cis-4-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-pyrimidine-2-carbonitrile;cis-1-(Cyclobutyl-methyl)-8-dimethylamino-3-(6-methylsulfanyl-pyrimidin-4-yl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-2-[3-(2-Cyano-pyrimidin-4-yl)-8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl]-N,N-dimethyl-acetamide;cis-6-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-pyrimidine-4-carbonitrile;cis-2-(8-Dimethylamino-2-oxo-3,8-diphenyl-1,3-diazaspiro[4.5]decan-1-yl)-N,N-dimethyl-acetamide;cis-1-(Cyclobutyl-methyl)-8-dimethylamino-3,8-diphenyl-1,3-diazaspiro[4.5]decan-2-one;cis-2-[8-Dimethylamino-1-(2-methoxy-ethyl)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-pyrimidine-5-carbonitrile;cis-8-Dimethylamino-1-(2-methoxy-ethyl)-3,8-diphenyl-1,3-diazaspiro[4.5]decan-2-one;cis-5-[8-Dimethylamino-1-(2-methoxy-ethyl)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-4-methyl-pyridine-2-carbonitrile;cis-N,N-Dimethyl-2-(8-methylamino-2-oxo-3,8-diphenyl-1,3-diazaspiro[4.5]decan-1-yl)-acetamide;cis-5-[1-[(1-Cyano-cyclobutyl)-methyl]-8-methylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-pyrimidine-2-carbonitrile;cis-5-[1-[(1-Cyano-cyclobutyl)-methyl]-8-(ethyl-methyl-amino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-pyrimidine-2-carbonitrile;CIS-4-[8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-benzonitrile;cis-3-[8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-benzonitrile;cis-5-[1-[(1-Cyano-cyclobutyl)-methyl]-8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-pyridine-2-carbonitrile;cis-2-[3-(2-Cyano-pyrimidin-5-yl)-8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl]-N-propyl-acetamide;cis-5-[1-(Cyclobutyl-methyl)-8-(ethyl-methyl-amino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-4-methoxy-pyrimidine-2-carbonitrile;cis-4-[1-(Cyclobutyl-methyl)-8-methylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-3-methoxy-benzonitrile;cis-5-[8-Dimethylamino-1-(3-methoxy-propyl)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-6-methoxy-pyridine-2-carbonitrile;cis-4-[8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-benzamide;cis-5-[8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-pyridine-2-carbonitrile;cis-5-[8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-N-[(1-hydroxy-cyclobutyl)-methyl]-pyridine-2-carboxylic acid amide;cis-2-[8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-benzonitrile;cis-3-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-benzonitrile;cis-1-(Cyclobutyl-methyl)-8-dimethylamino-8-phenyl-3-[2-(trifluoromethyl)-pyrimidin-5-yl]-1,3-diazaspiro[4.5]decan-2-one;cis-5-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-4-methyl-pyridine-2-carboxylic acid methyl ester;cis-1-(Cyclobutyl-methyl)-8-dimethylamino-3-(5-methoxy-pyrazin-2-yl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-1-(Cyclobutyl-methyl)-8-dimethylamino-3-(2-methoxy-pyrimidin-5-yl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-4-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-benzonitrile;cis-5-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-4-methyl-pyridine-2-carbonitrile;cis-1-(Cyclobutyl-methyl)-8-dimethylamino-3-(5-fluoro-pyrimidin-2-yl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-4-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-3-methoxy-benzonitrile;cis-4-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-benzoic acid methyl ester;cis-1-(Cyclobutyl-methyl)-8-dimethylamino-8-phenyl-3-(2-pyrrolidin-1-yl-pyrimidin-4-yl)-1,3-diazaspiro[4.5]decan-2-one;cis-1-(Cyclobutyl-methyl)-8-dimethylamino-8-phenyl-3-(5-pyridin-2-yl-thiophen-2-yl)-1,3-diazaspiro[4.5]decan-2-one;cis-1-(Cyclobutyl-methyl)-8-dimethylamino-3-[2-methylsulfonyl-4-(trifluoromethyl)-phenyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-1-(Cyclobutyl-methyl)-8-dimethylamino-8-phenyl-3-[6-(trifluoromethyl)-pyridin-3-yl]-1,3-diazaspiro[4.5]decan-2-one;cis-1-(Cyclobutyl-methyl)-3-(2,4-dimethoxy-phenyl)-8-dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-2-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-4-methylsulfonyl-benzonitrile;cis-5-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-2-fluoro-benzonitrile;cis-4-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-N,N-dimethyl-3-(trifluoromethyl)-benzenesulfonic acid amide;cis-2-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-benzonitrile;cis-1-(Cyclobutyl-methyl)-8-dimethylamino-3-(2-methyl-imidazo[1,2-a]pyrazin-6-yl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-1-(Cyclobutyl-methyl)-8-dimethylamino-3-(4-methylsulfonyl-phenyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-2-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-5-methoxy-benzonitrile;cis-1-(Cyclobutyl-methyl)-8-dimethylamino-3,8-diphenyl-1,3-diazaspiro[4.5]decan-2-one;cis-1-(Cyclobutyl-methyl)-8-dimethylamino-8-phenyl-3-pyrazin-2-yl-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-3-(2-morpholin-4-yl-pyrimidin-5-yl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-3-[2-(4-methyl-piperazin-1-yl)-pyrimidin-5-yl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-1-[(1-Hydroxy-cyclobutyl)-methyl]-8-methylamino-3-(2-morpholin-4-yl-pyrimidin-5-yl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-8-phenyl-3-(2-piperazin-1-yl-pyrimidin-5-yl)-1,3-diazaspiro[4.5]decan-2-one hydrochloride;cis-1-[(1-Hydroxy-cyclobutyl)-methyl]-methylamino-3-[2-(4-methyl-piperazin-1-yl)-pyrimidin-5-yl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-1-[(1-Hydroxy-cyclobutyl)-methyl]-8-methylamino-8-phenyl-3-(2-piperazin-1-yl-pyrimidin-5-yl)-1,3-diazaspiro[4.5]decan-2-one dihydrochloride;cis-1-(Cyclobutyl-methyl)-8-dimethylamino-3-[4-methyl-6-(trifluoromethyl)-pyridin-3-yl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-1-(Cyclobutyl-methyl)-8-methylamino-3-[4-methyl-6-(trifluoromethyl)-pyridin-3-yl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-1-(Cyclopropyl-methyl)-8-dimethylamino-3-(4-methylsulfonyl-phenyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-1-(Cyclopropyl-methyl)-8-methylamino-3-(4-methylsulfonyl-phenyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-1-(Cyclopropyl-methyl)-8-dimethylamino-3-(2-fluoro-4-methylsulfonyl-phenyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-2-[8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-benzamide; formic acid;cis-2-[8-Dimethylamino-1-[2-(1-methoxy-cyclobutyl)-ethyl]-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-benzamide;cis-8-Dimethylamino-1-[2-(1-methoxy-cyclobutyl)-ethyl]-3-(2-methyl-pyrimidin-5-yl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-5-[1-[(1-Hydroxy-cyclobutyl)-methyl]-8-methylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-pyrimidine-2-carbonitrile;cis-2-[1-[(1-Hydroxy-cyclobutyl)-methyl]-8-methylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-benzonitrile;cis-4-[1-[(1-Hydroxy-cyclobutyl)-methyl]-8-methylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-3-methoxy-benzonitrile;cis-4-[8-Ethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-3-methoxy-benzonitrile;cis-2-[8-Ethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-benzonitrile;cis-5-[1-[(1-Hydroxy-cyclobutyl)-methyl]-8-methylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-4-methoxy-pyrimidine-2-carbonitrile;cis-2-[8-Dimethylamino-1-(oxetan-3-yl-methyl)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-benzamide;cis-4-Methoxy-5-(8-methylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-pyrimidine-2-carbonitrile;cis-2-(8-Methylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-benzamide;cis-8-Dimethylamino-3-[2-(3-oxo-piperazin-1-yl)-pyrimidin-5-yl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-3-(2-Cyclopropyl-pyrimidin-5-yl)-8-dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-onecis-8-Dimethylamino-3-[4-methyl-6-(trifluoromethyl)-pyridin-3-yl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-3-(2-methylsulfonyl-phenyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-8-phenyl-3-(2-piperazin-1-yl-pyrimidin-5-yl)-1,3-diazaspiro[4.5]decan-2-one;trans-2-(8-Ethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-benzamide;cis-2-(8-Ethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-benzamide;cis-2-(8-Ethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-benzonitrile;cis-2-(8-Ethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-benzonitrile;cis-3-[5-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-pyrimidin-2-yl]-benzonitrile;cis-8-Dimethylamino-3-[2-(4-methylsulfonyl-piperazin-1-yl)-pyrimidin-5-yl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-3-[5-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-pyrimidin-2-yl]-benzamidecis-8-[(Cyclopropyl-methyl)-methyl-amino]-8-phenyl-3-[2-(trifluoromethyl)-pyrimidin-5-yl]-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-3-[2-(4-methyl-piperazine-1-carbonyl)-pyrimidin-5-yl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;trans-4-(8-Ethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-3-methoxy-benzonitrile;cis-4-(8-Ethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-3-methoxy-benzonitrile;cis-3-[2-(4-Acetyl-piperazin-1-yl)-pyrimidin-5-yl]-8-dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-8-phenyl-3-(2-pyridin-4-yl-pyrimidin-5-yl)-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-8-phenyl-3-(2-pyridin-3-yl-pyrimidin-5-yl)-1,3-diazaspiro[4.5]decan-2-one;cis-5-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-N-(2-hydroxy-ethyl)-pyrimidine-2-carboxylic acid amide;cis-5-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-pyrimidine-2-carboxylic acid amide;cis-8-Dimethylamino-3-[2-morpholin-4-yl-4-(trifluoromethyl)-pyrimidin-5-yl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-4-[5-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-pyrimidin-2-yl]-benzonitrile;cis-5-(8-Ethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-4-methoxy-pyrimidine-2-carbonitrile;trans-5-(8-Ethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-4-methoxy-pyrimidine-2-carbonitrile;cis-8-Dimethylamino-3-[2-(morpholine-4-carbonyl)-pyrimidin-5-yl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-2-[4-[5-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-pyrimidin-2-yl]-piperazin-1-yl]-acetic acid methyl ester;cis-8-Dimethylamino-3-[2-(methylsulfonyl-methyl)-phenyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-3-(4-methyl-2-morpholin-4-yl-pyrimidin-5-yl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-3-[2-(1,1-dioxo-[1,4]thiazinan-4-yl)-pyrimidin-5-yl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-3-(4-fluoro-pyridin-3-yl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-5-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-N-(2-hydroxy-ethyl)-N-methyl-pyrimidine-2-carboxylic acid amide;cis-5-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-2-morpholin-4-yl-isonicotinonitrile;cis-4-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-benzamide;cis-8-Dimethylamino-3-(2-fluoro-4-methylsulfonyl-phenyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-4-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-3-fluoro-benzonitrile;cis-4-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-3,5-difluoro-benzonitrile;cis-8-Dimethylamino-3-(2-methoxy-pyrimidin-5-yl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-3-[2-(Benzylamino)-pyrimidin-5-yl]-8-dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-3-[2-(4-fluorophenyl)-pyrimidin-5-yl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;trans-8-Benzyl-8-dimethylamino-3-(2-morpholin-4-yl-pyrimidin-5-yl)-1,3-diazaspiro[4.5]decan-2-one;cis-8-Benzyl-8-dimethylamino-3-(2-morpholin-4-yl-pyrimidin-5-yl)-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-8-phenyl-3-(2-pyridin-2-yl-pyrimidin-5-yl)-1,3-diazaspiro[4.5]decan-2-one;cis-4-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-3,5-difluoro-benzamide;cis-4-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-3-fluoro-benzamide;cis-8-Benzyl-8-dimethylamino-3-[2-(trifluoromethyl)-pyrimidin-5-yl]-1,3-diazaspiro[4.5]decan-2-one;trans-8-Benzyl-8-dimethylamino-3-[2-(trifluoromethyl)-pyrimidin-5-yl]-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-8-thiophen-2-yl-3-[2-(trifluoromethyl)-pyrimidin-5-yl]-1,3-diazaspiro[4.5]decan-2-one;trans-8-Dimethylamino-8-thiophen-2-yl-3-[2-(trifluoromethyl)-pyrimidin-5-yl]-1,3-diazaspiro[4.5]decan-2-one;cis-2-[2-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-phenoxy]-acetic acid;cis-8-Dimethylamino-8-phenyl-3-(2-piperidin-1-yl-pyrimidin-5-yl)-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-8-phenyl-3-(2-pyrrolidin-1-yl-pyrimidin-5-yl)-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-8-phenyl-3-(2-pyrimidin-5-yl-pyrimidin-5-yl)-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-8-phenyl-3-[2-(piperazine-1-carbonyl)-pyrimidin-5-yl]-1,3-diazaspiro[4.5]decan-2-one;trans-8-Benzyl-8-dimethylamino-3-[4-methyl-6-(trifluoromethyl)-pyridin-3-yl]-1,3-diazaspiro[4.5]decan-2-one;cis-5-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-2-morpholin-4-yl-pyridine-4-carboxylic acid amide;cis-8-Dimethylamino-3-[2-(3,5-dimethyl-isoxazol-4-yl)-pyrimidin-5-yl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-3-[2-(Benzothiazol-6-yl)-pyrimidin-5-yl]-8-dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-3-[2-fluoro-4-(trifluoromethyl)-phenyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-3-(6-morpholin-4-yl-pyridin-3-yl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-8-phenyl-3-(2-phenyl-thiazol-4-yl)-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-8-phenyl-3-[2-(tetrahydro-pyran-4-ylamino)-pyrimidin-5-yl]-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-3-[2-(4-hydroxy-piperidin-1-yl)-pyrimidin-5-yl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-8-phenyl-3-(4-phenyl-thiazol-2-yl)-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-8-phenyl-3-[2-(1H-pyrrolo [2,3-b]pyridin-1-yl)-pyrimidin-5-yl]-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-8-phenyl-3-[2-(3,4,5-trifluoro-phenyl)-pyrimidin-5-yl]-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-3-o-tolyl-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-3-m-tolyl-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-8-phenyl-3-p-tolyl-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-8-phenyl-3-[4-(trifluoromethyl)-phenyl]-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-8-phenyl-3-[3-(trifluoromethyloxy)-phenyl]-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-8-phenyl-3-[4-(trifluoromethyloxy)-phenyl]-1,3-diazaspiro[4.5]decan-2-one;cis-2-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-benzoic acid methyl ester;cis-3-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-benzoic acid methyl ester;cis-4-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-benzoic acid methyl ester;cis-3-(1,3-Benzodioxol-5-yl)-8-dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-8-phenyl-3-quinolin-5-yl-1,3-diazaspiro[4.5]decan-2-one;cis-3-(2,3-Dihydro-1H-indol-6-yl)-8-dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-5-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-4-methyl-pyridine-2-carboxylic acid methyl ester;cis-8-Dimethylamino-3-(6-methoxy-4-methyl-pyridin-3-yl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-3-[2-methyl-5-(trifluoromethyl)-2H-pyrazol-3-yl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-3-(3-methoxy-pyridin-2-yl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-8-phenyl-3-[5-(trifluoromethyl)-pyridin-2-yl]-1,3-diazaspiro[4.5]decan-2-one;cis-5-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-nicotinonitrile;cis-8-Dimethylamino-3-(3-methyl-pyridin-2-yl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-3-(6-methoxy-pyridin-3-yl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-8-phenyl-3-[3-(trifluoromethyl)phenyl]-1,3-diazaspiro[4.5]decan-2-one;cis-3-(1,3-Benzodioxol-4-yl)-8-dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-3-[2-(2-oxo-1,3-dihydro-indol-4-yl)-pyrimidin-5-yl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-3-[2-(3,5-dimethyl-1H-pyrazol-1-yl)-pyrimidin-5-yl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-3-[2-(3-hydroxy-piperidin-1-yl)-pyrimidin-5-yl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-3-[2-(3-hydroxy-piperidin-1-yl)-pyrimidin-5-yl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-3-[2-[4-(2-hydroxy-ethyl)-piperazin-1-yl]-pyrimidin-5-yl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-2-[4-[5-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-pyrimidin-2-yl]-piperazin-1-yl]-acetic acid;cis-8-Dimethylamino-3-[2-(1-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl)-pyrimidin-5-yl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-8-Benzyl-8-dimethylamino-3-[4-methyl-6-(trifluoromethyl)-pyridin-3-yl]-1,3-diazaspiro[4.5]decan-2-one;trans-8-Dimethylamino-3-[4-methyl-6-(trifluoromethyl)-pyridin-3-yl]-8-thiophen-2-yl-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-3-[4-methyl-6-(trifluoromethyl)-pyridin-3-yl]-8-thiophen-2-yl-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-3-[2-(1,1-dioxo-[1,4]thiazinan-4-yl)-4-(trifluoromethyl)-pyrimidin-5-yl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-8-(1-methyl-1H-benzoimidazol-2-yl)-3-[2-(trifluoromethyl)-pyrimidin-5-yl]-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-8-(1-methyl-1H-benzoimidazol-2-yl)-3-[4-methyl-6-(trifluoromethyl)-pyridin-3-yl]-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-3-[2-(2-hydroxy-ethyl amino)-pyrimidin-5-yl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-3-[2-(Benzyl-methyl-amino)-pyrimidin-5-yl]-8-dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-5-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-N-[2-[2-[2-(2-methoxy-ethoxy)-ethoxy]-ethoxy]-ethyl]-pyrimidine-2-carboxylic acid amide;cis-8-Dimethylamino-3-[2-(1H-indazol-1-yl)-pyrimidin-5-yl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-3-[2-[(2-hydroxy-ethyl)-methyl-amino]-pyrimidin-5-yl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-3-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-benzamide;cis-8-Dimethylamino-3-[3-fluoro-5-(trifluoromethyl)-pyridin-2-yl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-3-(5-methyl-pyrazin-2-yl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-3-(5-fluoro-pyrimidin-4-yl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-3-(5-fluoro-pyrimidin-2-yl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-8-phenyl-3-pyrazin-2-yl-1,3-diazaspiro[4.5]decan-2-one;cis-3-([2,1,3]Benzoxadiazol-5-yl)-8-dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-2-[2-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-phenoxy]-acetamide;cis-8-Dimethylamino-8-phenyl-3-(5-pyridin-4-yl-thiophen-2-yl)-1,3-diazaspiro[4.5]decan-2-one;cis-2-[2-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-phenoxy]-acetic acid methyl ester;cis-8-Dimethylamino-3-(2-morpholin-4-yl-pyrimidin-4-yl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-3-[2-(3,4-Difluoro-phenyl)-pyrimidin-5-yl]-8-dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-2-[5-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-pyrimidin-2-yl]-benzonitrile;cis-3-(2-Amino-pyrimidin-5-yl)-8-dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-N-[5-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-pyrimidin-2-yl]-cyclopropanecarboxylic acid amide;cis-2-[4-[5-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-pyrimidin-2-yl]-piperazin-1-yl]-acetamide;cis-8-Dimethylamino-8-phenyl-3-(6-piperazin-1-yl-pyridin-3-yl)-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-3-[6-(4-methyl-piperazin-1-yl)-pyridin-3-yl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-3-[2-(1,1-dioxo-[1,4]thiazinan-4-yl)-4-methyl-pyrimidin-5-yl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-8-phenyl-3-[2-(trifluoromethyl)-pyrimidin-5-yl]-1,3-diazaspiro[4.5]decan-2-one;cis-2-[8-Dimethylamino-1-(3-methoxy-propyl)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-pyrimidine-5-carbonitrile;cis-8-Dimethylamino-3-[2-(4-methyl-piperazin-1-yl)-pyrimidin-5-yl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-8-phenyl-3-[2-(trifluoromethyl)-pyrimidin-5-yl]-1,3-diazaspiro[4.5]decan-2-one;cis-2-[1-(3-Methoxy-propyl)-8-methylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-pyrimidine-5-carbonitrile;cis-8-Dimethylamino-8-phenyl-3-[6-(trifluoromethyl)-pyridin-3-yl]-1,3-diazaspiro[4.5]decan-2-one;cis-5-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-pyridine-2-carbonitrile;cis-8-Dimethylamino-3-(2-morpholin-4-yl-pyrimidin-5-yl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-3-(2-methyl-pyrimidin-5-yl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-1-[(2-methoxyphenyl)-methyl]-3-(2-methyl-pyrimidin-5-yl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-1-[(1-Hydroxy-cyclobutyl)-methyl]-8-methylamino-8-phenyl-3-[2-(trifluoromethyl)-pyrimidin-5-yl]-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-3-(2-methyl-pyrimidin-5-yl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-1-[(1-Hydroxy-cyclobutyl)-methyl]-8-methylamino-8-phenyl-3-pyrimidin-5-yl-1,3-diazaspiro[4.5]decan-2-one;cis-5-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-4-methyl-pyridine-2-carbonitrile;cis-8-Dimethylamino-3-(2-methyl-pyrimidin-5-yl)-8-phenyl-1-(pyridin-2-yl-methyl)-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-8-phenyl-3-pyrimidin-5-yl-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-8-phenyl-3-pyrimidin-5-yl-1,3-diazaspiro[4.5]decan-2-one;cis-8-Amino-1-[(1-hydroxy-cyclobutyl)-methyl]-8-phenyl-3-[2-(trifluoromethyl)-pyrimidin-5-yl]-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-3-(3-fluorophenyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-3-(3-methylsulfonyl-phenyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-3-(4-methylsulfonyl-phenyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-8-phenyl-3-pyridazin-3-yl-1,3-diazaspiro[4.5]decan-2-one;cis-3-Methoxy-4-(8-methylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-benzonitrile;cis-8-Dimethylamino-3-(2-fluorophenyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-8-phenyl-3-(2-phenyl-pyrimidin-5-yl)-1,3-diazaspiro[4.5]decan-2-one;cis-8-Methylamino-1-(oxetan-3-yl-methyl)-8-phenyl-3-[2-(trifluoromethyl)-pyrimidin-5-yl]-1,3-diazaspiro[4.5]decan-2-one;cis-1-(Cyclopropyl-methyl)-8-methylamino-8-phenyl-3-[2-(trifluoromethyl)-pyrimidin-5-yl]-1,3-diazaspiro[4.5]decan-2-one;cis-4-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-benzonitrile;cis-8-Dimethylamino-3-(4-fluorophenyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-2-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-benzonitrile;cis-8-Ethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-8-phenyl-3-[2-(trifluoromethyl)-pyrimidin-5-yl]-1,3-diazaspiro[4.5]decan-2-one;cis-1-[(1-Hydroxy-cyclobutyl)-methyl]-8-methylamino-3-(2-methyl-pyrimidin-5-yl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-3-[2-(morpholin-4-yl-methyl)-pyrimidin-5-yl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-3-[2-(methyl-tetrahydro-pyran-4-yl-amino)-pyrimidin-5-yl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-5-[8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-N-[2-[2-[2-(2-methoxy-ethoxy)-ethoxy]-ethoxy]-ethyl]-pyrimidine-2-carboxylic acid amide;cis-1-(Cyclopropyl-methyl)-3-(2-fluoro-4-methylsulfonyl-phenyl)-8-methylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-2-[[5-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-pyrimidin-2-yl]-methyl-amino]-acetamide;cis-2-[[5-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-pyrimidin-2-yl]amino]-acetamide;cis-1-(Cyclopropyl-methyl)-8-methylamino-3-[4-methyl-6-(trifluoromethyl)-pyridin-3-yl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-1-(Cyclopropyl-methyl)-8-dimethylamino-3-[4-methyl-6-(trifluoromethyl)-pyridin-3-yl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-N-[5-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-pyrimidin-2-yl]-thiophene-2-carboxylic acid amide;cis-N-[5-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-pyrimidin-2-yl]-benzamide;cis-8-Dimethylamino-8-phenyl-3-(5-phenyl-thiophen-2-yl)-1,3-diazaspiro[4.5]decan-2-one;cis-1-(Cyclopropyl-methyl)-8-dimethylamino-3-[2-(methylsulfonyl-methyl)-phenyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-1-(Cyclopropyl-methyl)-8-methylamino-3-[2-(methylsulfonyl-methyl)-phenyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-8-(3-fluorophenyl)-3-[2-(methylsulfonyl-methyl)-phenyl]-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-8-(4-fluorophenyl)-3-[2-(methylsulfonyl-methyl)-phenyl]-1,3-diazaspiro[4.5]decan-2-one;cis-8-[Methyl-(tetrahydro-furan-3-yl-methyl)-amino]-8-phenyl-3-[2-(trifluoromethyl)-pyrimidin-5-yl]-1,3-diazaspiro[4.5]decan-2-one (enantiomer 1);cis-8-[Methyl-(tetrahydro-furan-3-yl-methyl)-amino]-8-phenyl-3-[2-(trifluoromethyl)-pyrimidin-5-yl]-1,3-diazaspiro[4.5]decan-2-one (enantiomer 2);cis-8-Dimethylamino-8-(3-fluorophenyl)-3-(4-methyl-2-morpholin-4-yl-pyrimidin-5-yl)-1,3-diazaspiro[4.5]decan-2-one;cis-3-[6-(4-Acetyl-piperazin-1-yl)-4-methyl-pyridin-3-yl]-8-dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-3-[2-(4-Acetyl-piperazin-1-yl)-4-methyl-pyrimidin-5-yl]-8-dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-3-(4-methyl-6-pyridin-4-yl-pyridin-3-yl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-3-[2-(4-Acetyl-piperazin-1-yl)-4-(trifluoromethyl)-pyrimidin-5-yl]-8-dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-3-[2-(3-oxo-piperazin-1-yl)-4-(trifluoromethyl)-pyrimidin-5-yl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-3-isoquinolin-4-yl-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-3-isoquinolin-5-yl-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-8-phenyl-3-(1H-pyrrolo[2,3-b]pyridin-4-yl)-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-8-phenyl-3-(2-pyridin-4-yl-thiazol-4-yl)-1,3-diazaspiro[4.5]decan-2-one;cis-8-[Methyl-(tetrahydro-furan-3-yl-methyl)-amino]-3-(2-morpholin-4-yl-pyrimidin-5-yl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (enantiomer 1);cis-8-[Methyl-(tetrahydro-furan-3-yl-methyl)-amino]-3-(2-morpholin-4-yl-pyrimidin-5-yl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (enantiomer 2);cis-3-[2-(Azetidin-1-yl)-pyrimidin-5-yl]-8-dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-3-[2-(3,3-Difluoro-azetidin-1-yl)-pyrimidin-5-yl]-8-dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-3-[6-morpholin-4-yl-5-(trifluoromethyl)-pyridin-3-yl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-8-Methylamino-3-[6-morpholin-4-yl-5-(trifluoromethyl)-pyridin-3-yl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-8-phenyl-3-[5-(trifluoromethyloxy)-pyridin-2-yl]-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-3-(5-methylsulfonyl-pyridin-2-yl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-6-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-nicotinonitrile;cis-3-[2-(4-Cyclopropyl-1H-[1,2,3]triazol-1-yl)-pyrimidin-5-yl]-8-dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-3-[4-methyl-2-(3-oxo-piperazin-1-yl)-pyrimidin-5-yl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-5-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-pyridine-2-carboxylic acid amide;cis-3-[4-(Azetidin-1-yl)-2-methyl-pyrimidin-5-yl]-8-dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-2-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-benzamide;cis-8-Dimethylamino-3-[2-(methylsulfonyl-methyl)-phenyl]-8-thiophen-2-yl-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-8-(3-fluorophenyl)-3-[2-methyl-5-(trifluoromethyl)-2H-pyrazol-3-yl]-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-3-(4-methyl-2-morpholin-4-yl-pyrimidin-5-yl)-8-thiophen-2-yl-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-3-(6-methylsulfonyl-pyridin-3-yl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-8-phenyl-3-(1H-pyrrolo[2,3-b]pyridin-5-yl)-1,3-diazaspiro[4.5]decan-2-one;cis-N-[5-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-pyrimidin-2-yl]-acetamide;cis-3-[2-(4-Methyl-piperazin-1-yl)-pyrimidin-5-yl]-8-[methyl-(tetrahydro-furan-3-yl-methyl)-amino]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (enantiomer 1);cis-3-[2-(4-Methyl-piperazin-1-yl)-pyrimidin-5-yl]-8-[methyl-(tetrahydro-furan-3-yl-methyl)-amino]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (enantiomer 2);cis-8-Dimethylamino-3-(4,6-dimethyl-2-morpholin-4-yl-pyrimidin-5-yl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-3-(2-morpholin-4-yl-pyrimidin-5-yl)-8-thiophen-2-yl-1,3-diazaspiro[4.5]decan-2-one;cis-6-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-pyridine-3-carboxylic acid amide;cis-8-Dimethylamino-3-[2-methyl-5-(trifluoromethyl)-2H-pyrazol-3-yl]-8-thiophen-2-yl-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-3-[2-[(2-hydroxy-ethyl)-methyl-amino]-pyrimidin-5-yl]-8-thiophen-2-yl-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-3-[2-(2-oxo-1,3-dihydro-indol-4-yl)-pyrimidin-5-yl]-8-thiophen-2-yl-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-3-[4-methyl-6-(3-oxo-piperazin-1-yl)-pyridin-3-yl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-3-(4-methyl-6-pyridin-2-yl-pyridin-3-yl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-3-(4-methylsulfonyl-pyridin-3-yl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-3-(Benzothiazol-7-yl)-8-dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-8-(4-fluorophenyl)-3-(4-methyl-2-morpholin-4-yl-pyrimidin-5-yl)-1,3-diazaspiro[4.5]decan-2-one;cis-2-[8-Dimethylamino-3-[4-methyl-6-(trifluoromethyl)-pyridin-3-yl]-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl]-N,N-dimethyl-acetamide;cis-8-Dimethylamino-3-[2-(2-methyl-1-oxo-2,3-dihydro-isoindol-4-yl)-pyrimidin-5-yl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-2-[[5-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-2-methyl-pyrimidin-4-yl]amino]-acetamide;cis-2-[3-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-pyridin-4-yl]-acetamide;cis-8-Dimethylamino-3-[4-(methylsulfonyl-methyl)-pyridin-3-yl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-3-[6-(4-methyl-3-oxo-piperazin-1-yl)-pyridin-3-yl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-3-(2,4-dimethyl-pyrimidin-5-yl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-3-[2-(1-oxo-2,3-dihydro-isoindol-4-yl)-pyrimidin-5-yl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one; 2,2,2-trifluoro-acetic acid;cis-8-Dimethylamino-3-[6-[(2-hydroxy-ethyl)-methyl-amino]-5-(trifluoromethyl)-pyridin-3-yl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-8-phenyl-3-[2-[4-(trifluoromethyl)-1H-[1,2,3]triazol-1-yl]-pyrimidin-5-yl]-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-3-[2-(4-isopropyl-1H-[1,2,3]triazol-1-yl)-pyrimidin-5-yl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-3-[6-(1,1-dioxo-[1,4]thiazinan-4-yl)-pyridin-3-yl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-5-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-2-morpholin-4-yl-nicotinonitrile;cis-8-Dimethylamino-3-(1-methylsulfonyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-3-(1H-indol-4-yl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-3-(2-hydroxy-benzooxazol-7-yl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-3-[2-fluoro-4-(trifluoromethyloxy)-phenyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-4-[5-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-pyrimidin-2-yl]-benzamide; 2,2,2-trifluoro-acetic acid;cis-8-Dimethylamino-3-(1-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-3-(1-Acetyl-1H-indol-4-yl)-8-dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-3-(1H-indol-3-yl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-6-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-5-methyl-nicotinonitrile;cis-6-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-5-fluoro-nicotinonitrile;cis-8-Dimethylamino-3-[4-methyl-6-(trifluoromethyl)-pyridin-3-yl]-1-(2-oxo-2-pyrrolidin-1-yl-ethyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-6-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-5-methyl-pyridine-3-carboxylic acid amide;cis-6-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-5-fluoro-pyridine-3-carboxylic acid amide;cis-8-Dimethylamino-3-[4-methyl-6-(trifluoromethyl)-pyridin-3-yl]-8-m-tolyl-1,3-diazaspiro[4.5]decan-2-one;cis-3-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-isonicotinonitrile;cis-8-Dimethylamino-3-[3-fluoro-5-(2-oxo-1,3-dihydro-indol-4-yl)-pyridin-2-yl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-3-[4-methyl-6-(trifluoromethyl)-pyridin-3-yl]-8-[3-(trifluoromethyloxy)-phenyl]-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-3-[4-methyl-6-(trifluoromethyl)-pyridin-3-yl]-8-[3-(trifluoromethyl)phenyl]-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-8-(3-methoxyphenyl)-3-[4-methyl-6-(trifluoromethyl)-pyridin-3-yl]-1,3-diazaspiro[4.5]decan-2-one;cis-8-(5-Chloro-thiophen-2-yl)-8-dimethylamino-3-[4-methyl-6-(trifluoromethyl)-pyridin-3-yl]-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-8-(3-fluorophenyl)-3-[4-methyl-6-(trifluoromethyl)-pyridin-3-yl]-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-3-(2-methylamino-pyrimidin-5-yl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-8-(5-Chloro-thiophen-2-yl)-8-dimethylamino-3-(4-methyl-2-morpholin-4-yl-pyrimidin-5-yl)-1,3-diazaspiro[4.5]decan-2-one;cis-N-[5-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-pyrimidin-2-yl]-N-methyl-cyclopropanecarboxylic acid amide;cis-N-[5-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-pyrimidin-2-yl]-N,2,5-trimethyl-2H-pyrazole-3-carboxylic acid amide;cis-3-[4,6-Bis(trifluoromethyl)-pyridin-3-yl]-8-dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-3-[2-[(2-hydroxy-ethyl)-methyl-amino]-quinazolin-6-yl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-3-(2-morpholin-4-yl-quinazolin-6-yl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-8-[Methyl-(oxetan-3-yl-methyl)-amino]-8-phenyl-3-[2-(trifluoromethyl)-pyrimidin-5-yl]-1,3-diazaspiro[4.5]decan-2-one;cis-3-(1-Acetyl-1H-indol-3-yl)-8-dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-8-phenyl-3-quinazolin-6-yl-1,3-diazaspiro[4.5]decan-2-one;cis-5-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-2-(2-oxo-1,3-dihydro-indol-4-yl)-isonicotinonitrile;cis-N-[5-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-pyrimidin-2-yl]-N-methyl-tetrahydro-pyran-4-carboxylic acid amide;cis-N-[5-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-pyrimidin-2-yl]-N,2,2-trimethyl-propionamide;cis-8-Dimethylamino-3-[2-(1-methyl-2-oxo-1,3-dihydro-indol-4-yl)-pyrimidin-5-yl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-3-(2-morpholin-4-yl-1H-benzoimidazol-5-yl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-8-(3-fluoro-5-methyl-phenyl)-3-[4-methyl-6-(trifluoromethyl)-pyridin-3-yl]-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-3-[6-(2-oxo-1,3-dihydro-indol-4-yl)-pyridin-3-yl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-8-(3-hydroxyphenyl)-3-[4-methyl-6-(trifluoromethyl)-pyridin-3-yl]-1,3-diazaspiro[4.5]decan-2-one;cis-3-[6-(Azetidin-1-yl)-5-(trifluoromethyl)-pyridin-3-yl]-8-dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-3-[1-(Cyclopropyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-isonicotinonitrile;cis-3-[3,5-Bis(trifluoromethyl)-pyridin-2-yl]-8-dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-onecis-8-Dimethylamino-3-(5-fluoro-6-morpholin-4-yl-pyridin-3-yl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-8-(3-Chlorophenyl)-8-dimethylamino-3-[4-methyl-6-(trifluoromethyl)-pyridin-3-yl]-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-3-[5-(2-oxo-1,3-dihydro-indol-4-yl)-pyridin-2-yl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-8-phenyl-3-[5-(trifluoromethyl)-[1,3,4]thiadiazol-2-yl]-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-3-(2-oxo-1,3-dihydro-indol-4-yl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-3-[2-[(2-hydroxy-ethyl)-methyl-amino]-1H-benzoimidazol-5-yl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-3-(5-methyl-6-morpholin-4-yl-pyridin-3-yl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-1-(Cyclopropyl-methyl)-8-dimethylamino-8-(3-fluorophenyl)-3-(5-methylsulfonyl-pyridin-2-yl)-1,3-diazaspiro[4.5]decan-2-one;cis-1-(Cyclopropyl-methyl)-8-(3-fluorophenyl)-8-methylamino-3-(5-methylsulfonyl-pyridin-2-yl)-1,3-diazaspiro[4.5]decan-2-one;cis-1-(Cyclobutyl-methyl)-8-(3-fluorophenyl)-8-methylamino-3-[2-(trifluoromethyl)-pyrimidin-5-yl]-1,3-diazaspiro[4.5]decan-2-one;cis-1-(Cyclopropyl-methyl)-8-dimethylamino-8-(3-fluorophenyl)-3-[2-(trifluoromethyl)-pyrimidin-5-yl]-1,3-diazaspiro[4.5]decan-2-one;cis-1-(Cyclopropyl-methyl)-8-(3-fluorophenyl)-8-methylamino-3-[2-(trifluoromethyl)-pyrimidin-5-yl]-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-8-(3-fluorophenyl)-3-[2-(trifluoromethyl)-pyrimidin-5-yl]-1,3-diazaspiro[4.5]decan-2-one;cis-1-(Cyclopropyl-methyl)-8-dimethylamino-8-(3-fluorophenyl)-3-[2-methyl-5-(trifluoromethyl)-2H-pyrazol-3-yl]-1,3-diazaspiro[4.5]decan-2-one cis-1-(Cyclopropyl-methyl)-8-(3-fluorophenyl)-8-methylamino-3-[2-methyl-5-(trifluoromethyl)-2H-pyrazol-3-yl]-1,3-diazaspiro[4.5]decan-2-one;cis-8-Methylamino-3-(4-methyl-2-morpholin-4-yl-pyrimidin-5-yl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-3-[5-(Azetidin-1-yl)-3-methyl-pyridin-2-yl]-8-dimethylamino-8-(3-fluorophenyl)-1,3-diazaspiro[4.5]decan-2-one;cis-8-Dimethylamino-8-(3-fluorophenyl)-3-(5-methylsulfonyl-pyridin-2-yl)-1,3-diazaspiro[4.5]decan-2-one;cis-3-(6-(azetidin-1-yl)-4-fluoropyridin-3-yl)-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-3-(6-(azetidin-1-yl)pyridin-3-yl)-8-(dimethylamino)-8-(3-fluorophenyl)-1,3-diazaspiro[4.5]decan-2-one;cis-3-(1-(cyclopropanecarbonyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl)-8-(dimethylamino)-8-(3-fluorophenyl)-1,3-diazaspiro[4.5]decan-2-one;cis-8-(dimethylamino)-8-(3-fluorophenyl)-3-(1-(2-hydroxyethyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl)-1,3-diazaspiro[4.5]decan-2-one;cis-3-(1-(cyclopropylmethyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl)-8-(dimethylamino)-8-(3-fluorophenyl)-1,3-diazaspiro[4.5]decan-2-one;cis-8-(dimethylamino)-8-(3-fluorophenyl)-3-(1-(methylsulfonyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl)-1,3-diazaspiro[4.5]decan-2-one;cis-1-(cyclopropylmethyl)-8-(dimethylamino)-8-(3-fluorophenyl)-3-(1-(methylsulfonyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl)-1,3-diazaspiro[4.5]decan-2-one;cis-2-(5-(8-(dimethylamino)-8-(3-fluorophenyl)-2-oxo-1,3-diazaspiro[4.5]decan-3-yl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)-N,N-dimethylacetamide;cis-2-(5-(1-(cyclopropylmethyl)-8-(dimethylamino)-8-(3-fluorophenyl)-2-oxo-1,3-diazaspiro[4.5]decan-3-yl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)-N,N-dimethylacetamide;cis-8-(dimethylamino)-3-(1-methyl-1H-pyrrolo [2,3-b]pyridin-5-yl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-8-(dimethylamino)-3-(3-fluoro-1H-pyrrolo[2,3-b]pyridin-5-yl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-8-(dimethylamino)-8-phenyl-3-(1H-pyrrolo[2,3-c]pyridin-4-yl)-1,3-diazaspiro[4.5]decan-2-one;cis-8-(dimethylamino)-8-phenyl-3-(2-(pyridazin-4-yl)pyrimidin-5-yl)-1,3-diazaspiro[4.5]decan-2-one;cis-8-(dimethylamino)-3-(2-(2-oxo-1,2-dihydropyridin-4-yl)pyrimidin-5-yl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-8-(dimethylamino)-8-(3-fluorophenyl)-3-(1-methyl-3-(thiophen-2-yl)-1H-pyrazol-5-yl)-1,3-diazaspiro[4.5]decan-2-one;cis-8-(dimethylamino)-8-(3-fluorophenyl)-3-(1-methyl-3-morpholino-1H-pyrazol-5-yl)-1,3-diazaspiro[4.5]decan-2-one;cis-8-(dimethylamino)-8-phenyl-1-(2,2,2-trifluoroethyl)-3-(2-(trifluoromethyl)pyrimidin-5-yl)-1,3-diazaspiro[4.5]decan-2-one;cis-8-(dimethylamino)-8-phenyl-3-(2-(trifluoromethyl)pyrimidin-5-yl)-1-(3,3,3-trifluoropropyl)-1,3-diazaspiro[4.5]decan-2-one;cis-3-(4-methyl-6-(trifluoromethyl)pyridin-3-yl)-8-(methylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-3-(1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl)-8-(methylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;cis-8-(dimethylamino)-8-(3-fluorophenyl)-3-(4-(methylsulfonyl)pyridin-3-yl)-1,3-diazaspiro[4.5]decan-2-one;cis-8-(dimethylamino)-3-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-5-yl)-8-(3-fluorophenyl)-1,3-diazaspiro[4.5]decan-2-one;cis-3-(1-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-5-yl)-8-(dimethylamino)-8-(3-fluorophenyl)-1,3-diazaspiro[4.5]decan-2-one;cis-8-(dimethylamino)-8-(3-fluorophenyl)-3-(1-(oxetan-3-ylmethyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl)-1,3-diazaspiro[4.5]decan-2-one;cis-8-(dimethylamino)-8-(3-fluorophenyl)-3-(1-(2-(methylsulfonyl)ethyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl)-1,3-diazaspiro[4.5]decan-2-one;cis-8-(dimethylamino)-8-(3-fluorophenyl)-3-(4-methyl-2-(methylamino)pyrimidin-5-yl)-1,3-diazaspiro[4.5]decan-2-one;cis-3-(2-cyclopropoxy-4-methylpyrimidin-5-yl)-8-(dimethylamino)-8-(3-fluorophenyl)-1,3-diazaspiro[4.5]decan-2-one;cis-N-(5-(8-(dimethylamino)-8-(3-fluorophenyl)-2-oxo-1,3-diazaspiro[4.5]decan-3-yl)-4-methylpyrimidin-2-yl)-N-methylcyclopropanecarboxamide;cis-N-(5-(8-(dimethylamino)-8-(3-fluorophenyl)-2-oxo-1,3-diazaspiro[4.5]decan-3-yl)-4-methylpyrimidin-2-yl)-N-methylpivalamide;cis-3-(4-(azetidin-1-yl)-2-(trifluoromethyl)pyrimidin-5-yl)-8-(dimethylamino)-8-(3-fluorophenyl)-1,3-diazaspiro[4.5]decan-2-one;cis-8-(dimethylamino)-8-(3-fluorophenyl)-3-(4-(oxetan-3-ylmethoxy)-2-(trifluoromethyl)pyrimidin-5-yl)-1,3-diazaspiro[4.5]decan-2-one;cis-3-(2-cyclopropyl-4-(2,2,2-trifluoroethoxy)pyrimidin-5-yl)-8-(dimethylamino)-8-(3-fluorophenyl)-1,3-diazaspiro[4.5]decan-2-one;cis-3-(2-cyclopropyl-4-((2-hydroxyethyl)(methyl)amino)pyrimidin-5-yl)-8-(dimethylamino)-8-(3-fluorophenyl)-1,3-diazaspiro[4.5]decan-2-one and the physiologically acceptable salts thereof.
  • 27. The compound according to claim 1 adapted for use in the treatment of pain.
  • 28. A medicament comprising a compound according to claim 1.
  • 29. A method of treating pain, said method comprising administering to a patient in need thereof an effective amount therefor of at least one compound according to claim 1.
  • 30. A method of treating a disorder selected from the group consisting of neurodegenerative disorders, neuroinflammatory disorders, neuropsychiatric disorders, and substance abuse/dependence, said method comprising administering to a patient in need thereof an effective amount therefor of at least one compound according to claim 1.
Priority Claims (1)
Number Date Country Kind
16 151 012.8 Jan 2016 EP regional
Parent Case Info

This application is a continuation of U.S. patent application Ser. No. 16/207,854, filed Dec. 3, 2018, which is a continuation of U.S. patent application Ser. No. 15/923,948, filed Mar. 16, 2018, abandoned; which is a continuation of U.S. patent application Ser. No. 15/405,485, filed Jan. 13, 2017, abandoned; which claims foreign priority benefit under 35 U.S.C. § 119 of European Patent Application No. 16 151 012.8, filed Jan. 13, 2016, the disclosures of which are incorporated herein by reference.

Continuations (3)
Number Date Country
Parent 16207854 Dec 2018 US
Child 16450331 US
Parent 15923948 Mar 2018 US
Child 16207854 US
Parent 15405485 Jan 2017 US
Child 15923948 US